<SEC-DOCUMENT>0001144204-18-044671.txt : 20180814
<SEC-HEADER>0001144204-18-044671.hdr.sgml : 20180814
<ACCEPTANCE-DATETIME>20180814161156
ACCESSION NUMBER:		0001144204-18-044671
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20180630
FILED AS OF DATE:		20180814
DATE AS OF CHANGE:		20180814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		181017596

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv499850_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 6pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the quarterly period ended June 30,
2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;For the transition period from&nbsp;____&nbsp;&nbsp;to&nbsp;____&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-13341</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Titan
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>94-3171940</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction of</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S. Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>incorporation or organization)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>400 Oyster Point Blvd., Suite 505,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>South San Francisco, California</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>94080</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(650) 244-4990</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 24%"><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 24%"><FONT STYLE="font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Emerging growth company&nbsp;&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate the number
of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class</B></FONT></TD>
    <TD STYLE="width: 2%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Outstanding at August 10, 2018</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, Par value $0.001</FONT></TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">21,203,744</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 6pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Pharmaceuticals,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Index to Form&nbsp;10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; font-style: normal"><B>Part&nbsp;I. Financial Information</B></FONT></A></TD>
    <TD><I>&nbsp;</I></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 80%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Item&nbsp;1.</FONT></A></TD>
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Financial Statements (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Condensed Balance Sheets as of June 30, 2018 and December 31, 2017</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Condensed Statements of Operations and Comprehensive Loss for the three and six-months ended June 30, 2018 and 2017</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Condensed Statements of Cash Flows for the six-months ended June 30, 2018 and 2017</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Notes to Condensed Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Item&nbsp;2.</FONT></A></TD>
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Item&nbsp;3.</FONT></A></TD>
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Item&nbsp;4.</FONT></A></TD>
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_010"><FONT STYLE="font-size: 10pt"><B>Part&nbsp;II. Other Information</B></FONT></A></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Item&nbsp;1A.</FONT></A></TD>
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#b_001">Item 5. </A></TD>
    <TD><A HREF="#b_001">Other Information</A></TD>
    <TD STYLE="text-align: right"><A HREF="#b_001">23</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Item&nbsp;6.</FONT></A></TD>
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">24</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_013"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">27</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_001"></A>Part I. Financial Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_002"></A>Item&nbsp;1. Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>TITAN PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Note&nbsp;1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,614</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,522</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Contract assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">421</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">362</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,617</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued clinical trials expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Other accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Current portion of long-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,464</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Long-term debt, net of discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,584</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,930</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,048</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Common stock, at amounts paid-in</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,855</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,273</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(326,745</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(323,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,313</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">857</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,617</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Notes to Condensed Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>TITAN PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except per share amount)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months&nbsp;Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; text-indent: -12pt; padding-left: 0.5in">License revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,657</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">117</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Product revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 63pt">Total revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,380</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,995</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,548</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 63pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,698</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,778</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,175</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Income (loss) from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(639</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,046</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,058</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Other expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Other expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(230</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(428</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Non-cash gain on changes in the fair value of warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">190</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.75in">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(869</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,451</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,456</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Basic net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares used in computing basic net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,199</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares used in computing diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,201</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Notes to Condensed Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>TITAN PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;months&nbsp;Ended <BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,474</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,456</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash gain on changes in fair value of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(612</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">803</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(124</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,317</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Contract assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(59</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and other accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,988</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,855</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchases of furniture and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(53</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(53</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Payments on long-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net decrease in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,908</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,656</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,006</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,975</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,350</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Supplemental disclosure of cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: 9pt">Interest paid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Warrants issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides a reconciliation of cash, cash
equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown
in the condensed statement of cash flows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,614</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Restricted cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">361</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the statement of cash flows</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,975</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,350</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Notes to Condensed Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>TITAN PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Organization and Summary of Significant Accounting Policies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a
pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the
treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We
are currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&reg;, a product approved
in the U.S. for management of opiate dependence. We operate in only one business segment, the development of pharmaceutical
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited
condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;)
for interim financial information and with the instructions to Form&nbsp;10-Q and Article&nbsp;10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In
the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation
have been included. Operating results for the three and six-month periods ended June 30, 2018 are not necessarily indicative of
the results that may be expected for the year ending December&nbsp;31, 2017, or any future interim periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The balance sheet
at December&nbsp;31, 2017 has been derived from the audited financial statements at that date, but does not include all of the
information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements
should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals,&nbsp;Inc.
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, as filed with the Securities and Exchange Commission
(&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying financial
statements have been prepared assuming we will continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2018, we had cash and
cash equivalents of approximately $1.6 million, which we believe, along with the payment from L. Molteni &amp; C. Dei Frattelli
Alitti Societ&agrave; Di Esercizio S.P.A. (&ldquo;Molteni&rdquo;) in August, are sufficient to fund our planned operations into
mid-September 2018. If extended, the convertible loan from Molteni should provide funds through the end of the third quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will
require additional funds to finance our operations, including the commercialization of Probuphine in the U.S., completion of the
Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage
clinical studies. While we are currently considering the various financing alternatives available to us, our efforts to address
our liquidity requirements may not be successful.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Going concern assessment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With the implementation
of FASB's standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with the year ended December 31,
2016 and all annual and interim periods thereafter, we will assess going concern uncertainty in our financial statements to determine
if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at
least one year from the date the financial statements are issued or available to be issued, which is referred to as the &ldquo;look-forward
period&rdquo; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable
to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the
timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if
necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing
curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations
can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the above
assessment, we concluded that, at the date the financial statements in this Quarterly Report on Form 10-Q for the months ended
June 30, 2018, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore,
there was substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements
were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Beginning January 1, 2018, we have followed
the provisions of ASC Topic 606, <I>Revenue from Contracts with Customers</I>. The guidance provides a unified model to determine
how revenue is recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We generate revenue principally from collaborative
research and development arrangements, technology licenses, and government grants. Consideration received for revenue arrangements
with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone
selling price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">In determining the appropriate amount of
revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance
obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including
the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated
selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Performance Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">A performance obligation is a promise in
a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance
obligations include commercialization license rights, development services and services associated with the regulatory approval
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We have optional additional items in contracts,
which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future
commercial product supply and optional research and development services at the customer&rsquo;s discretion are generally considered
as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted
for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any
additional payments are recorded in revenue when the customer obtains control of the goods or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transaction Price</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We have both fixed and variable consideration.
Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining
the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at
which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative
estimated standalone selling prices of the promised goods or services for each performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">At the inception of each arrangement that
includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount
to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal
would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within
our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">For arrangements that include sales-based
royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement
is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of
(a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment
has been allocated has been satisfied (or partially satisfied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Allocation of Consideration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">As part of the accounting for these arrangements,
we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified
in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance
obligations, we use a cost-plus margin approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Timing of Recognition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Significant management judgment is required
to determine the level of effort required under an arrangement and the period over which we expect to complete our performance
obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement
and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized.
Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations
either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates.
Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is
recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from
the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we
have incurred to perform the services using the cost-to-cost input method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs and
Related Accrual</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs,
administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract
research organization, or CRO, activities, sponsored research studies, product registration, patent application and prosecution,
and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent
costs incurred by CROs and clinical sites. These costs are recorded as a component of research&nbsp;and development expenses. Under
our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the
clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of
accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting
period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period
in which the facts that give rise to the revision become known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November 2016,
the FASB issued ASU No. 2016-18, <I>Statement of Cash Flows (Topic 230): Restricted Cash</I>. ASU No. 2016-18 is intended to reduce
diversity in practice in the classification and presentation of changes in restricted cash on the Condensed Statement of Cash Flows.
The ASU requires that the Condensed Statement of Cash Flows explain the change in total cash, cash equivalents and amounts generally
described as restricted cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts.
The ASU also requires a reconciliation between the total of cash, cash equivalents and restricted cash presented on the Condensed
Statement of Cash Flows and the cash and cash equivalents balance presented on the Condensed Balance Sheet. We adopted ASU No.
2016-18, and the guidance has been retrospectively applied to all periods presented. The adoption of the guidance did not have
an impact on our Condensed Balance Sheet or Statement of Operations and Comprehensive Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July 2017, the
Financial Accounting Standards Board, or FASB, issued a two-part Accounting Standards Update, or ASU, No. 2017-11, <I>I. Accounting
for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable
Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception</I>
amending guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815,
Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial
instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite
deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.
Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017-
11 for the year ended December 31, 2017, and retrospectively applied ASU 2017-11 as required. There was no retrospective impact
as a result of the adoption of ASU 2017-11 on the financial statements. See Note 10, &ldquo;Debt Agreements&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August 2016, the
FASB issued ASU No. 2016-15, <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</I>
addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for
fiscal years beginning after December 31, 2017, and for interim periods within those years. The adoption of ASU No. 2016-15 did
not have a material impact on our statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March 2016, the
FASB issued ASU No. 2016-09, <I>Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</I>
(&ldquo;ASU 2016-09&rdquo;). ASU 2016-09 addresses several aspects of the accounting for share-based payment award transactions,
including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; (c) classification on the
statement of cash flows; and (d) accounting for forfeitures. We adopted the provisions of ASU 2016-09 in the first quarter of 2017.
We have elected to continue to estimate forfeitures based on the estimated number of awards expected to vest. In addition, the
adoption of ASU 2016-09 resulted in the recognition of $12.0 million of previously unrecognized excess tax benefits in deferred
tax assets, fully offset by a valuation allowance. All tax-related cash flows resulting from stock-based compensation, including
the excess tax benefits related to the settlement of stock-based payment awards, are now classified as cash flows from operating
activities on our statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The adoption of ASU
2016-09 did not have a material impact on our results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In February 2016,
the FASB issued ASU No. 2016-02, <I>Leases (Topic 842)</I>. This ASU requires most lessees to recognize right of use assets and
lease liabilities, but recognize expenses in a manner similar with current accounting standards. The new standard is effective
for fiscal years and interim periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach,
with early adoption permitted. We are currently evaluating the impact of this new standard on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2014, the FASB
issued ASU No. 2014-09, <I>Revenue from Contracts with Customers</I> and has subsequently issued several supplemental or clarifying
ASUs (collectively, &ldquo;ASC 606&rdquo;), ASC 606 supersedes nearly all existing revenue recognition guidance under U.S. GAAP.
The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount
that reflects the consideration to which an entity expects to be entitled for those goods or services. ASC 606 defines a five step
process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition
process than are required under existing U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard is effective
for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods:
(i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to
elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASC 606 recognized
at the date of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We adopted the new
standard effective January 1, 2018 under the modified retrospective transition method, applying the new guidance to the most current
period presented. Upon adoption, there was no change to the units of accounting previously identified under legacy GAAP, which
are now considered performance obligations under the new guidance, and there was no change to the revenue recognition pattern for
each performance obligation. Therefore, the adoption of the new standard resulted in no cumulative effect to the opening accumulated
deficit balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We assessed the impact
that the adoption of ASC 606 will have on our financial statements by analyzing our current portfolio of customer contracts, including
a review of historical accounting policies and practices to identify potential differences in the application of ASC 606. Additionally,
we performed a comprehensive review of our current processes and systems to determine and implement changes required to support
the adoption of ASC 606 on January 1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Subsequent Events</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have evaluated
events that have occurred after June 30, 2018 and through the date that the financial statements are issued. See Note 10. &ldquo;Subsequent Events&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value Measurements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We measure the fair
value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting
of three levels for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three
levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &ndash; quoted prices in active
markets for identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &ndash; quoted prices for similar
assets and liabilities in active markets or inputs that are observable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &ndash; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments,
including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due
to the short-term nature of these instruments. Our warrant liabilities are classified within level 3 of the fair value hierarchy
because the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recorded no fair
value adjustment of the warrant liabilities for the three and six-month periods ended June 30, 2018. We recorded non-cash gains
on decreases in the fair value of approximately $190,000 and $612,000 for the three and six-month periods ended June 30, 2017,
respectively, in our Condensed Statements of Operations and Comprehensive Loss. The underlying warrants expired by their terms
on April 18, 2018. See Note 7 &ldquo;Warrant Liability&rdquo; for further discussion on the calculation of the fair value of the
warrant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Stock Plans</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
summarizes the stock-based compensation expense recorded for awards under the stock option plans for the three and six-month periods
ended June 30, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -12pt; padding-left: 12pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">156</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">128</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">318</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">245</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">246</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">558</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Total stock-based compensation expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">402</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">382</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">834</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">803</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No tax benefit was
recognized related to stock-based compensation expense since we have accumulated operating losses and we have established a full
valuation allowance to offset all the potential tax benefits associated with our deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We use the Black-Scholes-Merton
option-pricing model with the following assumptions to estimate the stock-based compensation expense for the three and six-month
periods ended June 30, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -12pt; padding-left: 12pt">Weighted-average risk-free interest rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.7</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.1</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Expected dividend payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-size: 10pt">Expected holding period (years) <SUP>1</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-size: 10pt">Weighted-average volatility factor <SUP>2</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.88</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-size: 10pt">Estimated forfeiture rates <SUP>3</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expected holding period is
based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting
schedules and the expectations of future employee behavior.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Weighted average volatility is based on the historical volatility of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated forfeiture rates are based on historical data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Options to purchase
approximately 5,000 and 60,000 shares of common stock were granted during the three-month periods ended June 30, 2018 and 2017,
respectively. Options to purchase approximately 950,000 and 496,000 shares of common stock were granted during the six-month periods
ended June 30, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
summarizes option activity for the six-month period ended June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> Average <BR> Exercise <BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> Average <BR> Remaining <BR> Option <BR> Term</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate <BR> Intrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Outstanding at January 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,728</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cancelled or forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding at June 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,648</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.42</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.44</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">115</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at June 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,796</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No shares of restricted
stock were awarded to employees, directors and consultants during the three and six-month periods ended June 30, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2018,
there was approximately $0.6 million of total unrecognized compensation expense related to non-vested stock options. This expense
is expected to be recognized over a weighted-average period of 0.7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Net Loss Per Share</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average
number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities
or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted
for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number
of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth the reconciliation of the numerator and denominator used in the computation of
basic and diluted net loss per common share for the three and six-months ended June 30, 2018 and 2017:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">(in thousands, except per share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Numerator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 0.25in">Net loss used for basic earnings per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(869</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,451</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,474</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,456</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 45pt">Less change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(190</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Net loss used for diluted earnings per share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(869</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,641</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,068</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Basic weighted-average outstanding common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of dilutive potential common shares resulting from options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Effect of dilutive potential common shares resulting from warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Weighted-average shares outstanding&mdash;diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,201</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Net loss per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.30</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.33</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below
presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average
number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from
the calculation due to their anti-dilutive effect for the three and six-months ended June 30, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -12pt; padding-left: 12pt">Weighted-average anti-dilutive common shares resulting from options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,658</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,437</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,327</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,324</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Weighted-average anti-dilutive common shares resulting from warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,482</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,117</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,730</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">517</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,140</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,554</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,057</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,841</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Comprehensive
Loss</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Comprehensive loss for the periods presented is comprised solely of our net loss. We had no items of other comprehensive
loss during the three and six-month periods ended June 30, 2018 and 2017. Comprehensive loss for the three and six-month periods
ended June 30, 2018 was $0.9 million and $3.5 million, respectively. Comprehensive loss for the three and six-month periods ended
June&nbsp;30, 2017 was $3.5 million and $6.5 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Braeburn License</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until its termination
in May 2018, we were party to <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a license agreement (as
amended, the &ldquo;License Agreement&rdquo;) pursuant to which we had granted Braeburn Pharmaceuticals, Inc. (&ldquo;Braeburn&rdquo;)
the exclusive commercialization rights to Probuphine in the United States and its territories and Canada. Under the License Agreement,
we received certain milestone payments, as well as royalties on net sales of Probuphine. Upon receipt of approval, our obligation
was fulfilled and we recognized as revenue the full amount of the milestone payment. In addition, we were entitled to receive
a low single digit royalty on sales by Braeburn of other competing continuous delivery treatments for opioid dependence as defined
in the License Agreement. The License Agreement provided for us to be reimbursed by Braeburn for any development services and
activities undertaken at Braeburn&rsquo;s request. Under ASC 606, there was no change in the amount or timing of revenue recognized
under this agreement. In February 2016, Braeburn sublicensed rights to develop and commercialize Probuphine in Canada to Knight
Therapeutics, Inc. (&ldquo;Knight&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 25, 2018, we entered into a Termination
and Transition Services Agreement (the &ldquo;Transition Agreement&rdquo;) with Braeburn pursuant to which we regained all rights
to the commercialization and clinical development of Probuphine in the United States and Canada. Braeburn paid us $1.0 million,
transferred inventory to us with a value of approximately $1.1 million and agreed to provide support services through December
28, 2018. In addition, the Transition Agreement provides for the immediate transfer to us of all regulatory documentation and
development data related to Probuphine. The estimated fair value of the inventory received was determined using available inputs
such as existing supply agreements, prior selling prices and remaining life to expiration. We recognized approximately $2.1 million
of license related revenue related to this transaction in the three month period ended June 30, 2018. The sublicense to Knight
was assigned to Titan as part of the Transition Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Molteni Purchase Agreement</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 21, 2018,
we entered into an Asset Purchase, Supply and Support Agreement (the &ldquo;Purchase Agreement&rdquo;) with Molteni pursuant to
which Molteni acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application
(&ldquo;MAA&rdquo;) under review by the European Medicines Agency (&ldquo;EMA&rdquo;), and will have the exclusive right to commercialize
the Probuphine product supplied by us in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle
East and North Africa (the &ldquo;Molteni Territory&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We received an initial
payment of &euro;2.0 million (approximately $2.4 million) for the purchased assets and will receive additional potential payments
totaling upon the achievement of certain regulatory and product label milestones. Additionally, we are entitled to receive earn-out
payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the
mid-twenties. In August 2018, we entered into an amendment to the Purchase Agreement described below in Note 10. &ldquo;Subsequent
Events.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We concluded that the performance
obligations identified in the Purchase Agreement included the transfer of the intellectual property and our efforts towards the
approval by the EMA and other regulatory bodies. The initial closing payment was allocated between the transfer of the intellectual
property and our efforts related to the EMA approval as set forth below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We used the expected
cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards the approval
by the EMA and other regulatory bodies. This includes employee related expenses as well as other manufacturing, regulatory and
clinical costs which will be incurred as part of our efforts. We believe that the services will be at a consistent rate and will
be substantially complete as of December 31, 2018. As such we will recognize the revenue ratably over the balance of year ending
December 31, 2018. If the facts and circumstances change, we will reassess these assumptions. The costs associated with these services
will be expensed over the same period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We used the residual
approach to value the transfer of the intellectual property at approximately $1.0 million as we had not established and had no
reliable way to establish a standalone selling price for the intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of the
outcome of the milestone and earn-out payments being unpredictable due to the involvement of third parties, we believe that using
the most likely amount method is appropriate. Any subsequent revenue related to milestone and earn-out payments will be recognized
at the time the milestones are achieved or when the related net sales have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Agreement provides
that we will supply Molteni with semi-finished product (i.e., the implant, the applicator and related technology) on an exclusive
basis at a fixed price through December 31, 2019, with subsequent price increases not to exceed annual cost increases to us for
the active pharmaceutical ingredient and under our current manufacturing agreement. Revenue will be recognized when the semi-finished
product has been transferred to Molteni.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Molteni will be prohibited
from marketing a Competitor Product (as defined in the Agreement) in the Territory for the five year period following approval
of the MAA. Thereafter, Molteni will be required to pay us a low single digit royalty on net sales of any Competitor Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
presents changes in contract assets and liabilities during the six months ended June 30, 2018:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; border-bottom: Black 1pt solid; text-align: left"><B>(in thousands)</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><B>Beginning Balance</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><B>Additions</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><B>Deductions</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><B>Ending<BR>
 Balance</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Six months ended June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left">Contract assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contract liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,509</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">939</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: justify">Warrant Liability</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until they expired by their terms on April 18, 2018<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
we had warrants outstanding to purchase an aggregate of 983,395 shares of common stock at an exercise price of $4.85 per share.
The warrants contained a provision where the warrant holder had the option to receive cash equal to the Black Scholes fair value
of the remaining unexercised portion of the warrant as cash settlement in the event that there was a fundamental transaction (contractually
defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, <I>Distinguishing
Liabilities from Equity</I> required that these warrants be classified as liabilities. The fair value of these warrants was determined
using the Lattice valuation model, and the changes in the fair value were recorded in the Condensed Statements of Operations and
Comprehensive Loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify">Debt Agreements</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July 2017, we entered
into a venture loan and security agreement (&ldquo;Original Loan Agreement&rdquo;) with Horizon Technology Finance Corporation
(&ldquo;Horizon&rdquo;), pursuant to which we received a loan in the amount of $7.0 million</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Original Loan
Agreement provided for repayment of the loan on an interest-only basis through December 31, 2018, followed by monthly payments
of principal and accrued interest for the balance of the 46-month term. The loan bears interest at a floating coupon rate of one-month
LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of the loan will be due on the scheduled maturity date for such
loan. The Original Loan Agreement also contained a prepayment penalty based on a percentage of the then outstanding principal balance,
equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months
following such period, and 2% thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our obligations under
the Original Loan Agreement were secured by a first priority security interest in all of our assets, with the exception of our
intellectual property. We agreed not to pledge or otherwise encumber our intellectual property assets, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Original Loan
Agreement included customary affirmative and restrictive covenants, excluding any covenants to attain or maintain certain financial
metrics, and also included customary events of default, including for payment failures, breaches of covenants, change of control
and material adverse changes. Upon the occurrence of an event of default and following any applicable cure periods, a default interest
rate of an additional 5% could be applied to the outstanding loan balance, and Horizon could declare all outstanding obligations
immediately due and payable and take such other actions as set forth in such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
the Original Loan Agreement, we issued Horizon seven-year warrants to purchase an aggregate of 280,612 shares of our common stock
(&ldquo;Horizon Warrants&rdquo;). The per share exercise price of the Horizon Warrants is the lower of (i) $1.96 or (ii) the price
per share of any securities that may be issued by the Company in an equity financing during the 18 months following the agreement
date. We agreed to file a registration statement covering the resale of the shares underlying the Horizon Warrants. In accordance
with ASC 480, <I>Distinguishing Liabilities from Equity</I>, as amended by ASU, No. 2017-11, which we early adopted during 2017,
the Horizon Warrants have been classified as equity and their fair value at the time of issuance was determined using a Lattice
valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The key assumptions
used to value the Horizon Warrants were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="5" STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Assumption</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Date of issuance</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2017</FONT></TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="width: 87%; text-align: justify">Expected price volatility</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">47</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Expected term (in years)</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">7.00</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Risk-free interest rate</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2.12</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Dividend yield</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.00</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Weighted-average fair value of warrants</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">1.02</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The anti-dilution
provisions contained in the outstanding Series A warrants were triggered by the Horizon Warrant issuance, resulting in a reduction
of the exercise price of such warrants from $4.89 to $4.85 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 2, 2018,
we entered into an amendment to the Original Loan Agreement (the &ldquo;Amended Loan Agreement&rdquo;) pursuant to which we prepaid
$3.0 million of the outstanding $7.0 million principal amount and provided Horizon with a lien on our intellectual property. The
other terms of the Original Loan Agreement remained unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 21, 2018,
we entered into an Amended and Restated Venture Loan and Security Agreement (the &ldquo;Restated Loan Agreement&rdquo;) with Horizon
and Molteni pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of
the loan to Molteni and Molteni was appointed collateral agent and assumed majority and administrative control of the debt. Under
the Restated Loan Agreement, the interest only payment and forbearance periods were extended to December 31, 2019. In addition,
Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share
and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of
at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizon&rsquo;s
loan amount. The lien on our intellectual property remains in place at this time. As the present value of the cash flows under
the terms of the Restated Loan Agreement is less than 10% different from the remaining cash flows under the terms of the Amended
Loan Agreement prior to being amended and restated, the Restated Loan Agreement was accounted for as a debt modification. Accordingly,
expenses incurred as a result of the modification were expensed as incurred and the previously deferred fees and costs related
to the debt will continue to be amortized over the remaining term along with the related warrants issued as part of the agreement
described in Note 9 &ldquo;Rights Agreement.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
the Restated Loan Agreement, we issued Horizon seven-year warrants to purchase 40,000 shares of our common stock at an exercise
price of $1.20 per share. The Horizon Warrants have been classified as equity and their fair value at the time of issuance was
determined using a Black Scholes valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The key assumptions
used to value the new Horizon warrants were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="5" STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Assumption</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Date of issuance</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21, 2018</FONT></TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="width: 87%; text-align: justify">Expected price volatility</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">86</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Expected term (in years)</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">7.00</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Risk-free interest rate</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2.82</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Dividend yield</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.00</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Weighted-average fair value of warrants</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">0.81</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Rights Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In consideration
of Molteni&rsquo;s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into an agreement
(as amended in May 2018, the &ldquo;Rights Agreement&rdquo;) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year
warrants to purchase 540,000 shares of our common stock at an exercise price of $1.20 per share (the &ldquo;Molteni Warrants&rdquo;),
(ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon
conversion of its loan and exercise of the Molteni Warrants, (iii) appoint one member of our board of directors under certain
circumstances and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information
rights. The board designation, observer and information rights will terminate at such time as Molteni ceases to beneficially own
at least one percent of our outstanding capital stock (inclusive of the shares issuable upon conversion of debt under the Restated
Loan Agreement and exercise of the Molteni Warrants). The Molteni Warrants have been classified as equity and their fair value
at the time of issuance was determined using a Black Scholes valuation model. The amount was allocated equally between the Restated
Loan Agreement and the Purchase Agreement and was recorded in the Condensed Balance Sheet as a discount to the debt obligation
and a contract asset, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The key assumptions
used to value the Molteni Warrants were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="5" STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Assumption</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Date of issuance</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21, 2018</FONT></TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="width: 87%; text-align: justify">Expected price volatility</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">86</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Expected term (in years)</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">7.00</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Risk-free interest rate</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2.82</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Dividend yield</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.00</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: justify">Weighted-average fair value of warrants</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">0.81</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B>Subsequent Events</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 3, 2018,
we entered into an amendment (the &ldquo;Amendment&rdquo;) to the Purchase Agreement with Molteni. Under the Amendment, Molteni
made an immediate payment to us of &euro;950,000 (approximately $1,109,000) and has committed to make a convertible loan to us
of &euro;550,000 (approximately $642,000) provided we have submitted our response to the 120-day letter from the EMA on or prior
to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of &euro;2.0 million
(approximately $2,335,000) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019,
at the earliest. The loan (the &ldquo;Convertible Loan&rdquo;), if made, will convert automatically into shares of our common
stock upon the issuance by the EMA of marketing approval for Probuphine at a conversion price per share equal to the lower of
(i) the closing price on the loan funding date and (ii) the closing price on the conversion date. In the event the EMA has not
granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest
at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum. The Convertible Loan will contain other
covenants and events of default substantially consistent with the Restated Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 7, 2018, our stockholders approved
an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized
for awards thereunder from 2,500,000 to 3,500,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B><A NAME="a_007"></A>Item&nbsp;2. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>The <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
discussion contains &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934(the &ldquo;Exchange Act&rdquo;). Such statements include, but are not limited
to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements
involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from management&rsquo;s current expectations include those risks
and uncertainties relating to our transition to a commercial enterprise, the regulatory approval process, the development, testing,
production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any
such statement is based, except as required by law.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>Probuphine&reg; and ProNeura&trade;
are trademarks of Titan Pharmaceuticals, Inc. This Form 10-Q also includes trade names and trademarks of companies other than Titan
Pharmaceuticals, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>References herein to &ldquo;we,&rdquo;
 &ldquo;us,&rdquo; &ldquo;Titan,&rdquo; and &ldquo;our company&rdquo; refer to Titan Pharmaceuticals, Inc. and its subsidiaries
unless the context otherwise requires.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">We are
a pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the
treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We are
currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&reg;, a product approved in the
U.S. for management of opiate dependence. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">Probuphine,
our first product candidate based on our proprietary ProNeura&trade; platform, is a subdermal implant that provides continuous
delivery of buprenorphine for six months. Probuphine was approved by the FDA in May 2016 for the maintenance treatment of opioid
dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. We licensed development
and commercialization rights of Probuphine for the U.S. and Canadian markets to Braeburn Braeburn in December 2012. Braeburn subsequently
sublicensed the Canadian rights to Knight in February 2016. In April 2018, Knight announced that it had received regulatory approval
from Health Canada to commercialize the product for the maintenance treatment of stable patients with opioid use disorder and they
have indicated that they plan to launch the product in the fourth quarter of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">In early
2018, Braeburn substantially reduced its field sales force and medical liaison personnel following its receipt of a complete response
letter from the FDA for its weekly and monthly depot injection products. Anticipating a negative impact on Probuphine sales in
the U.S., we began discussing with Braeburn terms for the return of the Probuphine U.S. commercialization rights to Titan. On May
25, 2018, we completed that agreement under which we received a $1.0 million payment and Braeburn&rsquo;s undertaking to provide
transition services through 2018 to assist with commercialization activities and help maintain continuity in product supply for
patients and their physicians.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">Since
reacquiring the rights, we have begun implementation of a strategy to relaunch Probuphine to targeted market segments that we believe
are best suited to benefit from this product. We are currently considering all the financing alternatives available to us to obtain
sufficient capital to build our infrastructure, including a small sales and marketing team, that will enable us to successfully
transition to a commercial enterprise and position Probuphine as a specialty product. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">We believe
that our ProNeura long term drug delivery platform has the potential to be used in the treatment of other chronic conditions where
maintaining stable, around the clock blood levels of a medication may benefit the patient and improve medical outcomes. Our goal
is to expand our product pipeline using the ProNeura implant platform, and, depending on available funds, we have been opportunistically
evaluating other drugs and disease settings for use with the ProNeura platform in potential treatment applications such as Parkinson&rsquo;s
disease, where conventional treatment is limited by variability in blood drug levels and poor patient compliance. The pursuit
of any of these programs in the short-term will depend on our ability to obtain the necessary funding through either government
grants or third party collaborations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We operate in only one business segment,
the development of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">See Note 1 to the accompanying unaudited
condensed financial statements included in Part 1, Item&nbsp;1 of this Quarterly Report on Form 10-Q for information on recent
accounting pronouncements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Results of Operations for the Three and Six-Months Ended
June 30, 2018 and June&nbsp;30, 2017</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">License revenues
were approximately $2.6 million and $3.7 million for the three and six-month periods ended June 30, 2018, respectively.&nbsp;
Revenues for the three-month period ended June 30, 2018 period reflect approximately $0.5 million related to the amortization
of deferred revenue related to the sale to Molteni of the European intellectual property rights to our Probuphine product, approximately
$2.1 million related to the return of the Braeburn license in May 2018 and $7,000 related to the recognition of royalties earned
on net sales of our Probuphine product by Braeburn.&nbsp; Revenues for the six-month period ended June 30, 2018 period reflect
approximately $1.5 million related to the up-front payment and amortization of deferred revenue related to the sale to Molteni
of the European intellectual property rights to our Probuphine product, approximately $2.1 million related to the return of the
Braeburn license and $32,000 related to the recognition of royalties earned on net sales of our Probuphine product by Braeburn.&nbsp;
Revenue for the 2017 period reflects the recognition of royalties earned on net sales of our Probuphine product by Braeburn.&nbsp;License
revenues of approximately $77,000 and $117,000 for the three and six-month periods ended June 30, 2017 primarily reflect the recognition
of the royalties earned on net sales of our Probuphine product by Braeburn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Product revenues were approximately $75,000
for the three and six-month periods ended June 30, 2018. Product revenues reflect net revenues generated from sales of our Probuphine
product by us after the return of the Braeburn License on May 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Research and development expenses for the three-month
period ended June 30, 2018 were approximately $1.9 million, compared to approximately $2.5 million for the comparable period in
2017, a decrease of approximately $0.6 million, or 24%. The decrease in research and development costs was primarily associated
with decreases in external research and development expenses related to the support of the ropinirole implant program and some
expenses on other ProNeura product development programs, employee related expenses and other research and development expenses.
Research and development expenses for the six-month period ended June 30, 2018 were approximately $3.7 million, compared to approximately
$4.6 million for the comparable period in 2017, a decrease of approximately $0.9 million, or 20%. The decrease in research and
development costs was primarily associated with decreases in external research and development expenses related to the support
of the ropinirole implant program and limited expenses on other ProNeura product development programs, employee related expenses
and other research and development expenses. During the three and six-month periods ended June 30, 2018, external research and
development expenses relating to our product development programs were approximately $1.1 million and $1.7 million, respectively,
compared to approximately $1.5 million and $2.6 million, respectively, for the comparable periods in 2017. Other research and development
expenses include internal operating costs such as clinical research and development personnel-related expenses, clinical trials
related travel expenses, and allocation of facility and corporate costs. As a result of the risks and uncertainties inherently
associated with pharmaceutical research and development activities described elsewhere in this report, we are unable to estimate
the specific timing and future costs of our research and development programs or the timing of material cash inflows, if any, from
our product candidates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">General and administrative
expenses for the three-month periods ended June 30, 2018 and 2017 were approximately $1.4 million, compared to approximately $1.2
million for the comparable period in 2017, an increase of approximately $0.2 million, or 17%. The increase in general and administrative
expenses during the three-month period ended June 30, 2018 was primarily related to increases in employee related costs of approximately
$0.1 million and legal and professional fees of approximately $0.1 million. General and administrative expenses for the six-month
period ended June 30, 2018 were approximately $3.0 million, compared to approximately $2.5 million for the comparable period in
2017, an increase of approximately $0.5 million, or 20%. The increase in general and administrative expenses during the six-month
period ended June 30, 2018 was primarily related to increases in legal and professional fees of approximately $0.5 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Net other expense for the three and six-month
periods ended June 30, 2018 was approximately $0.2 million and $0.4 million, respectively. Net other expense consisted primarily
of interest expense. Net other income for the three and six-month periods ended June 30, 2017 was approximately $0.2 million and
$0.6 million, respectively. Net other income consisted primarily of non-cash gains on changes in the fair value of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Our net loss for
the three-month period ended June 30, 2018 was approximately $0.9 million, or approximately $0.04 per share, compared to our net
loss of approximately $3.5 million, or approximately $0.16 per share, for the comparable period in 2017. Our net loss for the
six-month period ended June 30, 2018 was approximately $3.5 million, or approximately $0.16 per share, compared to our net loss
of approximately $6.5 million, or approximately $0.30 per share, for the comparable period in 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity and Capital Resources </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We have funded our
operations since inception primarily through the sale of debt and equity securities, as well as with proceeds from warrant and
option exercises, technology licensing, collaborative agreements and government-sponsored research grants. At June 30, 2018, we
had working capital of approximately $1.8 million compared to working capital of approximately $3.8 million at December&nbsp;31,
2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Our operating activities used approximately
$2.9 million during the six months ended June 30, 2018. This consisted primarily of the net loss for the period of approximately
$3.5 million and approximately $0.6 million related to net changes in other operating assets and liabilities. This was offset,
in part, by non-cash charges of approximately $0.8 million related to stock-based compensation, approximately $0.2 million related
to depreciation and amortization and $0.2 million related to non-cash interest expense. Uses of cash in operating activities were
primarily to fund product development programs and administrative expenses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Our investing activities used approximately
$53,000 during the six months ended June 30, 2018, which was primarily related to purchases of equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Our financing activities used approximately
$3.0 million during the six months ended June 30, 2018, which was primarily related to the repayment of debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">In May 2018, we entered
into the Transition Agreement pursuant to which we regained all Probuphine commercialization and clinical development rights we
had granted to Braeburn. Braeburn paid us $1.0 million and transferred inventory to us with a value of approximately $1.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August 2018, we amended
the Purchase Agreement to eliminate an aggregate of &euro;2,000,000 in exchange for which Molteni made an immediate payment to
us of &euro;950,000 (approximately $1,109,000) and committed to make the Convertible Loan to us of &euro;550,000 (approximately
$642,000) provided we have submitted our response to the 120-day letter from the European Medicines Agency (&ldquo;EMA&rdquo;)
on or prior to September 14, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At June 30, 2018, we had
restricted cash of approximately $0.4 million. This represents a cash security deposit for an outstanding letter of credit established
to fund upcoming EMA filing fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At June 30, 2018,
we had cash and cash equivalents of approximately $1.6 million, which we believe, along with the payment from Molteni in August,
are sufficient to fund our planned operations into mid-September 2018. If extended, the convertible loan from Molteni should provide
funds through the end of the third quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We will
require additional funds to finance our operations, including the commercialization of Probuphine in the U.S., completion of the
Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage
clinical studies. While we are currently considering the various financing alternatives available to us, our efforts to address
our liquidity requirements may not be successful.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_008"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our market risk disclosures
set forth in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017 have not changed materially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_009"></A>Item&nbsp;4. Controls and Procedures
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disclosure Controls and Procedures
 &nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our President and
Chief Executive Officer, being our principal executive and financial officer, has evaluated the effectiveness of our disclosure
controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of June 30, 2018, the end of the period
covered by this report, and has concluded that our disclosure controls and procedures were effective to ensure that the information
required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated
to our principal executive and principal financial officer as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in Internal Control Over
Financial Reporting </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were no changes
in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the
six months ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, Titan&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B><A NAME="a_010"></A>PART&nbsp;II </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_011"></A>Item&nbsp;1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">In addition to the
other information set forth in this report, you should carefully consider the factors discussed in Part I, &ldquo;Item 1A. Risk
Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business,
financial condition or future results (the &ldquo;10-K Risk Factors&rdquo;). The risks described in our Annual Report on Form
10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem
to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Except for the
risks set forth below, there are no material changes to the 10-K Risk Factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>We may not be successful
in transitioning from a research and development company to a commercial enterprise.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Since our inception, we
have been engaged in product research and development and have never directly commercialized any product. Since we regained the
U.S. commercial rights to Probuphine in May 2018, we have been largely dependent on Braeburn&rsquo;s provision of support services,
as well as those of advisors and consultants, as we transition to a commercial enterprise. We do not currently employ a sales force
or have any internal sales and marketing capabilities. Without hiring or contracting for an experienced and active sales force,
we will not be in a position to relaunch Probuphine and sales, if any, will continue to be limited. We will face intense competition
for sales and marketing personnel with the necessary experience in addiction, reimbursement, specialty pharmacies and our targeted
markets and there can be no assurance that we will be successful in our efforts to transition to a commercial stage company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>If Probuphine does
not achieve broad market acceptance by physicians, patients or others in the medical community or coverage by third-party payors,
our business will  suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Although Braeburn commenced
a full commercial launch of Probuphine in the first quarter of 2017, minimal progress was made and for the year ended December
31, 2017 we derived royalty revenues of only $215,000 from sales of Probuphine. The commercial success of Probuphine and our product
relaunch will depend upon its acceptance by physicians, patients, healthcare payors and the medical community. Coverage and reimbursement
of Probuphine by third-party payors is also necessary for commercial success. Since its initial commercial launch by Braeburn,
Probuphine&rsquo;s adoption by physicians has been hindered both by the Risk Evaluation and Mitigation Strategy, or REMS, requirements
mandated by the product label, which are more expansive than those required for other buprenorphine products, as well as the current
payment and reimbursement model, which differs from some of the existing treatment options for opioid addiction. For example, the
current standard of care for outpatient treatment of opioid addiction is oral daily buprenorphine, which typically requires frequent
patient visits and a per visit fee, which the patient may pay directly to the healthcare provider in cash. Reimbursement for an
implantable drug product that requires administration by a healthcare provider requires drug codes as well as a separate procedure
code for the insertion and removal procedures and less frequent office visits. Physicians may prefer more frequent patient visits
and the accompanying reimbursement and payment model, which oftentimes includes cash payments. The commercial success of Probuphine
depends on several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to train and certify healthcare providers to
insert and remove implants of Probuphine in accordance with the REMS;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the perceived and actual advantages of our Probuphine over
current and emerging treatment options;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the willingness of healthcare providers to prescribe, and
the target patient population to try novel products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the competitiveness of our pricing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the willingness of healthcare providers to accept alternative
reimbursement models, such as the &ldquo;buy-and-bill&rdquo; system, where prescribers are required to buy Probuphine inventory
themselves and then bill patients or payors following the procedure, or the specialty pharmacy distribution model, where a specialty
pharmacy carries inventory and ships it to healthcare providers as requested and prescribed, and directly handles the subsequent
billing and payment process with payors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to provide adequate support to physicians and
other healthcare providers to lessen the burden of current reimbursement models;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to establish and maintain adequate levels
of coverage for Probuphine from commercial health plans and government health programs, which we refer to collectively as third-party
payors, particularly in light of the availability of other branded and generic competitive products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the willingness for patients to pay out-of-pocket in the
absence of third-party coverage and the success of patient assistance programs; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to promote products through marketing and sales
activities and any other arrangements; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to successfully educate prescribers and patients
on the applicable product&rsquo;s efficacy and safety;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In light of the difficulties
encountered to date, we cannot predict either the timing or the degree to which Probuphine will be accepted by the medical community.
If we are unable to generate ample royalty revenue from Probuphine, we will be unable to fund our research and development programs
without additional financing, which may not be available on acceptable terms, and our business will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>We must comply with
post-approval clinical trial requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The New Drug Application,
or NDA, for Probuphine mandated the post-approval completion of several Phase IV clinical trials. Prior to the reversion of the
commercialization rights to us, Braeburn had been in negotiations with the FDA with respect to the various trial protocols and
had not commenced the required clinical trials. Upon transfer of the NDA back to us, we began communicating with the FDA regarding
the Phase IV requirements. There can be no assurance that the FDA will provide us with the time we need to initiate and complete
the necessary clinical trials, or that we will have the necessary funds to do so, in which event we may be subject to possible
sanctions, including monetary penalties or suspension of Probuphine commercial activities. Furthermore, unexpected negative findings
from a Phase IV trial could negatively impact the product label and/or acceptance by patients, healthcare providers and insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>The Probuphine REMS
program has negatively impacted initial uptake and may continue to do so, which could materially adversely
impact our business prospects. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">There is currently a REMS
program in place for Probuphine as required by the FDA. The REMS program was implemented by Braeburn in May 2016 and is designed
to mitigate the risk of complications of migration, protrusion, expulsion and nerve damage associated with the insertion and removal
of Probuphine and the risks of accidental overdose, misuse and abuse. The REMS program requires training and certification of healthcare
providers who prescribe and implant Probuphine and provide patient counseling. Probuphine distribution is restricted to healthcare
providers who have completed training and received certification under the REMS program. We believe the REMS program has been an
obstacle to adoption of Probuphine to date by the medical community. Healthcare providers may be unwilling to undergo training
and certification in order to be able to prescribe or implant Probuphine due to time constraints or concerns with the product.
If we are unable to adequately address this issue, our ability (or the ability of potential future commercial partners) to generate
revenue from sales of Probuphine could be materially compromised, which would have a material adverse effect on our business, results
of operations, financial condition and prospects. In addition, if a patient suffers an injury during the insertion and removal
of Probuphine, it may give rise to liability against us by patients, clinicians or others or result in non-compliance with the
REMS program. Non-compliance with the REMS program may bring serious consequences to us, including warning letters from the FDA,
fines, criminal charges and other prohibitions and exclusions as well as reputational damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>The FDA-approved
product labeling for Probuphine allows prescribing for a limited patient population</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Probuphine was approved
with an indicated use limited to the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg
or less a day of oral buprenorphine. The approved labeling also contains other limitations on use and warnings and contraindications
for risks. If potential purchasers or those influencing purchasing decisions, such as physicians and pharmacists or third party
payers, react negatively to Probuphine because of their perception of the limitations or safety risks in the approved product labeling,
it may result in lower product acceptance and lower product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition, our promotion
of Probuphine must reflect only the specific approved indication as well as other limitations on use, and disclose the safety risks
associated with the use of Probuphine as set out in the approved product labeling. We must submit all promotional materials to
the FDA at the time of their first use. If the FDA raises concerns regarding our promotional materials or messages, we may be required
to modify or discontinue using them and provide corrective information to healthcare practitioners, and we may face other adverse
enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>Probuphine is a
controlled substance subject to DEA regulations and failure to comply with these regulations, or the cost of compliance with these
regulations, may adversely affect our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Probuphine contains buprenorphine,
a regulated Schedule III &ldquo;controlled substance&rdquo; under the CSA, which establishes, among other things, certain registration,
production quotas, security, recordkeeping, reporting, import, export and other requirements administered by the DEA. The DEA regulates
controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal
use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V,
with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk
of abuse among such substances. Our failure to comply with DEA requirements could result in the loss of our ability to supply Probuphine,
significant restrictions on Probuphine, civil penalties or criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The DEA, and some states,
also conduct periodic inspections of registered establishments that handle controlled substances. Facilities that conduct research,
manufacture, store, distribute, import or export controlled substances must be registered to perform these activities and have
the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure to maintain compliance,
particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse
effect on our business, results of operations, financial condition and prospects. The DEA may seek civil penalties, refuse to renew
necessary registrations or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead
to criminal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Individual states also
have controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are separate
jurisdictions, they may separately schedule drugs, as well. While some states automatically schedule a drug when the DEA does so,
in other states there has to be rulemaking or a legislative action. State scheduling may delay commercial sale of any controlled
substance drug product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect
on the commercial attractiveness of such product. We or our partners must also obtain separate state registrations in order to
be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable
regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise
arising under federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>We may be subject
to enforcement action if we engage in improper marketing or promotion of Probuphine. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our promotional materials
and training methods must comply with the Federal Food, Drug and Cosmetic Act, or the FDCA, and FDA regulations and other applicable
laws and regulations, including the prohibition of the promotion of unapproved, or &ldquo;off-label&rdquo;, use. Companies may
not promote drugs for off-label use, which include uses that are not described in the product&rsquo;s labeling and that differ
from those approved by the FDA. Physicians may prescribe drug products for off-label uses and such off-label uses are common across
some medical specialties. Although the FDA and other regulatory agencies do not regulate a physician&rsquo;s choice of treatments,
the FDCA and FDA regulations restrict communications on the subject of off-label uses of drug products by pharmaceutical companies.
The Office of Inspector General of the Department of Health and Human Services, or OIG, the FDA, and the Department of Justice,
or DOJ, all actively enforce laws and regulations prohibiting promotion of off-label use and the promotion of products for which
marketing approval has not been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Other federal, state and
foreign regulatory agencies, including the U.S. Federal Trade Commission, have issued guidelines and regulations that govern how
we promote our products, including how we use endorsements and testimonials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If we are found to be
out of compliance with the requirements and restrictions described above, and we are investigated for or found to have improperly
promoted off-label use, we may be subject to significant liability, including civil and administrative remedies as well as criminal
sanctions, and the off-label use of our products may increase the risk of product liability claims. In addition, management&rsquo;s
attention could be diverted from our business operations and our reputation could be damaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition to FDA and
related regulatory requirements, we are subject to health care &quot;fraud and abuse&quot; laws, such as the federal False Claims
Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal
and state anti-kickback laws prohibit, among other things, payments or other remuneration to induce or reward someone to purchase,
prescribe, endorse, or recommend a product that is reimbursed under federal or state healthcare programs. If we provide payments
or other remuneration to a healthcare professional to induce the prescribing of our products, we could face liability under state
and federal anti-kickback laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Federal false claims laws prohibit any
person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly
making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under
these laws for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers
with the expectation that the customers would bill federal programs for the product or submitting inflated best price information
to the Medicaid Rebate program. The majority of states also have statutes or regulations similar to the federal anti-kickback law
and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states,
apply regardless of the payer. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of
a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment. Even if it is determined
that we have not violated these laws, government investigations into these issues typically require the expenditure of significant
resources and generate negative publicity, which would harm our business, prospects, operating results, and financial condition.
Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities
could be challenged under one or more of such laws.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>We obtain some of
our raw materials, components and finished goods from a single source or a limited group of suppliers. The partial or complete
loss of one of these suppliers could cause significant production delays, an inability to meet customer demand and a substantial
loss in revenue</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We use a number of single-source
suppliers for certain of our raw materials, components and finished goods, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the supplier of the active ingredient for Probuphine;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the supplier of the finished Probuphine implants; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the manufacturer of the Probuphine applicator.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are in the process
of qualifying a new EVA manufacturer. In addition, the vendor that used to sterilize the Probuphine implants indicated that it
will no longer sterilize Schedule III controlled substances, including Probuphine. While we are in the process of qualifying another
sterilization vendor and will also be transitioning to a new sterilization process, we cannot guarantee that such qualification
or transition will be successful. Our use of these and other single-source suppliers of raw materials, components and finished
goods exposes us to several risks, including disruptions in supply, price increases, late deliveries and an inability to meet customer
demand. This could lead to customer dissatisfaction, damage to our reputation or customers switching to competitive products. Any
interruption in supply could be particularly damaging to our ability to develop and commercialize Probuphine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Finding alternative sources
for these raw materials, components and finished goods would be difficult and in many cases entail a significant amount of time,
disruption and cost. Any disruption in supply from any single-source supplier or manufacturing location could lead to supply delays
or interruptions which would damage our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>We rely on third
parties to provide services in connection with the manufacture and distribution of Probuphine, and these third parties may not
perform satisfactorily. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We do not own or operate,
and currently do not plan to own or operate, facilities for production and packaging of Probuphine or our other product candidates.
We are dependent on third parties for the timely supply of specified raw materials, equipment, contract manufacturing, formulation
or packaging services, product distribution services, customer service activities and product returns processing. For example,
we contract with DPT Laboratories, Ltd., or DPT, for the manufacture of Probuphine, which in turn depends on delivery of the active
ingredient buprenorphine hydrochloride and milled EVA, which we currently source from Teva and Southwest Research Institute, respectively.
We are similarly dependent on third parties for the manufacture and sterilization of Probuphine applicators and the assembly and
distribution of packaged kits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our reliance on third
parties for the activities described above will reduce our control over these activities but will not relieve us of our responsibility
to ensure compliance with all required regulations. If these third parties do not successfully carry out their contractual duties,
meet expected deadlines or manufacture our product in accordance with regulatory requirements, or proprietary specifications, or
adhere to product processing best practices, or if there are disagreements between us and these third parties, our business could
be materially adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face potential liability related to the privacy of
health information we obtain from clinical trials sponsored by us or our collaborators, from research institutions and our collaborators,
and directly from individuals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Numerous federal and state laws, including state security breach
notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection,
use, and disclosure of personal information. In addition, most health care providers, including research institutions from which
we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under the
Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act. Although we are not directly subject to HIPAA, we could potentially be subject to criminal penalties if
we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered
entity in a manner that is not authorized or permitted by HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="b_001"></A><B>Item 5. Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On August 9, 2018, the compensation committee
approved amendments to the existing employment agreements with each of Sunil Bhonsle and Marc Rubin to extend the expiration date
from September 29, 2018 to March 29, 2019 in order to provide continuity of service while the compensation committee undertakes
the process of evaluating new agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_012"></A>Item&nbsp;6. Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.1(1)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Certificate of Incorporation of the Registrant, as amended <SUP>5</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.1(2)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment to the Restated Certificate of Incorporation dated September 24, 2015 <SUP>14</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">By-laws of the Registrant <SUP>1</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312512157344/d333750dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312512157344/d333750dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Series A Warrant <SUP>7</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414058798/v389400_ex4-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414058798/v389400_ex4-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Class A Warrant <SUP>13</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414058798/v389400_ex4-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414058798/v389400_ex4-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Underwriter Warrant <SUP>13</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">4.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Lender Warrant <SUP>18</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">4.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Rights Agreement Warrant <SUP>20</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000091205702012701/a2074337zex-10_35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000091205702012701/a2074337zex-10_35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2001 Non-Qualified Employee Stock Option Plan <SUP>2</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000104746903011223/a2106594zex-10_37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000104746903011223/a2106594zex-10_37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2002 Stock Option Plan <SUP>3</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000110465905011174/a05-4705_1ex10d18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000110465905011174/a05-4705_1ex10d18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Lease for the Registrant&rsquo;s facilities, amended as of October 1, 2004 <SUP>4</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendments to lease for Registrant&rsquo;s facilities dated May 21, 2007 and March 12, 2009 <SUP>5</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510189763/dex1016.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312510189763/dex1016.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment to lease for Registrant&rsquo;s facilities dated June 15, 2010 <SUP>6</SUP></FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513084113/d493585dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.6*</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 64.45pt; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513084113/d493585dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl, dated &nbsp;December 14, 2012 <SUP>8</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513239704/d545611dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt"><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513239704/d545611dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment dated May 28, 2013 to License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl <SUP>9</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513283794/d564196dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.8</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt"><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513283794/d564196dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Second Amendment dated July 2, 2013 to License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl <SUP>10</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420413061109/v360394_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt"><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420413061109/v360394_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Third &nbsp;Amendment &nbsp;dated &nbsp;November &nbsp;12, &nbsp;2013 &nbsp;to &nbsp;License &nbsp;Agreement &nbsp;by &nbsp;and &nbsp;between &nbsp;Titan &nbsp;Pharmaceuticals, &nbsp;Inc. &nbsp;and &nbsp;Braeburn Pharmaceuticals Sprl <SUP>15</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 67.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414019329/v371702_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.10</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420414019329/v371702_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2014 Incentive Plan <SUP>12</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.11</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Titan
    Pharmaceuticals, Inc. Second Amended and Restated 2015 Omnibus Equity Incentive Plan <SUP></SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416122518/v448085_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.12</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416122518/v448085_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Controlled Equity OfferingSM Sales Agreement, dated September 1, 2016, between the Company and Cantor Fitzgerald &amp; Co. <SUP>16</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416126144/v449705_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.13</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416126144/v449705_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Employment Agreement between the Company and Sunil Bhonsle dated September 29, 2016 <SUP>17</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416126144/v449705_ex10-35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.14</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420416126144/v449705_ex10-35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Employment Agreement between the Company and Marc Rubin dated September 29, 2016 <SUP>17</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.15</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Venture Loan and Security Agreement, dated July 27, 2017, by and between Titan Pharmaceuticals, Inc. and Horizon Technology Finance Corporation <SUP>18</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418006087/tv484840_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.16</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418006087/tv484840_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment of Venture Loan and Security Agreement, dated February 2, 2018, by and between Titan Pharmaceuticals, Inc. and Horizon Technology Finance Corporation <SUP>19</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.17</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Venture Loan and Security Agreement, dated March 21, 2018, by and between Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni &amp; C. Dei Frattelli Alitti Societ&agrave; Di Esercizio S.P.A. <SUP>20</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.18*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Asset Purchase, Supply and Support Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni &amp; C. Dei Frattelli Alitti Societ&agrave; Di Esercizio S.P.A.<SUP>20</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.19</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Rights Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni &amp; C. Dei Frattelli Alitti Societ&agrave; Di Esercizio S.P.A. <SUP>20</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.20</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Termination and Transition Services Agreement dated May 25, 2018 by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals, Inc. <SUP>2</SUP></FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418041882/tv500139_ex10-1.htm" STYLE="-sec-extract: exhibit">10.21**</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000114420418041882/tv500139_ex10-1.htm" STYLE="-sec-extract: exhibit">Amendment
    to Asset Purchase, Supply and Support Agreement dated August 3, 2018 <SUP>22</SUP></A></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.22 **</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Distribution and Sublicense Agreement dated February 1, 2016 as amended by agreement dated August 2, 2018 between Titan Pharmaceuticals, Inc. and Knight Therapeutics Inc.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.23</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment to lease for Registrant&rsquo;s facilities dated March 21, 2016</FONT></A></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex10-24.htm" STYLE="-sec-extract: exhibit">10.24</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex10-24.htm" STYLE="-sec-extract: exhibit">Amendment to Employment Agreement with Sunil Bhonsle dated August 9, 2018</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex10-25.htm" STYLE="-sec-extract: exhibit">10.25</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex10-25.htm" STYLE="-sec-extract: exhibit">Amendment to Employment Agreement with Marc Rubin dated August 9, 2018</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513111045/d444155dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">14.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/910267/000119312513111045/d444155dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Code of Business Conduct and Ethics <SUP>13</SUP></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">31.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certification of the Principal Executive and Financial Officer pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv499850_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">32.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv499850_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certification of the Principal Executive and Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extensionalculation Linkbase Document </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy ExtensionPresentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(1)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-3 (File No. 333-21126).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(2)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2001.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(3)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2002.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(4)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2005.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(5)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form 10.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(6)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Quarterly Report on Form 10-Q for the period ended June 30, 2010.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(7)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K filed on April 10, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(8)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K/A filed on February 28, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(9)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated May 29, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(10)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated July 5, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(11)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated November 13, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(12)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(13)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1/A dated September 30, 2014.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(14)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated September 28, 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(15)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated August 3, 2016.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(16)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated September 1, 2016.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(17)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated October 3, 2016.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(18)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated July 27, 2017.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(19)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated February 7, 2018.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(20)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated March 26, 2018.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><SUP>(21)</SUP></TD><TD>Incorporated by reference from the Registrant&rsquo;s Current Report on Form 8-K dated May 30, 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><SUP>(22)</SUP></TD><TD STYLE="text-align: justify">Incorporated by reference from the Registrant&rsquo;s Current
Report on Form 8-K dated August 3, 2018.</TD>
</TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">*</TD><TD STYLE="text-align: justify">Confidential treatment has been granted with respect to
portions of this exhibit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">**</TD><TD STYLE="text-align: justify">Confidential treatment has been requested with respect
to portions of this exhibit.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>TITAN PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: August 14, 2018</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/&nbsp;<FONT STYLE="font-variant: small-caps">Sunil Bhonsle</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Sunil Bhonsle</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>President&nbsp;and Chief Executive Officer (Principal&nbsp;Executive&nbsp;and&nbsp;Principal&nbsp;Financial&nbsp;Officer)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>tv499850_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TITAN PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>SECOND AMENDED AND RESTATED</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2015 OMNIBUS EQUITY INCENTIVE PLAN</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TITAN PHARMACEUTICALS, INC.<BR>
SECOND AMENDED AND RESTATED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2015 OMNIBUS EQUITY INCENTIVE PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
I</FONT><BR>
PURPOSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purpose of this Titan Pharmaceuticals, Inc.
2015 Omnibus Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) is to benefit Titan Pharmaceuticals, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;) and its stockholders, by assisting the Company to attract, retain and provide incentives to
key employees and directors of, and consultants to, the Company and its Affiliates, and to align the interests of such service
providers with those of the Company&rsquo;s stockholders. Accordingly, the Plan provides for the granting of Non-qualified Stock
Options, Incentive Stock Options, Restricted Stock Awards, Restricted Stock Unit Awards, Stock Appreciation Rights, Performance
Stock Awards, Performance Unit Awards, Unrestricted Stock Awards, Distribution Equivalent Rights or any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
II</FONT><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following definitions shall be applicable
throughout the Plan unless the context otherwise requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
shall mean any corporation which, with respect to the Company, is a &ldquo;subsidiary corporation&rdquo; within the meaning of
Section 424(f) of the Code or other entity in which the Company has a controlling interest in such entity or another entity which
is part of a chain of entities in which the Company or each entity has a controlling interest in another entity in the unbroken
chain of entities ending with the applicable entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Award</U>&rdquo;
shall mean, individually or collectively, any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Award,
Performance Unit Award, Stock Appreciation Right, Distribution Equivalent Right or Unrestricted Stock Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Award
Agreement</U>&rdquo; shall mean a written agreement between the Company and the Holder with respect to an Award, setting forth
the terms and conditions of the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Board</U>&rdquo;
shall mean the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Base
Value</U>&rdquo; shall have the meaning given to such term in Section 14.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Cause</U>&rdquo;
shall mean (i)&nbsp;if the Holder is a party to an employment or service agreement with the Company or an Affiliate which agreement
defines &ldquo;Cause&rdquo; (or a similar term), &ldquo;<U>Cause</U>&rdquo; shall have the same meaning as provided for in such
agreement, or (ii) for a Holder who is not a party to such an agreement, &ldquo;<U>Cause</U>&rdquo; shall mean termination by the
Company or an Affiliate of the employment (or other service relationship) of the Holder by reason of the Holder&rsquo;s (A) intentional
failure to perform reasonably assigned duties, (B) dishonesty or willful misconduct in the performance of the Holder&rsquo;s duties,
(C) involvement in a transaction which is materially adverse to the Company or an Affiliate, (D) breach of fiduciary duty involving
personal profit, (E) willful violation of any law, rule, regulation or court order (other than misdemeanor traffic violations and
misdemeanors not involving misuse or misappropriation of money or property), (F) commission of an act of fraud or intentional misappropriation
or conversion of any asset or opportunity of the Company or an Affiliate, or (G) material breach of any provision of the Plan or
the Holder&rsquo;s Award Agreement or any other written agreement between the Holder and the Company or an Affiliate, in each case
as determined in good faith by the Board, the determination of which shall be final, conclusive and binding on all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Change
of Control</U>&rdquo; shall mean: (i)&nbsp;for a Holder who is a party to an employment or consulting agreement with the Company
or an Affiliate which agreement defines &ldquo;Change of Control&rdquo; (or a similar term), &ldquo;<U>Change of Control</U>&rdquo;
shall have the same meaning as provided for in such agreement, or (ii) for a Holder who is not a party to such an agreement, &ldquo;<U>Change
of Control</U>&rdquo; shall mean the satisfaction of any one or more of the following conditions (and the &ldquo;Change of Control&rdquo;
shall be deemed to have occurred as of the first day that any one or more of the following conditions shall have been satisfied):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
person (as such term is used in paragraphs 13(d) and 14(d)(2) of the Exchange Act, hereinafter in this definition, &ldquo;<U>Person</U>&rdquo;),
other than the Company or an Affiliate or an employee benefit plan of the Company or an Affiliate, becomes the beneficial owner
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than
fifty percent (50%) of the combined voting power of the Company&rsquo;s then outstanding securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
closing of a merger, consolidation or other business combination (a &ldquo;<U>Business Combination</U>&rdquo;) other than a Business
Combination in which holders of the Shares immediately prior to the Business Combination have substantially the same proportionate
ownership of the common stock of the surviving corporation immediately after the Business Combination as immediately before;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
closing of an agreement for the sale or disposition of all or substantially all of the Company&rsquo;s assets to any entity that
is not an Affiliate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
approval by the holders of shares of Shares of a plan of complete liquidation of the Company, other than a merger of the Company
into any subsidiary or a liquidation as a result of which persons who were stockholders of the Company immediately prior to such
liquidation have substantially the same proportionate ownership of shares of common stock of the surviving corporation immediately
after such liquidation as immediately before; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Within
any twenty-four (24) month period, the Incumbent Directors shall cease to constitute at least a majority of the Board or the board
of directors of any successor to the Company; <U>provided</U>, <U>however</U>, that any director elected to the Board, or nominated
for election, by a majority of the Incumbent Directors then still in office, shall be deemed to be an Incumbent Director for purposes
of this paragraph (e), but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result
of either an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened
solicitation of proxies or consents by or on behalf of an individual, entity or &ldquo;group&rdquo; other than the Board (including,
but not limited to, any such assumption that results from paragraphs (a), (b), (c), or (d) of this definition).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Code</U>&rdquo;
shall mean the Internal Revenue Code of 1986, as amended. Reference in the Plan to any section of the Code shall be deemed to include
any amendments or successor provisions to any section and any regulation under such section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Committee</U>&rdquo;
shall mean a committee comprised of two (2) or more members of the Board who are selected by the Board as provided in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
 &ldquo;<U>Company</U>&rdquo; shall have the meaning given to such term in the introductory paragraph, including any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Consultant</U>&rdquo;
shall mean any non-Employee (individual or entity) advisor to the Company or an Affiliate who or which has contracted directly
with the Company or an Affiliate to render bona fide consulting or advisory services thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Director</U>&rdquo;
shall mean a member of the Board or a member of the board of directors of an Affiliate, in either case, who is not an Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Distribution
Equivalent Right</U>&rdquo; shall mean an Award granted under Article XIII of the Plan which entitles the Holder to receive bookkeeping
credits, cash payments and/or Share distributions equal in amount to the distributions that would have been made to the Holder
had the Holder held a specified number of Shares during the period the Holder held the Distribution Equivalent Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Distribution
Equivalent Right Award Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Distribution
Equivalent Right Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
 &ldquo;<U>Effective Date</U>&rdquo; shall mean August 24, 2015 or such later date that the Plan is approved by the stockholders
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Employee</U>&rdquo;
shall mean any employee, including any officer, of the Company or an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Fair
Market Value</U>&rdquo; shall mean, as of any specified date, the closing sales price of the Shares for such date (or, in the event
that the Shares are not traded on such date, on the immediately preceding trading date) on the NASDAQ Stock Market (&ldquo;NASDAQ&rdquo;),
as reported by NASDAQ, or such other domestic or foreign national securities exchange on which the Shares may be listed. If the
Shares are not listed on NASDAQ or on a national securities exchange, but are quoted on the OTC Bulletin Board or by the National
Quotation Bureau, the Fair Market Value of the Shares shall be the mean of the highest bid and lowest asked prices per Share for
such date. If the Shares are not quoted or listed as set forth above, Fair Market Value shall be determined by the Board in good
faith by any fair and reasonable means (which means may be set forth with greater specificity in the applicable Award Agreement).
The Fair Market Value of property other than Shares shall be determined by the Board in good faith by any fair and reasonable means
consistent with the requirements of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Family
Member</U>&rdquo; of an individual shall mean any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling,
niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships,
any person sharing the Holder&rsquo;s household (other than a tenant or employee of the Holder), a trust in which such persons
have more than fifty percent (50%) of the beneficial interest, a foundation in which such persons (or the Holder) control the management
of assets, and any other entity in which such persons (or the Holder) own more than fifty percent (50%) of the voting interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Holder</U>&rdquo;
shall mean an Employee, Director or Consultant who has been granted an Award or any such individual&rsquo;s beneficiary, estate
or representative, who has acquired such Award in accordance with the terms of the Plan, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
 &ldquo;<U>Incentive Stock Option</U>&rdquo; shall mean an Option which is intended by the Committee to constitute an &ldquo;incentive
stock option&rdquo; and conforms to the applicable provisions of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Incumbent
Director</U>&rdquo; shall mean, with respect to any period of time specified under the Plan for purposes of determining whether
or not a Change of Control has occurred, the individuals who were members of the Board at the beginning of such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Non-qualified
Stock Option</U>&rdquo; shall mean an Option which is not an Incentive Stock Option or which is designated as an Incentive Stock
Option but does not meet the applicable requirements of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Option</U>&rdquo;
shall mean an Award granted under Article VII of the Plan of an option to purchase Shares and shall include both Incentive Stock
Options and Non-qualified Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Option
Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to an Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Criteria</U>&rdquo; shall mean the criteria selected by the Committee for purposes of establishing the Performance Goal(s) for
a Holder for a Performance Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Goals</U>&rdquo; shall mean, for a Performance Period, the written goal or goals established by the Committee for the Performance
Period based upon the Performance Criteria, which may be related to the performance of the Holder, the Company or an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Period</U>&rdquo; shall mean one or more periods of time, which may be of varying and overlapping durations, selected by the Committee,
over which the attainment of the Performance Goals shall be measured for purposes of determining a Holder&rsquo;s right to, and
the payment of, a Qualified Performance-Based Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Stock Award</U>&rdquo; or &ldquo;<U>Performance Stock</U>&rdquo; shall mean an Award granted under Article XII of the Plan under
which, upon the satisfaction of predetermined Performance Goals, Shares are paid to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Stock Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Performance Stock
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Unit</U>&rdquo; shall mean a Unit awarded to a Holder pursuant to a Performance Unit Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Unit Award</U>&rdquo; shall mean an Award granted under Article XI of the Plan under which, upon the satisfaction of predetermined
Performance Goals, a cash payment shall be made to the Holder, based on the number of Units awarded to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Performance
Unit Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Performance Unit Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Plan</U>&rdquo;
shall mean this Titan Pharmaceuticals 2015 Omnibus Equity Incentive Plan, as amended from time to time, together with each of the
Award Agreements utilized hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Qualified
Performance-Based Award</U>&rdquo; shall mean an Award that is intended to qualify as &ldquo;performance-based&rdquo; compensation
under Section 162(m) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Restricted
Stock Award</U>&rdquo; and &ldquo;<U>Restricted Stock</U>&rdquo; shall mean an Award granted under Article VIII of the Plan of
Shares, the transferability of which by the Holder is subject to Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Restricted
Stock Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Restricted Stock Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Restricted
Stock Unit Award</U>&rdquo; and &ldquo;<U>RSUs</U>&rdquo; shall refer to an Award granted under Article X of the Plan under which,
upon the satisfaction of predetermined individual service-related vesting requirements, a cash payment shall be made to the Holder,
based on the number of Units awarded to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Restricted
Stock Unit Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Restricted Stock
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
 &ldquo;<U>Restriction Period</U>&rdquo; shall mean the period of time for which Shares subject to a Restricted Stock Award shall
be subject to Restrictions, as set forth in the applicable Restricted Stock Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Restrictions</U>&rdquo;
shall mean the forfeiture, transfer and/or other restrictions applicable to Shares awarded to an Employee, Director or Consultant
under the Plan pursuant to a Restricted Stock Award and set forth in a Restricted Stock Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Rule
16b-3</U>&rdquo; shall mean Rule 16b-3 promulgated by the Securities and Exchange Commission under the Exchange Act, as such may
be amended from time to time, and any successor rule, regulation or statute fulfilling the same or a substantially similar function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Shares</U>&rdquo;
or &ldquo;<U>Stock</U>&rdquo; shall mean the common stock of the Company, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Stock
Appreciation Right</U>&rdquo; or &ldquo;<U>SAR</U>&rdquo; shall mean an Award granted under Article XIV of the Plan of a right,
granted alone or in connection with a related Option, to receive a payment equal to the increase in value of a specified number
of Shares between the date of Award and the date of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Stock
Appreciation Right Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to a Stock
Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Tandem
Stock Appreciation Right</U>&rdquo; shall mean a Stock Appreciation Right granted in connection with a related Option, the exercise
of some or all of which results in termination of the entitlement to purchase some or all of the Shares under the related Option,
all as set forth in Article XIV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
 &ldquo;<U>Ten Percent Stockholder</U>&rdquo; shall mean an Employee who, at the time an Option is granted to him or her, owns shares
possessing more than ten percent (10%) of the total combined voting power of all classes of shares of the Company or of any parent
corporation or subsidiary corporation thereof (both as defined in Section 424 of the Code), within the meaning of Section 422(b)(6)
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Termination
of Service</U>&rdquo; shall mean a termination of a Holder&rsquo;s employment with, or status as a Director or Consultant of, the
Company or an Affiliate, as applicable, for any reason, including, without limitation, Total and Permanent Disability or death,
except as provided in Section 6.4. In the event Termination of Service shall constitute a payment event with respect to any Award
subject to Code Section 409A, Termination of Service shall only be deemed to occur upon a &ldquo;separation from service&rdquo;
as such term is defined under Code Section 409A and applicable authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Total
and Permanent Disability</U>&rdquo; of an individual shall mean the inability of such individual to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which
has lasted or can be expected to last for a continuous period of not less than twelve (12) months, within the meaning of Section
22(e)(3) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Unit</U>&rdquo;
shall mean a bookkeeping unit, which represents such monetary amount as shall be designated by the Committee in each Performance
Unit Agreement, or represents one Share for purposes of each Restricted Stock Unit Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Unrestricted
Stock Award</U>&rdquo; shall mean an Award granted under Article IX of the Plan of Shares which are not subject to Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">2.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Unrestricted
Stock Agreement</U>&rdquo; shall mean a written agreement between the Company and a Holder with respect to an Unrestricted Stock
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
III</FONT><BR>
EFFECTIVE DATE OF PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Plan shall be effective as of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
IV</FONT><BR>
ADMINISTRATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Composition
of Committee</U>. The Plan shall be administered by the Committee, which shall be appointed by the Board. If necessary, in the
Board&rsquo;s discretion, to comply with Rule 16b-3 under the Exchange Act and Section 162(m) of the Code, the Committee shall
consist solely of two (2) or more Directors who are each (i) &ldquo;outside directors&rdquo; within the meaning of Section 162(m)
of the Code (&ldquo;<U>Outside Directors</U>&rdquo;), (ii) &ldquo;non-employee directors&rdquo; within the meaning of Rule 16b-3
(&ldquo;<U>Non-Employee Directors</U>&rdquo;) and (iii) &ldquo;independent&rdquo; for purposes of any applicable listing requirements;
<U>provided</U>, <U>however</U>, that the Board or the Committee may delegate to a committee of one or more members of the Board
who are not (x) Outside Directors, the authority to grant Awards to eligible persons who are not (A) then &ldquo;covered employees&rdquo;
within the meaning of Section 162(m) of the Code and are not expected to be &ldquo;covered employees&rdquo; at the time of recognition
of income resulting from such Award, or (B) persons with respect to whom the Company wishes to comply with the requirements of
Section 162(m) of the Code, and/or (y) Non-Employee Directors, the authority to grant Awards to eligible persons who are not then
subject to the requirements of Section 16 of the Exchange Act. If a member of the Committee shall be eligible to receive an Award
under the Plan, such Committee member shall have no authority hereunder with respect to his or her own Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Powers</U>.
Subject to the other provisions of the Plan, the Committee shall have the sole authority, in its discretion, to make all determinations
under the Plan, including but not limited to (i) determining which Employees, Directors or Consultants shall receive an Award,
(ii) the time or times when an Award shall be made (the date of grant of an Award shall be the date on which the Award is awarded
by the Committee), (iii) what type of Award shall be granted, (iv) the term of an Award, (v) the date or dates on which an Award
vests (including acceleration of vesting), (vi) the form of any payment to be made pursuant to an Award, (vii) the terms and conditions
of an Award (including the forfeiture of the Award, and/or any financial gain, if the Holder of the Award violates any applicable
restrictive covenant thereof), (viii) the Restrictions under a Restricted Stock Award, (ix) the number of Shares which may be
issued under an Award, (x) Performance Goals applicable to any Award and certification of the achievement of such goals, and (xi)
the waiver of any Restrictions or Performance Goals, subject in all cases to compliance with applicable laws. In making such determinations
the Committee may take into account the nature of the services rendered by the respective Employees, Directors and Consultants,
their present and potential contribution to the Company&rsquo;s (or the Affiliate&rsquo;s) success and such other factors as the
Committee in its discretion may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Additional
Powers</U>. The Committee shall have such additional powers as are delegated to it under the other provisions of the Plan. Subject
to the express provisions of the Plan, the Committee is authorized to construe the Plan and the respective Award Agreements executed
hereunder, to prescribe such rules and regulations relating to the Plan as it may deem advisable to carry out the intent of the
Plan, to determine the terms, restrictions and provisions of each Award and to make all other determinations necessary or advisable
for administering the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in any
Award Agreement in the manner and to the extent the Committee shall deem necessary, appropriate or expedient to carry it into
effect. The determinations of the Committee on the matters referred to in this Article IV shall be conclusive and binding on the
Company and all Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Committee
Action</U>. Subject to compliance with all applicable laws, action by the Committee shall require the consent of a majority of
the members of the Committee, expressed either orally at a meeting of the Committee or in writing in the absence of a meeting.
No member of the Committee shall have any liability for any good faith action, inaction or determination in connection with the
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
V</FONT><BR>
SHARES SUBJECT TO PLAN AND LIMITATIONS THEREON</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorized
Shares and Award Limits</U>. The Committee may from time to time grant Awards to one or more Employees, Directors and/or Consultants
determined by it to be eligible for participation in the Plan in accordance with the provisions of Article&nbsp;VI. Subject to
Article XV, the aggregate number of Shares that may be issued under the Plan shall not exceed Three Million Five Hundred Thousand
(3,500,000) Shares. Shares shall be deemed to have been issued under the Plan solely to the extent actually issued and delivered
pursuant to an Award. To the extent that an Award lapses, expires, is canceled, is terminated unexercised or ceases to be exercisable
for any reason, or the rights of its Holder terminate, any Shares subject to such Award shall again be available for the grant
of a new Award. Notwithstanding any provision in the Plan to the contrary, the maximum number of Shares that may be subject to
Awards granted to any one person during any calendar year, shall be Five Hundred Thousand (500,000) Shares (subject to adjustment
in the same manner as provided in Article XV with respect to Shares subject to Awards then outstanding). The limitation set forth
in the preceding sentence shall be applied in a manner which shall permit compensation generated in connection with the exercise
of Options or Stock Appreciation Rights to constitute &ldquo;performance-based&rdquo; compensation for purposes of Section 162(m)
of the Code, including, but not limited to, counting against such maximum number of Shares, to the extent required under Section
162(m) of the Code, any Shares subject to Options or Stock Appreciation Rights that are canceled or re-priced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Types
of Shares</U>. The Shares to be issued pursuant to the grant or exercise of an Award may consist of authorized but unissued Shares,
Shares purchased on the open market or Shares previously issued and outstanding and reacquired by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
VI</FONT><BR>
ELIGIBILITY AND TERMINATION OF SERVICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Eligibility</U>.
Awards made under the Plan may be granted solely to individuals or entities who, at the time of grant, are Employees, Directors
or Consultants. An Award may be granted on more than one occasion to the same Employee, Director or Consultant, and, subject to
the limitations set forth in the Plan, such Award may include, a Non-qualified Stock Option, a Restricted Stock Award, a Restricted
Stock Unit Award, an Unrestricted Stock Award, a Distribution Equivalent Right Award, a Performance Stock Award, a Performance
Unit Award, a Stock Appreciation Right, a Tandem Stock Appreciation Right, or any combination thereof, and solely for Employees,
an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
of Service</U>. Except to the extent inconsistent with the terms of the applicable Award Agreement and/or the provisions of Section
6.3 or 6.4, the following terms and conditions shall apply with respect to a Holder&rsquo;s Termination of Service with the Company
or an Affiliate, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Holder&rsquo;s rights, if any, to exercise any then exercisable Options and/or Stock Appreciation Rights shall terminate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
such termination is for a reason other than the Holder&rsquo;s Total and Permanent Disability or death, ninety (90) days after
the date of such Termination of Service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
such termination is on account of the Holder&rsquo;s Total and Permanent Disability, one (1) year after the date of such Termination
of Service; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
such termination is on account of the Holder&rsquo;s death, one (1) year after the date of the Holder&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Upon such applicable date the Holder (and such
Holder&rsquo;s estate, designated beneficiary or other legal representative) shall forfeit any rights or interests in or with respect
to any such Options and Stock Appreciation Rights. Notwithstanding the foregoing, the Committee, in its sole discretion, may provide
for a different time period in the Award Agreement, or may extend the time period, following a Termination of Service, during which
the Holder has the right to exercise any vested Non-qualified Stock Option or Stock Appreciation Right, which time period may not
extend beyond the expiration date of the Award term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
the event of a Holder&rsquo;s Termination of Service for any reason prior to the actual or deemed satisfaction and/or lapse of
the Restrictions, vesting requirements, terms and conditions applicable to a Restricted Stock Award and/or Restricted Stock Unit
Award, such Restricted Stock and/or RSUs shall immediately be canceled, and the Holder (and such Holder&rsquo;s estate, designated
beneficiary or other legal representative) shall forfeit any rights or interests in and with respect to any such Restricted Stock
and/or RSUs. Notwithstanding the immediately preceding sentence, the Committee, in its sole discretion, may determine, prior to
or within thirty (30) days after the date of such Termination of Service that all or a portion of any such Holder&rsquo;s Restricted
Stock and/or RSUs shall not be so canceled and forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Special
Termination Rule</U>. Except to the extent inconsistent with the terms of the applicable Award Agreement, and notwithstanding
anything to the contrary contained in this Article VI, if a Holder&rsquo;s employment with, or status as a Director of, the Company
or an Affiliate shall terminate, and if, within ninety (90) days of such termination, such Holder shall become a Consultant, such
Holder&rsquo;s rights with respect to any Award or portion thereof granted thereto prior to the date of such termination may be
preserved, if and to the extent determined by the Committee in its sole discretion, as if such Holder had been a Consultant for
the entire period during which such Award or portion thereof had been outstanding. Should the Committee effect such determination
with respect to such Holder, for all purposes of the Plan, such Holder shall not be treated as if his or her employment or Director
status had terminated until such time as his or her Consultant status shall terminate, in which case his or her Award, as it may
have been reduced in connection with the Holder&rsquo;s becoming a Consultant, shall be treated pursuant to the provisions of
Section 6.2, provided, however, that any such Award which is intended to be an Incentive Stock Option shall, upon the Holder&rsquo;s
no longer being an Employee, automatically convert to a Non-qualified Stock Option. Should a Holder&rsquo;s status as a Consultant
terminate, and if, within ninety (90) days of such termination, such Holder shall become an Employee or a Director, such Holder&rsquo;s
rights with respect to any Award or portion thereof granted thereto prior to the date of such termination may be preserved, if
and to the extent determined by the Committee in its sole discretion, as if such Holder had been an Employee or a Director, as
applicable, for the entire period during which such Award or portion thereof had been outstanding, and, should the Committee effect
such determination with respect to such Holder, for all purposes of the Plan, such Holder shall not be treated as if his or her
Consultant status had terminated until such time as his or her employment with the Company or an Affiliate, or his or her Director
status, as applicable, shall terminate, in which case his or her Award shall be treated pursuant to the provisions of Section
6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
of Service for Cause</U>. Notwithstanding anything in this Article&nbsp;VI or elsewhere in the Plan to the contrary, and unless
a Holder&rsquo;s Award Agreement specifically provides otherwise, in the event of a Holder&rsquo;s Termination of Service for
Cause, all of such Holder&rsquo;s then outstanding Awards shall expire immediately and be forfeited in their entirety upon such
Termination of Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
VII</FONT><BR>
OPTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Option
Period</U>. The term of each Option shall be as specified in the Option Agreement; <U>provided</U>, <U>however</U>, that except
as set forth in Section 7.3, no Option shall be exercisable after the expiration of ten (10) years from the date of its grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Limitations
on Exercise of Option</U>. An Option shall be exercisable in whole or in such installments and at such times as specified in the
Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Special
Limitations on Incentive Stock Options</U>. To the extent that the aggregate Fair Market Value (determined at the time the respective
Incentive Stock Option is granted) of Shares with respect to which Incentive Stock Options are exercisable for the first time by
an individual during any calendar year under all plans of the Company and any parent corporation or subsidiary corporation thereof
(both as defined in Section 424 of the Code) which provide for the grant of Incentive Stock Options exceeds One Hundred Thousand
Dollars ($100,000) (or such other individual limit as may be in effect under the Code on the date of grant), the portion of such
Incentive Stock Options that exceeds such threshold shall be treated as Non-qualified Stock Options. The Committee shall determine,
in accordance with applicable provisions of the Code, Treasury Regulations and other administrative pronouncements, which of a
Holder&rsquo;s Options, which were intended by the Committee to be Incentive Stock Options when granted to the Holder, will not
constitute Incentive Stock Options because of such limitation, and shall notify the Holder of such determination as soon as practicable
after such determination. No Incentive Stock Option shall be granted to an Employee if, at the time the Incentive Stock Option
is granted, such Employee is a Ten Percent Stockholder, unless (i) at the time such Incentive Stock Option is granted the Option
price is at least one hundred ten percent (110%) of the Fair Market Value of the Shares subject to the Incentive Stock Option,
and (ii) such Incentive Stock Option by its terms is not exercisable after the expiration of five (5) years from the date of grant.
No Incentive Stock Option shall be granted more than ten (10) years from the Effective Date. The designation by the Committee of
an Option as an Incentive Stock Option shall not guarantee the Holder that the Option will satisfy the applicable requirements
for &ldquo;incentive stock option&rdquo; status under Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Option
Agreement</U>. Each Option shall be evidenced by an Option Agreement in such form and containing such provisions not inconsistent
with the other provisions of the Plan as the Committee from time to time shall approve, including, but not limited to, provisions
intended to qualify an Option as an Incentive Stock Option. An Option Agreement may provide for the payment of the Option price,
in whole or in part, by the delivery of a number of Shares (plus cash if necessary) that have been owned by the Holder for at least
six (6) months and having a Fair Market Value equal to such Option price, or such other forms or methods as the Committee may determine
from time to time, in each case, subject to such rules and regulations as may be adopted by the Committee. Each Option Agreement
shall, solely to the extent inconsistent with the provisions of Sections 6.2, 6.3, and 6.4, as applicable, specify the effect of
Termination of Service on the exercisability of the Option. Moreover, without limiting the generality of the foregoing, a Non-qualified
Stock Option Agreement may provide for a &ldquo;cashless exercise&rdquo; of the Option, in whole or in part, by (a)&nbsp;establishing
procedures whereby the Holder, by a properly-executed written notice, directs (i)&nbsp;an immediate market sale or margin loan
as to all or a part of Shares to which he is entitled to receive upon exercise of the Option, pursuant to an extension of credit
by the Company to the Holder of the Option price, (ii)&nbsp;the delivery of the Shares from the Company directly to a brokerage
firm and (iii)&nbsp;the delivery of the Option price from sale or margin loan proceeds from the brokerage firm directly to the
Company, or (b)&nbsp;reducing the number of Shares to be issued upon exercise of the Option by the number of such Shares having
an aggregate Fair Market Value equal to the Option price (or portion thereof to be so paid) as of the date of the Option&rsquo;s
exercise. An Option Agreement may also include provisions relating to: (i)&nbsp;subject to the provisions hereof, accelerated vesting
of Options, including but not limited to, upon the occurrence of a Change of Control, (ii) tax matters (including provisions covering
any applicable Employee wage withholding requirements) and (iii) any other matters not inconsistent with the terms and provisions
of the Plan that the Committee shall in its sole discretion determine. The terms and conditions of the respective Option Agreements
need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Option
Price and Payment</U>. The price at which an Share may be purchased upon exercise of an Option shall be determined by the Committee;
<U>provided</U>, <U>however</U>, that such Option price (i)&nbsp;shall not be less than the Fair Market Value of an Share on the
date such Option is granted (or 110% of Fair Market Value for an Incentive Stock Option held by Ten Percent Stockholder, as provided
in Section 7.3), and (ii)&nbsp;shall be subject to adjustment as provided in Article XV. The Option or portion thereof may be
exercised by delivery of an irrevocable notice of exercise to the Company. The Option price for the Option or portion thereof
shall be paid in full in the manner prescribed by the Committee as set forth in the Plan and the applicable Option Agreement,
which manner, with the consent of the Committee, may include the withholding of Shares otherwise issuable in connection with the
exercise of the Option. Separate share certificates shall be issued by the Company for those Shares acquired pursuant to the exercise
of an Incentive Stock Option and for those Shares acquired pursuant to the exercise of a Non-qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stockholder
Rights and Privileges</U>. The Holder of an Option shall be entitled to all the privileges and rights of a stockholder of the
Company solely with respect to such Shares as have been purchased under the Option and for which share certificates have been
registered in the Holder&rsquo;s name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Options
and Rights in Substitution for Stock or Options Granted by Other Corporations</U>. Options may be granted under the Plan from
time to time in substitution for stock options held by individuals employed by entities who become Employees, Directors or Consultants
as a result of a merger or consolidation of the employing entity with the Company or any Affiliate, or the acquisition by the
Company or an Affiliate of the assets of the employing entity, or the acquisition by the Company or an Affiliate of stock or shares
of the employing entity with the result that such employing entity becomes an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Prohibition
Against Re-Pricing</U>. Except to the extent (i)&nbsp;approved in advance by holders of a majority of the shares of the Company
entitled to vote generally in the election of directors, or (ii)&nbsp;as a result of any Change of Control or any adjustment as
provided in Article&nbsp;XV, the Committee shall not have the power or authority to reduce, whether through amendment or otherwise,
the exercise price under any outstanding Option or Stock Appreciation Right, or to grant any new Award or make any payment of
cash in substitution for or upon the cancellation of Options and/or Stock Appreciation Rights previously granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
VIII</FONT><BR>
RESTRICTED STOCK AWARDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Restricted Stock Award shall constitute an Award of Shares to the Holder as of the date of the Award which are subject to a
 &ldquo;substantial risk of forfeiture&rdquo; as defined under Section 83 of the Code during the specified Restriction Period.
At the time a Restricted Stock Award is made, the Committee shall establish the Restriction Period applicable to such Award. Each
Restricted Stock Award may have a different Restriction Period, in the discretion of the Committee. The Restriction Period applicable
to a particular Restricted Stock Award shall not be changed except as permitted by Section 8.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article VIII, the Company and the Holder shall enter into a Restricted
Stock Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to
be appropriate. Shares awarded pursuant to a Restricted Stock Award shall be represented by a share certificate registered in
the name of the Holder of such Restricted Stock Award. If provided for under the Restricted Stock Agreement, the Holder shall
have the right to vote Shares subject thereto and to enjoy all other stockholder rights, including the entitlement to receive
dividends on the Shares during the Restriction Period, except that (i)&nbsp;the Holder shall not be entitled to delivery of the
share certificate until the Restriction Period shall have expired, (ii)&nbsp;the Company shall retain custody of the share certificate
during the Restriction Period (with a share power endorsed by the Holder in blank), (iii)&nbsp;the Holder may not sell, transfer,
pledge, exchange, hypothecate or otherwise dispose of the Shares during the Restriction Period and (iv) a breach of the terms
and conditions established by the Committee pursuant to the Restricted Stock Agreement shall cause a forfeiture of the Restricted
Stock Award. At the time of such Award, the Committee may, in its sole discretion, prescribe additional terms and conditions or
restrictions relating to Restricted Stock Awards, including, but not limited to, rules pertaining to the effect of Termination
of Service prior to expiration of the Restriction Period. Such additional terms, conditions or restrictions shall, to the extent
inconsistent with the provisions of Sections 6.2, 6.3 and 6.4, as applicable, be set forth in a Restricted Stock Agreement made
in conjunction with the Award. Such Restricted Stock Agreement may also include provisions relating to: (i)&nbsp;subject to the
provisions hereof, accelerated vesting of Awards, including but not limited to accelerated vesting upon the occurrence of a Change
of Control, (ii)&nbsp;tax matters (including provisions covering any applicable Employee wage withholding requirements) and (iii)&nbsp;any
other matters not inconsistent with the terms and provisions of the Plan that the Committee shall in its sole discretion determine.
The terms and conditions of the respective Restricted Stock Agreements need not be identical. All Shares delivered to a Holder
as part of a Restricted Stock Award shall be delivered and reported by the Company or the Affiliate, as applicable, to the Holder
at the time of vesting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment
for Restricted Stock</U>. The Committee shall determine the amount and form of any payment from a Holder for Shares received pursuant
to a Restricted Stock Award, if any, provided that in the absence of such a determination, a Holder shall not be required to make
any payment for Shares received pursuant to a Restricted Stock Award, except to the extent otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
IX</FONT><BR>
UNRESTRICTED STOCK AWARDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
Shares may be awarded (or sold) to Employees, Directors or Consultants under the Plan which are not subject to Restrictions of
any kind, in consideration for past services rendered thereby to the Company or an Affiliate or for other valid consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions.</U>&nbsp;&nbsp;At the time any Award is made under this Article IX, the Company and the Holder shall enter into
an Unrestricted Stock Agreement setting forth each of the matters contemplated hereby and such other matters as the Committee
may determine to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment
for Unrestricted Stock</U>. The Committee shall determine the amount and form of any payment from a Holder for Shares received
pursuant to an Unrestricted Stock Award, if any, provided that in the absence of such a determination, a Holder shall not be required
to make any payment for Shares received pursuant to an Unrestricted Stock Award, except to the extent otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #010000; text-align: center"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
X</FONT><BR>
RESTRICTED STOCK UNIT AWARDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Restricted Stock Unit Award shall constitute a promise to grant Shares (or cash equal to the Fair Market Value of Shares) to
the Holder at the end of a specified Restriction Period. At the time a Restricted Stock Unit Award is made, the Committee shall
establish the Restriction Period applicable to such Award. Each Restricted Stock Unit Award may have a different Restriction Period,
in the discretion of the Committee. A Restricted Stock Unit shall not constitute an equity interest in the Company and shall not
entitle the Holder to voting rights, dividends or any other rights associated with ownership of Shares prior to the time the Holder
shall receive a distribution of Shares pursuant to Section 10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article X, the Company and the Holder shall enter into a Restricted
Stock Unit Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine
to be appropriate. The Restricted Stock Unit Agreement shall set forth the individual service-based vesting requirement which
the Holder would be required to satisfy before the Holder would become entitled to distribution pursuant to Section 10.3 and the
number of Units awarded to the Holder. Such conditions shall be sufficient to constitute a &ldquo;substantial risk of forfeiture&rdquo;
as such term is defined under Section 409A of the Code. At the time of such Award, the Committee may, in its sole discretion,
prescribe additional terms and conditions or restrictions relating to Restricted Stock Unit Awards in the Restricted Stock Unit
Agreement, including, but not limited to, rules pertaining to the effect of Termination of Service prior to expiration of the
applicable vesting period. The terms and conditions of the respective Restricted Stock Unit Agreements need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Distributions
of Shares</U>. The Holder of a Restricted Stock Unit shall be entitled to receive a cash payment equal to the Fair Market Value
of an Share, or one Share, as determined in the sole discretion of the Committee and as set forth in the Restricted Stock Unit
Agreement, for each Restricted Stock Unit subject to such Restricted Stock Unit Award, if the Holder satisfies the applicable
vesting requirement. Such distribution shall be made no later than by the fifteenth (15<SUP>th</SUP>) day of the third (3<SUP>rd</SUP>)
calendar month next following the end of the calendar year in which the Restricted Stock Unit first becomes vested (i.e., no longer
subject to a &ldquo;substantial risk of forfeiture&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XI</FONT><BR>
PERFORMANCE UNIT AWARDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Performance Unit Award shall constitute an Award under which, upon the satisfaction of predetermined individual and/or Company
(and/or Affiliate) Performance Goals based on selected Performance Criteria, a cash payment shall be made to the Holder, based
on the number of Units awarded to the Holder. At the time a Performance Unit Award is made, the Committee shall establish the
Performance Period and applicable Performance Goals. Each Performance Unit Award may have different Performance Goals, in the
discretion of the Committee. A Performance Unit Award shall not constitute an equity interest in the Company and shall not entitle
the Holder to voting rights, dividends or any other rights associated with ownership of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article XI, the Company and the Holder shall enter into a Performance
Unit Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to
be appropriate. The Committee shall set forth in the applicable Performance Unit Agreement the Performance Period, Performance
Criteria and Performance Goals which the Holder and/or the Company would be required to satisfy before the Holder would become
entitled to payment pursuant to Section 11.3, the number of Units awarded to the Holder and the dollar value or formula assigned
to each such Unit. Such payment shall be subject to a &ldquo;substantial risk of forfeiture&rdquo; under Section 409A of the Code.
At the time of such Award, the Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions
relating to Performance Unit Awards, including, but not limited to, rules pertaining to the effect of Termination of Service prior
to expiration of the applicable performance period. The terms and conditions of the respective Performance Unit Agreements need
not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payments</U>.
The Holder of a Performance Unit shall be entitled to receive a cash payment equal to the dollar value assigned to such Unit under
the applicable Performance Unit Agreement if the Holder and/or the Company satisfy (or partially satisfy, if applicable under
the applicable Performance Unit Agreement) the Performance Goals set forth in such Performance Unit Agreement. If necessary to
satisfy the requirements of Code Section 162(m), if applicable, the achievement of such Performance Goals shall be certified in
writing by the Committee prior to any payment. All payments shall be made no later than by the fifteenth (15<SUP>th</SUP>) day
of the third (3<SUP>rd</SUP>) calendar month next following the end of the Company&rsquo;s fiscal year to which such performance
goals and objectives relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XII</FONT><BR>
PERFORMANCE STOCK AWARDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Performance Stock Award shall constitute a promise to grant Shares (or cash equal to the Fair Market Value of Shares) to the
Holder at the end of a specified Performance Period subject to achievement of specified Performance Goals. At the time a Performance
Stock Award is made, the Committee shall establish the Performance Period and applicable Performance Goals based on selected Performance
Criteria. Each Performance Stock Award may have different Performance Goals, in the discretion of the Committee. A Performance
Stock Award shall not constitute an equity interest in the Company and shall not entitle the Holder to voting rights, dividends
or any other rights associated with ownership of Shares unless and until the Holder shall receive a distribution of Shares pursuant
to Section 11.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article XII, the Company and the Holder shall enter into a Performance
Stock Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to
be appropriate. The Committee shall set forth in the applicable Performance Stock Agreement the Performance Period, selected Performance
Criteria and Performance Goals which the Holder and/or the Company would be required to satisfy before the Holder would become
entitled to the receipt of Shares pursuant to such Holder&rsquo;s Performance Stock Award and the number of Shares subject to
such Performance Stock Award. Such distribution shall be subject to a &ldquo;substantial risk of forfeiture&rdquo; under Section
409A of the Code. If such Performance Goals are achieved, the distribution of Shares (or the payment of cash, as determined in
the sole discretion of the Committee), shall be made no later than by the fifteenth (15<SUP>th</SUP>) day of the third (3<SUP>rd</SUP>)
calendar month next following the end of the Company&rsquo;s fiscal year to which such goals and objectives relate. At the time
of such Award, the Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions relating to
Performance Stock Awards, including, but not limited to, rules pertaining to the effect of the Holder&rsquo;s Termination of Service
prior to the expiration of the applicable performance period. The terms and conditions of the respective Performance Stock Agreements
need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Distributions
of Shares</U>. The Holder of a Performance Stock Award shall be entitled to receive a cash payment equal to the Fair Market Value
of a Share, or one Share, as determined in the sole discretion of the Committee, for each Performance Stock Award subject to such
Performance Stock Agreement, if the Holder satisfies the applicable vesting requirement. If necessary to satisfy the requirements
of Code Section 162(m), if applicable, the achievement of such Performance Goals shall be certified in writing by the Committee
prior to any payment. Such distribution shall be made no later than by the fifteenth (15<SUP>th</SUP>) day of the third (3<SUP>rd</SUP>)
calendar month next following the end of the Company&rsquo;s fiscal year to which such performance goals and objectives relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XIII</FONT><BR>
DISTRIBUTION EQUIVALENT RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Distribution Equivalent Right shall entitle the Holder to receive bookkeeping credits, cash payments and/or Share distributions
equal in amount to the distributions that would have been made to the Holder had the Holder held a specified number of Shares
during the specified period of the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article XIII, the Company and the Holder shall enter into a Distribution
Equivalent Rights Award Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee
may determine to be appropriate. The Committee shall set forth in the applicable Distribution Equivalent Rights Award Agreement
the terms and conditions, if any, including whether the Holder is to receive credits currently in cash, is to have such credits
reinvested (at Fair Market Value determined as of the date of reinvestment) in additional Shares or is to be entitled to choose
among such alternatives. Such receipt shall be subject to a &ldquo;substantial risk of forfeiture&rdquo; under Section 409A of
the Code and, if such Award becomes vested, the distribution of such cash or Shares shall be made no later than by the fifteenth
(15<SUP>th</SUP>) day of the third (3<SUP>rd</SUP>) calendar month next following the end of the Company&rsquo;s fiscal year in
which the Holder&rsquo;s interest in the Award vests. Distribution Equivalent Rights Awards may be settled in cash or in Shares,
as set forth in the applicable Distribution Equivalent Rights Award Agreement. A Distribution Equivalent Rights Award may, but
need not be, awarded in tandem with another Award (other than an Option or a SAR), whereby, if so awarded, such Distribution Equivalent
Rights Award shall expire, terminate or be forfeited by the Holder, as applicable, under the same conditions as under such other
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Interest
Equivalents</U>. The Distribution Equivalent Rights Award Agreement for a Distribution Equivalent Rights Award may provide for
the crediting of interest on a Distribution Rights Award to be settled in cash at a future date (but in no event later than by
the fifteenth (15<SUP>th</SUP>) day of the third (3<SUP>rd</SUP>) calendar month next following the end of the Company&rsquo;s
fiscal year in which such interest is credited and vested), at a rate set forth in the applicable Distribution Equivalent Rights
Award Agreement, on the amount of cash payable thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XIV</FONT><BR>
STOCK APPRECIATION RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award</U>.
A Stock Appreciation Right shall constitute a right, granted alone or in connection with a related Option, to receive a payment
equal to the increase in value of a specified number of Shares between the date of Award and the date of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
and Conditions</U>. At the time any Award is made under this Article XIV, the Company and the Holder shall enter into a Stock
Appreciation Right Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may
determine to be appropriate. The Committee shall set forth in the applicable Stock Appreciation Right Agreement the terms and
conditions of the Stock Appreciation Right, including (i) the base value (the &ldquo;<U>Base Value</U>&rdquo;) for the Stock Appreciation
Right, which shall be not less than the Fair Market Value of a Share on the date of grant of the Stock Appreciation Right, (ii)
the number of Shares subject to the Stock Appreciation Right, (iii) the period during which the Stock Appreciation Right may be
exercised; <U>provided</U>, <U>however</U>, that no Stock Appreciation Right shall be exercisable after the expiration of ten
(10) years from the date of its grant, and (iv) any other special rules and/or requirements which the Committee imposes upon the
Stock Appreciation Right. Upon the exercise of some or all of the portion of a Stock Appreciation Right, the Holder shall receive
a payment from the Company, in cash or in the form of Shares having an equivalent Fair Market Value or in a combination of both,
as determined in the sole discretion of the Committee, equal to the product of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
excess of (i) the Fair Market Value of an Share on the date of exercise, over (ii) the Base Value, multiplied by,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
number of Shares with respect to which the Stock Appreciation Right is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Tandem
Stock Appreciation Rights</U>. If the Committee grants a Stock Appreciation Right which is intended to be a Tandem Stock Appreciation
Right, the Tandem Stock Appreciation Right shall be granted at the same time as the related Option, and the following special
rules shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Base Value shall be equal to or greater than the per Share exercise price under the related Option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Tandem Stock Appreciation Right may be exercised for all or part of the Shares which are subject to the related Option, but solely
upon the surrender by the Holder of the Holder&rsquo;s right to exercise the equivalent portion of the related Option (and when
a Share is purchased under the related Option, an equivalent portion of the related Tandem Stock Appreciation Right shall be canceled);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Tandem Stock Appreciation Right shall expire no later than the date of the expiration of the related Option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
value of the payment with respect to the Tandem Stock Appreciation Right may be no more than one hundred percent (100%) of the
difference between the per Share exercise price under the related Option and the Fair Market Value of the Shares subject to the
related Option at the time the Tandem Stock Appreciation Right is exercised, multiplied by the number of the Shares with respect
to which the Tandem Stock Appreciation Right is exercised; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Tandem Stock Appreciation Right may be exercised solely when the Fair Market Value of the Shares subject to the related Option
exceeds the per Share exercise price under the related Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XV</FONT><BR>
RECAPITALIZATION OR REORGANIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Adjustments
to Shares</U>. The shares with respect to which Awards may be granted under the Plan are Shares as presently constituted; <U>provided</U>,
<U>however</U>, that if, and whenever, prior to the expiration or distribution to the Holder of Shares underlying an Award theretofore
granted, the Company shall effect a subdivision or consolidation of the Shares or the payment of an Share dividend on Shares without
receipt of consideration by the Company, the number of Shares with respect to which such Award may thereafter be exercised or
satisfied, as applicable, (i)&nbsp;in the event of an increase in the number of outstanding Shares, shall be proportionately increased,
and the purchase price per Share shall be proportionately reduced, and (ii)&nbsp;in the event of a reduction in the number of
outstanding Shares, shall be proportionately reduced, and the purchase price per Share shall be proportionately increased. Notwithstanding
the foregoing or any other provision of this Article XV, any adjustment made with respect to an Award (x) which is an Incentive
Stock Option, shall comply with the requirements of Section 424(a) of the Code, and in no event shall any adjustment be made which
would render any Incentive Stock Option granted under the Plan to be other than an &ldquo;incentive stock option&rdquo; for purposes
of Section 422 of the Code, and (y) which is a Non-qualified Stock Option, shall comply with the requirements of Section 409A
of the Code, and in no event shall any adjustment be made which would render any Non-qualified Stock Option granted under the
Plan to become subject to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Recapitalization</U>.
If the Company recapitalizes or otherwise changes its capital structure, thereafter upon any exercise or satisfaction, as applicable,
of a previously granted Award, the Holder shall be entitled to receive (or entitled to purchase, if applicable) under such Award,
in lieu of the number of Shares then covered by such Award, the number and class of shares and securities to which the Holder
would have been entitled pursuant to the terms of the recapitalization if, immediately prior to such recapitalization, the Holder
had been the holder of record of the number of Shares then covered by such Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Events</U>. In the event of changes to the outstanding Shares by reason of an extraordinary cash dividend, reorganization, merger,
consolidation, combination, split-up, spin-off, exchange or other relevant change in capitalization occurring after the date of
the grant of any Award and not otherwise provided for under this Article XV, any outstanding Awards and any Award Agreements evidencing
such Awards shall be adjusted by the Board in its discretion in such manner as the Board shall deem equitable or appropriate taking
into consideration the applicable accounting and tax consequences, as to the number and price of Shares or other consideration
subject to such Awards. In the event of any adjustment pursuant to Sections 15.1, 15.2 or this Section 15.3, the aggregate number
of Shares available under the Plan pursuant to Section 5.1 (and the Code Section 162(m) limit set forth therein) may be appropriately
adjusted by the Board, the determination of which shall be conclusive. In addition, the Committee may make provision for a cash
payment to a Holder or a person who has an outstanding Award. The number of Shares subject to any Award shall be rounded to the
nearest whole number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">15.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Powers
Not Affected</U>. The existence of the Plan and the Awards granted hereunder shall not affect in any way the right or power of
the Board or of the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other
change of the Company&rsquo;s capital structure or business, any merger or consolidation of the Company, any issue of debt or
equity securities ahead of or affecting Shares or the rights thereof, the dissolution or liquidation of the Company or any sale,
lease, exchange or other disposition of all or any part of its assets or business or any other corporate act or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">15.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Adjustment for Certain Awards</U>. Except as hereinabove expressly provided, the issuance by the Company of shares of any class
or securities convertible into shares of any class, for cash, property, labor or services, upon direct sale, upon the exercise
of rights or warrants to subscribe therefor or upon conversion of shares or obligations of the Company convertible into such shares
or other securities, and in any case whether or not for fair value, shall not affect previously granted Awards, and no adjustment
by reason thereof shall be made with respect to the number of Shares subject to Awards theretofore granted or the purchase price
per Share, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XVI</FONT><BR>
AMENDMENT AND TERMINATION OF PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Plan shall continue in effect, unless sooner
terminated pursuant to this Article XVI, until the tenth (10<SUP>th</SUP>) anniversary of the date on which it is adopted by the
Board (except as to Awards outstanding on that date). The Board in its discretion may terminate the Plan at any time with respect
to any shares for which Awards have not theretofore been granted; <U>provided</U>, <U>however</U>, that the Plan&rsquo;s termination
shall not materially and adversely impair the rights of a Holder with respect to any Award theretofore granted without the consent
of the Holder. The Board shall have the right to alter or amend the Plan or any part hereof from time to time; <U>provided</U>,
<U>however</U>, that without the approval by a majority of the votes cast at a meeting of stockholders at which a quorum representing
a majority of the shares of the Company entitled to vote generally in the election of directors is present in person or by proxy,
no amendment or modification of the Plan may (i)&nbsp;materially increase the benefits accruing to Holders, (ii)&nbsp;except as
otherwise expressly provided in Article XV, materially increase the number of Shares subject to the Plan or the individual Award
Agreements specified in Article V, (iii)&nbsp;materially modify the requirements for participation in the Plan, or (iv)&nbsp;amend,
modify or suspend Section 7.7 (re-pricing prohibitions) or this Article XVI. In addition, no change in any Award theretofore granted
may be made which would materially and adversely impair the rights of a Holder with respect to such Award without the consent of
the Holder (unless such change is required in order to cause the benefits under the Plan to qualify as &ldquo;performance-based&rdquo;
compensation within the meaning of Section 162(m) of the Code or to exempt the Plan or any Award from Section 409A of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #010000; text-align: center; text-indent: 7.9pt"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000">Article
XVII</FONT><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Right to Award</U>. Neither the adoption of the Plan by the Company nor any action of the Board or the Committee shall be deemed
to give an Employee, Director or Consultant any right to an Award except as may be evidenced by an Award Agreement duly executed
on behalf of the Company, and then solely to the extent and on the terms and conditions expressly set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Rights Conferred</U>. Nothing contained in the Plan shall (i)&nbsp;confer upon any Employee any right with respect to continuation
of employment with the Company or any Affiliate, (ii)&nbsp;interfere in any way with any right of the Company or any Affiliate
to terminate the employment of an Employee at any time, (iii)&nbsp;confer upon any Director any right with respect to continuation
of such Director&rsquo;s membership on the Board, (iv)&nbsp;interfere in any way with any right of the Company or an Affiliate
to terminate a Director&rsquo;s membership on the Board at any time, (v)&nbsp;confer upon any Consultant any right with respect
to continuation of his or her consulting engagement with the Company or any Affiliate, or (vi)&nbsp;interfere in any way with
any right of the Company or an Affiliate to terminate a Consultant&rsquo;s consulting engagement with the Company or an Affiliate
at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Laws; No Fractional Shares; Withholding</U>. The Company shall not be obligated by virtue of any provision of the Plan to recognize
the exercise of any Award or to otherwise sell or issue Shares in violation of any laws, rules or regulations, and any postponement
of the exercise or settlement of any Award under this provision shall not extend the term of such Award. Neither the Company nor
its directors or officers shall have any obligation or liability to a Holder with respect to any Award (or Shares issuable thereunder)
(i)&nbsp;that shall lapse because of such postponement, or (ii)&nbsp;for any failure to comply with the requirements of any applicable
law, rules or regulations, including but not limited to any failure to comply with the requirements of Section 409A of this Code.
No fractional Shares shall be delivered, nor shall any cash in lieu of fractional Shares be paid. The Company shall have the right
to deduct in cash (whether under this Plan or otherwise) in connection with all Awards any taxes required by law to be withheld
and to require any payments required to enable it to satisfy its withholding obligations. In the case of any Award satisfied in
the form of Shares, no Shares shall be issued unless and until arrangements satisfactory to the Company shall have been made to
satisfy any tax withholding obligations applicable with respect to such Award. Subject to such terms and conditions as the Committee
may impose, the Company shall have the right to retain, or the Committee may, subject to such terms and conditions as it may establish
from time to time, permit Holders to elect to tender, Shares (including Shares issuable in respect of an Award) to satisfy, in
whole or in part, the amount required to be withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Restriction on Corporate Action</U>. Nothing contained in the Plan shall be construed to prevent the Company or any Affiliate
from taking any corporate action which is deemed by the Company or such Affiliate to be appropriate or in its best interest, whether
or not such action would have an adverse effect on the Plan or any Award made under the Plan. No Employee, Director, Consultant,
beneficiary or other person shall have any claim against the Company or any Affiliate as a result of any such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Restrictions
on Transfer</U>. No Award under the Plan or any Award Agreement and no rights or interests herein or therein, shall or may be
assigned, transferred, sold, exchanged, encumbered, pledged or otherwise hypothecated or disposed of by a Holder except&nbsp;by
will or by the laws of descent and distribution. An Award may be exercisable during the lifetime of the Holder only by such Holder
or by the Holder&rsquo;s guardian or legal representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Beneficiary
Designations</U>. Each Holder may, from time to time, name a beneficiary or beneficiaries (who may be contingent or successive
beneficiaries) for purposes of receiving any amount which is payable in connection with an Award under the Plan upon or subsequent
to the Holder&rsquo;s death. Each such beneficiary designation shall serve to revoke all prior beneficiary designations, be in
a form prescribed by the Company and be effective solely when filed by the Holder in writing with the Company during the Holder&rsquo;s
lifetime. In the absence of any such written beneficiary designation, for purposes of the Plan, a Holder&rsquo;s beneficiary shall
be the Holder&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Rule
16b-3</U>. It is intended that the Plan and any Award made to a person subject to Section 16 of the Exchange Act shall meet all
of the requirements of Rule&nbsp;16b-3. If any provision of the Plan or of any such Award would disqualify the Plan or such Award
under, or would otherwise not comply with the requirements of, Rule&nbsp;16b-3, such provision or Award shall be construed or
deemed to have been amended as necessary to conform to the requirements of Rule&nbsp;16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
162(m)</U>. The following conditions shall apply if it is intended that the requirements of Section 162(m) of the Code be satisfied
such that Awards under the Plan which are made to Holders who are &ldquo;covered employees&rdquo; (as defined in Section 162(m)
of the Code) shall constitute &ldquo;performance-based&rdquo; compensation within the meaning of Section 162(m) of the Code: Any
Performance Goal(s) applicable to Qualified Performance-Based Awards shall be objective, shall be established not later than ninety
(90) days after the beginning of any applicable Performance Period (or at such other date as may be required or permitted for
 &ldquo;performance-based&rdquo; compensation under Section 162(m) of the Code) and shall otherwise meet the requirements of Section
162(m) of the Code, including the requirement that the outcome of the Performance Goal or Goals be substantially uncertain (as
defined in the regulations under Section 162(m) of the Code) at the time established. The Performance Criteria to be utilized
under the Plan to establish Performance Goals shall consist of objective tests based on one or more of the following: earnings
or earnings per share, cash flow or cash flow per share, operating cash flow or operating cash flow per share revenue growth,
product revenue growth, financial return ratios (such as return on equity, return on investment and/or return on assets), share
price performance, stockholder return, equity and/or value, operating income, operating margins, earnings before interest, taxes,
depreciation and amortization, earnings, pre- or post-tax income, economic value added (or an equivalent metric), profit returns
and margins, credit quality, sales growth, market share, working capital levels, comparisons with various share market indices,
year-end cash, debt reduction, assets under management, operating efficiencies, strategic partnerships or transactions (including
co-development, co-marketing, profit sharing, joint venture or other similar arrangements), and/or financing and other capital
raising transaction. Performance criteria may be established on a Company-wide basis or with respect to one or more Company business
units or divisions or subsidiaries; and either in absolute terms, relative to the performance of one or more similarly situated
companies, or relative to the performance of an index covering a peer group of companies. When establishing Performance Goals
for the applicable Performance Period, the Committee may exclude any or all &ldquo;extraordinary items&rdquo; as determined under
U.S. generally accepted accounting principles including, without limitation, the charges or costs associated with restructurings
of the Company, discontinued operations, other unusual or non-recurring items, and the cumulative effects of accounting changes,
and as identified in the Company&rsquo;s financial statements, notes to the Company&rsquo;s financial statements or management&rsquo;s
discussion and analysis of financial condition and results of operations contained in the Company&rsquo;s most recent annual report
filed with the U.S. Securities and Exchange Commission pursuant to the Exchange Act. Holders who are &ldquo;covered employees&rdquo;
(as defined in Section&nbsp;162(m) of the Code) shall be eligible to receive payment under a Qualified Performance-Based Award
which is subject to achievement of a Performance Goal or Goals only if the applicable Performance Goal or Goals are achieved within
the applicable Performance Period, as determined by the Committee. If any provision of the Plan would disqualify the Plan or would
not otherwise permit the Plan to comply with Section&nbsp;162(m) of the Code as so intended, such provision shall be construed
or deemed amended to conform to the requirements or provisions of Section 162(m) of the Code. The Committee may postpone the exercising
of Awards, the issuance or delivery of Shares under any Award or any action permitted under the Plan to prevent the Company or
any subsidiary from being denied a federal income tax deduction, provided that such deferral satisfies the requirements of Section&nbsp;409A
of the Code. For purposes of the requirements of Treasury Regulation Section&nbsp;1.162-27(e)(4)(i), the maximum aggregate amount
that may be paid in cash during any calendar year to any one person (measured from the date of any payment) with respect to one
or more Awards payable in cash shall be Ten Million Dollars ($10,000,000)].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
409A</U>. Notwithstanding any other provision of the Plan, the Committee shall have no authority to issue an Award under the Plan
with terms and/or conditions which would cause such Award to constitute non-qualified &ldquo;deferred compensation&rdquo; under
Section&nbsp;409A of the Code unless such Award shall be structured to be exempt from or comply with all requirements of Code
Section 409A. The Plan and all Award Agreements are intended to comply with the requirements of Section&nbsp;409A of the Code
(or to be exempt therefrom) and shall be so interpreted and construed and no amount shall be paid or distributed from the Plan
unless and until such payment complies with all requirements of Code Section 409A. It is the intent of the Company that the provisions
of this Agreement and all other plans and programs sponsored by the Company be interpreted to comply in all respects with Code
Section 409A, however, the Company shall have no liability to the Holder, or any successor or beneficiary thereof, in the event
taxes, penalties or excise taxes may ultimately be determined to be applicable to any payment or benefit received by the Holder
or any successor or beneficiary thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification</U>.
Each person who is or shall have been a member of the Committee or of the Board shall be indemnified and held harmless by the
Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred thereby in connection
with or resulting from any claim, action, suit, or proceeding to which such person may be made a party or may be involved by reason
of any action taken or failure to act under the Plan and against and from any and all amounts paid thereby in settlement thereof,
with the Company&rsquo;s approval, or paid thereby in satisfaction of any judgment in any such action, suit, or proceeding against
such person; <U>provided</U>, <U>however</U>, that such person shall give the Company an opportunity, at its own expense, to handle
and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification
shall not be exclusive and shall be independent of any other rights of indemnification to which such persons may be entitled under
the Company&rsquo;s Articles of Incorporation or By-laws, by contract, as a matter of law, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Benefit Plans</U>. No Award, payment or amount received hereunder shall be taken into account in computing an Employee&rsquo;s
salary or compensation for the purposes of determining any benefits under any pension, retirement, life insurance or other benefit
plan of the Company or any Affiliate, unless such other plan specifically provides for the inclusion of such Award, payment or
amount received. Nothing in the Plan shall be construed to limit the right of the Company to establish other plans or to pay compensation
to its employees, in cash or property, in a manner which is not expressly authorized under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Limits
of Liability</U>. Any liability of the Company with respect to an Award shall be based solely upon the contractual obligations
created under the Plan and the Award Agreement. None of the Company, any member of the Board nor any member of the Committee shall
have any liability to any party for any action taken or not taken, in good faith, in connection with or under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. Except as otherwise provided herein, the Plan shall be construed in accordance with the laws of the State of Delaware,
without regard to principles of conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability
of Provisions</U>. If any provision of the Plan is held invalid or unenforceable, such invalidity or unenforceability shall not
affect any other provision of the Plan, and the Plan shall be construed and enforced as if such invalid or unenforceable provision
had not been included in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Funding</U>. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make
any other segregation of funds or assets to ensure the payment of any Award. Prior to receipt of Shares or a cash distribution
pursuant to the terms of an Award, such Award shall represent an unfunded unsecured contractual obligation of the Company and
the Holder shall have no greater claim to the Shares underlying such Award or any other assets of the Company or Affiliate than
any other unsecured general creditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #010000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #010000">17.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>.
Headings used throughout the Plan are for convenience only and shall not be given legal significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>tv499850_ex10-22.htm
<DESCRIPTION>EXHIBIT 10.22
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #010000"><B>Exhibit 10.22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: #010000">EXECUTION VERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-variant: small-caps; color: #010000"><B>CONFIDENTIAL
TREATMENT REQUESTED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-variant: small-caps; color: #010000"><B>INFORMATION
FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-variant: small-caps; color: #010000"><B>REQUESTED
IS OMITTED AND MARKED WITH &ldquo;[*******]&rdquo; OR OTHERWISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-variant: small-caps; color: #010000"><B>CLEARLY
INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-variant: small-caps; color: #010000"><B>ALSO
BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B><U>DISTRIBUTION
AND SUBLICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">THIS
DISTRIBUTION AND SUBLICENSE AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of February 1, 2016 (the &ldquo;<B>Effective
Date</B>&rdquo;), by and between <FONT STYLE="text-transform: uppercase"><B>Braeburn Pharmaceuticals, inc.</B></FONT>, a corporation
formed under the laws of Delaware (&ldquo;<B>Braeburn</B>&rdquo;), and <FONT STYLE="text-transform: uppercase"><B>Knight Therapeutics
Inc.</B></FONT>, a corporation incorporated under the laws of Canada (&ldquo;<B>Knight</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B><U>RECITALS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>WHEREAS
</B>reference is made to that certain License Agreement, dated as of December 14, 2012, by and between Titan Pharmaceuticals,
Inc. (&ldquo;<B>Titan</B>&rdquo;) and Braeburn, as amended by that certain first amendment dated May 28, 2013, as further amended
by that certain second amendment dated July 2, 2013, as further amended by that certain third amendment dated November 12, 2013,
and as assigned to Braeburn pursuant to that certain letter of assignment, dated May 28, 2015, from Braeburn Pharmaceuticals BVBA
SPRL and acknowledged by Titan (as amended, the &ldquo;<B>Titan Agreement</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>WHEREAS
</B>pursuant to the terms and conditions of the Titan Agreement, Braeburn owns or licenses all right, title and interest in and
to certain patents, trademark(s) and Know-How relating to Braeburn&rsquo;s buprenorphine subdermal implant known as Probuphine;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>WHEREAS
</B>Knight wishes to be appointed by Braeburn as exclusive distributor to offer to sell and sell the Sublicensed Products in the
Territory and Braeburn is willing to grant such exclusive appointment; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>WHEREAS
</B>Knight wishes to procure the Sublicensed Products from Braeburn and Braeburn wishes to supply the Sublicensed Products to
Knight, and the Parties agree to enter into a separate Supply Agreement providing therefor, as more particularly described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>NOW
THEREFORE </B>in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound,
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>DEFINITIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Definitions.
                                         </B>The following terms as used hereinafter in this Agreement shall have the meaning
                                         set forth in this Section:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Accounting
Standards</B>&rdquo; means, with respect to Knight, IFRS, and with respect to Braeburn, US GAAP, in each case, as generally and
consistently applied by such Party. Each Party shall promptly notify the other in the event that it changes the Accounting Standards
pursuant to which its records are maintained, it being understood that each Party may only use internationally recognized accounting
principles (e.g., IFRS or US GAAP) in general use for public company accounting and reporting in Canada, with respect to Knight,
or the United States, with respect to Braeburn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Adverse
Experience</B>&rdquo; means adverse drug experiences, as defined by 21 CFR Section&nbsp;314.80 or any comparable law in the Territory,
including any noxious and unintended response to a drug which occurs at doses normally used or tested for the diagnosis, treatment,
or prevention of a disease or the modification of an organic function <FONT STYLE="background-color: white">and any untoward medical
occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily
have to have a causal relationship with the treatment</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Affiliate</B>&rdquo;
of a Party means (i) any corporation or business entity of which at least fifty percent (50%) of the securities or other ownership
interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or
indirectly, by a Party; (ii) any corporation or business entity which, directly or indirectly, owns, controls or holds at least
fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing
the equity, voting stock or general partnership interest of a Party; (iii) any corporation or business entity of which, directly
or indirectly, an entity described in the immediately preceding subsection (ii) controls or holds at <FONT STYLE="font-size: 10pt">least
fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing
the equity, voting stock or general partnership interest of such corporation or entity; or (iv) any corporation or business entity
of which a Party has the right to acquire, directly or indirectly, at least fifty percent (50%) of the securities or other ownership
interests representing the equity, voting stock or general partnership interest thereof. Notwithstanding the foregoing, Apple
Tree Partners IV, L.P., ATP III, G.P., and their portfolio companies, other than Braeburn and its subsidiaries, shall not be deemed
to be Affiliates of Braeburn under this Agreement unless and until this Agreement, the Sublicensed Product, any Subsequent Indication
or any ROFN Product or any rights or obligations related hereto or thereto are assigned, transferred or conveyed to any of them</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the initial paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Applicable
Laws</B>&rdquo; means any law, regulation, rule, guidance, order, judgment or decree having the force of law applicable to the
Parties and their activities under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Audit
Disagreement</B>&rdquo; has the meaning set forth in Section 6.5(a)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Braeburn</B>&rdquo;
has the meaning set forth in the initial paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Braeburn
Indemnified Party</B>&rdquo; has the meaning set forth in Section&nbsp;9.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Braeburn
Know-How</B>&rdquo; means all unpatented information and Data that are as of the Effective Date or become during the Term Controlled
by Braeburn, including discoveries, Improvements, processes, formulas, inventions, Know-How and trade secrets, to the extent necessary
or useful for the development, manufacture, and/or Commercialization of a Sublicensed Product. Braeburn Know-How does not include
any Patent Rights. Braeburn Know-How also includes all marketing authorizations and marketing approvals granted by Regulatory
Authorities (e.g., approved NDAs, INDs and related applications and other forms of marketing authorization) to and Controlled
by Braeburn for the marketing of Sublicensed Products. Such marketing authorizations and marketing approvals shall be deemed embodiments
of Data and Braeburn Know-How.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Braeburn
Marks</B>&rdquo; means the marks owned or licensed by Braeburn set forth in <U>Schedule A</U> and any other marks Braeburn may
adopt from time to time, for use for the Sublicensed Products which shall be deemed to automatically be incorporated into <U>Schedule
A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Braeburn
Patents</B>&rdquo; means all Patent Rights in the Territory that are as of the Effective Date or become during the Term Controlled
by Braeburn and that generically or specifically claim, or would be reasonably necessary for, the making, having made, use, offer
for sale, sale or importation of the Sublicensed Products or claim any Improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Business
Day</B>&rdquo; means any day other than (i) Saturday or Sunday or (ii) a day that is a legal holiday in either of Montreal, Qu&eacute;bec
or New York, New York, or (iii) any other day on which banks in either of Montreal, Qu&eacute;bec or New York, New York are required
to be closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Calendar
Quarter</B>&rdquo; means the three (3) month periods ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31
in each Calendar Year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Calendar
Year</B>&rdquo; means, in respect of any particular year, the one (1) year period beginning on January&nbsp;1 and ending on December
31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Commercialize</B>&rdquo;
means marketing, using, distributing, Promoting, offering for sale, and selling the Sublicensed Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Commercialization
Plan</B>&rdquo; means the plan relating to the Promotion and sale of Sublicensed Product for the Initial Indication and, as applicable,
each Subsequent Indication, which shall set forth in reasonable detail at least the following: (a)&nbsp;activities and estimated
timelines relating to the Launch of Sublicensed Product in the Territory, including a description of the educational, marketing,
commercialization and other Promotion activities and materials related to the Sublicensed Product (including a summary of sales
efforts to be dedicated to the Promotion of the Sublicensed Product,); (b) a budget estimating costs to be incurred in performing
such activities, in the aggregate, by Calendar Quarter and by Calendar Year; and (c) sales forecasts for the first three (3) Calendar
Years commencing in the Calendar Year in which Launch is projected to occur, including forecasted Permitted Deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Commercially
Reasonable Efforts</B>&rdquo; means, with respect to (a) Knight, that degree of skill, effort, expertise, and resources normally
used (including the promptness in which such efforts and resources would be applied) consistent with standards generally accepted
in the pharmaceutical industry, including with respect to the diligent commercialization of pharmaceutical products of similar
market and profit potential at a similar stage in development or product life as the Sublicensed Products; and (b) Braeburn, that
degree of skill, effort, expertise, and resources normally used (including the promptness in which such efforts and resources
would be applied) consistent with standards generally accepted in the pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Competitive
Product</B>&rdquo; means any pharmaceutical product that (i) contains buprenorphine (in any form or formulation, including any
pharmaceutically acceptable salts, esters, solvates, hydrates, polymorphs, crystal forms, prodrugs and tautomers) as an active
ingredient and (ii) is intended for a treatment duration of six months or more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Confidential
Information</B>&rdquo; has the meaning set forth in Section 10.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Control</B>&rdquo;
means, with respect to any material, information, or intellectual property right, that a Party (i) owns or (ii) has a license
to, and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing
on the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other arrangement
with any Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Data</B>&rdquo;
means any and all research data, pharmacology data, preclinical data, clinical data, medical chemistry, commercial, marketing,
process development, manufacturing and other data or information, including investigator reports (both preliminary and final),
statistical analyses, expert opinions and reports, and safety data, in each case generated from clinical or non-clinical studies,
research or testing specifically related or directed to the Sublicensed Product(s), together with all documentation submitted,
or required to be submitted, to a Regulatory Authority in association with a Regulatory Submission or similar application for
a Sublicensed Product (excluding any Drug Master Files (DMFs), Chemistry, Manufacturing and Control (CMC) data, or similar documentation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Data
Package</B>&rdquo; has the meaning set forth in Section 2.9(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Effective
Date</B>&rdquo; means the date specified in the initial paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>EMA</B>&rdquo;
has the meaning set forth in Section 3.5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Excluded
Transaction</B>&rdquo; has the meaning set forth in Section 2.9(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration and any successor agency having substantially the same functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Field</B>&rdquo;
means the Initial Indication and/or any Subsequent Indications for Sublicensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Final
Royalty Period</B>&rdquo; has the meaning set forth in Section 6.3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Final
Royalty True-Up Report</B>&rdquo; has the meaning set forth in Section 6.3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>First
Commercial Sale</B>&rdquo; means the first sale to a Third Party of a Sublicensed Product in the Territory for value after Regulatory
Approval has been obtained in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Force
Majeure</B>&rdquo; has the meaning set forth in Section&nbsp;13.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Government
List</B>&rdquo; has the meaning set forth in Section 9.2(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Governmental
Authority</B>&rdquo; means any domestic or foreign entity exercising executive, legislative, judicial, regulatory or administrative
functions of or pertaining to government, including any governmental authority, agency, department, board, commission, court,
tribunal, judicial body or instrumentality of any union of nations, federation, nation, state, municipality, county, locality
or other political subdivision thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Health
Canada</B>&rdquo; means Health Canada and any successor agency having substantially the same functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>IFRS</B>&rdquo;
means, at any time, the International Financial Reporting Standards, promulgated by the International Accounting Standards Board,
as amended, supplemented or replaced from time to time, and in general use for public company accounting and reporting in Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Improvements</B>&rdquo;
<FONT STYLE="font-size: 10pt">means all modifications, alterations, improvements,</FONT> any reformulation or line extension,
other advances, enhancements<FONT STYLE="font-size: 10pt">, inventions and Know-How, patentable or otherwise, made, created, developed,
discovered, conceived or reduced to practice by or on behalf of a Party and/or any of its Affiliates during the Term, that apply
to Sublicensed Products, including developments in the manufacture, formulation, ingredients, preparation, presentation, means
of delivery or administration, dosage, Indication, methods of use or packaging and/or sale of Sublicensed Products, including
a process for manufacturing a Sublicensed Product, an intermediate used in such process, a formulation of a Sublicensed Product,
or a use or Indication of a Sublicensed Product. Notwithstanding anything in the preceding sentence, an Improvement shall not
include Regulatory Approval to Commercialize a Sublicensed Product for a Subsequent Indication. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Independent
Expert</B>&rdquo; has the meaning set forth in Section 6.5(a)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Indication</B>&rdquo;
means any human disease or condition, or sign or symptom of a human disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Initial
Indication</B>&rdquo; means the use of a Sublicensed Product for the treatment of opioid addiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Initial
Term</B>&rdquo; has the meaning set forth in Section&nbsp;11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Invention</B>&rdquo;
has the meaning set forth in Section 8.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Knight</B>&rdquo;
has the meaning set forth in the initial paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Knight
Indemnified Party</B>&rdquo; has the meaning set forth in Section&nbsp;9.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Knight
Offer</B>&rdquo; has the meaning set forth in Section 2.9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Knight
Sales Force</B>&rdquo; means the professional trained sales force employed or retained (as consultants, contract sales force or
otherwise) by Knight to support its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Knight
Waiver Notice</B>&rdquo; has the meaning set forth in Section 2.9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Know-How</B>&rdquo;
means any non-public information, ideas, Data, inventions, works of authorship, trade secrets, technology, or materials, including
formulations, molecules, assays, reagents, compounds, compositions, human or animal tissue, samples or specimens, and combinations
or components thereof, whether or not proprietary or patentable, and whether stored or transmitted in oral, documentary, electronic
or other form, including all Regulatory Submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Launch</B>&rdquo;
means the First Commercial Sale of a Sublicensed Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Losses</B>&rdquo;
means any and all damages of any kind whatsoever (including all incidental, consequential, statutory and treble damages), awards,
deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, judgments (including penalties imposed by any
Governmental Authority), costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including court
costs, interest and reasonable fees of attorneys, accountants and other experts) and other monetary obligations arising out of
or resulting from claims or judgments, arbitral awards, including amounts paid in settlement of claims, judgments, legal (including
judicial, arbitral and administrative) proceedings and the like, incurred or otherwise payable to Third Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>NDA
Transfer Date</B>&rdquo; means the NDA Transfer Date as such term is defined in the Titan Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Net
Sales</B>&rdquo; means the total gross amount invoiced (such amount, &ldquo;<B>Gross Sales</B>&rdquo;) for all commercial sales
of Sublicensed Products to Third Parties in the Territory by Knight, its Affiliates or its or their sublicensees, less the following
deductions actually allowed, granted or reserved in accordance with IFRS (collectively, the &ldquo;Permitted Deductions&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">credits
                                         or allowances for damaged or spoiled Sublicensed Product, returns, Recalls or rejections
                                         of such Sublicensed Product, and to the extent granted or allowed with respect to the
                                         then-current Calendar Year, retroactive price adjustments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">ii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">normal
                                         and customary trade, cash and quantity discounts, allowances and credits for such Sublicensed
                                         Product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">iii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">sales,
                                         excise or similar taxes, tariffs and duties paid or allowed, or other governmental charges
                                         imposed upon the importation, use or sale of such Sublicensed Product in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">iv.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">fees
                                         paid to Third Party distributors and legally allowed chargebacks, rebates or similar
                                         payments to customers with respect to such Sublicensed Product, including managed health
                                         care organizations, wholesalers, distributors, buying groups, retailers, health care
                                         insurance carriers, pharmacy benefit management companies, health maintenance organizations
                                         or other institutions or health care organizations or to any Governmental Authority or
                                         Regulatory Authority, including, but not limited to any federal, state/provincial, local
                                         and other governments, their agencies and purchasers and reimbursers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">v.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">special
                                         packaging costs, freight, postage, shipping and insurance charges related to delivery
                                         of such Sublicensed Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">Sales
or other transfers between Knight, its Affiliates or its or their sublicensees and any dispositions of such Sublicensed Product
for pre-clinical or clinical testing required in connection with obtaining Regulatory Approval of Sublicensed Product, in each
case, without charge, shall be excluded from the computation of Net Sales and no payments will be payable to Braeburn on such
sales or transfers except where such Affiliates or sublicensees are end users, but Net Sales shall include the subsequent sales
to Third Parties by such Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">Any
of the Permitted Deductions shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such entity
and there shall be no double-counting in determining Permitted Deductions. For purposes of determining Net Sales, a Sublicensed
Product shall be deemed to be sold when paid or invoiced in accordance with Knight&rsquo;s Accounting Standards. No more than
one royalty payment shall be due with respect to a sale of a particular Sublicensed Product. In the event that Knight, its Affiliate
or its or their sublicensees sells the Sublicensed Product as part of a bundle or group sale with other products not covered by
this Agreement, and Knight, its Affiliate or its or their sublicensees provides a discount, allowance or rebate to the purchaser
of the Sublicensed Product based on the aggregate amount invoiced for all products sold, such discount, allowance or rebate shall
be allocated to each of the products pro rata based on the gross amount invoiced for each such product less all other Permitted
Deductions specifically related to each such product, provided that Sublicensed Products do not bear a disproportionate portion
of such deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Non-Renewal
Notice</B>&rdquo; has the meaning set forth in Section&nbsp;11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>OFAC</B>&rdquo;
has the meaning set forth in Section 9.2(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Party</B>&rdquo;
means either Braeburn or Knight and &ldquo;<B>Parties</B>&rdquo; means both Braeburn and Knight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Patent
Rights</B>&rdquo; means any of the following, whether existing now or in the future, in the Territory: (i) patents and patent
applications (including provisional applications); (ii) all patent applications filed either from such patents or patent applications
or from an application claiming priority from either of these, including continuations, continuations-in-part, divisionals, converted
provisionals, continued prosecution applications, and substitute applications; (iii) any patents issued based on or claiming priority
to any such patent applications in (i) and (ii); (iv) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including adjustments, revalidations, renewals, reissues, reexaminations and extensions (including any
supplementary protection certificates and the like) of the foregoing patents or patent applications in (i), (ii) and (iii); (v)
any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent
or registration patent or patents of addition to any of such foregoing patents or patent applications; and (vi) any other patents
and patent applications that dominate the foregoing patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Patriot
Act Offense</B>&rdquo; has the meaning set forth in Section 9.2(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Promotion</B>&rdquo;
means those activities normally undertaken by a pharmaceutical company to implement promotion plans and strategies aimed at encouraging
the appropriate use of a particular prescription pharmaceutical product under a common trademark, up to the point of offering
a product for sale, in each case, in accordance with Applicable Law. When used as a verb, &ldquo;Promote&rdquo; means to engage
in such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Quality
Agreement</B>&rdquo; has the meaning set forth in Section 7.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Recall</B>&rdquo;
has the meaning set forth in Section 5.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Regulatory
Approval</B>&rdquo; means with respect to a pharmaceutical or biological product or medical device in a country or regulatory
jurisdiction, any and all approvals, licenses, permits, certifications, registrations or authorizations from the relevant Regulatory
Authority in such regulatory jurisdiction that is specific to such product and necessary for the Promotion and commercial sale
of such product in such country or regulatory jurisdiction (including pricing and/or reimbursement approval in any country in
which pricing and/or reimbursement approval is required by Applicable Laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Regulatory
Authority</B>&rdquo; means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved
in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement
approval of a Sublicensed Product in such country or regulatory jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Regulatory
Submissions</B>&rdquo; means all applications, filings, dossiers, modifications, amendments, supplements, revisions, reports,
submissions, authorizations and approvals, and any reports or amendments necessary to maintain Regulatory Approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Renewal
Term</B>&rdquo; has the meaning set forth in Section&nbsp;11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>ROFN
Negotiation Period</B>&rdquo; has the meaning set forth in Section 2.9(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>ROFN
Product</B>&rdquo; means a product, other than a Sublicensed Product, Controlled by Braeburn or its Affiliates during the Term,
rights to which have not been licensed or sublicensed in the Territory to a Third Party prior to the Term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Royalties</B>&rdquo;
has the meaning set forth in Section 6.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Royalty
Report</B>&rdquo; has the meaning set forth in Section 6.3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Royalty
True-Up</B>&rdquo; has the meaning set forth in Section 6.3(a)(iii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>SDEA</B>&rdquo;
means the Safety Data Exchange Agreement to be entered into by the Parties in accordance with the terms and conditions of this
Agreement and the Titan Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Sublicensed
Product</B>&rdquo; means that certain buprenorphine subdermal implant licensed by Braeburn and known as of the Effective Date
as Probuphine for use in the Field, including all Improvements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Sublicensed
Product Label(ing)</B>&rdquo; has the same meaning as defined in the United States Food, Drug, and Cosmetic Act of 1938, as amended,
and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time,
and as interpreted by the FDA, and any analogous Applicable Laws as interpreted by an applicable Regulatory Authority in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Sublicensed
Product NDS</B>&rdquo; means a New Drug Submission that is submitted to Health Canada to apply for Regulatory Approval of a Sublicensed
Product for the Initial Indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Sublicensed
Product Trademark(s)</B>&rdquo; means the Probuphine trademark, owned by Titan, and licensed to Braeburn under the Titan Agreement,
and all related domain names and other trademark related rights, and/or any other trademark that Braeburn may apply to register
in the Territory if such alternate trademark is selected for use in the Promotion of a Sublicensed Product by the Parties under
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Subsequent
Indication</B>&rdquo; means the use of a Sublicensed Product for the treatment of an Indication that is not the Initial Indication.
For clarity, references herein to a &ldquo;Subsequent Indication in the Territory&rdquo; mean a Subsequent Indication as set forth
in a Regulatory Approval for Sublicensed Products in the Territory, and Knight&rsquo;s rights and obligations hereunder with respect
to Subsequent Indications following Launch refer to Subsequent Indications as set forth in a Regulatory Approval for Sublicensed
Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Supply
Agreement</B>&rdquo; has the meaning set forth in Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Supply
Price</B>&rdquo; has the meaning set forth in Section&nbsp;6.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000"><B>&ldquo;Term&rdquo;
</B>means the Initial Term and any Renewal Term, as applicable<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000"><B>&ldquo;Territory</B>&rdquo;
means Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Third
Party</B>&rdquo; means any person other than the Parties and their Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Third
Party Claims</B>&rdquo; has the meaning set forth in Section&nbsp;9.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Third
Party Offer</B>&rdquo; has the meaning set forth in Section&nbsp;2.9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Third
Party Transaction</B>&rdquo; has the meaning set forth in Section&nbsp;2.9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Third
Party Transaction Notice</B>&rdquo; has the meaning set forth in Section&nbsp;2.9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Titan</B>&rdquo;
has the meaning set forth in the recitals to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>Titan
Agreement</B>&rdquo; has the meaning set forth in the recitals to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&ldquo;<B>US
GAAP</B>&rdquo; means, at any time, then-applicable United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Other
                                         Definitional and Agreement References</B>. References to any agreement, contract, statute,
                                         act, or regulation are to that agreement, contract, statute, act, or regulation as amended,
                                         modified or supplemented from time to time in accordance with the terms hereof and thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Ambiguities</B>.
                                         Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective
                                         of which Party may be deemed to have authored the ambiguous provision.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Sections
                                         and Headings</B>. The term &ldquo;Section&rdquo; refers to the specified Section of this
                                         Agreement, unless otherwise specified. Headings and captions of the Sections hereof are
                                         for convenience only and are not to be used in the interpretation of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>United
                                         States Dollars</B>. References in this Agreement to &ldquo;Dollars&rdquo; or &ldquo;$&rdquo;
                                         shall mean the legal tender of United States, unless otherwise noted. Except as otherwise
                                         provided in this Agreement, all payments required to be made by or on behalf of a Party
                                         under this Agreement shall be paid in United States Dollars, and to the extent necessary,
                                         shall be converted into United States Dollars using the spot rate of exchange for conversion
                                         into United States Dollars as published in The Wall Street Journal on the Business Day
                                         prior to the date any such payment is made.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Date
                                         References</B>. References from or through any date mean, unless otherwise specified,
                                         from and including or through and including, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Gender
                                         and Person</B>. Words of one gender include the other gender. Unless the context otherwise
                                         requires, references to a &ldquo;person&rdquo; in this Agreement include any individual,
                                         corporation, company, partnership, joint venture, trust, governmental body, authority,
                                         or other entity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Include,
                                         Includes, Including</B>. Whenever the words &ldquo;include&rdquo;, &ldquo;includes&rdquo;
                                         or &ldquo;including&rdquo; are used in this Agreement, they shall be deemed to be followed
                                         by the words &ldquo;without limitation&rdquo;, whether or not they are in fact followed
                                         by those words or words of like import.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Knowingly</B>.
                                         The term &ldquo;knowingly&rdquo; as used in this Agreement means actual knowledge or
                                         reasonable reason to suspect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>No
                                         Strict Construction</B>. This Agreement has been prepared jointly and shall not be strictly
                                         construed against either Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Number
                                         of Days</B>. Whenever this Agreement refers to a number of days, unless otherwise specified,
                                         such number shall refer to calendar days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Party
                                         References</B>. Reference to any Party includes the successors and permitted assigns
                                         of that Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Singular/Plural</B>.
                                         Words using the singular or plural number also include the plural or singular number,
                                         respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>GRANT
                                         OF RIGHTS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Effectiveness</B>.
                                         This Agreement shall be effective as of the Effective Date, but the Parties agree and
                                         acknowledge that certain rights and obligations under this Agreement shall not become
                                         effective until the NDA Transfer Date. Notwithstanding the foregoing, the Parties agree
                                         and acknowledge that following the Effective Date, Knight may, to the extent permitted
                                         under the Titan Agreement, undertake such activities as are reasonably necessary to prepare
                                         for the NDA Transfer Date, provided that Knight shall keep Braeburn reasonably informed
                                         with respect to any such activities, and Braeburn shall reasonably cooperate with and
                                         assist Knight in any such activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>General</B>.
                                         Pursuant to Section 2.6 of the Titan Agreement, this Agreement is subject to, and Knight
                                         agrees that it shall be bound by, the terms and conditions of the Titan Agreement, including
                                         the provisions relating to payments set forth in Article 6 of the Titan Agreement. In
                                         the event of any conflict between the terms and conditions of this Agreement and the
                                         terms and conditions of the Titan Agreement, the terms and conditions of the Titan Agreement
                                         shall govern and control.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Appointment;
                                         Sublicense</B>. Subject to the terms and conditions of this Agreement and the Titan Agreement,
                                         Braeburn, on behalf of itself and its Affiliates, hereby (a) appoints Knight as its exclusive
                                         distributor of Sublicensed Products in the Territory and in the Field for the Term, and
                                         (b) grants to Knight, and Knight hereby accepts, for the Term, and for the Territory
                                         and in the Field, an exclusive sublicense under the Braeburn Patents and Braeburn Know-How
                                         to Commercialize the Sublicensed Products. For the avoidance of doubt, references to
                                         &ldquo;Sublicensed Products&rdquo; in this Section 2.3 include the Sublicensed Products
                                         for the Initial Indication, any Subsequent Indications, and Sublicensed Products with
                                         any Improvements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Sublicensing</B>.
                                         Subject to the terms and conditions of this Agreement and the Titan Agreement, Knight
                                         may sublicense its rights granted hereunder to any Affiliate of Knight or any Third Party,
                                         or use any sub-distributors or Third Party contractors to exercise its rights or fulfill
                                         its obligations hereunder. Knight shall advise Braeburn in advance of any proposed sublicense
                                         and consider in good faith Braeburn&rsquo;s comments with respect thereto. Without limiting
                                         the foregoing, and notwithstanding anything else contained herein to the contrary, Knight
                                         may not make, grant, enter into or otherwise commit to any sublicense of its rights granted
                                         hereunder, including to any Affiliate, prior to the NDA Transfer Date without the prior
                                         written consent of Braeburn. <FONT STYLE="background-color: white">All</FONT> sublicense
                                         agreements, distribution or other arrangements or agreements shall be subject to and
                                         consistent with the terms and conditions of this Agreement and the Titan Agreement, and
                                         any sublicensees, distributors or other party shall be bound by the terms and conditions
                                         of this Agreement and the Titan Agreement, including the provisions relating to payments
                                         set forth in Article 6 of the Titan Agreement. Knight assumes full responsibility for
                                         any actions taken or any failures to act by any sublicensee, distributor or other person
                                         and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other
                                         person. In the event Knight grants a sublicense to an Affiliate, any payment due to Braeburn
                                         under this Agreement must be received in its full amount by Braeburn in the United States,
                                         and in United States Dollars, without any tax withholding or tax deduction therefrom,
                                         except as provided under Section 13.1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>No
                                         Implied Licenses</B>. All rights not specifically granted to Knight herein are reserved
                                         and retained by Braeburn, including, without limitation, with respect to the period between
                                         the Effective Date and the NDA Transfer Date. Neither Party grants to the other Party
                                         any right or license to use any of its intellectual property, Know-How or other proprietary
                                         information, materials or technology, or to practice any of its patent, trademark, or
                                         trade dress rights, except as expressly set forth in this Agreement. Except as otherwise
                                         permitted in this Agreement, Knight shall not grant any license to, or permit or authorize,
                                         any Third Party to Promote Sublicensed Products in the Territory without the prior written
                                         consent of Braeburn.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Restriction
                                         on Knight Sales</B>. Knight shall not, either directly or indirectly (including through
                                         any Affiliate, representative, agent or sublicensee) knowingly: (i) sell or otherwise
                                         dispose of Sublicensed Products to any Third Party outside the Territory; (ii) sell or
                                         otherwise dispose of Sublicensed Products to any Third Party within the Territory for
                                         the purpose of sale or other disposition to any Third Party outside the Territory; (iii)
                                         knowingly distribute any Sublicensed Products for sale or use outside the Territory;
                                         or (iv) supply any Third Party that has distributed or offered to distribute Sublicensed
                                         Products outside the Territory after Knight has knowledge that said Third Party has distributed
                                         or offered to distribute Sublicensed Products outside the Territory. If Knight knows
                                         or has reason to suspect that a Third Party to whom Knight sells or otherwise disposes
                                         of Sublicensed Products is engaged in the sale or distribution of Sublicensed Products
                                         for use outside the Territory, then Knight shall (A) within two (2) Business Days after
                                         gaining knowledge of, or reason to suspect, such activities notify Braeburn thereof and
                                         provide all information in Knight&rsquo;s possession that Braeburn may reasonably request
                                         concerning such activities, and (B) take all reasonable steps (including cessation of
                                         sales, directly or indirectly, to such Third Party) necessary to limit such sale or other
                                         disposition for use outside the Territory. All inquiries or orders received by Knight
                                         for Sublicensed Product to be delivered outside the Territory shall be referred to Braeburn.
                                         Knight shall use Commercially Reasonable Efforts to cause each of its Affiliates, representatives,
                                         agents and sublicensees (other than Braeburn) to comply with the obligations of Knight
                                         under this Section 2.6. For the avoidance of doubt, references to &ldquo;Sublicensed
                                         Products&rdquo; in this Section 2.6 include the Sublicensed Products for the Initial
                                         Indication, any Subsequent Indications, and Sublicensed Products with any Improvements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Restriction
                                         on Braeburn Sales. </B>Braeburn shall not knowingly: (i) solicit or accept orders <FONT STYLE="background-color: white">for
                                         </FONT>distribution of Sublicensed Products to a Third Party for sale or distribution
                                         in the Territory; (ii) distribute any Sublicensed Products for sale or use in the Territory;
                                         or (iii) supply any Third Party that has distributed or offered to distribute Sublicensed
                                         Products in the Territory after Braeburn has knowledge that said Third Party has distributed
                                         or offered to distribute Sublicensed Products obtained from Braeburn in the Territory.
                                         For the avoidance of doubt, references to &ldquo;Sublicensed Products&rdquo; in this
                                         Section 2.7 include the Sublicensed Products for the Initial Indication, any Subsequent
                                         Indications, and Sublicensed Products with any Improvements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Performance
                                         by Affiliates</B>. The Parties agree that their respective rights and obligations may
                                         be exercised or performed by any of their Affiliates; provided, however, that each Party
                                         shall (a) provide prior written notice to the other Party of such exercise or performance
                                         by any such Affiliate, (b) be fully responsible and liable for the actions and omissions
                                         of such Affiliate(s) in the exercise or performance of such rights and obligations, and
                                         (c) ensure that such Affiliate(s) comply with the terms and conditions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Right
                                         of First Negotiation.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If,
                                         at any time during the Term, Braeburn or any of its Affiliates intends to license or
                                         sublicense its right to develop or Commercialize a ROFN Product in the Territory (or
                                         any part thereof) to any Third Party in order to permit such Third Party to develop or
                                         Commercialize the ROFN Product in the Territory (but not including any Excluded Transaction),
                                         then prior to negotiating with any Third Party to license or sublicense such development
                                         or commercialization right, Braeburn shall first notify Knight of its intent, provide
                                         to Knight a copy of material data with respect to the development and commercialization
                                         of such ROFN Product in Braeburn&rsquo;s possession and Control not previously provided
                                         to Knight and that shall be reasonably sufficient to assess the ROFN Product (the &ldquo;<B>Data
                                         Package</B>&rdquo;), and shall, unless Knight notifies Braeburn in writing during the
                                         ROFN Negotiation Period that it is not interested in acquiring rights to a particular
                                         ROFN Product (a &ldquo;<B>Knight Waiver Notice</B>&rdquo;), negotiate solely and in good
                                         faith with Knight for a period commencing upon the date Knight receives the Data Package
                                         from Braeburn and expiring forty-five (45) days thereafter (the &ldquo;<B>ROFN Negotiation
                                         Period</B>&rdquo;) with respect to mutually agreeable binding financial terms (&ldquo;<B>Binding
                                         Financial Terms&rdquo;) </B>for the acquisition by Knight, by license, sublicense, or
                                         otherwise, of the right to develop or Commercialize the ROFN Product in the Territory
                                         (or the applicable part thereof). The Parties agree and acknowledge that such commercially
                                         reasonable terms and conditions may be substantially different from the terms and conditions
                                         of this Agreement. All information provided by Braeburn to Knight pursuant to this Section
                                         2.9 shall constitute Confidential Information of Braeburn.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         Knight delivers a Knight Waiver Notice regarding a ROFN Product, then Braeburn may subsequently
                                         offer a Third Party, or solicit offers from Third Parties for, and take any action in
                                         furtherance of (including providing information, participating in discussions, and/or
                                         engaging advisors or agents), a license, sublicense or other transfer of its rights to
                                         develop or Commercialize such ROFN Product in the Territory (or any part thereof) (a
                                         &ldquo;<B>Third Party Offer</B>&rdquo;), and Braeburn shall have no further obligations
                                         to Knight regarding such ROFN Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         Knight does not provide a Knight Waiver Notice and the Parties do not sign a letter related
                                         the Binding Financial Terms with respect to the development or commercialization of a
                                         ROFN Product during the ROFN Negotiation Period, then Braeburn may subsequently offer
                                         a Third Party, or solicit offers from Third Parties for, and take any action in furtherance
                                         of (including providing information, participating in discussions, and/or engaging advisors
                                         or agents), a license, sublicense or other transfer of its rights to develop or Commercialize
                                         such ROFN Product in the Territory (or any part thereof) (a &ldquo;<B>Third Party Offer</B>&rdquo;);
                                         provided, that Braeburn may not accept or enter into any agreement with any Third Party
                                         with respect to a Third Party Offer (a &ldquo;<B>Third Party Transaction</B>&rdquo;)
                                         without first (i) notifying Knight in writing of any proposed Third Party Transaction,
                                         which notice shall include, in reasonable detail, the material terms and conditions thereof
                                         (a &ldquo;<B>Third Party Transaction Notice</B>&rdquo;), and (ii) providing Knight a
                                         period of five (5) Business Days to propose, in reasonable detail, terms and conditions
                                         for the acquisition by Knight, by license, sublicense, or otherwise, of the right to
                                         develop or Commercialize such ROFN Product in the Territory that are, as a, at least
                                         favorable to Braeburn as the proposed Third Party Transaction (a &ldquo;<B>Knight Offer</B>&rdquo;).
                                         In the event Knight delivers a Knight Offer within such five (5) Business Day period,
                                         Braeburn shall negotiate in good faith with Knight for a period of not less than ten
                                         (10) Business Days with respect to the Knight Offer, and during such period Braeburn
                                         may not enter into a Third Party Transaction unless Knight withdraws the Knight Offer.
                                         If Knight withdraws the Knight Offer or the Parties do not enter into a written agreement
                                         with respect to the Knight Offer within such ten (10) Business Day period, then Braeburn
                                         shall be free to enter into such Third Party Transaction, or any other transaction involving
                                         Braeburn&rsquo;s rights to develop or Commercialize the ROFN Product in the Territory
                                         and Braeburn shall have no obligation to provide Knight any further opportunity to offer
                                         a new proposal for the acquisition by Knight of the ROFN product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Notwithstanding
                                         anything contained herein to the contrary, it is agreed and acknowledged that the rights
                                         and obligations of Knight and Braeburn under this Section 2.9 shall apply only to potential
                                         licenses or sublicenses of Braeburn&rsquo;s right to develop or Commercialize a ROFN
                                         Product in the Territory (or any part thereof) without a grant of rights with respect
                                         to the ROFN Product in any other country or jurisdiction (or any part thereof). For clarity,
                                         the rights and obligations of Knight and Braeburn under this Section 2.9 shall not apply
                                         to (i) any sale or change of control of Braeburn or any of its Affiliates, (ii) any sale
                                         or transfer of all or substantially all of the assets, business or operations of Braeburn
                                         or any of its Affiliates, or all or substantially all of the business or operations of
                                         Braeburn or any of its Affiliates relating to any ROFN Product, or (iii) any license,
                                         sublicense or other transfer of Braeburn&rsquo;s right to develop or Commercialize a
                                         ROFN Product that relates to a geographic territory that includes the Territory and at
                                         least one other country (each of (i)-(iii), without limitation, an &ldquo;<B>Excluded
                                         Transaction</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">2.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Non-Competition.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">During
                                         the Term, Knight will not Promote, or permit its Affiliates to Promote, market or sell
                                         a Competitive Product in the Territory, or acquire, or permit its Affiliates to acquire,
                                         directly or indirectly any rights or interest in or to any Competitive Product that is
                                         being Promoted, marketed or sold in the Territory, if such Competitive Product has Regulatory
                                         Approval for, or is otherwise not prohibited by a Regulatory Authority from being marketed
                                         for, either the Initial Indication or a Subsequent Indication other than Sublicensed
                                         Product sublicensed to Knight under this Agreement. Notwithstanding anything in the preceding
                                         sentence, Knight shall only be prohibited from Promoting, marketing or selling a Competitive
                                         Product for a Subsequent Indication if there is FDA Regulatory Approval for such Subsequent
                                         Indication prior to such time as Knight begins to Promote, market or sell such Competitive
                                         Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">During
                                         the Term, Braeburn will not Promote, or permit its Affiliates to Promote, market or sell
                                         a Competitive Product in the Territory, or acquire, or permit its Affiliates to acquire,
                                         directly or indirectly any rights or interest in or to any Competitive Product that is
                                         being Promoted, marketed or sold in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Subject
                                         to Section 2.9, nothing in this Section 2.10 shall prevent either party from marketing,
                                         in the Territory, pharmaceutical products other than Sublicensed Products and Competitive
                                         Products, including pharmaceutical products that contain buprenorphine with a treatment
                                         duration of one week or one month.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>REGULATORY
                                         AND DEVELOPMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">Following
the NDA Transfer Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>General</B>.
                                         Subject to the terms and conditions of this Agreement, Knight shall during the Term use
                                         Commercially Reasonable Efforts to obtain and maintain Regulatory Approval in the Territory
                                         for the Sublicensed Products for (a) the Initial Indication and (b) any Subsequent Indication
                                         that receives Regulatory Approval in any jurisdiction.&nbsp; Without limiting the foregoing,
                                         Knight shall file or cause to be filed with Health Canada a Sublicensed Product NDS with
                                         respect to the Sublicensed Products and the Initial Indication the later of i) ten (10)
                                         months from receiving the complete FDA dossier from Braeburn or ii) ten (10) weeks from
                                         having received the GMP approval from Health Canada.. Knight will be solely responsible
                                         for all costs associated with, or required for the approval of, the Sublicensed Products
                                         by Health Canada and other applicable Regulatory Authorities in the Territory. Knight
                                         shall notify Braeburn of all Regulatory Submissions relating to a Sublicensed Product
                                         in the Territory, and provide Braeburn with (i) a written semiannual report summarizing
                                         in reasonable detail Knight&rsquo;s activities and progress related to the development
                                         of the Sublicensed Products in the Territory, including information regarding the status
                                         of Regulatory Submissions filed and intended to be filed with Regulatory Authorities
                                         and Regulatory Approvals in the Territory, (ii) a copy of any annual reports submitted
                                         to Regulatory Authorities by or on behalf of Knight with respect to the Sublicensed Products
                                         in connection with the periodic reporting requirements set forth by Applicable Laws,
                                         and (iii) such other information as may be reasonably requested by Braeburn or required
                                         under the Titan Agreement. Knight shall use the FDA Regulatory Submissions it receives
                                         from Braeburn as the basis of the Sublicensed Product NDS and Knight shall be responsible
                                         for the filing and maintenance fees in connection therewith. For the avoidance of doubt,
                                         under no circumstance shall Knight be responsible for conducting any additional clinical
                                         or non-clinical studies (or any costs associated therewith) with respect to the Sublicensed
                                         Product and it shall not be considered to be commercially reasonable to require Knight
                                         to do so.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Regulatory
                                         Submissions</B>. With respect to the Commercialization of the Sublicensed Products in
                                         the Territory:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Unless
                                         otherwise required by Applicable Law, any Regulatory Approvals and all Regulatory Submissions
                                         relating to Sublicensed Products in the Territory shall be filed, owned and held in the
                                         name of Knight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         shall be solely responsible, at its expense, and shall use Commercially Reasonable Efforts
                                         to timely prepare, file, prosecute, and maintain all Regulatory Submissions relating
                                         to Sublicensed Products in the Territory, including any reports or amendments necessary
                                         to maintain Regulatory Approvals, and for seeking any revisions of the conditions of
                                         each Regulatory Approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         shall have sole authority and responsibility and shall use Commercially Reasonable Efforts
                                         to develop, modify, seek and/or obtain any necessary Regulatory Approvals of any Sublicensed
                                         Product Labeling, packaging, advertising or other promotional or informational materials
                                         used in connection with Sublicensed Products in the Territory, and Promotional Materials
                                         and for determining whether the same requires Regulatory Approval. Braeburn shall provide
                                         to Knight copies of all material FDA Regulatory Submissions in its possession and Control
                                         reasonably related to the Sublicensed Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         will be the primary contact with the Regulatory Authorities in the Territory and shall
                                         be solely responsible for all communications with such Regulatory Authorities that relate
                                         to any Regulatory Submission relating to Sublicensed Products in the Territory prior
                                         to and after any Regulatory Approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Subject
                                         to the terms and conditions of this Agreement, Knight may file any submissions that are
                                         intended to change or modify Sublicensed Product Labeling or prescribing information
                                         approved by the applicable Regulatory Authority for, or the Indications of, Sublicensed
                                         Products in the Territory provided that, except as required by Applicable Laws, it provides
                                         to Braeburn a draft of such submission at least fifteen (15) Business Days prior to planned
                                         submission to the applicable Regulatory Authority and gives prompt and reasonable consideration
                                         to any comments Braeburn may have.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">To
                                         the extent Braeburn reasonably believes that a filing or submission relating to Sublicensed
                                         Products in the Territory is required by Applicable Laws in order to sell or continue
                                         selling the Sublicensed Products, Braeburn shall notify Knight in writing. If Knight
                                         decides not to prepare such filing or submission, it shall promptly notify Braeburn of
                                         such decision and Braeburn shall, acting reasonably, be entitled to prepare such filing
                                         or submission, at Knight&rsquo;s sole cost and expense (provided that such costs and
                                         expenses are commercially reasonable given such filing requirements), to be filed or
                                         submitted by Knight; provided that Braeburn shall use good faith efforts to include any
                                         comments of Knight in such filing or submission.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         shall permit Braeburn to access, and shall provide Braeburn on a timely basis with the
                                         right to cross-reference and use in exercising its rights and performing its obligations
                                         hereunder with respect to Sublicensed Products in the Territory and for Braeburn to use
                                         in connection with the development and commercialization of Sublicensed Products outside
                                         of the Territory, any and all Regulatory Submissions related to the Sublicensed Products
                                         Controlled by Knight. At the request of Braeburn and to the extent legally permitted
                                         and in accordance with the terms and conditions of this Agreement, Knight shall notify
                                         the appropriate Regulatory Authorities, as applicable, of Braeburn&rsquo;s right to reference
                                         such Regulatory Submissions in regulatory submissions filed by Braeburn in accordance
                                         with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         shall permit Knight to access, and shall provide Knight on a timely basis with the right
                                         to cross-reference and use in exercising its rights and performing its obligations hereunder
                                         with respect to Sublicensed Products in the Territory (including for Knight to use in
                                         connection with its Commercialization of Sublicensed Products in the Territory), any
                                         and all Regulatory Submissions related to the Sublicensed Products Controlled by Braeburn.
                                         At the request of Knight and to the extent legally permitted and in accordance with the
                                         terms and conditions of this Agreement, Braeburn shall notify the appropriate Regulatory
                                         Authorities in the Territory of Knight&rsquo;s right to reference such Regulatory Submissions
                                         in regulatory submissions filed by Knight in accordance with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Regulatory
                                         Correspondence</B>. Each Party shall notify the other Party within twenty-four (24) hours
                                         of its receipt of information that: (i) raises any concern regarding the safety of any
                                         Sublicensed Product(s); (ii) concerns suspected or actual tampering, counterfeiting or
                                         contamination or other similar problems with respect to any Sublicensed Product(s); (iii)
                                         is reasonably likely to lead to a Recall or market withdrawal of any Sublicensed Product(s);
                                         or (iv) concerns any ongoing or potential investigation, inspection, detention, seizure
                                         or injunction by a Regulatory Authority involving any Sublicensed Product(s). Each Party
                                         shall provide the other Party with copies of any such information. In the event that
                                         a Party receives any material regulatory letter requiring a response, the other Party
                                         will cooperate fully with the receiving Party in preparing such response and will promptly
                                         provide the receiving Party with any data or information reasonably required by the receiving
                                         Party in preparing any such response.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Other
                                         Covenants of Knight</B>. In addition to its other obligations, commitments and undertakings
                                         set out in this Agreement, Knight agrees to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">assume
                                         all expenses related to the Commercialization of the Sublicensed Products in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">use
                                         Commercially Reasonable Efforts to obtain pricing and, if applicable, reimbursement approval
                                         for the Sublicensed Products in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">determine
                                         the actual selling price of the Sublicensed Products to customers in the Territory; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">prepare
                                         an annual marketing and sales plan relating to the Sublicensed Products in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Other
                                         Covenants of Braeburn</B>. In addition to its other obligations, commitments and undertakings
                                         set out in this Agreement, Braeburn agrees to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">provide
                                         Knight with all relevant documentation relating to the submissions for Regulatory Approval
                                         to the FDA or the European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;) for the Sublicensed
                                         Products within one (1) month from such FDA or EMA submissions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">where
                                         applicable, provide reasonable assistance to Knight with Regulatory Submissions concerning
                                         Sublicensed Products in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">provide
                                         full assistance and cooperation with respect to securing intellectual property protection
                                         in the Territory for the Sublicensed Products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">assume
                                         the reasonable costs of intellectual property filings, procurement and maintenance for
                                         all intellectual property applications and registrations associated with the Sublicensed
                                         Products in the Territory<B>]</B>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">not
                                         assign the intellectual property associated with Sublicensed Products to any Third Party;
                                         and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">coordinate
                                         Launch activities with Knight, including pharmacovigilance, pricing, reimbursement, positioning
                                         and health care conferences; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">promptly
                                         provide copies of marketing and sales materials related to the Sublicensed Products used
                                         by Braeburn in the United States.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">For avoidance
                                         of doubt, in the event that the Initial Indication does not receive Regulatory Approval,
                                         Knight shall continue to benefit from the rights granted hereunder with respect to Subsequent
                                         indications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">For the
                                         avoidance of doubt, except as expressly provided herein, Knight&rsquo;s rights and obligations
                                         under this Section 3 shall apply to any Subsequent Indication as contemplated by Section
                                         3.1; provided, that any such rights and obligations with respect to Subsequent Indications
                                         following Launch shall apply only to Subsequent Indications that receive Regulatory Approval
                                         in the Territory</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>TRADEMARKS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Trademark
                                         License</B>. Subject to the terms and conditions of this Agreement, Braeburn hereby grants
                                         to Knight, for the Term, an exclusive, fully paid, right and license to use the Braeburn
                                         Marks and Sublicensed Product Trademarks on or in connection with the Commercialization
                                         of Sublicensed Products in the Territory following the NDA Transfer Date. All representations
                                         of the Braeburn Mark(s) and Sublicensed Product Trademark(s) that Knight intends to use,
                                         if not previously approved by Braeburn, will first be submitted to Braeburn for approval,
                                         such approval not to be unreasonably withheld, conditioned or delayed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Ownership</B>.
                                         Knight acknowledges that the Braeburn Marks and Sublicensed Product Trademarks are owned
                                         or licensed by Braeburn. The Braeburn Marks and Sublicensed Product Trademarks shall
                                         be and remain the sole and exclusive property of Braeburn. Knight shall not contest the
                                         ownership of the Braeburn Marks or the Sublicensed Product Trademarks or the validity
                                         of any registration relating thereto or assist any Third Party in doing so. Knight agrees,
                                         at the request of Braeburn, to execute any and all proper and reasonable documents appropriate
                                         to assist Braeburn in obtaining and maintaining Braeburn&rsquo;s rights in and to the
                                         Braeburn Marks and Sublicensed Product Trademarks.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Sublicensed
                                         Products to Bear Mark</B>. All packaging materials, package inserts, labels, labeling,
                                         and marketing, sales, advertising and Promotional Materials relating to Sublicensed Products
                                         distributed by Knight under this Agreement shall bear the Braeburn Marks and Sublicensed
                                         Product Trademarks together with a notice that the such marks are used under license
                                         from Braeburn, subject to the approval of such labeling by appropriate Governmental Authorities.
                                         Knight shall submit to Braeburn, for prior approval, which shall not be unreasonably
                                         withheld, conditioned or delayed, all materials bearing the Braeburn Marks and/or Sublicensed
                                         Product Trademarks that Knight intends to use with respect to Sublicensed Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Enforcement</B>.
                                         <FONT STYLE="font-size: 10pt">Braeburn and Knight shall cooperate with each other and
                                         use Commercially Reasonable Efforts to protect the Braeburn Marks and Sublicensed Product
                                         Trademarks from infringement by Third Parties. Without limiting the foregoing, each Party
                                         shall promptly notify the other Party of any known, threatened or suspected infringement,
                                         imitation or unauthorized use of or unfair competition relating to the Braeburn Marks
                                         and Sublicensed Product Trademarks and shall share with the other Party all information
                                         available to it regarding such infringement. Braeburn shall have the first right to determine
                                         in its discretion whether to and to what extent to institute, prosecute and/or defend
                                         any action or proceedings involving or affecting any rights relating to the Braeburn
                                         Marks and Sublicensed Product Trademarks in the Territory. Upon Braeburn&rsquo;s reasonable
                                         request, Knight shall cooperate with and assist Braeburn in any of Braeburn&rsquo;s enforcement
                                         efforts with respect to the Braeburn Marks and Sublicensed Product Trademarks in the
                                         Territory. If Braeburn determines not to take action against any actual or suspected
                                         infringement of the Sublicensed Product Trademark in the Territory within ninety (90)
                                         days after having become aware of such infringement, then Knight shall have the right,
                                         but not the obligation, to bring or assume control of any action against the allegedly
                                         infringing Third Party as Knight determines may be necessary in its sole discretion,
                                         </FONT>to the extent permitted under the Titan Agreement<FONT STYLE="font-size: 10pt">.
                                         In the event that Knight brings or assumes control of any such action, then Braeburn
                                         agrees to reasonably assist Knight in connection therewith. The Parties shall share equally
                                         in all costs and expenses reasonably incurred by either of them in connection with any
                                         such action and, following each Party&rsquo;s recovery of its respective costs and expenses,
                                         the Parties will share equally in all money damages, if any, recovered in connection
                                         with such action.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>No
                                         Similar Mark</B>. Neither Knight nor any of its Affiliates or sublicensees <FONT STYLE="background-color: white">will,
                                         without </FONT>Braeburn<FONT STYLE="background-color: white">&rsquo;s prior written consent,
                                         register or use in connection with the </FONT>Commercialization of <FONT STYLE="background-color: white">any
                                         product other than a Sublicensed Product under the Braeburn Marks or the Sublicensed
                                         Product Trademarks or any trade-mark that is confusingly similar to the </FONT>Braeburn
                                         <FONT STYLE="background-color: white">Marks or the Sublicensed Product Trademarks.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>COMMERCIALIZATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>General</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Subject
                                         to the terms and conditions of this Agreement, Knight shall during the Term use Commercially
                                         Reasonable Efforts to Commercialize and Promote the Sublicensed Products in the Territory
                                         following the Regulatory Approval in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Without
                                         limiting the generality of the foregoing, and in accordance with the Commercialization
                                         Plan, Knight shall (i) Launch Sublicensed Product for the Initial Indication and each
                                         Subsequent Indication in the Territory in each case no later than <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]
                                         </B></FONT>after receipt of Regulatory Approval; (ii) expend, in connection with such
                                         Launch of Sublicensed Product, such amounts as are commercially reasonable in connection
                                         with the marketing and Promotion of Sublicensed Products in the Territory, with the objective
                                         of maximizing the commercial potential and promoting the therapeutic profile and benefits
                                         of the Sublicensed Products; and (iii) devote marketing and sales resources and other
                                         personnel to such commercialization consistent with such Commercially Reasonable Efforts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Commercialization
                                         Plan and Promotional Materials and Activities</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Promotional
                                         Materials shall be subject to Braeburn&rsquo;s approval, such approval not to be unreasonably
                                         withheld, conditioned or delayed. Knight will prepare an initial Commercialization Plan,
                                         which will be provided to Braeburn no later than one-hundred and twenty (120) days prior
                                         to estimated receipt of Regulatory Approval for the Sublicensed Product for the Initial
                                         Indication in the Territory, as mutually agreed by the Parties. Knight shall also provide
                                         to Braeburn (i) updates of the Commercialization Plan at least forty-five (45) days prior
                                         to the estimated Launch of the Sublicensed Product for the Initial Indication and, if
                                         applicable, each Subsequent Indication, and thereafter on an annual basis or as necessary
                                         to reflect any significant amendments to the Commercialization Plan last provided to
                                         Braeburn under this Section 5.2(a), (ii) updated information regarding the expected and
                                         actual date of Launch for the Initial Indication and each Subsequent Indication, and
                                         (iii) any sales or tracking reports received by Knight from Third Parties with respect
                                         to the Sublicensed Products. Notwithstanding anything to the contrary in this Agreement,
                                         Braeburn may share the Commercialization Plan and the foregoing information with Titan
                                         to the extent required by the Titan Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">all
                                         Promotional Materials used by Knight will indicate that a Sublicensed Product is sold
                                         under license from Titan and Braeburn. Knight shall limit its statements, discussions
                                         and claims regarding Sublicensed Products, including those as to safety and efficacy,
                                         to those that are consistent with the Sublicensed Product Labeling and the Promotional
                                         Materials. Knight shall not distort claims of safety or efficacy in the Promotion of
                                         the Sublicensed Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         shall be solely responsible for preparing all Regulatory Submissions with Regulatory
                                         Authorities in the Territory regarding approval of all Promotional Materials that require
                                         such approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         and its sublicensees and Third Party contractors shall be responsible for responding
                                         to medical questions or inquiries from members of the medical and paramedical professions
                                         and consumers in or relating to the Territory regarding Sublicensed Products, including
                                         the distribution of standard medical information letters resulting from the marketing
                                         activities of the Knight Sales Force. The Knight Sales Force shall be trained using Braeburn&rsquo;s
                                         training materials, except as otherwise required by Applicable Laws in the Territory.
                                         Braeburn shall refer all medical inquiries that it receives related to the Territory
                                         to Knight. Knight shall provide copies of the responses given, all in accordance with
                                         Applicable Laws, including regulations and policies of Health Canada or the applicable
                                         Regulatory Authority, to Braeburn. Braeburn shall, at Knight&rsquo;s request, from time
                                         to time, assist Knight with the formulation of responses to such inquiries, including
                                         the content of any frequently asked questions materials. If mutually agreed by the Parties,
                                         the Parties shall establish a centralized database to document and track medical inquiries.
                                         Braeburn shall provide information and access to data, records and reports reasonably
                                         requested by Knight to fulfill its obligations under this Section 5.2(d).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         covenants that the Knight Sales Force shall (i) limit its claims of efficacy and safety
                                         for the Sublicensed Products in the Territory to those that are consistent with the prescribing
                                         information approved by the applicable Regulatory Authority for Sublicensed Products
                                         in the Territory; (ii) not add, delete or modify claims of efficacy and safety in the
                                         Promotion of Sublicensed Products under this Agreement from those claims of efficacy
                                         and safety that are consistent with the prescribing information approved by the applicable
                                         Regulatory Authority and with Applicable Law; (iii) use the Promotional Materials in
                                         accordance with this Section 5.3; and (iv) Promote Sublicensed Products under this Agreement
                                         in accordance with Applicable Laws, and in compliance with the then current industry
                                         standards concerning interactions with healthcare professionals.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Safety
                                         Data Exchange Agreement</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">The
                                         Parties agree to develop and commit to a SDEA that allows them to fulfill their respective
                                         regulatory and pharmacovigilance obligations relating to Adverse Experience reporting
                                         to Regulatory Authorities in accordance with Applicable Laws. Such SDEA will be completed
                                         within ninety (90) days after the Effective Date and prior to Launch. Knight shall be
                                         responsible for the timely filing with the applicable Regulatory Authority of all Adverse
                                         Experience reports in the Territory. The SDEA shall provide for the exchange of safety
                                         information between the Parties sufficient to enable each Party to comply with its legal
                                         obligations to report to the applicable Regulatory Authority, for Braeburn to comply
                                         with the Titan Agreement, and include any measures necessary for each Party to comply
                                         with Applicable Laws. Each Party shall promptly provide the other Party with copies of
                                         all such reports, analyses, summaries and all submissions to the applicable Regulatory
                                         Authority. The Adverse Experience procedures utilized in the preparation and filing of
                                         such reports will incorporate the provisions set forth in Section 5.3(b).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Prior
                                         to Launch, Knight will establish a system for the reporting of Adverse Experiences by
                                         patients, physicians and others that is customary for the Territory and that complies
                                         with all Applicable Laws. The costs of such reporting and of all services provided by
                                         any Third Party contractor in connection with Adverse Experiences hereunder shall be
                                         borne by Knight. Knight or a Third Party contractor will timely collect reasonable information
                                         about the Adverse Experiences, initiate and conduct reasonably required investigations,
                                         interact with Braeburn if physical or other testing of a Sublicensed Product appears
                                         to be reasonably required, determine the nature of the Adverse Experience based on data
                                         and reports it has obtained, and issue any reports, analyses or summaries of its activities
                                         as may be required by Applicable Laws. Copies of such reports will be promptly provided
                                         to Braeburn.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">All
                                         safety related reports and correspondence shall be addressed to such safety representative
                                         as may be designated by Braeburn and Knight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Quality
                                         Complaint Reporting. </B>Knight shall be solely responsible for collecting and responding
                                         to any product quality complaint relating to the Sublicensed Products received from a
                                         customer in or relating to the Territory and resulting from use in the Field. Knight
                                         shall investigate and provide Braeburn, in a timely manner, with reports resulting from
                                         such investigations. If Braeburn receives a product quality complaint relating to the
                                         Sublicensed Products from a customer in or relating to the Territory resulting from use
                                         in the Field, it shall promptly notify Knight of such complaint, and Knight will investigate
                                         and promptly report the investigation results to Braeburn and be solely responsible for
                                         communication and response, if any, to any customer(s) in the Territory. Furthermore,
                                         Braeburn shall also be responsible for investigating and reporting the investigation
                                         results to Knight respecting any product quality complaints related to the manufacturing
                                         of the Sublicensed Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Other
                                         Information</B>. In addition to the foregoing information to be provided, each Party
                                         shall provide to the other Party with any: (i) information relating to the efficacy and/or
                                         safety of the Sublicensed Products, including any Recall of the Sublicensed Products;
                                         (ii)&nbsp;complaints from customers, healthcare professionals or competitors in or relating
                                         to the Territory and relating to the Sublicensed Products; (iii) information relating
                                         to any potential liability to any Third Party in or relating to the Territory that is
                                         reasonably likely to arise for either Party in connection with the manufacture<FONT STYLE="background-color: white">,
                                         </FONT>or Commercialization of the Sublicensed Products in or for the Territory; (iv)
                                         information relating to any inspections, inquiries, issues raised or actions taken by
                                         any Governmental Authority <FONT STYLE="background-color: white">in</FONT> or related
                                         to the Territory; and (v) any other information necessary or reasonably desirable to
                                         enable each Party to comply with any Applicable Laws in the Territory or elsewhere.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Recall</B>.
                                         If any Regulatory Authority in the Territory issues or requests a recall, market withdrawal
                                         or other corrective action (a &ldquo;<B>Recall</B>&rdquo;) of a Sublicensed Product,
                                         or if either Party determines that an event, incident or circumstance has occurred that
                                         may indicate the need for a Recall in the Territory, the Party notified of such Recall,
                                         or the Party that desires such Recall, will advise the other Party thereof by telephone
                                         or fax within twenty-four (24) hours of (i) its receipt of notice from a Regulatory Authority
                                         requiring or requesting a Recall or (ii) such Party&rsquo;s determination that a Recall
                                         is indicated, and Braeburn and Knight shall convene a joint telephonic meeting to discuss
                                         such Recall request within twenty-four (24) hours of such notification. Knight shall
                                         include any reasonable recommendation from Braeburn as to the manner of conducting the
                                         Recall, provided that such recommendation is agreeable to the applicable Regulatory Authority
                                         and in accordance with the Applicable Laws. Except as otherwise provided in the foregoing,
                                         Knight shall make all decisions with respect to the execution of any Recall related to
                                         a Sublicensed Product in the Territory, including communicating directly with the applicable
                                         Regulatory Authorities. At Knight&rsquo;s request, Braeburn shall provide, at its cost
                                         reasonable assistance in conducting any such Recall, including providing all pertinent
                                         records that Knight may reasonably request to assist in effecting such action. Neither
                                         Party shall have any obligation to reimburse or otherwise compensate the other Party
                                         or its Affiliates for any consequential damages, lost profits or income that may arise
                                         in connection with any Recall with respect to the Sublicensed Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>NDA
                                         Transfer Date</B>. Notwithstanding anything contained herein to the contrary, to the
                                         extent that certain rights of Knight under this Article 5 (or the exercise by Knight
                                         of such rights, including the filing by Knight of any Regulatory Submission or communication
                                         by Knight with any Regulatory Authority) (a)&nbsp;would require, to the extent provided
                                         in the Titan Agreement, Titan&rsquo;s prior review, consent, or participation, as applicable,
                                         or (b) do not vest in Braeburn under the Titan Agreement in or in relation to the Territory
                                         until the NDA Transfer Date, such rights shall not vest in Knight until the NDA Transfer
                                         Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B><U>PRICES
                                         AND PAYMENTS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Royalties</B>.
                                         In consideration of the rights granted by Braeburn hereunder, during the Term, Knight
                                         will pay to Braeburn the following royalties (&ldquo;<B>Royalties</B>&rdquo;):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Base
                                         royalty: <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>%
                                         of Net Sales on all annual Net Sales up to $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Tier
                                         1: <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>% of
                                         Net Sales on all annual Net Sales exceeding $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>but
                                         below $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Tier
                                         2: <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>% of
                                         net Sales on all annual Net Sales exceeding $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>but
                                         below $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Tier
                                         3: <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>% of
                                         Net Sales on all annual Net Sales exceeding $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">provided,
that if at any time beginning two (2) years following Launch, Braeburn is paying royalties to Titan under the Titan Agreement
in the amount of <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT> percent (<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>%)
of net sales (as described in the Titan Agreement), then the Base royalty and the Tier 1 royalty shall be increased to <FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>percent
<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>%) of Net Sales, such increase to occur coinciding
with any date on which Braeburn owes the above-referenced royalty to Titan and provided further that following the NDA Transfer
Date, Braeburn shall contact Titan to seek to discuss the ability to keep Canadian sales made by Knight as a separate royalty
rate calculation. To the extent royalty rights are successfully renegotiated with Titan, Knight&rsquo;s royalty rates shall remain
as contemplated by (a) through (d) above.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Supply
                                         Price</B>. Knight will pay Braeburn under the Supply Agreement a supply price for each
                                         final packaged kit containing four Sublicensed Product implant rods and applicator in
                                         an amount equal to $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>per
                                         kit (the &ldquo;<B>Supply Price</B>&rdquo;). Nothing other than the final packaged kit
                                         manufactured and/or supplied by Braeburn hereunder or under the Supply Agreement and
                                         included in the Supply Price is required by Knight to fully commercialize the Sublicensed
                                         Product in the Territory. In the event Braeburn changes the format of the packaging or
                                         number of rods contained within each final packaged kit, the Supply Price will be recalculated
                                         to reflect an amount equal to $<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>per
                                         rod. In the event there are greater-than-anticipated cost increases for the manufacture
                                         of Sublicensed Products, Braeburn will be entitled to increase the Supply Price provided
                                         that Braeburn consults with Knight in relation to the reasons for its intended price
                                         increase and it delivers to Knight at least six (6) months advance written notice of
                                         a proposed increase in price and is able to demonstrate based on reasonable documentary
                                         evidence that the proposed price increase corresponds to an increase in the prices of
                                         raw materials and/or production and/or manufacturing processes that necessitate an increase
                                         of the Supply Price (&ldquo;<B>Supply Price Increase</B>&rdquo;). </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Reports
                                         and Payments.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Within
                                         twenty (20) calendar days after the end of each Calendar Quarter following Launch that
                                         begins or ends during the Term, Knight shall furnish to Braeburn a written report (each,
                                         a &ldquo;<B>Royalty Report</B>&rdquo;) showing:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">all
                                         Net Sales during (A) such Calendar Quarter, including a reconciliation to Gross Sales
                                         and a breakdown of all estimated Permitted Deductions from the gross amount invoiced
                                         to arrive at Net Sales, and (B) the Calendar Year to date through the end of such Calendar
                                         Quarter; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">a calculation
                                         of Royalties for such Calendar Quarter; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">if
                                         the actual Net Sales and/or Permitted Deductions for a previous Calendar Quarter differ
                                         from the amounts previously reported to Braeburn, a reconciliation of such difference
                                         (increase or decrease), and a calculation of the adjustment to the Royalties payable
                                         with respect to such preceding Calendar Quarter as a result of such review (a &ldquo;<B>Royalty
                                         True-Up</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Each
                                         such Royalty Report shall be accompanied by payment of the Royalties due under Section
                                         6.1, plus or minus any adjustment of Royalties previously paid, calculated in accordance
                                         with the immediately preceding clause (a)(iii) of this Section 6.3, as applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Within
                                         ninety (90) days after the Calendar Quarter during which this Agreement terminates or
                                         expires (the &ldquo;<B>Final Royalty Period</B>&rdquo;), Knight shall furnish to Braeburn
                                         a final Royalty True-Up with respect to such Calendar Quarter (the &ldquo;<B>Final Royalty
                                         True-Up Report</B>&rdquo;). If the Final Royalty True-Up Report indicates that additional
                                         Royalties are payable with respect to the Final Royalty Period, such Final Royalty True-Up
                                         Report shall be accompanied by payment of such additional Royalties. If the Final Royalty
                                         True-Up Report indicates that Royalties were overpaid with respect to the Final Royalty
                                         Period, Braeburn shall pay to Knight an amount equal to such overpayment within thirty
                                         (30) days following the delivery of the Final Royalty True-Up to Braeburn. If Braeburn
                                         disagrees with the Final Royalty True-Up Report, Braeburn shall notify Knight within
                                         fifteen (15) days after receipt thereof and such disagreement shall be resolved pursuant
                                         to Section 6.5 below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         shall keep and shall require its Affiliates and its or their sublicensees to keep complete
                                         and accurate records in connection with the purchase, use and/or sale by or for it of
                                         Sublicensed Products hereunder in sufficient detail to permit accurate determination
                                         of all amounts necessary for calculation and verification of all payment obligations
                                         set forth in this Article 6.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Without
                                         limiting any Party&rsquo;s remedies hereunder, in the event payments required to be made
                                         under this Section 6.3 or any other provision of this Agreement are not made on or prior
                                         to the required payment date, the amount of the late payment shall bear interest at the
                                         per annum rate of two percent (2%) over the then-current thirty (30)-day LIBOR rate,
                                         or the maximum rate allowable by Applicable Law, whichever is lower.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Except
                                         as otherwise defined herein, all financial calculations by either Party under this Agreement
                                         shall be calculated in accordance with its Accounting Standards. All payments due by
                                         one Party to the other Party under this Agreement shall be payable in United States Dollars,
                                         except as otherwise set forth in this Agreement. In addition, all calculations herein
                                         shall give pro-rata effect to and shall proportionally adjust (by giving effect to the
                                         number of applicable days in such Calendar Quarter) for any Calendar Quarter that is
                                         shorter than a standard Calendar Quarter or any Calendar Year (or twelve month period)
                                         that is shorter than four consecutive full Calendar Quarters or twelve consecutive months,
                                         as applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Record
                                         Retention</B>. Knight will maintain complete and accurate books, records, and accounts
                                         in sufficient detail to confirm the accuracy of any payments required under this Agreement
                                         and the Royalty Reports delivered under Section 6.3, which books, records, and accounts
                                         will be retained until three (3) years after the end of the period to which such books,
                                         records, and accounts pertain.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Audits</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Independent
                                         Audit.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">During
                                         the Term and for three (3) years thereafter, Braeburn, upon prior written notice to Knight
                                         and at a mutually agreeable time, but in no event more than once in any twelve (12) month
                                         period, may request, and Knight shall permit, an independent certified public accounting
                                         firm of internationally recognized standing selected by Braeburn and reasonably acceptable
                                         to the Knight, to have access during normal business hours to the records of Knight as
                                         may be reasonably necessary to verify any payment made or due hereunder and the accuracy
                                         of the reports, including the Royalty Report; provided, however, that any audit conducted
                                         under this Section 6.5 may only be for any Calendar Year or Calendar Years (or any portion
                                         thereof) ending not more than thirty-six (36) months prior to the date of such request.
                                         The accounting firm shall disclose to Braeburn only whether the payments and reports
                                         are correct or incorrect, the specific details concerning any discrepancies (including,
                                         if applicable, the accuracy of the calculation of Net Sales, and the resulting effect
                                         of such calculations on the amounts payable by Knight under this Agreement), but no other
                                         information shall be disclosed to Braeburn.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         there is a dispute between the Parties following any audit performed pursuant to Section
                                         6.5(a)(i), either Party may refer the issue (an &ldquo;<B>Audit Disagreement</B>&rdquo;)
                                         to a second independent certified public accounting firm of internationally recognized
                                         standing (the &ldquo;<B>Independent Expert</B>&rdquo;) for resolution. In the event an
                                         Audit Disagreement is submitted for resolution by either Party, the Parties shall comply
                                         with the following procedures: (A) the Party submitting the Audit Disagreement for resolution
                                         shall provide written notice to the other Party that it is invoking the procedures of
                                         this Section 6.5(a)(ii); (B) within five (5) Business Days of the giving of such notice,
                                         the Parties shall jointly select an independent internationally recognized accounting
                                         firm to act as the Independent Expert to resolve such Audit Disagreement; (C) the Audit
                                         Disagreement submitted for resolution shall be described by the Parties to such Independent
                                         Expert, which description may be in written form, within ten (10) Business Days of the
                                         selection of such Independent Expert; (D) such Independent Expert shall render a decision
                                         on the matter as soon as practicable; and (E) the decision of such Independent Expert
                                         shall be final and binding on the Parties and shall not be subject to Article 12 or Section
                                         13.11 unless such Audit Disagreement involves good faith allegations of fraud or willful
                                         breach of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If,
                                         pursuant to Section 6.5(a)(i) or 6.5(a)(ii), as applicable, an accounting firm concludes
                                         that additional amounts were owed during a Calendar Year, Knight shall pay the additional
                                         amounts plus interest as set forth in Section 6.3(e) above on the amount of such additional
                                         payments, within ten (10) calendar days of the date such accounting firm&rsquo;s written
                                         report so concluding is delivered to Knight. In the event such accounting firm concludes
                                         that amounts were overpaid by Knight during such period, Braeburn shall, to the extent
                                         such overpayment was known to Braeburn, repay Knight the amount of such overpayment plus
                                         interest as set forth in Section 6.3(e) above on the amount of such overpayment, within
                                         ten (10) days after the date such accounting firm&rsquo;s written report so concluding
                                         is delivered to Braeburn, or, to the extent such overpayment was not known to Braeburn,
                                         Knight may reduce subsequent payment(s) to Braeburn under this Agreement by the amount
                                         of such overpayment. The fees charged by such accounting firm(s) shall be paid by Braeburn;
                                         provided, however, that, (i) if an error in favor of Braeburn of more than five percent
                                         (5%) of the payments due hereunder for the period being reviewed is discovered, or (ii)
                                         if Knight requested an Independent Expert under Section 6.5(a)(ii) and an error in favor
                                         of Braeburn is discovered, then, in either case, the fees and expenses of the accounting
                                         firm(s) shall be paid by Knight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Each
                                         Party shall treat all financial information subject to review under this Section 6.5
                                         in accordance with the confidentiality provisions of Article 10.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Payment
                                         Method</B>. All payments due to Braeburn hereunder will be paid in United States Dollars
                                         by wire transfer to an account designated by Braeburn.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>MANUFACTURE
                                         AND SUPPLY</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Manufacture
                                         and Supply by Braeburn</B>. During the Term, Knight agrees to obtain exclusively from
                                         Braeburn all Knight&rsquo;s requirements of the Sublicensed Products for the Territory
                                         at the Supply Price and otherwise on the terms and subject to the conditions of a manufacturing
                                         and supply agreement in customary form for the pharmaceutical industry to be mutually
                                         agreed between the Parties following the Effective Date (the &ldquo;<B>Supply Agreement</B>&rdquo;);
                                         provided, that the Parties shall negotiate in good faith and use Commercially Reasonable
                                         Efforts to execute and deliver the Supply Agreement within three (3) months of the NDA
                                         Transfer Date. Subject to the execution and delivery of the Supply Agreement, Braeburn
                                         agrees to supply Knight with all of its requirements of Sublicensed Products for Commercialization
                                         in the Territory during the Term. For the avoidance of doubt, Braeburn may, at its discretion,
                                         use the services of a Third Party to manufacture and/or package some or all of the Sublicensed
                                         Products supplied to Knight under the Supply Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Quality
                                         Agreement</B>. To the extent Braeburn manufactures Sublicensed Products supplied to Knight
                                         under the Supply Agreement, as required under Applicable Laws, or as reasonably requested
                                         by a Party, the Parties shall enter into a separate quality agreement in customary form
                                         for the pharmaceutical industry mutually agreed by the Parties regarding the supply,
                                         quality control and quality assurance of Sublicensed Products supplied to Knight under
                                         the Supply Agreement (the &ldquo;<B>Quality Agreement</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Conflicts</B>.
                                         Except as may be expressly set forth in the Supply Agreement or Quality Agreement, in
                                         the event of any conflict or inconsistency between the terms and conditions of the Supply
                                         Agreement or Quality Agreement, on the one hand, and this Agreement, on the other hand,
                                         the Supply Agreement or Quality Agreement, as applicable, shall govern and control with
                                         respect to all matters relating to the manufacturing, supply, quality control and quality
                                         assurance of or relating to the Sublicensed Products supplied to Knight under the Supply
                                         Agreement, and this Agreement shall govern and control with respect to all other matters.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>INTELLECTUAL
                                         PROPERTY</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Ownership</B>.
                                         As between the Parties, Braeburn shall have and retain all right, title and interest
                                         in or Control over, as applicable, all Braeburn Patents, inventions, discoveries, and
                                         Braeburn Know-How concerning Sublicensed Products, including formulations thereof, or
                                         methods of making or using same which have been made, conceived, reduced to practice
                                         or generated by its employees, agents, or other persons acting under its authority prior
                                         to the Effective Date. As between the Parties, during the Term, except as otherwise provided
                                         in and subject to the terms and conditions of this Agreement, Braeburn shall have and
                                         retain all rights, title and interest in all inventions, discoveries and know-how relating
                                         to Sublicensed Products, including formulations thereof, or methods of making or using
                                         same, or Improvements thereof (collectively, &ldquo;<B>Inventions</B>&rdquo;), that are
                                         made, conceived, reduced to practice or generated, whether solely or jointly, by Braeburn&rsquo;s
                                         employees, agents, or other persons acting under its authority <FONT STYLE="font-size: 10pt">and/or
                                         </FONT>by Knight&rsquo;s employees or agents, or, to the extent Knight becomes aware
                                         of any such Inventions, by other persons acting under its authority. Knight shall notify
                                         Braeburn promptly of any Inventions that are made, conceived, reduced to practice or
                                         generated solely by Knight&rsquo;s employees, agents, or other persons acting under its
                                         authority. To the extent required by Applicable Law, Knight shall assign or otherwise
                                         transfer all rights, title and interest in any of the foregoing Inventions to Braeburn,
                                         and Knight agrees, at the request of Braeburn, to execute any and all proper documents
                                         appropriate to assist Braeburn in obtaining and maintaining Braeburn&rsquo;s rights in
                                         and to the foregoing Inventions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Patent
                                         Prosecution</B>. Braeburn shall have the first right to prosecute and maintain the Braeburn
                                         Patents and any patent application(s) or patent(s) arising from this Agreement, using
                                         patent counsel selected by Braeburn, and shall be responsible for the payment of all
                                         prosecution and maintenance costs. Braeburn shall not abandon prosecution or maintenance
                                         of any or all patents or patent applications directly related to the Sublicensed Products
                                         in the Territory without notifying Knight in a timely manner of Braeburn&rsquo;s intention
                                         and reason therefore and providing Knight with reasonable opportunity to comment upon
                                         such abandonment and to assume responsibility for prosecution or maintenance of such
                                         Patent Rights. To the extent allowed under the Titan Agreement, in the event that Braeburn
                                         abandons prosecution or maintenance of any or all patents or patent applications directly
                                         related to the Sublicensed Products in the Territory, Knight may assume prosecution and
                                         filing responsibility for such Patent Rights in the Territory, at its sole expense, and
                                         thereafter such patent rights will be owned solely and exclusively by Knight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Notification
                                         of Third Party Infringement</B>. Each Party shall promptly disclose to the other in writing,
                                         and share within five (5) Business Days all available information known to the Party
                                         in connection with any actual, suspected, alleged, or threatened infringement or misappropriation
                                         of any Braeburn Patent, or any actual, suspected, alleged or threatened infringement
                                         or passing off of the Braeburn Mark, in the Territory, of which such Party becomes aware.
                                         The Parties will thereafter consult and cooperate to determine a course of action, including
                                         the commencement of legal action by any Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Response
                                         to Third Party Infringement</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         shall have the first right, but not any obligation, to initiate and respond to any actual
                                         or threatened infringement of a Braeburn Patent, the Braeburn Mark or of any unfair trade
                                         practices, trade dress imitation, passing off of counterfeit goods, or like offenses
                                         in the Territory relating to the Sublicensed Products. If Braeburn elects to respond
                                         to any actual or threatened infringement by initiating a proceeding, Braeburn shall use
                                         legal counsel of its choice at its expense and shall have full control over the conduct
                                         of such proceeding, including whether to initiate any legal proceeding and/or the settlement
                                         thereof. Braeburn may settle or compromise any such proceeding without the consent of
                                         Knight; provided, however, that if such settlement adversely affects Knight&rsquo;s rights
                                         under this Agreement, or Knight&rsquo;s ability to Commercialize the Sublicensed Products
                                         within the Territory, or otherwise requires Knight to admit wrongdoing, fault, or liability,
                                         Braeburn will not settle or compromise any such proceeding without the consent of Knight,
                                         such consent not to be unreasonably withheld, conditioned or delayed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If,
                                         within a period of sixty (60) days after the first notice of infringement is provided
                                         under Section 8.4, Braeburn elects not to initiate and respond to any actual or threatened
                                         infringement of a Braeburn Patent, a Braeburn Mark or of any unfair trade practices,
                                         trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory
                                         relating to the Sublicensed Products, then Knight shall have the right, but not the obligation,
                                         to take action, at its sole expense and to the extent permitted under the Titan Agreement,
                                         in which case Knight shall have full control over the conduct of such proceeding and
                                         Knight may settle or compromise any such proceeding without the consent of Braeburn;
                                         provided, however, that if such settlement adversely affects Braeburn&rsquo;s intellectual
                                         property rights or its rights under this Agreement, or Braeburn&rsquo;s ability to Commercialize
                                         the Sublicensed Products outside the Territory, results in any monetary payment by or
                                         financial loss to Braeburn or otherwise requires Braeburn to admit wrongdoing, fault,
                                         or liability, Knight will not settle or compromise any such proceeding without the consent
                                         of Braeburn, such consent not to be unreasonably withheld, conditioned or delayed. Knight
                                         shall be solely responsible for any legal costs or damages awards made in any proceeding
                                         that is initiated by Knight in the event that Braeburn elects not to respond to any actual
                                         or threatened infringement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Cooperation</B>.
                                         Each Party shall cooperate reasonably, at its expense, in any enforcement effort initiated
                                         by the other Party. The Parties nor their Affiliates shall contest any joinder in any
                                         proceeding sought to be brought by the other Party if such joinder is required by Applicable
                                         Law. For any legal action or defense described in Section 8.4 above, in the event that
                                         any Party is unable to initiate, prosecute or defend such action solely in its own name,
                                         the other Party will join such action voluntarily and will execute all documents necessary
                                         for the Party to defend, prosecute and maintain such action. In connection with any such
                                         action, the Parties will cooperate fully and will provide each other with any information
                                         or assistance that either reasonably may request.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Recovery</B>.
                                         Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any
                                         monetary award recovered from a Third Party in connection with any proceeding described
                                         in Section 8.4 above shall be shared as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">the
                                         Party that initiated and prosecuted or maintained the <FONT STYLE="font-size: 10pt">defense
                                         of, the action shall recoup all of its costs and expenses (including all court and reasonable
                                         attorneys&rsquo; fees) incurred in connection with the action, whether the recovery is
                                         by settlement or otherwise; </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: #010000">the
                                         other Party then shall, to the extent possible, recover its reasonably documented costs
                                         and expenses (including reasonable outside attorneys&rsquo; fees) incurred in connection
                                         with the action;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: #010000">if
                                         Braeburn initiated and prosecuted, or maintained the defense of, the action, the amount
                                         of any recovery remaining then shall be retained by Braeburn; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: #010000">if
                                         Knight initiated and prosecuted, or maintained the defense of, the action, the amount
                                         of any recovery remaining shall be retained by Knight, net of an amount that shall be
                                         paid to Braeburn equal to the Royalties that would have been payable to</FONT> <FONT STYLE="color: #010000">Braeburn
                                         <FONT STYLE="font-size: 10pt">if such remainder of the recovery or settlement proceeds
                                         constituted Net Sales. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">8.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Infringement
                                         of Third Party IP</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         either Party becomes aware that its activities performed hereunder may constitute actual
                                         or alleged infringement or misappropriation of the intellectual property rights of a
                                         Third Party in the Territory, it shall promptly notify the other Party and the Parties
                                         shall discuss a strategy to defend or mitigate against any actual or alleged infringement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: #010000">Braeburn
                                         shall have the first right, but not the obligation, to defend any action in the Territory
                                         related to the intellectual property rights of any Third Party or to initiate and prosecute
                                         legal action related to the intellectual property rights of any Third Party at its own
                                         expense and in the name of Braeburn and/or Knight. Knight shall render, at its expense,
                                         all assistance reasonably requested in connection with any action taken by Braeburn.
                                         However, the control of such action, including whether to initiate any legal proceeding
                                         and/or the settlement thereof, shall solely be under the control of Braeburn; </FONT><FONT STYLE="color: #010000">provided,
                                         however, that if such settlement adversely affects Knight&rsquo;s rights under this Agreement,
                                         or Knight&rsquo;s ability to Commercialize the Sublicensed Products within the Territory,
                                         or otherwise requires Knight to admit wrongdoing, fault, or liability, Braeburn will
                                         not settle or compromise any such proceeding without the consent of Knight, such consent
                                         not to be unreasonably withheld, conditioned or delayed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         Braeburn elects not to defend an infringement action in the Territory as provided in
                                         Section 8.4(b), and Knight elects to do so, the cost of any agreed-upon course of action,
                                         including the costs of any legal action commenced or any infringement action defended,
                                         shall be borne solely by Knight; provided, however, that if such settlement adversely
                                         affects Braeburn&rsquo;s intellectual property rights or its rights under this Agreement,
                                         or Braeburn&rsquo;s ability to Commercialize the Sublicensed Products outside the Territory,
                                         results in any monetary payment by or financial loss to Braeburn or otherwise requires
                                         Braeburn to admit wrongdoing, fault, or liability, Knight will not settle or compromise
                                         any such proceeding without the consent of Braeburn, such consent not to be unreasonably
                                         withheld, conditioned or delayed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: #010000">For
                                         any such legal action or defense, in the event that any Party is unable to initiate,
                                         prosecute, or defend such action solely in its own name, the other Party will join such
                                         action voluntarily and will execute all documents necessary for the Party to prosecute,
                                         defend and maintain such action. In connection with any such action, the Parties will
                                         cooperate fully and will provide each other with any information or assistance that either
                                         reasonably may request.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>REPRESENTATION
                                         AND WARRANTIES</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Braeburn
                                         Covenants, Representations and Warranties</B>. Braeburn covenants, represents and warrants
                                         (as the case may be) to Knight as of the Effective Date that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         is a corporation duly organized, validly existing and in good standing under the laws
                                         of Delaware.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has the corporate power and authority to enter into this Agreement and will continue
                                         during the Term to have, all of the corporate power and authority necessary to enter
                                         into this Agreement and to grant the licenses hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has taken all necessary corporate actions to authorize the execution, delivery and performance
                                         of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">The
                                         Titan Agreement (i) is in full force and effect, enforceable in accordance with its terms,
                                         except to the extent enforceability is limited by bankruptcy, insolvency or similar laws
                                         affecting creditors&rsquo; rights and remedies or equitable principles, and (ii) has
                                         not been terminated; and Braeburn has not taken any action to terminate the Titan Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         shall provide Knight with (i) written notice within five (5) Business Days of any alleged
                                         material breach of the Titan Agreement or written (including by email) threat of termination
                                         of the Titan Agreement received by Braeburn from Titan thereunder, and (ii) written notice
                                         within two (2) Business Days of the adoption of any amendment to the Titan Agreement
                                         relating to the Territory or Knight&rsquo;s rights under this Agreement, in each case,
                                         in any material respect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has obtained all consents, licenses and authorizations that are necessary to perform
                                         its obligations under this Agreement and that such rights will continue to be enforceable
                                         during the Term, except to the extent enforceability is limited by bankruptcy, insolvency
                                         or similar laws affecting creditors&rsquo; rights and remedies or equitable principles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Upon
                                         the execution and delivery of this Agreement, this Agreement shall constitute a valid
                                         and binding obligation of Braeburn, enforceable against Braeburn in accordance with its
                                         terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar
                                         laws affecting creditors&rsquo; rights and remedies or equitable principles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">The
                                         performance of Braeburn&rsquo;s obligations under this Agreement will not conflict with
                                         its organizational documents, as amended, or result in a breach of any material agreements
                                         or contracts to which it is a party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has not and will not, during the term of this Agreement, enter into any material agreements
                                         or contracts that would conflict with its obligations under this Agreementand Braeburn
                                         has no knowledge of any agreement entered into by Titan which would conflict or restrict
                                         the terms hereof;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         owns or licenses all of the Braeburn Patents licensed to Knight pursuant to this Agreement
                                         and the Braeburn Patents licensed or sublicensed to Knight pursuant to this Agreement
                                         are all of the patents owned or licensed by Braeburn that are reasonably necessary for
                                         Knight to carry out its obligations and exercise its rights under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has not received any notice that the manufacture, sale or use of the Sublicensed Products
                                         in the Territory infringes upon any intellectual property rights of any Third Party(ies)
                                         in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has not received any notice from a Third Party that any issued Braeburn Patent is invalid
                                         or unenforceable for any reason.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">To
                                         the knowledge of Braeburn, there are no activities being carried out by Third Parties
                                         in the Territory that would constitute infringement or misappropriation of the Braeburn
                                         Patents or the Braeburn Marks.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         shall use its Commercially Reasonable Efforts to maintain the Titan Agreement in full
                                         force and effect throughout the Term; provided, however, that the Parties agree and acknowledge
                                         that it may be commercially reasonable for Braeburn to terminate the Titan Agreement
                                         or take actions that result in the termination of the Titan Agreement and provided further
                                         that for avoidance of doubt, this Section does not provide Braeburn with any termination
                                         right not contemplated by Section 11.2 hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(o)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         has provided Knight all material information in its possession and Control sufficient
                                         for Knight to assess the safety and efficacy of the Sublicensed Product, and any side
                                         effects, injury, toxicity or sensitivity reactions and incidents associated with all
                                         uses, studies, investigations or tests involving the Sublicensed Product (animal or human)
                                         throughout the world;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(p)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">As
                                         of the Effective Date, Braeburn is not aware of any material facts not otherwise disclosed
                                         to Knight that could reasonably lead Braeburn to conclude that the Sublicensed Product
                                         will be unable to receive Regulatory Approval from relevant Governmental Authorities
                                         in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(q)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Neither
                                         Braeburn nor, to the knowledge of Braeburn, any Third Party acting by or on behalf of
                                         Braeburn in connection with the manufacture, development or Commercialization of the
                                         Sublicensed Products has been debarred or is subject to debarment, and Braeburn shall
                                         not knowingly engage or use any Third Party in connection with the manufacture, development
                                         or Commercialization of the Sublicensed Products that has been debarred; Braeburn agrees
                                         to notify Knight in writing promptly if it, or if it has knowledge that, any of its licensors
                                         or any entity acting on its behalf in any capacity in connection with the manufacture,
                                         development or Commercialization of the Sublicensed Products is debarred or becomes the
                                         subject of any threatened or pending action, suit, claim, investigation, legal or administrative
                                         proceeding relating to debarment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Knight
                                         Covenants, Representations and Warranties</B>. Knight covenants, represents and warrants
                                         to Braeburn (as the case may be) as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         is a corporation duly organized, validly existing and in good standing, under the laws
                                         of Canada.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         has the legal right, authority, and power to enter into this Agreement and will continue
                                         during the Term to have, all of the rights necessary to enter into this Agreement and
                                         to perform its obligations hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         has taken all necessary action to authorize the execution, delivery, and performance
                                         of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Without
                                         limiting Knight&rsquo;s obligations to use Commercially Reasonable Efforts to Commercialize
                                         the Sublicensed Products under this Agreement, Knight will seek to obtain and, once obtained,
                                         maintain all consents, licenses and authorizations that are necessary to perform its
                                         obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Upon
                                         the execution and delivery of this Agreement, this Agreement shall constitute a valid
                                         and binding obligation of Knight, enforceable against Knight in accordance with its terms,
                                         except to the extent enforceability is limited by bankruptcy, insolvency or similar laws
                                         affecting creditors&rsquo; rights and remedies or equitable principles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">The
                                         performance of Knight&rsquo;s obligations under this Agreement will not conflict with
                                         its organizational documents, as amended, or result in a breach of any material agreements
                                         or contracts to which any is a party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         has not and will not, during the term of this Agreement, enter into any material agreements
                                         or contracts that would be inconsistent with its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Neither
                                         Knight nor its Affiliates and sublicensees will initiate a proceeding to challenge the
                                         validity or enforceability of any Braeburn Patent or Braeburn Mark, or directly or indirectly
                                         assist any Third Party with respect to any such proceeding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         has utilized its own scientific, marketing and distribution expertise and experience
                                         to analyze and evaluate both the scientific and commercial value of Sublicensed Products
                                         in the Territory and has solely relied on such analysis and evaluation in deciding to
                                         enter into this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Neither
                                         Knight nor, to the knowledge of Knight, any Third Party acting by or on behalf of Knight
                                         in connection with the manufacture, development or Commercialization of the Sublicensed
                                         Products has been debarred or is subject to debarment, and Knight shall not knowingly
                                         engage or use any Third Party in connection with the manufacture, development or Commercialization
                                         of the Sublicensed Products that has been debarred; Knight agrees to notify Braeburn
                                         in writing promptly if it, or if it has knowledge that, any of its licensors or any entity
                                         acting on its behalf in any capacity in connection with the manufacture, development
                                         or Commercialization of the Sublicensed Products is debarred or becomes the subject of
                                         any threatened or pending action, suit, claim, investigation, legal or administrative
                                         proceeding relating to debarment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Neither
                                         Knight nor, to the knowledge of Knight, any of its equity holders nor any of their respective
                                         beneficial owners (a) is listed on any Government Lists (as defined below), (b) is a
                                         person who has been determined by competent authority to be subject to the prohibitions
                                         contained in Presidential Executive Order No. 13224 (Sept. 23, 2001) or any other similar
                                         prohibitions contained in the rules and regulations of the Office of Foreign Assets Control
                                         (&ldquo;<B>OFAC</B>&rdquo;) or in any enabling legislation or other Presidential Executive
                                         Order in respect thereof, (c) has been previously indicted for or convicted of any Patriot
                                         Act Offense (as defined below), or (d) is currently under investigation by any governmental
                                         authority for alleged criminal activity in connection with any Patriot Act Offense. For
                                         purposes hereof, the term &ldquo;<B>Patriot Act Offense</B>&rdquo; means (i) any violation
                                         of the criminal laws of the United States of America, or that would be a criminal violation
                                         if committed within the jurisdiction of the United States of America, relating to terrorism
                                         or the laundering of monetary instruments, including any offense under (A) the criminal
                                         laws against terrorism, (B) the criminal laws against money laundering, (C) the Bank
                                         Secrecy Act, (D) the Money Laundering Control Act of 1986, or (E) the Uniting and Strengthening
                                         America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA
                                         PATRIOT ACT) Act of 2001; and (ii) the crime of conspiracy to commit, or aiding and abetting
                                         another to commit, a Patriot Act Offense under clause (i). For purposes hereof, the term
                                         &ldquo;<B>Government Lists</B>&rdquo; means (x) the Specially Designated Nationals and
                                         Blocked Persons Lists maintained by the OFAC, (y) any other list of terrorists, terrorist
                                         organizations, or narcotics traffickers maintained pursuant to any of the Rules and Regulations
                                         of OFAC that is now included in &ldquo;Government Lists,&rdquo; or (z) any similar lists
                                         maintained by the United States Department of State, the United States Department of
                                         Commerce, or any other government authority or pursuant to any Executive Order of the
                                         President of the United States of America that is now included in Government Lists.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">9.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>WARRANTY
                                         DISCLAIMER</B>. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES
                                         ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY
                                         OR OTHERWISE, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT
                                         OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED PRODUCTS OR ANY TECHNOLOGY
                                         OR ANY LICENSE GRANTED BY EITHER PARTY HEREUNDER, EVEN IF EITHER PARTY HAS BEEN ADVISED
                                         OF SUCH PURPOSE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>LIMITATIONS
                                         OF LIABILITY</B>. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT BY
                                         A PARTY, A BREACH OF ARTICLE 10, FOR THE PAYMENT OF AN INDEMNIFIED CLAIM UNDER SECTIONS
                                         9.5 OR 9.6 BELOW (BUT ONLY TO THE EXTENT OF SUCH CLAIM), NEITHER PARTY SHALL BE LIABLE
                                         TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT
                                         FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES
                                         RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER
                                         ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY&rsquo;S PERFORMANCE
                                         OR NON-PERFORMANCE HEREUNDER.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Indemnification
                                         by Braeburn</B>. Braeburn hereby agrees to defend, indemnify, and hold Knight, its Affiliates
                                         and their respective officers, directors, employees, shareholders, members, partners,
                                         agents and successors and assigns (each a &ldquo;<B>Knight Indemnified Party</B>&rdquo;)
                                         harmless from and against any and all Losses incurred by a Knight Indemnified Party in
                                         connection with any and all suits, investigations, claims or demands of Third Parties
                                         (collectively, &ldquo;<B>Third Party Claims</B>&rdquo;) in connection with, arising from
                                         or resulting from: (i) any breach of this Agreement or any representation, warranty or
                                         covenant provided in this Agreement by Braeburn or an Affiliate of Braeburn; (ii) any
                                         violation of Applicable Law by Braeburn or its Affiliates; (iii) the gross negligence
                                         or willful misconduct of Braeburn; (iv) any claim that the Sublicensed Products supplied
                                         hereunder do not comply with the specifications or submissions made in government filings
                                         (v) any claim that the sale by Knight or its Affiliates, of the Sublicensed Products
                                         infringes on intellectual property rights in the Territory of a Third Party; (vi) any
                                         damage to property, personal injury or death arising in any way from a fault or defect
                                         in the Sublicensed Product, except to the extent that damage, personal injury or death
                                         arises out of the act or omission of Knight or is beyond Braeburn&rsquo;s control; (vii)
                                         any claim by Titan that this Agreement breaches, or is inconsistent with, the Titan Agreement;
                                         and (viii) any claim arising from any use, within the approved labeling, by any person
                                         of any of the Sublicensed Products; in all cases, except to the extent such Third Party
                                         Claim for Losses is in connection with, arising from or resulting from: (x) any breach
                                         of this Agreement by Knight or a Knight Indemnified Party, (y) any violation of Applicable
                                         Law by Knight or a Knight Indemnified Party, or (z) the gross negligence or willful misconduct
                                         of Knight or a Knight Indemnified Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Indemnification
                                         by Knight</B>. Knight hereby agrees to defend, indemnify, and hold Braeburn, its Affiliates
                                         and their respective officers, directors, employees, shareholders, members, partners,
                                         agents and successors and assigns (each a &ldquo;<B>Braeburn Indemnified Party</B>&rdquo;)
                                         harmless from and against any and all Losses incurred by a Braeburn Indemnified Party
                                         in connection with any and all Third Party Claims in connection with, arising from or
                                         resulting from: (i) any breach of this Agreement or any representation, warranty or covenant
                                         provided in this Agreement by Knight or an Affiliate of Knight; (ii) any violation of
                                         Applicable Law by Knight or its Affiliates; (iii) any claim or assertion that any representative
                                         or other person who is employed by Knight is an employee of Braeburn; (iv) the, use,
                                         marketing, sale, Promotion, storage or distribution of Sublicensed Products in the Territory
                                         by Knight, its Affiliates or any of its or their respective sublicensees or distributors,
                                         including any death, personal injury or other product liability arising out of or related
                                         to the Sublicensed Products, excluding any claims by a Third Party (1) that the marketing,
                                         sale, Promotion, storage or distribution of Sublicensed Products in the Territory by
                                         Knight infringes or misappropriates any patent or other intellectual property or proprietary
                                         right of such Third Party or (2) that relate to any damage to property, personal injury
                                         or death arising in any way from a fault or defect in the Sublicensed Product; and (v)
                                         the gross negligence or willful misconduct of any Knight Indemnified Party in performing
                                         any activities in connection with this Agreement; in all cases, except to the extent
                                         such Third Party Claim for Losses is in connection with, arising from or resulting from:
                                         (x) any breach of this Agreement by Braeburn or an Braeburn Indemnified Party, (y) any
                                         violation of Applicable Law by Braeburn or an Braeburn Indemnified Party, or (z) the
                                         gross negligence or willful misconduct of Braeburn or an Braeburn Indemnified Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Indemnification
                                         Procedure</B>. If a Party intends to claim indemnification under this Article&nbsp;9,
                                         such indemnified Party shall promptly notify the other Party of any Third Party Claim
                                         in respect of which the indemnified Party intends to claim such indemnification, and
                                         the indemnifying Party shall have a first opportunity to assume the sole defense thereof
                                         with counsel selected by the indemnifying Party. The indemnified Party shall have the
                                         right to retain its own counsel and participate fully in the defense, with the fees and
                                         expenses to be paid by the indemnified Party; provided, however, that the indemnifying
                                         Party shall have no obligations with respect to any Losses resulting from the indemnified
                                         Party&rsquo;s settlement of such Third Party Claim without the prior written consent
                                         of the indemnifying Party. The failure or delay to deliver notice to the indemnifying
                                         Party, within a reasonable time after the commencement of any such proceeding, if irreparably
                                         prejudicial to the indemnifying Party&rsquo;s ability to defend such proceeding, shall
                                         relieve the indemnifying Party of any and all liability to the indemnified party under
                                         this Article 9. The indemnified Party shall cooperate fully with the indemnifying Party
                                         and their legal representatives in the investigation of any loss, claim, damage, or liability
                                         covered by this indemnification, and shall mitigate such loss and damages. Any amount
                                         payable in order to satisfy an indemnity hereunder shall be paid as soon as reasonably
                                         possible after the indemnified Party has incurred an indemnified expense and notified
                                         the indemnifying Party thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Compliance
                                         with Applicable Law</B>. Each Party shall comply, and shall require their Affiliates
                                         and permitted sublicensees to comply, with all Applicable Laws relative to their obligations
                                         hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">9.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Insurance</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Both
                                         Knight and Braeburn shall maintain, during the Term and for a period of three (3) years
                                         after any expiration or termination of this Agreement, a Commercial General Liability
                                         Insurance policy or policies (including coverage for Product Liability, Contractual Liability,
                                         Bodily Injury, Property Damage and Personal Injury), with minimum limits of Five Million
                                         Dollars ($5,000,000) per occurrence and Ten Million Dollars ($10,000,000) in the aggregate.
                                         In the case of Knight, such insurance shall insure against all liability arising out
                                         of Knight&rsquo;s use, sale, distribution, or marketing of Sublicensed Products in the
                                         Territory and shall name Braeburn as an additional insured on all policies. In the case
                                         of Braeburn, such insurance shall insure against all liability arising out of Braeburn&rsquo;s
                                         manufacture of Sublicensed Products for use, sale, distribution, or marketing in the
                                         Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">During
                                         the Term, Knight shall not permit such insurance to be reduced (other than by payment
                                         of Third Party Claims), expired or canceled without reasonable prior written notice,
                                         unless outside of the control of Knight, to Braeburn. Upon request, Knight shall provide
                                         certificates of insurance to Braeburn evidencing the coverage specified herein. The Parties
                                         acknowledge and agree that such insurance shall not be construed to create a limit with
                                         respect to their indemnification obligations or liability to the other.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>CONFIDENTIALITY
                                         AND PUBLICITY</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Non-Disclosure
                                         and Non-Use Obligations</B>. All Confidential Information disclosed by one Party to the
                                         other Party hereunder shall be maintained in confidence and shall not be disclosed to
                                         any Third Party or used for any purpose except as expressly permitted herein without
                                         the prior written consent of the Party that disclosed the Confidential Information to
                                         the other Party during the Term and for a period of seven (7) years thereafter. For purposes
                                         of this Agreement, &ldquo;<B>Confidential Information</B>&rdquo; means any and all Know-How,
                                         scientific, clinical, regulatory, marketing, financial, technical, non-technical, commercial
                                         or other confidential information or data of a confidential nature, whether communicated
                                         in writing, orally or by any other means, that is under the protection of one Party and
                                         is provided by that Party to the other Party in connection with this Agreement. The foregoing
                                         non-disclosure and non-use obligations shall not apply to the extent that such Proprietary
                                         Information:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">is
                                         known by the receiving Party at the time of its receipt, and not through a prior disclosure
                                         by the disclosing Party, as documented by business records;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">is
                                         or becomes properly in the public domain or knowledge without breach by either Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">is
                                         subsequently disclosed to a receiving Party by a Third Party who, to the knowledge of
                                         the receiving Party, is lawfully able do so and, to the knowledge of the receiving Party,
                                         is not under an obligation of confidentiality to the disclosing Party; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">is
                                         developed by the receiving Party independently of Confidential Information received from
                                         the other Party, as documented by research and development records.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">10.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Permitted
                                         Disclosure of Proprietary Information</B>. Notwithstanding Section 10.1, a Party receiving
                                         Confidential Information of another Party may disclose such Confidential Information:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">to
                                         governmental or other regulatory agencies as required by Applicable Law, in order to
                                         file Regulatory Submissions, but such disclosure may be made only to the extent reasonably
                                         necessary to file such Regulatory Submissions and in accordance with the terms and conditions
                                         of this Agreement or as otherwise requested by the relevant Governmental Authority;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">in
                                         connection with the performance of this Agreement and solely on a need-to-know basis,
                                         to Affiliates; potential or actual collaborators (including potential sublicensees);
                                         potential or actual investment bankers, accountants, investors, lenders, or acquirers;
                                         or employees, independent contractors (including consultants and clinical investigators)
                                         or agents, each of whom prior to disclosure must be bound by written obligations of confidentiality
                                         and non-use no less restrictive than the obligations set forth in this Article 10 or
                                         to counsel for such Party; provided, however, that the receiving Party shall (i) undertake
                                         reasonable precautions to safeguard and protect the confidentiality of the Confidential
                                         Information; (ii) remain responsible for any failure by any person who receives Confidential
                                         Information pursuant to this Article 10 to treat such Confidential Information as required
                                         under this Article 10; and (iii) take all reasonable measures to restrain the receiving
                                         Party and any such persons from prohibited or unauthorized disclosure or use in violation
                                         of this Article 10;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">if
                                         required to be disclosed by Applicable Law or court order, provided that notice is promptly
                                         delivered to the non-disclosing Party in order to provide an opportunity to challenge
                                         or limit the disclosure obligations; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">with
                                         respect to Braeburn, to Titan to the extent required by Braeburn to exercise its rights
                                         or perform its obligations under the Titan Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: #010000">If
and whenever any Confidential Information is disclosed in accordance with this Section 10.2, such disclosure shall not cause any
such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure
of such information (other than in breach of this Agreement). Where reasonably possible and subject to Section 10.3, the receiving
Party shall notify the disclosing Party of the receiving Party&rsquo;s intent to make such disclosure pursuant to Sections 10.2(a)-(c)
sufficiently prior to making such disclosure so as to allow the disclosing Party adequate time to take whatever action it may
deem appropriate to protect the confidentiality of the information, and the receiving Party shall cooperate with the disclosing
Party in such efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">10.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Disclosure
                                         of Agreement to Governmental Authority</B>. Without limiting any of the foregoing, it
                                         is understood that the Parties or their Affiliates may make disclosure of this Agreement
                                         and the terms hereof in any filings required by a Governmental Authority or securities
                                         exchange, may file this Agreement as an exhibit to any filing with such Governmental
                                         Authority or securities exchange, and may distribute any such filing in the ordinary
                                         course of its business; provided however, that the Party seeking such disclosure first
                                         provides the other Party a copy of the proposed disclosure, and provided further that
                                         (except to the extent that the Party seeking disclosure is required to disclose such
                                         information to comply with Applicable Law) if the other Party demonstrates to the reasonable
                                         satisfaction of the Party seeking disclosure, within two (2) Business Days of such Party&rsquo;s
                                         providing the copy, that the public disclosure of previously undisclosed information
                                         will materially adversely affect the development and/or commercialization of a Sublicensed
                                         Product, the Party seeking disclosure will remove from the disclosure such specific previously
                                         undisclosed information as the other Party shall reasonably request to be removed, or
                                         otherwise provide a good faith reason to the other Party why such disclosure was not
                                         removed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">10.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Other
                                         Public Statements</B>. Except as set forth in this Agreement or as required by Applicable
                                         Law, neither Party shall make any press release or other public announcement or other
                                         disclosure to a Third Party concerning the existence or terms of this Agreement or relating
                                         to Sublicensed Products without the prior written consent of the other Party, which consent
                                         shall include agreement upon the nature and text of such announcement or disclosure and
                                         shall not be unreasonably withheld, conditioned or delayed. Each Party agrees to provide
                                         to the other Party a copy of any public announcement as soon as reasonably practicable
                                         under the circumstances prior to its scheduled release. Each Party shall have the right
                                         to expeditiously (but in any event within twenty-four (24) hours of receipt) review and
                                         recommend changes to any press release or announcement regarding this Agreement or the
                                         subject matter of this Agreement; provided, however that such right of review and recommendation
                                         shall only apply for the first time that specific information is to be disclosed, and
                                         shall not apply to the subsequent disclosure of substantially similar information that
                                         has previously been disclosed unless there have been material developments relating to
                                         Sublicensed Products since the date of the previous disclosure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">10.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>No
                                         Rights to Use Name of Other Party</B>. Except as provided herein, neither Party shall
                                         use the name, trademark, trade name or logo of the other Party in any publicity, promotion,
                                         news release or disclosure relating to this Agreement or its subject matter, without
                                         the prior express written permission of the other Party, except as may be required by
                                         Applicable Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>TERM
                                         AND TERMINATION</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">11.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Term</B>.
                                         Except as expressly provided in Section 2.1, and unless earlier terminated pursuant to
                                         Section 11.2(a), this Agreement will take effect on the Effective Date and, unless earlier
                                         terminated in accordance with the terms herein, will continue in full force and effect
                                         for fifteen (15) years from the date of Launch of the Initial Indication (from the Effective
                                         Date until the fifteenth (15<SUP>th</SUP>) anniversary of the date of Launch of the Initial
                                         Indication, unless earlier terminated, the &ldquo;<B>Initial Term</B>&rdquo;); provided,
                                         that if a Subsequent Indication for the Sublicensed Product received Regulatory Approval
                                         in the Territory on or after the fifth (5<SUP>th</SUP>) anniversary of the Launch of
                                         the Initial Indication, the Parties shall negotiate in good faith with respect to an
                                         appropriate extension of the Initial Term. Any such extension shall be mutually agreed
                                         in writing. Upon the expiration of the Initial Term and any subsequent Term thereafter,
                                         this Agreement shall automatically renew for successive two (2) year periods (each a
                                         &ldquo;<B>Renewal Term</B>&rdquo;) unless, at least one hundred eighty (180) days prior
                                         to the scheduled expiry of the Initial Term or Renewal Term], either Party provides the
                                         other with written notice of its intention not to renew the Agreement (a &ldquo;<B>Non-Renewal
                                         Notice</B>&rdquo;), in which case this Agreement shall expire at the end of the applicable
                                         period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">11.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Early
                                         Termination</B>. This Agreement may be terminated as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         the NDA Transfer Date has not occurred within six (6) months of the Effective Date, either
                                         Party may provide written notice of an intent to terminate this Agreement, provided that
                                         if a Party intends to terminate the Agreement, such Party shall first discuss in good
                                         faith the reasons for seeking termination and considers potential alternatives to termination,
                                         including potential amendments to the Agreement. Termination under this Section 11.2(a)
                                         shall not effective be sooner than thirty (30) days from the date of notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Either
                                         Party may, without prejudice to any other remedies available to it under this Agreement
                                         or at Applicable Law or in equity:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">immediately
                                         terminate this Agreement upon the filing or institution of bankruptcy, reorganization,
                                         liquidation or receivership proceedings, or upon an assignment of a substantial portion
                                         of the assets for the benefit of creditors by the other Party; provided, however, in
                                         the case of any involuntary bankruptcy, reorganization, liquidation, receivership or
                                         assignment proceeding such right to terminate shall only become effective if such other
                                         Party consents to the involuntary proceeding or such proceeding is not dismissed within
                                         sixty (60) days after the filing thereof; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">terminate
                                         this Agreement prior to expiration of the Term in the event the other Party is in material
                                         default or breach of the performance of its obligations hereunder, and has not cured
                                         such breach within (i) thirty (30) days after written notice thereof provided by the
                                         non-breaching Party to the breaching Party, in case such breach is a non-payment of any
                                         amount due under this Agreement (which shall be deemed a material breach) and (ii) sixty
                                         (60) days after written notice thereof provided by the non-breaching Party to the breaching
                                         Party for other cases of breach. The termination shall become effective at the end of
                                         the (x) thirty (30) day period in case the breach is a non-payment of any amount due
                                         under this Agreement if the breaching Party has not cured such breach during such thirty
                                         (30) day period, or (y) sixty (60) day period for other cases of breach unless the breaching
                                         Party cures such breach during such sixty (60) day period. The right of either Braeburn
                                         or Knight to terminate this Agreement as provided in this Section 11.2 shall not be affected
                                         in any way by such Party&rsquo;s waiver or failure to take action with respect to any
                                         previous breach or default.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         may, without prejudice to any other remedies available to it under this Agreement or
                                         at Applicable Law or in equity, terminate this Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">on thirty
                                         (30) days written notice to Knight, if Knight, <FONT STYLE="font-size: 10pt">following
                                         Launch, discontinues commercial sale of Sublicensed Product for a period of three (3)
                                         months or more for reasons unrelated to Force Majeure, regulatory or safety issues or
                                         supply or manufacturing or Sublicensed Product quality issues and subsequently fails
                                         to resume sales of a Product within thirty (30) days of having been notified in writing
                                         of such failure by Braeburn; </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">upon
                                         written notice to Knight in the event Knight or any of its Affiliates or sublicensees
                                         commences any legal proceeding seeking to challenge or otherwise dispute the validity
                                         or ownership of any of the Braeburn Patents or any of the claims therein, or knowingly
                                         assists any Third Party to do any of the foregoing, which termination shall be effective
                                         on the date set forth in such notice; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">If
                                         Braeburn determines, in its sole discretion, that it is in its best interests to terminate
                                         the Titan Agreement pursuant to any one of Sections 12.2(c)(i), 12.2(c)(iii), and 12.2(c)(iv)
                                         of the Titan Agreement, then Braeburn shall provide Knight with at least ninety (90)
                                         days&rsquo; prior notice and, during such ninety-day (90-day) period, Braeburn shall
                                         discuss with Knight, in good faith, whether the grounds upon which Braeburn judges termination
                                         to be in its best interests can be adequately mitigated. If, after discussions with Knight,
                                         Braeburn still decides it is in Braeburn&rsquo;s best interests to terminate the Titan
                                         Agreement, then Braeburn shall negotiate in good faith with Titan and Knight to determine
                                         whether Titan would agree to license rights in the Territory directly to Knight, including
                                         a commitment to supply Sublicensed Products to Knight. Notwithstanding the foregoing,
                                         Braeburn may not terminate this Agreement under this Section 11.2(c)(iii) prior to three
                                         (3) years following the NDA Transfer date and then only upon at least one (1) year prior
                                         notice. If Braeburn terminates the Titan agreement pursuant to this Section 11.2(c)(iii),
                                         then, notwithstanding the termination of this Agreement, the ROFN outlined in Section
                                         2.9 shall survive for the remainder of the Initial Term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Either
                                         Party may, without prejudice to any other remedies available to it under this Agreement
                                         or at Applicable Law or in equity, terminate this Agreement <FONT STYLE="font-size: 10pt">immediately
                                         upon written notice to the other Party, if either Party determines in good faith that
                                         it is not advisable for Knight to continue to Commercialize any Sublicensed Products
                                         in the Territory as a result of a bona fide safety issue regarding any Sublicensed Products.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">This
                                         Agreement shall automatically terminate in the event the Titan Agreement is terminated
                                         prior to the expiration of the Term; provided that Braeburn shall not seek to terminate
                                         the Titan Agreement for any reason other than what is contemplated in Section 11.2(c)
                                         hereof, or Section 12.2(a) of the Titan Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">11.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Effect
                                         of Termination</B>. Upon expiry or termination of this Agreement, all sublicenses and
                                         rights granted by Braeburn hereunder shall terminate and:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Knight
                                         undertakes to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">except
                                         as provided for in Section&nbsp;11.5, cease any Commercialization of Sublicensed Products
                                         in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">commence,
                                         within thirty (30) days of expiry or termination, and complete as promptly as practicable,
                                         the transfer of title to all current and pending Regulatory Submissions and Regulatory
                                         Approvals for the Sublicensed Products to Braeburn or its designee and assist Braeburn
                                         in submitting appropriate documents to transfer the Regulatory Submissions and Regulatory
                                         Approvals for the Sublicensed Products to Braeburn or its designee;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">pay
                                         Braeburn all Royalties generated by sales of Sublicensed Products, including any sales
                                         in accordance with Section 11.5; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">promptly
                                         transfer to Braeburn or its designee copies of all data, reports, records and materials
                                         in Knight&rsquo;s possession or Control that relate to Sublicensed Products and return
                                         to Braeburn all relevant records and materials in Knight&rsquo;s possession or Control
                                         containing Confidential Information of Braeburn (provided that Knight may keep (a) one
                                         (1) copy of such Confidential Information of Braeburn for archival purposes solely for
                                         the purpose of compliance with this Agreement and (b) electronic copies stored in automatic
                                         computer back-up systems ).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Braeburn
                                         undertakes to <FONT STYLE="font-size: 10pt">promptly return to Knight all relevant records
                                         and materials in Braeburn&rsquo;s possession or Control containing Confidential Information
                                         of Knight (provided that Braeburn may keep one (1) copy of such Confidential Information
                                         of Knight for archival purposes solely for the purpose of compliance with this Agreement).</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">11.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Survival</B>.
                                         In the event of the expiration or termination of this Agreement for any reason, the following
                                         provisions of this Agreement shall survive: Article 1; Sections 6.3(c); 6.4; 6.5; 8.1;
                                         9.3 through 9.9; Articles 10 through 13; and any other terms which, by their nature,
                                         require or contemplate performance by the Parties after expiry or termination. In any
                                         event, expiration or termination of this Agreement shall not relieve the Parties of any
                                         liability which accrued hereunder prior to the effective date of such expiration or termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">11.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Sell-Off
                                         of Inventory</B>. Subject to the payment of all amounts due to Braeburn hereunder, upon
                                         expiration or termination of this Agreement, Knight shall be entitled to sell off or
                                         otherwise dispose of any of Knight&rsquo;s inventory of Sublicensed Products existing
                                         on the date such expiration or termination is effective; provided, however, that, at
                                         Braeburn&rsquo;s request, Knight shall promptly return to Braeburn all or any portion
                                         of such inventory of Sublicensed Products that has not been sold or used within nine
                                         (9) months following such expiration or termination and Braeburn shall reimburse Knight
                                         any Supply Price previously paid by Knight for such Sublicensed Products that are returned
                                         to Braeburn</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>DISPUTE
                                         RESOLUTION</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">12.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Arbitration</B>.
                                         Except as otherwise expressly provided herein, any dispute or claim arising out of or
                                         relating to this Agreement, or to the breach, termination, or validity of this Agreement,
                                         will be resolved as follows: each Party shall discuss the matter and make reasonable
                                         efforts to attempt to resolve the dispute. If the Parties are unable to resolve the dispute,
                                         the chief executive officer of each Party, or their designees, will meet within thirty
                                         (30) days of a request to attempt to resolve such dispute being made by a Party. If the
                                         chief executive officers, or their designees, cannot resolve the dispute through good
                                         faith negotiations within sixty (60) days after a Party requests such meeting, then the
                                         Parties shall resort to binding arbitration before a single arbitrator, in New York,
                                         New York, using the arbitration procedures set forth under the laws of the State of New
                                         York. The decision of the arbitrator shall be final and not subject to appeal and the
                                         arbitrator may apportion the costs of the arbitration, including the reasonable fees
                                         and disbursements of the Parties, between or among the Parties in such manner as the
                                         arbitrator considers reasonable. All matters in relation to the arbitration shall be
                                         kept confidential to the full extent permitted by law, and no individual shall be appointed
                                         as an arbitrator unless he or she agrees in writing to be bound by this provision.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">12.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Irreparable
                                         Harm</B>. Notwithstanding anything to the contrary in Section&nbsp;12.1, if either Party
                                         in its sole judgment, acting reasonably, believes that any such dispute could cause it
                                         irreparable harm, such Party will be entitled to seek temporary equitable relief from
                                         a court of competent jurisdiction in order to avoid such irreparable harm during the
                                         pendency of the procedure set forth in Section&nbsp;12.1. For the avoidance of any doubt,
                                         nothing in this Article 12 shall preclude, interfere with or modify either Party&rsquo;s
                                         rights under Article 11 above with respect to the termination of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; color: #010000">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; color: #010000"><U>OTHER
                                         PROVISIONS</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Withholding
                                         Tax</B>. Knight will make all payments to Braeburn under this Agreement without deduction
                                         or withholding for taxes except to the extent that any such deduction or withholding
                                         is required by Applicable Law in effect at the time of payment. Any tax required to be
                                         withheld on amounts payable by Knight under this Agreement will be timely paid by Knight
                                         on behalf of Braeburn to the appropriate Governmental Authority, and Knight will furnish
                                         Braeburn with the corresponding proof of payment of such tax, as may be required in order
                                         to enable Braeburn to request reimbursement or deduction of the withheld amount, or to
                                         otherwise comply with its duties. Knight and Braeburn agree to cooperate to legally minimize
                                         and reduce such withholding taxes and provide any information or documentation required
                                         by any taxing authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Further
                                         Assurances</B>. Upon request by either Party and at such Party&rsquo;s expense, the other
                                         Party shall do such further acts and execute such additional agreements and instruments
                                         as may be reasonably necessary to give effect to the purposes of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Independent
                                         Status</B>. Each Party&rsquo;s legal relationship under this Agreement to the other Party
                                         shall be that of independent contractor, and not partners or joint venturers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Assignment</B>.
                                         This Agreement may not be, directly or indirectly, assigned or otherwise transferred,
                                         in whole or in part, by a Party to a Third Party without the prior written consent of
                                         the other Party; provided, however, that each Party may assign this Agreement to (a)
                                         any of its Affiliate or (b) in connection with its acquisition or the transfer or sale
                                         of all or substantially all of its assets or its business to which this Agreement relates,
                                         without such consent; provided, further, that the assigning Party shall promptly notify
                                         the other Party of any such assignment. The rights and obligations contained herein shall
                                         inure to the benefit of each Party&rsquo;s successors and permitted assigns, and shall
                                         be binding on and enforceable against the relevant Party&rsquo;s successors and permitted
                                         assigns. Any reference in this Agreement to any Party shall be construed accordingly.
                                         Any purported assignment not in accordance with this Agreement shall be void.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Compliance
                                         with Applicable Law</B>. In connection with their activities under this Agreement, each
                                         Party shall comply with, and shall not be in violation of, any Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Force
                                         Majeure</B>. No Party shall be responsible for a failure or delay in performance of any
                                         of the obligations hereunder due to any fire, flood, earthquake, explosion, storm, blockage,
                                         embargo, war, acts of war (whether war be declared or not), terrorism, insurrection,
                                         riot, civil commotion, strike, lockout or other labor disturbance, failure of public
                                         utilities or common carriers, act of God or act, omission or delay in acting by any Governmental
                                         Authority (such events being defined as &ldquo;<B>Force Majeure</B>&rdquo;), provided
                                         that the Party seeking relief from its obligations advises the other Party forthwith
                                         of the Force Majeure. A Party whose performance of obligations has been delayed by Force
                                         Majeure shall use Commercially Reasonable Efforts to overcome the effect of the Force
                                         Majeure as soon as possible. The other Party will have no right to demand indemnity for
                                         damage or assert a breach against such Party, provided, however, that if the event of
                                         Force Majeure preventing performance shall continue for more than six (6) months and
                                         such underlying cause would not also prevent other parties from performing such obligations,
                                         then the Party not subject to the event of Force Majeure may terminate this Agreement
                                         with a written notice to the other without any liability hereunder, except the obligation
                                         to make payments due to such date and any obligations surviving under Section 11.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Notices
                                         and Amendments</B>. Any notice or other communication required or permitted to be given
                                         hereunder shall be in writing and shall be given by facsimile or other means of electronic
                                         communication or by hand delivery as hereinafter provided. Any such notice, if sent by
                                         fax or other means of electronic communication, shall be deemed to have been received
                                         on the day of sending, or if delivered by hand shall be deemed to have been received
                                         at the time it is delivered to the applicable address noted below. Notices of change
                                         of address shall also be governed by this Section&nbsp;13.7. Notices and other communications
                                         shall be addressed as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">In
                                         the case of Braeburn:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Braeburn
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">47 Hulfish
Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Suite
441</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Princeton,
NJ 08542</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">United
States</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Attention:
General Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">with
copies (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000"><U>notices@braeburnpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Hogan
Lovells US LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">100 International
Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Suite
2000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Baltimore,
MD 21202</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">United
States</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">Asher
                                         Rubin</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Fax:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">+1
                                         410 659 2701</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">asher.rubin@hoganlovells.com</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">In
                                         the case of Knight:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Knight
Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">376 Victoria
Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Suite
220</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Westmount,
Qu&eacute;bec, H3Z 1C3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Canada</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">Jeffrey
                                         Kadanoff</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Fax:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">+1
                                         514 481 4116</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">jkadanoff@gud-Knight.com</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">With
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Davies
Ward Phillips &amp; Vineberg LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">1501 McGill
College Ave.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Suite
2600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Montreal,
Qu&eacute;bec H3A 3N9</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Canada</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">Hillel
                                         W. Rosen</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">Fax:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">+1
                                         514 841 6400</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #010000">hrosen@dwpv.com</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Complete
                                         Agreement</B>. This Agreement, together with the SDEA and any quality agreement entered
                                         into between the Parties with respect to Sublicensed Products, and all exhibits, schedules
                                         and other attachments hereto or thereto, embodies all of the understandings and obligations
                                         between the Parties with respect to the Sublicensed Products and supersedes any prior
                                         or contemporaneous agreements and understandings, whether written or oral, between the
                                         Parties with respect to the subject matter hereof. Any amendments or supplements to this
                                         Agreement shall not be valid unless executed in writing by duly authorized officers of
                                         both parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Waiver</B>.
                                         No failure to exercise and no delay in exercising any right or remedy hereunder shall
                                         operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the
                                         specific acts covered thereby and shall not apply to any subsequent events, acts, or
                                         circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Severability</B>.
                                         In the event any portion of this Agreement shall be held illegal, void or ineffective,
                                         the remaining portion hereof shall remain in full force and effect. If any of the terms
                                         or provisions of this Agreement are in conflict with any applicable statute or rule of
                                         law, then such terms or provisions shall be deemed inoperative to the extent that they
                                         may conflict therewith and shall be deemed to be modified to conform with such statute
                                         or rule of law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Governing
                                         Law</B>. This Agreement all disputes arising out of or relating to this Agreement, or
                                         the performance, enforcement, breach or termination hereof or thereof, and any remedies
                                         relating thereto, shall be construed, governed by and interpreted in accordance with
                                         the laws of the State of New York without regard to any conflict of laws principle thereof
                                         that would result in the application of the laws of any other jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Counterparts</B>.
                                         This Agreement may be executed in any number of counterparts, each of which shall be
                                         considered one and the same Agreement and shall become effective when a counterpart hereof
                                         has been signed by each of the Parties and delivered to the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>Time
                                         of Essence. </B>Time shall be of the essence of this Agreement and of each provision
                                         hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">13.14</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000"><B>English
                                         Language</B>. At the request of the parties, this Agreement has been negotiated in the
                                         English language and will be or have been executed in the English language. <I>Les soussign&eacute;s
                                         ont express&eacute;ment demand&eacute; que ce document et tous les documents annexes
                                         soient r&eacute;dig&eacute;s en langue anglaise.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000"><B>[<I>Signature
page follows</I>]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: #010000"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000"><B>In
witness whereof</B></FONT><FONT STYLE="color: #010000">, the Parties have caused this Distribution and Sublicense Agreement to
be signed by their duly authorized representatives as of the Effective Date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify; font-size: 10pt"><FONT STYLE="color: #010000"><B>BRAEBURN PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify; font-size: 10pt"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: justify; font-size: 10pt"><FONT STYLE="color: #010000"><B>KNIGHT THERAPEUTICS INC.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: left"><FONT STYLE="color: #010000">By:</FONT></TD>
    <TD STYLE="width: 43%; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">/s/ Behshad Sheldon</FONT></TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: left"><FONT STYLE="color: #010000">By:</FONT></TD>
    <TD STYLE="width: 43%; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">&nbsp;/s/ Amal Khouri</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">Name:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">Behshad Sheldon</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">Name:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">&nbsp;Amal Khouri</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">Title:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">President and CEO</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">Title:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">VP, Business Development</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #010000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>SCHEDULE A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>BRAEBURN MARKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">[To be provided
separately]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">ASSIGNMENT, ASSUMPTION
AND AMENDMENT AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">THIS
ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;), dated July __, 2018, is entered into between
Titan Pharmaceuticals, Inc., a Delaware corporation (&ldquo;<U>Titan</U>&rdquo;), and Knight Therapeutics Inc., a company licensed
under the laws of Canada (&ldquo;<U>Knight</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #010000">RECITALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">WHEREAS,
Braeburn Pharmaceuticals, Inc., a Delaware corporation (&ldquo;<U>Braeburn</U>&rdquo;) and Knight were parties to that certain
Distribution and Sublicense Agreement dated February 1, 2016 (the &ldquo;<U>Knight Agreement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">WHEREAS,
pursuant to that certain Termination and Transition Services Agreement dated as of May 25, 2018 (as amended, restated, supplemented
or otherwise modified in accordance with its terms through the date hereof, the &ldquo;<U>Termination Agreement</U>&rdquo;), by
and between Titan and Braeburn, Titan assumed the Knight Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">WHEREAS,
the parties hereto agree that for purposes of clarification, the Knight Agreement shall be amended to (i) confirm the nature of
the rights granted to Knight, (ii) address the references to Braeburn, (iii) change the notice provisions, and (iv) replace Schedule
A in accordance with the assignment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">WHEREAS,
the parties hereto further agree that the Knight Agreement be amended to address certain economic issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">NOW,
THEREFORE, in consideration of the above premises and for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment
of License</U>. The parties hereto acknowledge that pursuant to the Termination Agreement, Braeburn has assigned to Titan and
Titan has assumed all of Braeburn&rsquo;s rights, title, benefits, interest and privileges arising under, or pursuant to, the
Knight Agreement, as amended pursuant to Section 2 of this Agreement. The parties acknowledge that the rights of Knight are those
of a direct licensee rather than a sublicensee, that references in the Knight Agreement to the Titan Agreement are no longer applicable
and that Knight shall perform all duties and other obligations of Knight arising under the Knight Agreement to the benefit of
Titan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
The Knight Agreement shall be further amended as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
references in the Knight Agreement to Braeburn are replaced with Titan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: #010000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
6.1(b) is hereby amended by changing &ldquo;<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>%&rdquo;
to &ldquo;<FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>[*******]</B></FONT>%;&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
13.7(a) is hereby deleted in its entirety and replaced with the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="color: #010000">In
the case of Titan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Titan
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">400 Oyster
Point Boulevard, Suite 505</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">South
San Francisco, CA 94080-1921</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">United
States</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">President</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">fstoller@loeb.com</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="color: #010000">with copies
(which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Loeb &amp;
Loeb LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">345 Park
Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">New York,
NY 10154</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">United
States</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Fran
                                         Stoller</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">fstoller@loeb.com</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1in"><FONT STYLE="color: #010000">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
13.7(b) is hereby deleted in its entirety and replaced with the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Knight
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">3400 De
Maisonneuve W., Suite 1055</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Montreal
QC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">H3Z 3B8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Canada</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Samira
                                         Sakhia</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Fax:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">+1
                                         514 678 8930</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">ssakhia@gud-Knight.com</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">With
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Davies
Ward Phillips &amp; Vineberg LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">1501 McGill
College Ave.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Suite
2600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Montreal,
Qu&eacute;bec H3A 3N9</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">Canada</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Attention:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">Hillel
                                         W. Rosen</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">Fax:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">+1
                                         514 841 6400</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="color: #010000">E-mail:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">hrosen@dwpv.com</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule
A is hereby replaced in its entirety with Schedule A attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. THIS AGREEMENT, AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF
OR RELATE TO THIS AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION
BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS AGREEMENT OR AS AN
INDUCEMENT TO ENTER INTO THIS AGREEMENT), SHALL BE GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS
MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES OF SUCH STATE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The heading references herein and the recitals herein have been inserted only for convenience of reference and shall not be deemed
to modify, explain, enlarge or restrict any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Assignment shall be binding upon and inure to the benefit of the parties hereto and their successors and
permitted assigns and nothing herein is intended or shall be construed to confer upon any person other than the parties hereto
and their respective successors and permitted assigns any rights, remedies or claims under, or by any reason of, this Assignment
or any term, covenant or condition hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which, together, shall constitute
one and the same instrument. A copy transmitted via facsimile or e-mail of this Agreement, bearing the signature of any party
shall be deemed to be of the same legal force and effect as an original of this Agreement bearing such signature(s) as originally
written of such one or more parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">IN
WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed by its respective duly authorized officer
as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">TITAN PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">/s/ Sunil Bhonsle</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">Name: Sunil Bhonsle</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">KNIGHT THERAPEUTICS INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #010000">/s/Samira Sakhia</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">Name: Samira Sakhia</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="color: #010000">Title: President</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000">Schedule
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000"><B>TITAN
MARKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #010000"><IMG SRC="tv499850_ex10-22img01.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #010000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>4
<FILENAME>tv499850_ex10-23.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.23</B></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: Transparent">OYSTER
POINT MARINA PLAZA</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 4pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 4pt; background-color: transparent"><FONT STYLE="font-size: 12pt">Thirteenth
Amendment to Office lease</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-indent: 24pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-indent: 0.25in; background-color: transparent; text-align: justify">THIS THIRTEENTH AMENDMENT TO OFFICE LEASE (the &ldquo;Thirteenth Amendment&rdquo;) is made and entered into as of March 21,
2016, by and between <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>KASHIWA FUDOSAN
AMERICA, INC., </B></FONT>a California corporation (&ldquo;Landlord&rdquo;) and <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>TITAN
PHARMACEUTICALS, INC., </B></FONT>a Delaware corporation (&ldquo;Tenant&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent"><B>Recitals</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in; background-color: Transparent">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
and Tenant have heretofore entered into that certain lease dated February 14, 1996 (the &ldquo;Lease&rdquo;) for premises originally
described as Suite 505 (the &ldquo;Premises&rdquo;), initially containing approximately 3,866 rentable square feet of space in
the building located at 400 Oyster Point Boulevard, South San Francisco, California (the &ldquo;Building&rdquo;), which forms part
of the office building complex commonly known as Oyster Point Marina Plaza (the &ldquo;Complex&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in; background-color: transparent">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Lease has heretofore been amended by the following instruments (collectively the &ldquo;Addenda&rdquo;): (i) First Amendment
to Lease dated as of March 25, 1997; (ii) Second Amendment to Lease dated as of May 22, 1998; (iii) Third Amendment to Lease
dated as of November 11, 2000; (iv)&nbsp;Fourth Amendment to Lease dated as of April 9,
2001; (v) Fifth Amendment to Lease dated as of December 5, 2001; (vi) Sixth Amendment to Lease dated as of August 1, 2002;
(vii) Seventh Amendment to Lease dated as of October 1, 2004; (viii) Eighth Amendment to Lease dated as of May 22, 2007; (ix)
Ninth Amendment to Lease dated as of February 11, 2009; (x) Tenth Amendment to Lease dated as of June 15, 2010; (xi) Eleventh
Amendment to Lease dated as of January 14, 2013; and (xii) Twelfth Amendment to Lease dated as of June 16, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in; background-color: transparent">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties mutually desire to amend the terms of the Lease to extend the Term and to effect certain related changes, all on and subject
to the terms and conditions hereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent"><FONT STYLE="font-size: 10pt; background-color: white"><B>Agreement</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 35pt; background-color: transparent"><B>Now,
therefore,</B> in consideration of the mutual terms and conditions herein contained and of other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Summary
Table</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">The Table set forth in &para; 3 of Twelfth Amendment is hereby superseded and replaced
in its entirety by the following table, which shall constitute the Table under &sect; 1.2 of the Lease as heretofore amended for
all purposes from and after the Effective Date of this Thirteenth Amendment:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: small-caps"><B>Periods</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Suite</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>No.</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: small-caps"><B>RSF</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: small-caps"><B>USF</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-variant: small-caps"><B>Monthly</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-variant: small-caps"><B>Base Rent</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: normal"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Tenant&rsquo;s</B></FONT></P> <P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Share</B></FONT></P> <P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Bldg</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Tenant&rsquo;s</B></FONT></P> <P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Share</B></FONT></P> <P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Complex</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Base</B></FONT></P> <P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps; background-color: white"><B>Year</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 26%; text-indent: 0in">July 1, 2016, through June 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">505</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">9,255</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">8,048</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">22,582.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3.993</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1.992</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">July 1, 2017, through June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,485.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.993</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.992</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">July 1, 2018, through June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,424.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.993</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.992</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">July 1, 2019, through June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,401.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.993</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.992</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">July 1, 2020, through June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,909.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.993</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.992</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Oyster Point Marina Plaza Thirteenth Amendment to Office Lease </I></P><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 11pt; font-style: italic">Kashiwa Fudosan America, Inc.:: Titan Pharmaceuticals, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: italic 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 45%"><I>titan pharmaceuticals 13a2-032416.doc (3/24/2016)</I></TD><TD STYLE="width: 10%; text-align: center">&nbsp;page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 5</TD><TD STYLE="width: 45%; text-align: right">[Suite 505, 9,255 rsf<FONT STYLE="font-size: 10pt; line-height: 107%">]</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event of any conflict between the terms contained in the Table and the terms contained in subsequent paragraphs of this Thirteenth
Amendment, the terms of the Table shall control, except as may be expressly varied in any subsequent paragraph of this Thirteenth
Amendment.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Effect
of Amendment</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord and Tenant agree that, notwithstanding
anything contained in the Lease to the contrary, the provisions set forth herein will be deemed to be part of the Lease and shall
supersede, to the extent they differ, any contrary provisions in the Lease as heretofore amended. Terms defined in the Lease shall
have the same meanings in this Thirteenth Amendment, unless a different definition is set forth in this Thirteenth Amendment.
The term <FONT STYLE="background-color: white"><I>Lease</I></FONT> as used herein shall be deemed to include the Addenda, each
of which may also be referred to separately herein. A true and complete copy of the Lease as heretofore amended is attached hereto
as <FONT STYLE="background-color: white"><B><U>Exhibit A</U></B></FONT> and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Effective
Date</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendments and changes specified in this
Thirteenth Amendment shall become effective on <FONT STYLE="background-color: white"><B>July 1, 2016 </B></FONT>(the &ldquo;Effective
Date&rdquo;). Notwithstanding the foregoing, this Thirteenth Amendment shall constitute the fully-binding agreement and contract
of the parties from and after the date of the parties&rsquo; execution and delivery of this Thirteenth Amendment to each other.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Premises</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The parties acknowledge and agree that the
Premises comprise approximately <FONT STYLE="font-weight: normal; font-style: normal; background-color: white">9,255 rentable
square feet of rentable space in the Building, as depicted on the Space Plan attached as </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><U>Exhibit
B</U></B> <FONT STYLE="font-weight: normal; font-style: normal">to the Tenth Amendment.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Extension
Term Base Year</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-weight: normal; font-style: normal">As&nbsp;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">specified
in the Table above, the Base Year for the purposes calculating Tenant&rsquo;s Share of Increased Operating Expenses and Increased
Taxes under Article 4 of the Lease as heretofore amended shall be calendar year 2016 from and after the Effective Date.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Modification
of Base Rent</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Base Rent for the Premises specified
in &sect; <FONT STYLE="font-weight: normal; font-style: normal; background-color: white">1.5 </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">of
the Lease, as heretofore modified in</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Addenda,
shall be the amounts specified as Monthly Base Rent in the Table above for the various periods and spaces set forth in the Table
from and after the Effective Date.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Condition
of Premises</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise expressly provided in
this <FONT STYLE="background-color: white">&para;<FONT STYLE="font-weight: normal; font-style: normal">7 with respect to Landlord&rsquo;s
preparation of the Premises for Tenant&rsquo;s continued occupancy, Tenant shall accept the Premises, any existing Improvements
in the Premises, and the Systems and Equipment serving the same in an &ldquo;as is&rdquo; condition on the Effective Date, and
Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Premises in connection with Tenant&rsquo;s
continued occupancy of the Premises from and after the Effective Date. The target date for substantial completion of Landlord&rsquo;s
Work (as defined below) is July 1, 2016 (the &ldquo;Target Date&rdquo;).</FONT></FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1&nbsp;&nbsp;<FONT STYLE="background-color: white">Landlord&rsquo;s
Preparation. </FONT></B>Landlord shall use reasonable diligence in completing and preparing the Premises for Tenant&rsquo;s continued
occupancy as provided hereinbelow on or before the Effective Date. The facilities, materials, and work to be furnished, installed,
and performed in the Premises by Landlord are referred to as the &ldquo;Work.&rdquo; Any other installations, materials, and work
which may be undertaken by or for the account of Tenant to prepare, equip, decorate, and furnish the Premises for Tenant&rsquo;s
continued occupancy are referred to as the &ldquo;Tenant&rsquo;s Work,&rdquo; which shall include the connection and/or rewiring
of Tenant&rsquo;s telephone and data lines. The parties agree that Landlord&rsquo;s Work, to be completed at Landlord&rsquo;s
sole cost and expense, shall consist of the following items only, which shall include Title 24 costs if any and moving services
necessary for construction of the Work, as shown on the space plan dated March 23, 2016, which is attached hereto as <FONT STYLE="background-color: white"><B><U>Exhibit
B</U> </B></FONT>and incorporated herein by reference (the &ldquo;Space Plan&rdquo;):</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 22pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">construction of two (2) 10&rsquo; x 15&rsquo; private offices;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">installation of flatwire electrical in the main conference
room;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">refinishing of the front door to the Premises;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">installation of new Building-standard carpet throughout
the Premises;</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify; text-indent: 0in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Oyster Point Marina Plaza Thirteenth Amendment to Office Lease </I></P><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 11pt; font-style: italic">Kashiwa Fudosan America, Inc.:: Titan Pharmaceuticals, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: italic 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 45%"><I>titan pharmaceuticals 13a2-032416.doc (3/24/2016)</I></TD><TD STYLE="width: 10%; text-align: center">&nbsp;page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 5</TD><TD STYLE="width: 45%; text-align: right">[Suite 505, 9,255 rsf<FONT STYLE="font-size: 10pt; line-height: 107%">]</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">application of Building-standard new paint throughout the
Premises; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">delivery of the Premises with all Systems and Equipment
serving the same in good working order and condition.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 62pt; text-indent: -20pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>7.1.1
Interference with Tenant&rsquo;s Business. </B></FONT>The parties acknowledge that Tenant shall be in possession of the Premises
and shall conduct its business in the Premises during the Work required under this Thirteenth Amendment. Landlord shall have no
liability to Tenant, nor shall Tenant&rsquo;s obligations under the Lease be reduced or abated in any manner whatsoever, by reason
of any inconvenience, annoyance, interruption, or injury to business arising from Landlord&rsquo;s performance of the Work or from
Landlord&rsquo;s making any repairs or changes which Landlord is required or permitted to perform by this Thirteenth Amendment
or by any other tenant&rsquo;s lease or required by law to make in or to any portion of the Complex, Property, Building, or the
Premises. Landlord shall nevertheless use reasonable efforts to minimize any interference with Tenant&rsquo;s business in the Premises.
Landlord agrees to use reasonable efforts to avoid interference with Tenant&rsquo;s use and occupancy of the Premises during the
performance of the Work and agrees to cause the application of paint and any work generating unreasonable noise outside of normal
business hours. The parties agree that Landlord shall not be liable for any damages which Tenant may incur during the performance
of the Work, except to the extent that Tenant&rsquo;s actual damages are the result of Landlord&rsquo;s negligence or wilfull misconduct.
In no circumstances shall Landlord be liable to Tenant for business interruption, lost profits, or compensatory or consequential
damages of any kind by virtue of Landlord&rsquo;s Work. Tenant specifically agrees that any interference with Tenant&rsquo;s use
or occupancy of the Premises caused by the performance of the Work shall not constitute a constructive eviction.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in; background-color: transparent"><B>7.2&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Notice
of Defects. </FONT></B>It shall be conclusively presumed upon Tenant&rsquo;s taking actual possession of the Premises that the
same were in satisfactory condition (except for latent defects) as of the date of such taking of possession, unless within thirty
(30) days after the Effective Date Tenant shall give Landlord notice in writing specifying the respects in which the Premises were
not in satisfactory condition. Landlord agrees to correct any such defect within thirty (30) days from the date of Tenant&rsquo;s
written notice.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 22pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Security
Deposit</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Tenant&rsquo;s Security Deposit specified in &sect; 5.1 of the Lease as heretofore amended
shall remain unchanged in consequence of the parties&rsquo; execution and delivery of this Thirteenth Amendment to each other.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Notices</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Landlord&rsquo;s</FONT> address for notices under the Lease as heretofore amended is
hereby amended as follows:</P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">if
to Landlord:</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">KASHIWA
FUDOSAN AMERICA, INC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">c/o
Cushman &amp; Wakefield of California, Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">Attn:
Property Manager</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">400
Oyster Point Boulevard, Suite 117</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">South
San Francisco, CA 94080</P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">copy
to:</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: transparent">Metro
Properties, LLC, Agent</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">Attn:
Oyster Point Asset Manager</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">3029
Wilshire Boulevard, Suite 210</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">Santa
Monica, CA 90403</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Oyster Point Marina Plaza Thirteenth Amendment to Office Lease </I></P><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 11pt; font-style: italic">Kashiwa Fudosan America, Inc.:: Titan Pharmaceuticals, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: italic 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 45%"><I>titan pharmaceuticals 13a2-032416.doc (3/24/2016)</I></TD><TD STYLE="width: 10%; text-align: center">&nbsp;page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 5</TD><TD STYLE="width: 45%; text-align: right">[Suite 505, 9,255 rsf<FONT STYLE="font-size: 10pt; line-height: 107%">]</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>10&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Access
Inspection Disclosure</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Pursuant to California C<FONT STYLE="font-weight: normal; font-style: normal">ivil Code
 &sect; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">1938, </FONT>Landlord hereby notifies
Tenant that, as of the date of this Thirteenth Amendment, the Premises have not undergone inspection by a &ldquo;Certified Access
Specialist&rdquo; to determine whether the Premises meet all applicable construction-related accessibility standards under California
Civil Code &sect; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">55.53, </FONT>and the Premises
have not been determined to meet all applicable construction-related accessibility standards pursuant to Civil Code &sect; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">55.53.</FONT></FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">11<FONT STYLE="font-weight: normal">&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>No
<FONT STYLE="background-color: white">Disclosure</FONT></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; background-color: white">.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Tenant
agrees that it shall not disclose any of the matters set forth in this Thirteenth Amendment or disseminate or distribute any information
concerning the terms, details, or conditions hereof to any person, firm, or entity without obtaining the express written approval
of Landlord.</FONT></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>12&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Defined
Terms</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Terms used herein that are defined in the Lease shall have the meanings therein defined,
unless a different definition is set forth in this Thirteenth Amendment. In the event of any conflict between the provisions of
the Lease, and this Thirteenth Amendment, the terms of this Thirteenth Amendment shall prevail.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>13&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Survival</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Warranties, representations, agreements, and obligations contained in this Thirteenth
Amendment shall survive the execution and delivery of this Thirteenth Amendment and shall survive any and all performances in
accordance with this Thirteenth Amendment.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>14&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Counterparts</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">This Thirteenth Amendment may be executed in any number of counterparts, which each severally
and all together shall constitute one and the same Thirteenth Amendment.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>15&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Attorneys&rsquo;
Fees</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">If any party obtains a judgement against any other party or parties by reason of breach
of this Thirteenth Amendment, reasonable attorneys&rsquo; fees and costs as fixed by the court shall be included in such judgement
against the losing party or parties.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>16&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Successors</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">This Thirteenth Amendment and the terms and provisions hereof shall inure to the benefit
of and be binding upon the heirs, successors, and assigns of the parties.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>17&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Authority</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Each of the individuals executing this Thirteenth Amendment represents and warrants that
he or she is authorized to execute this Thirteenth Amendment on behalf of the party for whom he or she is executing this Thirteenth
Amendment and that by his or her signature such party is legally bound by the terms, covenants, and conditions of this Thirteenth
Amendment.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>18&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Governing
Law</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. </FONT></B><FONT STYLE="font-size: 10pt">This
Thirteenth Amendment shall be construed and enforced in accordance with the laws of the State of California.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>19&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Continuing
Validity of Lease</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Except as expressly modified herein, the Lease remains in full force and effect.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>20&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Conflicts</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">In the event of any conflict between the provisions of this Thirteenth Amendment and
those of the Lease or of the Addenda, the terms and conditions of this Thirteenth Amendment shall control.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>21&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Landlord&rsquo;s
Representative</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">Tenant acknowledges and agrees that, in executing this Thirteenth Amendment, TAK Development,
Inc., a California corporation, is acting solely in its capacity as Landlord&rsquo;s authorized attorney-in-fact. TAK Development,
Inc. is not acquiring or assuming any legal liability or obligation to any other party executing this Thirteenth Amendment, and
any claim or demand of any such other party arising under or with respect to this Thirteenth Amendment shall be made and enforced
solely against Landlord.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>22&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Exhibit</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">The following exhibit, which is incorporated herein by reference, has been attached to
this Thirteenth Amendment by the parties prior to their exec</FONT>ution and deliver of the same to each other:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; background-color: transparent">Exhibit
A &ndash; The Lease</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; background-color: transparent"><B>Exhibit
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">B </FONT>&ndash; Space Plan</B></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Oyster Point Marina Plaza Thirteenth Amendment to Office Lease </I></P><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 11pt; font-style: italic">Kashiwa Fudosan America, Inc.:: Titan Pharmaceuticals, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: italic 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 45%"><I>titan pharmaceuticals 13a2-032416.doc (3/24/2016)</I></TD><TD STYLE="width: 10%; text-align: center">&nbsp;page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 5</TD><TD STYLE="width: 45%; text-align: right">[Suite 505, 9,255 rsf<FONT STYLE="font-size: 10pt; line-height: 107%">]</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>23&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Whole
Agreement</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
</FONT></B><FONT STYLE="font-size: 10pt">The mutual obligations of the parties as provided herein are the sole consideration for
this Thirteenth Amendment, and no representations, promises, or inducements have been made by the parties other than as appear
in this Thirteenth Amendment, which supersedes any previous negotiations. There have been no representations made by the Landlord
or understandings made between the parties other than those set forth in this Thirteenth Amendment. This Thirteenth Amendment
may not be amended except in writing signed by all the parties.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 34pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>In
Witness whereof, </B></FONT><FONT STYLE="font-size: 10pt">the parties have executed this Thirteenth Amendment as of the date first
above written.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 34pt; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; text-align: center; text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Landlord:</I></FONT></TD>
    <TD STYLE="width: 50%; text-align: center; text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Tenant:</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center; text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in; line-height: 12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>KASHIWA
    FUDOSAN AMERICA, INC., </B><FONT STYLE="font-weight: normal; font-style: normal">a </FONT></FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>TITAN
    PHARMACEUTICALS, INC., </B><FONT STYLE="font-weight: normal; font-style: normal">a</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">California corporation</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Delaware corporation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>TAK
    Development, Inc.,</B> a California corporation</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">/s/
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Sunil Bhonsle</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Its:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Attorney-in-Fact</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sunil Bhonsle</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>[name typed]</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in; line-height: 12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; width: 4%">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">By: </FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; width: 37%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">/s/ Yujin Yamaai</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; width: 8%; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in; line-height: 12pt; width: 41%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Yujin Yamaai, Vice President</FONT></TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; line-height: 12pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Its:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0in; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CEO &amp; PRESIDENT</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%; border-bottom: Black 1pt solid; line-height: 107%"><IMG SRC="tv499850_ex10-23img02.jpg" ALT=""></TD>
    <TD STYLE="width: 2%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 75%; line-height: 107%; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert L. Delsman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved as to Legal Form &amp; Sufficiency </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Berkeley, California </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016.04.06 12:17:21 -07&rsquo;00&rsquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Oyster Point Marina Plaza Thirteenth Amendment to Office Lease </I></P><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 11pt; font-style: italic">Kashiwa Fudosan America, Inc.:: Titan Pharmaceuticals, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: italic 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 45%"><I>titan pharmaceuticals 13a2-032416.doc (3/24/2016)</I></TD><TD STYLE="width: 10%; text-align: center">&nbsp;page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 5</TD><TD STYLE="width: 45%; text-align: right">[Suite 505, 9,255 rsf<FONT STYLE="font-size: 10pt; line-height: 107%">]</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: transparent"><FONT STYLE="text-transform: uppercase">Exhibit
B</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv499850_ex10-23img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>5
<FILENAME>tv499850_ex10-24.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.24</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT TO EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AMENDMENT AGREEMENT dated
August 9, 2018 between Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) and Sunil Bhonsle (&ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and
Executive are parties to an employment agreement dated September 29, 2016 (the &ldquo;Employment Agreement&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and
Executive wish to extend the Employment Agreement to provide for uninterrupted service by the Executive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for and
in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows.
Capitalized terms not defined herein shall have the meanings set forth in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Section 1.2 of the Employment Agreement is hereby amended by deleting the reference to &ldquo;two (2) years&rdquo;
and replacing it with &ldquo;thirty (30) months&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>. Except as expressly amended by this Amendment Agreement, the Agreement remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Amendment Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">TITAN PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">/s/ Marc Rubin</u></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Marc Rubin</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title: Executive Chairman</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">EXECUTIVE</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Sunil Bhonsle</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Sunil Bhonsle</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-align: left">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>6
<FILENAME>tv499850_ex10-25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.25</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT TO EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AMENDMENT AGREEMENT dated
August 9, 2018 between Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) and Marc Rubin (&ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and
Executive are parties to an employment agreement dated September 29, 2016 (the &ldquo;Employment Agreement&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and
Executive wish to extend the Employment Agreement to provide for uninterrupted service by the Executive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for and
in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows.
Capitalized terms not defined herein shall have the meanings set forth in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Section 1.2 of the Employment Agreement is hereby amended by deleting the reference to &ldquo;two (2) years&rdquo;
and replacing it with &ldquo;thirty (30) months&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>. Except as expressly amended by this Amendment Agreement, the Agreement remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Amendment Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">TITAN PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Sunil Bhonsle</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Sunil Bhonsle</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">EXECUTIVE</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Marc Rubin</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Marc Rubin</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>tv499850_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sunil Bhonsle, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1. I have reviewed
this Quarterly Report on Form 10-Q of Titan Pharmaceuticals, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4. I am responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)&nbsp;and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and
have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5. I have disclosed,
based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit
committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34px; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 14, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: #0F0F0F 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Sunil Bhonsle&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 45%"><FONT STYLE="font-size: 10pt">Sunil Bhonsle</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">(Principal&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Principal</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Financial Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>tv499850_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;<B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
this quarterly report on Form 10-Q of Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) for the period ended June 30, 2018,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned officer of
the Company hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, that to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The Report fully
complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 14, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: #0F0F0F 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Sunil Bhonsle&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 45%"><FONT STYLE="font-size: 10pt">Sunil Bhonsle</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">(Principal Executive Officer and Principal</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Financial Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv499850_ex10-22img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv499850_ex10-22img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ GP(! P$1  (1 0,1 ?_$ .X  0 #  (# 0$!
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MGH3_ *Z[CN6_=)=^R+[HZ6LD,N*TUL^4R:UKN=2$M(DQKD18*J13+!8&2?\
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M(8]:AN5E)+F,8BHV3&U465ZJ;9EQ_A/1=$6<F/.48 P!@# & , 8 P!@# &
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MOA*E(JJRFIV1233RXYFRVYUR6WJ^8J6GJ22S5'68P!@# & , 8 P!@# & ,
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M.G3T]0RB16 5892$W;_[HD-SPV#>Z%&Z:F-:*T>FM+>I)R5RC[*G(INIMO#
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MTI_V.8*K[[T971C.A8Y\JY+QF,GPRV9-:UC$F+^ZV=)EL5=A9J&R3.<'C ,
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M<O4"(5^W@@!1'T%"25')RURP(N39/HNPKR1+L#C]:^/,]("M9M&31I"M(KK
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MN/A?#-QX,P[1X4PU3MI;BH)#9,F6WW+&[*KG<]ZQ?,>N5[W.<N52Q7M1=O\
M>\W]ZD>W!@[2X_:H=1\UM"2 BB2-G?B<',)K-@Y*)!]9L/E"I('(/B;1A#CU
M*HLCUW.Y[M6OJ(O\&9E=N[3>GL[A\X:VFL)(T&8#61<TQBZ0KV8^50LBBK(9
M"S-K7MR]3)C"4BY'SE;G:Q\-[3!@QBF#*+C&;6.C8UHV81\>R02:LF+%FB1N
MT9M&R)2(MVK9NF4B:9  I"%    #.Q$1$2"9$0\ JBHGU=0^KJGNF54U[GO>
MY5<YSG*JN<YRQ57.55557*JK%3^O,E(P!@# & 53]ZCYO3;O_'M9_P X->R;
M.$1=F*W/HZ?^\>6'\6U!_C[ R4S8,--/>5$Q@# & , 8!7GW7?F\^4'\B8G\
M-:ODF\)##LQ1O]'F^41OWX%XC\.(_)S,Q%N<UJ943& , 8 P!@$8N:WR0.3_
M , VU/P+F,DWA(87,98.PO\ +D<? 5?_ +=4G+9G!(,]@V>906# & , 8!&/
MF3R 8\7^,^V]U.C)&D*G5W2=69JF('V2N<T=.%J3 I#_ /.E5GGZ!E2@ CY!
M#C]3,M2*P,+D0S%=CK0DKNKEE9N0MP*O,16EV,A85Y9^07 3&V-AA)M(]955
M41\;UE'K24B8P=3)KB@;T=0RUZP2!%J16)L1RDF<;;CU=6]V:JV%J2W(%7KF
MQ*E-U23\2953-TY=BJV1D&Y#"!?7(MT8CE >H>%9(H_4S*+!8@Q*\&=JV/@1
MS_AHO8)E89C$W:=T+N%NN)TD$X25F"09YE8@?W[6(G6C&53-Z0,@EU >ANN7
M.ZIN0K3(INR 0$ $! 0$.H"'I 0'V! ?J@.4%AYP!@# & 8D>>'SO]F^'S0?
M^R:VR].!TB"\(VW903.,MQZ?U_OO6MLU+M"!0L=*N<8I&2\>MT(LD(B55G)1
MKH"F4CY>*>)D<-'!/;HKIE,'L=!RBJBQ09S$;N[4/(/M/\N8.7J\VZ2<0CYS
M8]2[ ! Y838]%47!M(0=A9IF!!151HH#&<CA-[0YBK)"!#MU,N14>A6L44V%
M\,.7NN^:&EX?:E'4+'RR I0VP*4X7(K*T>X(MDU7T0[Z>$SB/< ?SF#L"@F[
M:F*8.AP4(2E45JP)HL26F8,F(_DO\\[,?TN-1?;"B9<G Z17[KIFW#*2P8 P
M!@# & , 8 P!@$+.1_RC^ OPU[8_JS[?S057A5-W1WQ;CNW1K]VND'T'0?35
MWDT\UYTD0;[F'R >7/P&W?[6FS;[U^;9W<U.]M6+\P>#_3M+[\ZZX/8#]X,Z
MS/T=+G/!BE. E,4#%'T"4P ("'[H#U <&4546*9%/W!PY!#U8'3H&WL>K Z<
M VZ>ST]7!3R>G7]S$5A#8*^+E6^-L,XWKK*1WX1/P*4I  I"E*4/8*4 * ?O
M '0 P6*JJL5RJ<O:'T?L/DCMNDZ4U9$FE[I>I9.-8%.53U")9)@*\O8YM=(I
MQ9P-?CB*.G:HA[5-/PEZG,4HW4]/-JIS9$E(S'+O;:KN(</Q]CK#FC3"%=C?
M%<[B;DH)*O?"%N8Y<DN3*186ILY\&2V[+EBN1%5.Q#XD<7M>\/M$TS1VNF_B
M85YJ+RPSRR9"25QN,B1)2QVR6,4.IG<L\)];)U$&[4B2!!\"1<[,HJ2714[:
M>5F3.NVNRO3/SEZ7]*>(M,F/:W'6(W0J*A]F3*1>HIZ9BJDFGE_NRVKE7W;U
M?,7JGJ25S5'60P!@# & , JG[U'S>FW?^/:S_G!KV39PB+LQ6Y]'3_WCRP_B
MVH/\?8&2F;!AII[RHF, 8 P!@# *\^Z[\WGR@_D3$_AK5\DWA(8=F*-_H\WR
MB-^_ O$?AQ'Y.9F(MSFM3*B8P!@# & , C%S6^2!R?\ @&VI^!<QDF\)#"YC
M+!V%_ER./@*O_P!NJ3ELS@D&>P;/,H+!@# & , RY?2".20/)S5G%J"DP%I!
M-QVULEL@?J'V2>)NHJAQ;T _O3M(\7[X4QZ^APW/_P G+9:;)!R[!#;5?:D[
MEZM+@;1KA9"D5^\PT-;F\<PW:XIKY9M,QC9['*SL/&JM_(E4V#@A5$UO$JB/
M4AN@@(!E7M,65.1?V5O=O^[E]_VFIO\ Z;BVT65'[*WNW_=R^_[34W_TW%MH
MLJ0.Y?<(N4W%@M;MW(]@T<?E*DI2/8VEC= N[E],Q+-JX<-YN5'Q/$'ZS%4#
MH"L8PK$1/X1^MB 2:Y'9@J*F<U[=KODF;DWPZUI:)9\5Y>*2U-K#8(F.4SE2
MQ4U%LS;2CDOC,IX[!7U&3XQS=/&HX/T]C*7)!2:+%"PS(F1@# & 8D>>'SO]
MF^'S0?\ LFMLO3@=(@O"-MV4$Q@$4N9'$?77,S2\UJB]HE8R!1/+T2YMVZ:L
MQ1K>W1.2/FH\QNAE6:OB\E\U$P)O&AS)CT-X#DRBJBQ,*D3';IK:?(;M.\O)
M:,M$(\1<P;U& VC1//52@-GZ_7<BJRG*^Z5 K=<RS;J]A)#PB**WB15 "F<)
MY<J(]"&5JFW#36XM>[\UK5-LZNGVUDI=PC4I&+?H"4JZ!Q]H\BI1KXC*1TS$
MNRG;NVRG0Z*Z9BC['4:52"P4L,;W)?YYV8_I<:B^V%$RU.!TBOW73-N&4E@P
M!@# & , 8 P!@# (6<C_ )1_ 7X:]L?U9]OYH*KPJF[H[XMQW;HU^[72#Z#H
M/IJ[R:>:\Z2(-]S#Y /+GX#;O]K39M]Z_-L[N:G>VK%^8/!_IVE]^==<'L!^
M\&=9GZ.ESC & /\ N"(B( !2E,8QA$>@%*0H"8YC"/0  !$1] 8!M_[,7;Q+
MQ2U%^6K:4&FCR"W+$,W2[5ZB47^M->.01?Q%*3\7B%I-2QBIOID0$# MY+8P
M!ZL(FY]<=V<SD\?.3^I>G8IM=%<Z[VP>&.NKK&+I9QA]2,*SU=H\N6<YJ.:O
M4UM6V+)E2O72I>653;%FW-3^:D+MLWX^'1@# & , 8 P"J?O4?-Z;=_X]K/^
M<&O9-G"(NS%;GT=/_>/+#^+:@_Q]@9*9L&&FGO*B8P!@# & , KS[KOS>?*#
M^1,3^&M7R3>$AAV8HW^CS?*(W[\"\1^'$?DYF8BW.:U,J)C & , 8 P",7-;
MY(')_P" ;:GX%S&2;PD,+F,L'87^7(X^ J__ &ZI.6S."09[!L\R@L& , 8!
MZ.SV2%IM:L%NLCY&+KU6A)6Q3LDX'PH1\/"L5Y*2>JC]1-LS;'./[A< P_Z*
M@ION6]S!M.6EL[=5R^[+D]G7%JL)E20^I*2HD[C:VJH;J"+<\,PC84O_ )QS
MZ ZCEZ]2PK3*IN9333133223(DDD0J:2292D333(4"D33(4 *0A"@   !T ,
MH+#_ '@# *_NYUQN-R=X=[/IT6R]<NM29EV9KXI"@9<]II:+E_\ 8U#T>(3S
M\(=Y'@4!#J9R4?J!DFK!3"I%#/IV'^2(:UY(6'14](F;5;?D#XX)!P?RV[?9
M=/0<2,64"G'PI+SE:,_;" =#*+H-R>D>@99,3)':(M7+ V&923& , 8!B1YX
M?._V;X?-!_[)K;+TX'2(+PC;=E!,8 P"LGN8]OJO\VM6?9"N(QT-OW7[%VYU
MM9W %;IS3;V[IWKZQNP !&"G%@ZMU3^+['O1!8O0AERJ2:ZRNX85(]$SC]M_
MG7=NW]NR<U/N-I.QVG)^T+0&UJ9*H."RFK;HT73BU[LPC3 91%S'"@5&7;)@
M(/61"JD\2B*7BM<VTF3.018'KN0<I&SG>*6FH:092T/,<J=+RD5*1KI%['R4
M<_<T!TR?,GC8ZB#EJZ;JE.0Y#"4Q1ZAF$X ]UTS;_E)8, 8 P!@# & , 8 P
M"%G(_P"4?P%^&O;']6?;^:"J\*INZ.^+<=VZ-?NUT@^@Z#Z:N\FGFO.DB#?<
MP^0#RY^ V[_:TV;?>OS;.[FIWMJQ?F#P?Z=I??G77![ ?O!G69^CI<XP!@&@
M+L>]O -\;#2Y6;:@R.-/ZHG?*U[!RC4QVFPMG19TUB2:B"Q/(>UBAK"50_7Q
M)N93RTQ Q4%RYR.X+LYQ-YY.3^ Q<B+LN]I/UGGMKTZQBX!PXNB;",]6XRO:
MGC5S6.@ZDHGQ16(J+%L^J2*)F5DBTZ*+,8ILSSG)XL# & , 8 P!@# *I^]1
M\WIMW_CVL_YP:]DV<(B[,5N?1T_]X\L/XMJ#_'V!DIFP8::>\J)C & , 8 P
M"O/NN_-Y\H/Y$Q/X:U?)-X2&'9BC?Z/-\HC?OP+Q'X<1^3F9B+<YK4RHF, 8
M P!@# (Q<UOD@<G_ (!MJ?@7,9)O"0PN8RP=A?Y<CCX"K_\ ;JDY;,X)!GL&
MSS*"P8 P!@%*O?)Y(?DBXIHZBA7HH6_D/,'JQBI' %VVOZ^+.6N[OJ4Y5$RO
MQ591OL=#D?*!_@B&3EI%8F'+!#@[L \<AJ^JMD<F)Z.!*6VC+!1:.X63,59.
MC4YR<TV\;"8/#ZM.VXQDQ$O]]]BRC['3,S%RP,-3)$T-Y62& , \" " @( (
M"'00'T@(#[("'U0' ,'W//4L_P '.>UI6H/FPC2*NT'O;3SM %$4FL9+RWOE
M91[8XE*!F\%8VCR-,4.I?)0 !]!NF7M6TTK5(*;:-#;?KN_=-:UW+5%"F@]B
MU&(LK9$IP4,P<O6Q0DXA<P?^M0THFLT6#ZBJ)@RE4@L"Q,IRUF , 8!B1YX?
M._V;X?-!_P"R:VR].!TB"\(VW903& , 8!0UW@NVN&]Z[(<FM(00&W53XH#7
MNK1B!2J[3J$4@<?6VC=(G5S>ZVT)_H_^'(,R>KB(J)MRC8QT,BYB+DCE0S"\
M63&-R>XY>,3B8N\]3I]%!/XR G=X-,$Q!3VY/* OA\(]/" =.@=.F6.S+T""
M9SL7\TY:, 8 P!@# & , 8 P"%G(_P"4?P%^&O;']6?;^:"J\*INZ.^+<=VZ
M-?NUT@^@Z#Z:N\FGFO.DB#?<P^0#RY^ V[_:TV;?>OS;.[FIWMJQ?F#P?Z=I
M??G77![ ?O!G69^CI<XP"8?!CA[=>;O(&LZ<JXNXRND\%@V=<T&_G(4FA,G"
M9).2ZFZ(FF),YRLHQ$XAYSQ8HC];34$NMN^BF5]2DAF1N=R[2>WL)NG3>G?3
M)<F@W1Y58SO6Q-O%?X-%3*L%J:MR*K&;?%L3^).<G!EM5$ZIS47L--6ZRI6F
M-=4W56N81M7:10X!A7*W#M2@!&L>P2 A3K* 4IG+YVJ)EW*YNJB[A0ZAQ$QA
M$>RY,J7(E-DRDA+:D$0_.GBO%%^8UQ'6XLQ)/=4W[>%0^=.F.]T]ZQ@B>Y:U
M(-8U,C&(UJ01$/OLL./C & , 8 P!@# (N\R.,K'E]H&V:'D;@]HC2U/JV]/
M98^(;SKID:NS\?.D3)&NGL>BN5V=@"1A%4O@ WB#J(=,RU8+$PJ1(Z]OGMQP
MO 9QM-Q$[9F-G#L].I)KDE:FPK(0WO4&>%,4!93,L+SUW[.CXO%X/!Y0=.OB
M'IESK01(%EF1,C & , 8 P#@'E+H=IR<T!LO0[ZRNJ<TV1"M8=:RLHU"8=1)
M6LS&3 .$8UPZ9(NS'/&@F)3*D  .(]?1TS*+!8F%2*0(3\ NUW!<#]@7N^Q.
MY9O9:UXIS.H*QDI38VM)1J;2;0F?7DW+*<E3N5#F0!/P"4@  ]>OU,RYUI#"
M) M6R)(8 P!@# & <:[EURAN#4NR]4N99:!;['HUHI*TVV:IOG$2E9H9Y$'D
M462RS=)VHS*[\P$S'(!Q+T$P=>N918+$%87!GM&5[A)NM3<T7O2?V(Y/2)VE
M>]^2HT776P)3CR&=GD/L@SL$FL*C88<"@GY?0WF"(F#IZ9.?:2!%&P+A\@2&
M , 8!4-SL[4WZ<^W([9MEY&62CQU?J#*HU>F1M BIQA!MTW+J0E9 D@[LD<J
MY>S4DZ\Q412+X2(I)]1 @#DVOLI BK8EE6E=45K1>I==Z>J"?AKFN:E#52-4
M,D1%5Z$6S31<RCI),QB%>R[WS'2_01 5EC#D56*Q))D.3\P!@# & 5J=P+MK
M4;GJXUO,2M^D]86K7:<Y'$L4/6V-D6G*]-"U<?8-^V>R<65)*/DVOK""A3F$
MAE52^'V_4)-<K3"I$YCX.<37G"_3!]*?E4E-JP+.T35AK;^7K;2MNJ\SGA0=
MR$"BBSEI9-RQ&8!=V0PF()3N3EZ"'3,.6TL0B0)D9@R, 8!3#O+L[5O=G+62
MY6.=]V&NOY&]42[FI+:AQ4BQ25HZ-<23CBS2UB:N3)2/O> 3*"W R?FCT WA
M#K-'P2!&SEB7/9 D, 8 P!@%.6T>S;IZZ<K8#E#1K]*ZJ.QO-5V//ZWA:I&2
ME:G+=7I]"=DI%@Z5E(]:O$M"K8HNDDDE4R.#*+)@'C$@31ZV;)&SEB7&Y D,
M 8 P!@# & , 8 P"%G(_Y1_ 7X:]L?U9]OYH*KPJF[H[XMQW;HU^[72#Z#H/
MIJ[R:>:\Z2(-]S#Y /+GX#;O]K39M]Z_-L[N:G>VK%^8/!_IVE]^==<'L!^\
M&=9GZ.ESGO*U6K#<[' U"I0TA8[3:9>/@*Y 13<[J2F9J5<ILXZ.9-TP$RB[
MIRJ4H?4 .HB(  B$F,=,<C&(JO58(FVJFAO.\[NN6[:B^+WG2Z:ZJ22^;.FS
M%1K)<J6U7/>Y5S(UJ*OZ$RJ=@+VT>"=?X+<?XZJ.DF,CN"\ QL^Y;2V$BY7E
MD,U K:L13H"@8U9IZ"IFK0 ]"RHK.1 #+B4.Q[JN]MWTR,7+/=E<N[M=!-C?
M/SV:SFGJ\-/&D*9>TI7R\&T%J1=TA8I9DVNJGS&\O4*B/F=:VQ*S2XK8IFYG
MS@, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$+.1_P H_@+\
M->V/ZL^W\T%5X53=T=\6X[MT:_=KI!]!T'TU=Y-/->=)$&^YA\@'ES\!MW^U
MILV^]?FV=W-3O;5B_,'@_P!.TOOSKK@] !^]_P"#.LC]'>R:ONQ!V\/L%&M.
M;VX8'PS<XS<->/L!*(""D37GJ*K24V>LV5+[1_8VZAVL0)@\2; 55P#_ $A(
MQ>8X>NRRG/YZ=4O 3<Z[I[&YT3R4U]]8SG]2_09@VHC0R'M=>TUBY)DYJHYE
M"CDSMDJB/J$3(LVQ+5?X;T73OG+#RY& , 8 P!@# .#.4$Y,5CC1R(LM=DWD
M+8*]HS;<Y!3,<N9M(1,Q$T&P/XR38.2>W;O&#UN15(X>DAR (>Q@&;OMM=M[
M8O+WMW<7>6$EW2.ZG0.2.YM116P)"WQG+JSVS7\3;GSA^FF8=/W&/DZI+UE/
MU9,JL>J8AEDP$//(8PGP"R[LN<N]\\G-$;YUUREEH*W\BN$G+'<'#/:>T*O%
M-X2O[?DM2J0RT7LMK$,>D;%2$_$3J17K=N!$@=(&4*1,%03*!\7W=]P;5U=O
M[LV0FM]C72B0^UNYGK;7NS8RIV*3@V%_HLA3[4Y?T^WM6#A%&?K;Q= AU&;D
M%$#'(4PE\12B %WN 4H\'MO;4N/=W[SFK;9L6Y636NI1X-?DNH<U/OY"J:]]
M^6D)N8MOO/A'"QV4%[Y)9$CE[Y!2>L+% Y^HAUP"Z[ ,MW?BWKR^OFX-=\:>
M EMF*]LCA5I^?[JN_P!:!=RR!K/7-,SJ,1IW0KTT,L@+Y;:SY*PNE8AR95)^
MA'(>-!1,< T.\8N0-%Y6<>-+\DM9O"O*-NS6]4V+7Q\P%%F3>R1+=^YAGP@4
MGERL _458O$Q !2=-U"" "40P#ZO<TE(0NG]K3$2\<1TK$ZVO4E&2#104G3&
M08U>4=,GC94OI2<-7*13D,'I*8H#@&7'M6]O+8O-SMP\:N7ER[H7=6IG([<U
M*GK=(VJN<PK3*42%L;*[6JOQQFNJ+-&2M4D(%%I"H><Q7ZBO[?ZZ3Q]2@6>=
MF/E5R+WC0>5?'WEI:H79V_\ @1RLOO%2V[NKT*TK;#=L)6&<;+5'83^N1Z#:
M/@[,_BI 49!! A4Q41(H/51101 YR[Q>W[/H;M;<[MK4BSS5+NM7XW[#3IMN
MK<F[AK%6[98(P:O6YJ"EV"B+Z-F(Z:FD%6RZ)R*I+%*8H@8 ' .'>QUR_P!B
M\I^$<#5.0XS#/E]Q0L<CQAY4PMH7*M;/RCZZ0;(1%QFE!$57ZFPJ8NPDSOO2
MF\?*.C$,<"B; /N.\?RHV%Q@X3V]GH,';[E?R/L$#Q?XH042L"4\]W1MX[B(
M:6"*.!@.V-KJIH2ED.Z,'DM@B@,H(%' /[>RCNBU<@NU/P;VM>[//76\SFCH
M:&NELM4L^GK-8;;1I.6H5CEK#,RBSF2E)I[,5E91RNNH=5583&,81'K@%HV
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MSW-1S5ZFMJTBR94K#(Z5+RRZ;85MN:G\Q(7<YOY\-C & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# ,[/TCWY,FA_AX'\ +9G&<4>"2^Z
M>PIZ._ZU_O0O_P! ?_7(*\.Q]V\#;WV*ARKVU!F4T_J>=3'743)-@%EL39T4
ML54DB=%4/"\K-!<%(J?J I.93RT_;%;KD';+@NSG$WGDY/X#%ZG]YR>PGZSZ
M+UZ-8Q, X;=HGPC/1,97O(7GDQCNJHZ*8D%9%.#/JTBU/=,D6G9%F2U-FN<Y
M/%<8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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@@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tv499850_ex10-23img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv499850_ex10-23img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ &P"- P$1  (1 0,1 ?_$ '@   $$ P #
M       %!P@) 00& @,* 0$                     $   !@$# @0#!08'
M       ! @,$!08' !$2$P@A%!46(C(7,4$C& E187'!0B:")#14)34H$0$
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M,F4NXA(^K9^KLK1IN[VP(_'+.M3\E!3_ +LG(U")8.(]8R(I(V1-0(B2456
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MH_@,"]MRJJ;QQCNE868IP5D5F)]GYB!?Y&E;J[F2RK=-^;K(Q"@,"+IMG"I
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?\_CV^;QWT"AH#0&@- : T!H#0&@- : T!H#0&@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv499850_ex10-23img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv499850_ex10-23img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"$ ,T P$1  (1 0,1 ?_$ +4  0 ! P4! 0
M       )!@<( 0(#!0H$"P$!                     !    8" @$# @,#
M!P0)"@(K 0(#! 4&  <1"!(A$PDQ%$$B%5%A%G&!D3(C%QBA0E(*L=%B<C-3
M)-=8P8*2TD.3)9>8&?#AHF-S@S14E-25)M8G5[+31%75EBCQPJ.SPW2$-46%
MI396IC='9X<I&J?'2!$!                     /_:  P# 0 "$0,1 #\
M]_& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!3CZX5*+G(VL25H
MKT?99EJ[?1%=>S4<VG95DP356?/(Z(6<DD'S5DD@<RRB29B)E((F$  <"@++
MV(Z_TR;?5JX;RT]4['&?;C(P%FV92X&:8 [;)/&HO(N5FFCYL5RT7(JF)TP
MZ9P,'(" X%QX*RURT1$=8*U/PMA@9=HC(1,W!RC*6AY1@X PMWT;)L%UV3YF
MN!1\%4CG(;CT' [CW4O^,3_[,O\ MX'1V*U5>GPKZR6VR0-7KL6F163G[%,1
M\)"QR2JR;=)5_*R3ALQ9IJ.%B)E,HH4!.<I0]1 ,#N2.&ZA"*)KHG34(51,Y
M%2&(=,Y0,0Y# 80,0Y1 0$/00'D,"G;5=Z918=>Q7>VUFFU]LL@W<3UKG8NN
MPJ"[H_MMD5968=,V*:KA3\I"BH G-Z!R.!9XG;_J8HL1LGVBZ[*.%%2HIH$W
M9K4RQUCF A$B)%LPG,J<P@ % .1$<#MC]H.M":ZS53L1HQ-RW6,V7;GVW02K
MHN"&\#MUDC6 %$UB']!(( 8!].,#B-VFZQ$,4A^QNARG.!3$(;;VOBF.!_/P
M$I1L("8#^V;CCZ^(_LP-O^*GK!X^7^(_0OB'/YO[X->^/IX<^O\ $7'I[A>?
M]\'[0P-@=K>K@B<H=D]!"9)(ZRI0W%KP1313$ 45.'\1<D2((\"8?0/QP.0G
M:CK"HH1%/L=H=1919%NFBGM[7RBRCAPJ@@W032)83**+N%W21"$ !,<ZA0 !
M$P (7FB9J'GF#*5@Y2/F8J2:)/XZ3BGC>0CI!BN4IT'C%\T46:NVJY#@)%$S
MF(<!Y 1P/@M=OJ=$@9"U7BSUZFU>)3(K*V2US4;7H",245(BFI(3$NY9QS)-
M190I"F44* F, !ZB&!98G<'J4H0RB?:/KHHF0QB'.3=NM#$(8OCY%,8MF$I3
M%\PY ?4.0_;@;$^XO454%C)=I^N*A6X>2XI[PUD<$ X >5A+9Q!,.!_SN,#E
M1[>]37*15VW:#KPX0-SXK-]U:V62-XCP/BHE93$-P/UX' ^=YW)ZA1X$-(=J
M>N+ JH\)F>[OUFU*<W/'B4R]F3*8P_@'/(\#^P<#X1[N=,"B8#=NNL)1*)@,
M!M^:J*)1*(E, @:U@("4Q1 ?V" A]0P*VU_V2Z[;8F%Z[JO?6F-F6!JQ5E',
M'K[:-(NDPVC4%44%I%Q&5N<DGJ+%%9PF0RQB F4QR@(\B&!>(738/JX0#^54
MG^SY8%.,[U29&RS=-C[A6'UOK32.D+%5FD]%N;% L)CG])?3$*BZ/)1K.3X_
MY.JLF0BW^:(X%3>ZER(>XGR'U#S+R'\H<^F ]Y+GCW4^?V>9>?Z.<"UVQM[:
M0TZM"M]N;CU7JQ>R&>%KJ.Q]A5*CJSYH])-9^6%3LTO%GE18HJE,M[ *>T4P
M";@!# Y:)N_3&TF$O*ZQVWK/8\5 .2,IZ3H5[J]QCH1XJT,_2:3#ZNRDDUC'
M*C(@K%37.0XI!Y 'CZX%04K85!V3!-;1KN[5*^UE\HLDRL5,L41:()VLV4]I
MRBVEX1X^CUEFROY5"%4$Q#>A@ <"L,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@4_:;%!U2N3UCL<JRA8. AY&8F)1\Y;M6T=&1S51T
M]>KK.E$D$DFR!!,)CF H>G(A@0[=(FDAV<V9LKY$[NP!9EL,LAJ/J6V6!-1Q
M7M!UV243G;Y%-G7MECW&X;7'E3;N"F**L#&I."G CXQ!"1.3UWKN8?N96<UU
M1IV4>@D#J3GJK5I>1<@W2!!$5Y"1C'#YR*:!2D 5%#\%* !P <8'?L8QI%L6
MD7$Q+6+C&")&S&,BT&<9&LFR0>*2#./CR-F31%,.>"IID+^[ ^KS,8. 2 >/
MV. $?3T]?[7 B[^:YL5Q\5W<E)RR370&@U58Z#A0YD53-]HT-PD0Y2%<B8ON
M)@/ E_#Z@.!)O$I*$A8, 1,8"P$$0!!;TX+$LB_43$/Z<?B4!_=@<<E!Q4ZT
M4C9Z"C9V+74357BYMHQEXU95 ZJB"JS&33=M%#HF5'Q_)Z>@_7UP,$.^&E]*
M1_33MO.--'Z8:3;#KKMUZTET-:41C*-'2-'EQ2=MI*/@2R+1VW^J2R(E53,
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M^PVOEO[%W0]X:_7)!WB#.V.8QTF;E\B#MKQRF*+@"D,/@(X&>F P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P+(=C=Y4?KAI78FY=B/T6%8I
M%:DY9P"IE"C(.46:QV42@")3+'<R3D@)%*F!CCSZ (\!@8 _'SJJ_P!>U=9.
MP6^FZQNQ_;:Q#N&^)R#1M'RNNZ&Z>O'.F-(*LF8%28FUK2'""<F@/(FFG3WS
M$W!/ ,_P4 P<C[Q1 ?HFN)"C]/ZQ0*/E_M8&WW_]Q_ZE_P"E@?./B'^<1#]_
MW;5KY?SLR'$_'^ZXX_#\<#<10QU")E!,/J8QUG!4DP*4Z:8?\H4 J13F46+P
M)A !#D?PP(W-,5Z&[>=G9GN#:*]$R.J>N,S9]0])S/&C-X:5L8!^F;V[*0_N
MHJ@FC/SK?^':\N?S$8]@NX)X^ZF)0DD\P('!2>@<^)0 I0*7GT(4J9"D*4@>
M@     &!Q ?U$Q2+F-]? %_RCZ@'B1$P!YJ&YX(0O)C'$ #U' AI^0'N3)2'
M6/N-#T73<?;=1PU1V1U_L^^Y+?-'I5?/M"2AV]*FX/7U,DXN0E=@%JEUM"$&
MLL+F,;NYEF^;)J@#514 Q2ZI]]NRVQNK.A]*];OCEG>T:77%CK^&L_Z;W!ZK
M5"&NJ6L$)2(9V%[6YVW.+_"5F2MD8QEX51S"':22:) .KP80$)-NK/R-=H=D
M]LX'J?VSZ O^FEGO.FK]NC7TI+=F=7[H4M,3KJTT:J3\8E#Z^BRGC52*W9%8
MAUURBJ":@E((%,8H3#\X# \K_P U79J<WUL%QT9U 8TC#:T:UN:W.G#IQ\U(
M77L3M\!JO5'KA$QS@Y6JUJFK1*HSCQ=904(1HW-,*)F+!K@4)KKQV#U_\>'4
MK6-Y[C[3COO*K6M7ZWO%R@:LJ3^.=ENXB)@I)Y3M?TZ'!PH@X?,UWIFK)F4K
M"':*K"F4B)@P,F]0;OU7ORF0VQ-.7NL[)H\\B9:-L]0E$)>*/XD2.9LZ42$J
M\;(H^Z!56CE-%TB<! Z9?J(7/=M4'K=5HY3(LV<$,DN@J0JB*Z*A1(J@LDH!
MDUD5DS"4Y# )3%$0$! 1# \['5HO_FT^\M\^,^Q<L^L?9=[=NSGQQ2[Y<I(F
MIS3ETI,=ANH\65<PHIKU.<>A.UM@!A,I#O023*=?R' SB[?=_P#J_P!((N&<
M;RO:I[M;RMT=::)UTPD+[OS:\PNFW%K&Z^U#4D'EAE?)VN5,[Q9-M'H&$IUG
M)?4H!@&.KOD8^2GRD]_R,[\773>9]LZ>A]:V"+L'=_;\2L90_.V]I*(+PF@8
MV42.D+J+@$/UHH@9([H Y$ HCI]TKTU\>5UD4ME]3]N;0M%7M5SE].[WUAKA
MUO74K*#F99R[KDI6-=U875GU'MPU?<)-)22L,?.3S]Z1=P6P+(.")I!(MH/O
M]0]\=D]N]5WFK]PZ.VYK"BT/:\15M]Q415+/L_5-T4,P>;"J->:3<L^81%6G
MR@Q>H/C)/2J'!0R1"%/P&=Q@+^Q4>!'_ (<2.>/Y/>2,!/W\?7^; LGV-TA5
MNR^C]AZ/MTI)UR/O$0@E%7!@[1_6Z%<X5^TG:'?ZT=R3AK8:/;XYG*-5"%,(
M&:"4P>V8X&"TG2;L#<MV:ME:SN5G!UWLQH"RN=-]EZBS<IIL6^RH-$BS3859
MCE4U#IZ^W'7#-Y^%6\2HBDX522X]HV!F:"X 0. 4-Z ')5_)N/[TTP2(0"_L
MXX  P-#G_()@52*(@'Y%7IBE#U#^LC[0E#^G XRJ<  ^X FX'@2O#?9_B'J'
MM\<?M_W6!S)N/$2&$1.8!Y_L7(G;#ZB'!DA3\3^GU# A2[(R;SXW^_E%[P1I
MW3#I_P!T9FDZ$[NQY#'-$:WW2F=**T7V5=$03(2,93PH# V)R4"D4]P5E^55
MDA$/0VW7*X2(J7C@Y"G 2G*H0Q#\B0Z:I!%-0BA0\BB ^I1 <#GP& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P&!M.82E$0+Y#R'IR <@(@ \<_B
M #]/QP(7MQ.O\<W>!MH_]-<R'6#IC(U78NY7BRK<E>VQV$!-Q-ZSU0U4;N73
MJ4BZ(HV3GK F=! B8-FK8152D#@4).!<K*AYN#%,H JB900(0! ZJBOD<$D$
MP\Q]P1,(%$1-R/[L#4ABG#DIR']>.2"80#^7S(0>?YL 4WESZ<<8' <P>GY
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MR8"S4:-W*5S"ZUJ5_LUSJ].!9NSV+I%LVL(L&DW*.(F:&4CW<<J,A(-^%PD
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MA2B >KYFU0:-6K9!NU;)-FZ+=%!HB1!L@B@D5))%LBF $1023*!2%* %*4.
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MW:5R;L7N.G=%(L'3BD+,X?;O<B31;JF91^E6#]%W3=.*O. !I.[QM#9LD]3
MIE4JXBXY*7[CR($A)2)H$321(BDV011:M46Q$TVR#1N42-F[5-(I$4FJ*7HF
M4@ 0I?0H &!R!Z^N!H("/!2_4QB$ 1$"$*)S 4!44,)2))\CZF,(%#Z?40P/
M*9NKM.XW[VZL7=V?U!OV\]$NI@[.Z]Z8W'I6LQER;:RVV^A8)&1[5O:,Z?\
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M'DH1K+QI# 4P* ) S)HEUJVR:55=@TB>92]0N5;A;5 22"#90'<7/-"/&1_
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M9=@TV=MF=L+>HL].];&<TTC-BSY[6]($15+KM]TH2B4Y=RX:F-*RKAXD85&
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M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*T^M:HG+?/W]_2A_596&3M]C61<R<ZP&=DY-W#NB*-DP;?:*H%8IIE(V!(H
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ME+K4(&RR^O+>U(RM%'EI9@BZE:I/- .J*$C R)U&YP\AY!,!'ZX%P$SK^ $
MY@*//)0,! XYY'\Q1*8O/'X"&!Q*&5*8">X8I1#U RAE2CSR ^1C'.?@0^H
M8/W8$7GRM;2/!]<V?7NGU>&V5O'N794-!Z2UK*,4GC"0L#Y(9::V!+M'Y1"/
MCM31#<TPG(&6:JQ\B1JY;J%51]0SKT/K6<TUI'4VJ[+LBV;8LFOJ#6JC8=E7
MB9>3UMNTQ!QJ+5]/S4L_;(.7ZKI;DJ:RGFJ=,@>X8Q@YP+I<J$_JF,3GZ^(A
MZ\?MY ?IS@<WCY<\^H$(*AO4 $"%,0AC?4/\Y0 _E' @(^3?;UC[/=@:/\:6
MG5WDM!1#>%VYW!4KQ(U1^^C0>Q2VH^OK-6P15AK))N\V9XP=O4I)@^;H-W#9
MPLW609/4Q"\_0!_O>HWXO5G?>V=/;0ZLV;2Z+^ATG<R3$=X-HU^=C&U?7=?;
M(-E:)LO4I85"2:N1='.Y;*,TVR<;'(G^U($Y\"O1ZPSA*/7G%=AFT37TPK]3
MBS1T>+"KPOLQB7Z17F14/M(&)X3;$!! C9O^1(H%_*7 J\ARJ% Y# 8H_00^
MG_T0P-V!M,4IRF(< ,4Y1*8H@ @8I@X$! ?00$!P,?M]=6="=FJ8YHV\=<0^
MP80S=9.-6DSNT;%6UU4P(,C3[6S<M;)5)CDA1^Z8NT%C>( 8QBAXX%E=*=1+
M91MQ.]K[6WY>.P"E/I+K6_7YEL2O0$?8=24^R2365OKF8ME?!JUV3>[<K"Q;
M%2?<1T?(?HD4@V6!559XX<AG:&!A/WP[/(=8]$R]HA47,YL:RO4:3K"G1!??
ML-LO%B,$/!1$"@!%14EUIM^U1:_D4*+Y=NF(?VI1P+4=3/CETEK73T"7?.G]
M.[AW]<EG>P-U["NM"J5_?OMC6TC=W-P%?G;/#2;TM&I#=%O!PB)!2+^GQQ%E
M""X7744#)\O3GJ07T+U=ZZE*'T(&C]7@4 _8 !5>0# CB[X]>8OJ-(ZU^1KJ
M%I^N5>W]5E)-#L-K;4M/@JF7>_3^WN&"FYJ^Z@ZY'1[.P7#6"48C;J^<Z8K@
MYC5D"F'W_ P2[:[V'3=HT:G;%H=DCK73+_6X.W5&PQ:R:[&;KMCC$I>%DFQT
MP  1?1ZH*  \" \E'U 0 *4WY?+SK'3VS-@:XU=-;KNU-I<U9*SJJ EH^!F+
MY+1#?[I*LQ<M)-G;9L_DTP,"?*2ASF)[:9#*'(40@E6U!>^[-'@^_MH[FZ=D
M.S^@HBU[!ZH4[3,@2B];^M-N:QS=S<=:[HD[@5CMB]2%Y@8US6+NYN!8-O%,
M7:ZK:"CW2":N!*)U;['T;MGHN@;\UHX]JNWN)%P\A4532CVG6J+<KQ%TH\XY
MCY$K<DI2;0Q=1BZ@\E74;"N3A%9'D,@UCF/X^XN0_'/'*BTAXCZ<E$ =L_8/
M^T!Y-^T _$-#<B >;@$P_#Q7=K\C_O$SA[?I^T1_9ZX&HE* !^=)+GCA5)1P
MJH?_ 'Z8.VIB ;ZCR8>!_# Y/+@H?\HX#T#S]YRJ8?\ [F^\3\/(/K_:F\?W
MX'$;R$!,5P8QOP%11RDD/J ?U$EUE2^GT_.;U_=Z8&SA?^L95 2?B!5WX<_R
M*'>B8OK_ .JA_P"K@<A#'X#Q4*  /^:^7.8/]Z0YTBF']PB ?OP.3S5$0_M1
M$?\ U:[.B;^8J2[@O'[_ " ?W8'=UTP!--O?43\C)G(F'W1EA,8.3 4ON&\N
M>?P# NM@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#YE'*!4U3>^B7P34,)
MCJ%*0H)EY,<YC#X@0GU,/T /4<",V_?(8:W6^2TUTHI"'9[:\;(+P]EM<4\*
MEH;6+QL8"/RW'83-[]O/S,2*R8*QL48Q 6*9%P\9JB!0"''Y1.N.^M-531WR
M!]IK-.=S-;:4VM'27<?K=(LI%OJ6%TC=BHP@7K6] ;NHR$]_14V9L^7;+('2
ME$3&/)G>^R#D ]&E(EZQ.T^GS.NUX1S0I:JPDQ1S4_VV]34J<Q&LG\*ZK36.
M!NR;0KJ/61.@5$A$P(8/R@/.!4I^3" JA[XE,4QD%$%B@!R>H"*WF!Q,F< $
M! P&Y#GG C_[<?&[UD[55K>\K(ZUIE3[![CI4+$-.PC:'=/+Q6[=06HJ:PM#
M=P9RJ+1:N/44D7:[,C=Z]BQ4;JK*$$H %+_%QV>V!V(T!)4S>+5&'[2]7;4_
MZ]]DZPHB+>1-=J5YL(R_D0()O<BKW"M$G/N@ )*/A<^V8R1$S'"2D2K@0WDA
MR3@?+S(;QX_W0\AP'.!\+ETSCFCF3D'4=%L(UNX?O7,@FN2*:-&*"KQTZE'9
MBG009HMFYU#G 3%(F0QE/$H<B$+_ ,?[][WV[+[8^4*>8+.]-PJ5BZT?'XQD
M6#A 3:MJLXN&TNP3$52$%LON:T1@DCUE" L:(042,<#B5$0FM$BROJ"8F OH
M(D#D/V^H@)@ <#@ %E/ZB8G$/KX&!7CG]O@F3CGC]^!C5W&[04OIGUNV=V/V
M C]Y%4"$]R"KY/,7UQO$LX+'4:GQ:!1*9=W8+.*")A Q?90!13U\.,".[XL=
M#.]*TN\]L.SUFK,?O7=MILVT;H^NMIC8 )/9UE9.73JLLWL^Z!5)IJNNN#UY
MF/\ :?;R$A,^)!131P/K83&JMHP,ZUL%5J\] P+&Q[2NM,1<)K[AV'N&_NIE
MK!470_@@VML&C3+2>.BJ?8Z]-2%<D&_W13E*<BQ$ MQL_H5LS=.VM"3@V7<.
MI.P]7UZ\BJOV(LE]A#;3H%5J[)Y.R;96,JEEEUKGJ-U>I-A'BTG7<+8BJR1S
MDE5TDUF(A>KI?\BW9DNWZ5U?[)T V["V6USU-I_:K1E9DOX8E_T)6P*#/;5K
M+Z+K9ZQ!NV<(J)9]!E'LEU2$!%JZ15!Z8)Y4'C9QY BX06,F82G]I0IP*(&X
MX$2F, #ZA@?2 @/T'G@>!_E#\,#7 8'SN7*#1(R[E=%N@F11159=0B22::1#
M*JJ'4.8I"$33()C"(@ % 1' AGTRW+WK[R6G>;P[A?KQTVGY"DZB9G R\->=
M^K,A_7;:B5;W6;I'5]:E4U4E0*/MS$Z@ '!Y#_V03/$*)2%*(@(E* "(% H"
M(!QSXAZ%Y_8&!NP/E?-T';-PU<MDGC=RD=NNT<)$7;ND5@]M5LX14*=-1NX3
M,)% , E$@CR''.!#/T97<=(.T6S_ (S;0N+74DS'6#LCT!E'ZSLZ9]-S$VY7
MW!UZ0=.A.0\EH2]R'WD<W _(5B9;^!"IMQ' F?,4JJ9B\CXG*(<E'@>#!]2C
M_(.!#QW\ZV]5;KO7J<TVEJ/1T=$[!VM<K_N?9UDIU#BIZRU[0.J[%LF"JMJO
MTO'-G(5R0M49'/98[EX!G,7$JM5#&;*KEP,2=3]V.M5)^0ES2]+#<2=9.^\B
MNA2]N/-;S%5ZT3W=K64%&Q4M$:*OTJVCH>[-MU:KC$4Y%:-8J0CB=K:*K1XZ
M4=K@4)Q/$ $P&]LIBB!1*050$O #P53W$D@.</\ 3'R.;\1'TP % 1, F1#P
M_K>)E2^( )"B8XKIID H&4* B B "8/VA@1Y]M_DVZK=2+&EK"Q[ IUQ[ 2$
M(]L,9HN%N]>B;!%P4<W4</[/LV?FW+2$U;4XU%,5'"KY1666*(%CHV17,1N<
M,8?C1^6!AW2W-MO1FPOX.@[S'1378^GOX2AK!7JW<=?( 2)NT#!GN<DXMEFE
MM>V J"PR;]E NY>,D0<?H[ C<2F":\2I^'H8.! I@_,'J!N# /[>! >< 3Q
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M$,"J\"''Y>NKVP;AK;77='K!$$<=SNA5ID-UZ?;(#]O_ 'FT%9%(N\-!SH)
M"DG7]FTQNL=)L<3 $LV0.4 \C@8,I.K?9+7?;GKKJ#LMJ9Z9_0]O4R(LT65;
MD'T))JMQ;V2GS28_F1L5/L#1TP>D^@*H"(#ZX%]A%(QA.*1@./\ 6.1PN0PC
M^/ >8D+S^X,"S/8P=1*: W.UWS%MI32KW6ULC-GQJ\>]FW4M392*7CY:(81C
M--R]EIJ42= WCVZ"*BZSU1$B91.(8$2'Q;_%/7]*U6&W-VQU\?8>]Z_).XCK
MZKNNWS&SK1I+KK",6D3JFJR]-FY:Q42B[H)70%.R-XE61;HO6W_)E4_;*4H2
MYWS?ND=8W2HZVONX]9T78-[;R4G5:1<]@UZHVZP1T< *24E!QLQ*1DG]N@LX
M3\%#%_M1,)43G,7@ P#[9:<[#=J.SU9ZVNNS<WUWZ;3^@$MJW**Z_,D*ON_L
M,[8VQU2]B:_7W>G(OE->ZY:H34.[7)7V:+V01E" 5T4QC^(4OL/X5^J<;%5*
M=Z6N[3\?V^=;1J3*A;KT(^D73YX1N54XM]LU:??.H[;K*7?+'6EEGBA)=\!S
MBLX53$R8AA[OKOY\FO4REO.KW8#KS5=G]A]XQ3S673KN!UQF$6&M-DWZ;=I5
M_P"XO>GIM9*UZKV? PTE^KE19-G4<X?@@)0*0 $P20==>J3#JUU^T;\?>O99
MZ2X7:-=[2[4[4J[YZQFSPRRR']YUE3M#-RF_C[#LZRD0J4 [,L5\G$-WCLAB
MN&9SX$?.]'^L^TL!<H2.5KW??JI4Y1]08K6UIM%<G=RT& C;O"5^9L%$V,^.
MS>M]C[GV29C5*@::6C[B6JQ<C*Q\FX(J450C<U=I3M3H&O1FTNFC:D[LTW6I
M>%G++T0[!-'MHCHF>J,C28@+-J&PWB9CYJ)F;7NR6_2Z[ IOF$[)R;*0%0[T
MJ ,A"3+K+\FFN^S^Y+DVN4QN[3^TI^PL(;9?59]:ZYJS;%4G:U$-*JI3];VU
M2#A76Z*]%3#61<-HDLK5[:BY=.19-98IBG$)+K/I_KC:8"&W#JR;MK5\QML#
MK[<URKVR-C,-PH4VU'<5-[6]J2-GFW-V.VJ$I/)NE(>?:%&/1,X61215#W@"
MC>\W;ZA=2X.#L!=?3NVX/3=[H5"U=U^UPFV9V+=W9:S()DJNN*<R(UDT52:?
MHSLT\]'[90I9)W&I 85T1 0Q+H^V(_YF^X>J99AKR^T;JGT_:H6W:%$W755Z
MG?'W8.>%=@IJFXT]VY<&BW$0O#F:/&BZ@D7BV<A_9KQ\ZS65#TC)I EY 7^J
M(\@4"@4"_B/T#U$QA$?V?@ >F!RX$2/9>O177+O%H#N?:(Y*;U?L""<]2-G3
MDLX<+M]!6S9%@A5=1;EA@<"5C%UV^ST.QHEO<@8@IE=PZH&(BD]]\);"#R4O
M(<&\0$2CQR'IZ@/ B'H/I]1P-V P&!C9VU[(5CJEH+8^[K,U5E?X/AR$K%5:
MKH(2E^O\PX0BJ#KR$^X 2GE+O:7K:/34X$C<JIUCB4B1C%#'SXUNMUOT/H.1
MG-I.RFW3V"V+:.Q>YV$:W"+K41L+9KLLY)Q->KS8C>/B6\>V5104$J8N%5$N
M5U%%2^6!(M@!P/,IWYT?I_HY\FN@OE4L>K-?V/2>^9*N]8^T-RG:3$SDCU\V
MC:%V\%HGM)7Y%\B*-98RCUJVK%K>AX>VBH@H8X** 8H3XG_MA$QP(OSP<%%!
M.L50#@(D5*<%>3^X7U PF-R _4?K@<0E /04TS!SZ <IQ('^] #E'^3U' QW
M[5;0MVG]+REHUM%Q\OM6>M6O-7ZCCY4AQKY-G[?NT)K:FRME*"@'&JUF3LH2
MDD4!]P[%DJ5(2JBF<H6MT)KCK#\?U:K6BU]NT6MWO?\ LVS7MPO?[E2Z;;M_
M[VO4LW4OUAH]!6=,&<6G8)U=+V(6ML&\=')E0: 43^2A@S@$G":8"8IA,F0Y
MA( ^(&,')B@!N#AXFY#@>!], "(>//D// _A^S U(B!OJ8?KQ]/Y,#O8)J1.
M5CU?R',#DQ \R&\B\I"/D42J% ./W@.!=O 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# Z6Q6")JT+(V&=D8Z(AHAJL_E967?MXN+C6#5,R[MZ_D79B-6;5L@F8QSJ&
M*0 #U$,",Z5[P7KLK*2-"^/FHL-E1S25D8*V]I[PB^8=?:'),'8QKUE7$EV[
M"5VW/QRZ:@G;1YDF1#D#^W<$,)<#!/LOINT]"=[]<OD/V_L2R]FM<?K:6B.\
M$ULUNT>16J:GLJ=B$=4=A-:TY)J:#UW!:@V2NDRFF[9%-+]!EC.E"E6:^\(>
MBB-< [:).2J-UD5@*JW7;*>\W<('(4Z;A%7CA5%?R\R' Q@.0P& ?7@ ^Q0O
MFF<G(!YD,7D0$0#R 0Y$ $HB <_M# C5[C?&AH?LEK'?;>N46F4#?&V6L9:H
M[><)"M8^^,=M4=%DIKFTN[(D4),6[!>);M7R9%2%>L3G(L!S 0Y0^WXP>V$Y
MVCZ^K-MGM4H/L?HJQ.M*]C*J=<AW[#8E1*+,;&HEYF5(RNS!(KX#<%3^_P#O
M$R<^T8<"2# PA[2=O[!UYO.K:#5>L^Z>R,SL*"V';YB+T:_UHK;*;3M=+TQA
M)V M7V+=*/\ Q>+N6O+-!-G'.%7GB!S@F80 HA!+T'[/:?ZV?(WMCI=4D-BZ
MXT/W;=6'LOUNU+NO5=^TI<-$=A'"J(;XT,,'L"!@XX:]L [,;'7OTA>0C_N$
M739-<IS>"@>D500 1(4Y%0] ]Q,3"F<> Y,D)BE,9,1_JB( (AP/ ?3 L'V?
M-UR)H389NW,O08'KK^E$<;"EMD6<M2J[="%<H6./]V<))P[YC--9**0=1PL7
M'Z@5R@51 HG(7D/,#NO;W=-EJNZ=I_C%L_R"ZTZ!ZF10LNTMT=B[G&;@D=BZ
MM%^UB[C>NH'7GLM3[GN9W#ZZK#US,FEY*P0C"4:-/^1MS&2_,$['63XZ^C-0
MUR%]C*?"=LK+OFK5NV77M%V4;L-];1WK#ST6WEX"7F;7=(>6CXNN/&CM-9I%
MP:,;&-2"!42%$GG@7QTCT>ZL=;;[8]BZ(UBKK*8L]7+3W<)!W*[.:)#09II"
MQ/6E*H$I87E0H02\RR;+/?T=FS*\^S0*J4P)A@92J.D$4W"KA9JW2;HBX76=
MK@U0;-B$7.Z?.')RE1;,F"*0J+J"8!33Y-QZ8'F2;[X[$;?[4PGS 0G32U]K
MN@NF%]JZ5ZYM-76P[C>E=IE??(P=P[D4;1\VR;1.UJU<K(TGDXY-F^+-&BT$
M'+=/A%OYAED;O?H3?\;M_8O0_L?1MW.MRUYO_B'U%/,CT[<FAM9TVF*1]JL-
M:_B9E!SE4E(2&=*Q[>NV%FYCEKU,B1%^U<+*E.$;LGUO,P6E+9U7MMDUY;M4
MQLM'IZ2M5U=:XW?UH:UVOR5BM%2UGN2V,+5*-]:Z JUBAZ\E![+CKO19JYRZ
MK"!_0@]IP0.YK>_*17I)YJ_:%;W%H%EK*3J$TYW8J^N"&\-!62&H=1UG)[,[
M":MC"R=KI=;U#4XZ?+7'%?'8.LY*R3Y',K+LW#=9,0J[<G6K6/;2IU9ON>BQ
MVQ*M-5^(K6F>T.AS,'FR],0"5<A9>-CK4GK99VK<*+UQTOS-648%2:K$S?;*
M4D@P:G03 P=1N@=[_')'5T;?V6IG>[15ML,QHF"N*%GC-2]T-72"E>5L32@-
MK/,R-DUOO"$B*H\0<J0%M.ZCF4H)$44XPSDO 8E=G=Z1O:/LMU>4U==[@754
M"Y9Z_P!"V,[NR-=^Z_[4["=,@NVR>RVHJ/:-<[OKFTTMCS0V.-E*BTFZ^^DH
MF'9+"NU.\8D#W3Z_K1JS7&$<[D%)V:29P[>PVM]'QS&=N<S$P<9"+VRR'BVS
M1B]G9E&-346513*B'H1, 3(0H!76 P+9;DU%1M]:OO>G=EQ"<]0=D56<IUKB
M3F,D=U$3S%1DX.T<D$%6,DR,<KAHY)PJU=))K)B51,A@##WX_=IW9U7]@]6-
MYS3N:[']/)B+UE>;%)FX>[;UC(LCO=#=AD /^=RCMFAL0))'*)@0M41,-S"(
MI 8X2'X# XU3'(0QB)BJ8.." /CSZ@ ^O _0/7Z".!"[>C&[Y_(7!4 BH.NL
M?0&Q1]@O[<?>4C]A=K)R*DF<1"K$ /8>L]10;L$P]1(G)/GW("9!)0 FA11*
MB42E]1,83G'D?S'$  Q@ 1$"@/'T#T#\/3 Y<!@67[#:%USV?TMLW0.W85"Q
M:TVW2;!1+A"KIE-]Q%SS,S<'C10WJUE8AV5)VS7+^9!TB10O!B@(!#I\6.\]
MBQD3MSX[.S$ZK,]L/CZE(S7DG:)(7B2V]>M<LF7_  Z]B([[@AEI4D]4RH1L
MXJE]P=F_9A[G"R_BH$MQ%#JF(5,CHYCG*!DU#BJ*93>@^VW1(HHLL4X@4J:?
MF<XCP4!' AP^1[O-J%W&2?2O0SC9^_N]T_*5>;UIJ_J<PJETV)I6]U*<B;%5
M]D[,LMG^]UCJ2$K<PU*#EQ815(1+W2F;G,'@(0.]:OBX[7_(1MVP[+WCM2TZ
MNKE+VO(P.Q-SN;1-6G;JFU-=RRR-QI>L)2QK,ME35GK<RHLU)9)<*G2H\BZB
MD+5'B)FKS ]MZ"8LD46"KA1=PW2:I*_>N@<2Y@.0 0?2Y@32$SJ7(BJO[O@F
M1=4#B4I0] #[D?(ZB21"'.=10B9"$ !.<ZAP*0I0'@!$3&#\<#J*W:ZS<HH)
MZGV* MD$+U]&A,UB<BK#%A(Q;E1E)1YY"&=OF:<@P>(F37;F."R!P\5"%-R4
M K6N_P!I-L_P]L%%/V\\D,3C\./K@7;P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P.)=4
M44Q.!#*#R  4H&$>1] ]"%.<?7]A1' CD[2_(MK/2O\ %U+UC4+7V:WO3H:P
M3SG46GTOU5:(4K<0O,.&=PM:31_%5F159IB)(],CV6.!@'[0$C"L4,>.N&IW
M/R2:]U;VS[!;HC]N:<V/"16P-7:#UR=]"Z4KY#&649FN#+[UP_M5S@7B)V,@
M244<NV+M-5,IVO*K; F,KU=A*K"Q]>KT5'0T+%(?:QT7%LT&3%FV!0ZA$4&S
M=--,A0,<1$>!,<PB8PF,(F$*;VGK>D[?UK?=4['KT?:Z!LBISM*NE9DT2JL9
MZM66-7AYF+<%X$0^\CW1TRG+P=,PE,40,4! (M/BRVA<-:N=K?&7O*<?S6Y>
MCQ:^TU?=9H@H2.^.F=K,X1Z_;9144,8DK*UN'8?PE9%$N10F8D#*<"N43!,5
M@;3E Q#%,/ "40$?3T#CZ^H"'(?OP(%.W[0_QW=YM;]]H,SMKUY[+&A]!=S8
MEN@!H2!G3"5/6NZU6:*(BW>MEB@W=NS>)!(BJB)CN)%(I@E&W]W-Z^=:*\QF
M=I7A!.7GRE2H^O:DU=77:6S))P(EC(C6NN:\D\MMR>2Z@E*@JU:F9_G QUR)
M\GP,&Z)2^\_:[M3U^[3VVO5GIMUTTFELE:OZ3N48E=.T^Y(G9L"W@'Z.TG\/
M*A2M,5%^DV;R24"S6E)5M)Q;55VI[@"1,+U?*%TL+W2ZGV:B5VPI47>&N9"*
MW#UHVQ[K=D_UCOC7*GZ]2)X)=R)4V4!+O&?Z9*HG$J"S!T<#B' " 17:-^9C
M9O;;3M!H74+J9<-_=]%(%O7^P]2E3KT?J]U;V9&.WM<MLKN7>;@CI@M"/)>-
M<2$1"5[[V:D(U4@$]@.!P,R=*_$H-WV%6^S/R7[=#O1V+@'",O2*7*01JUU"
MZ\2A?:.#72'7]1=Y!OY*)73\$;#9"R,LJ! 4 $3CR 2%]MKK<=6]9]TW37>M
M(';UGJNNYJ19:RG7@1D#9(EG'J?KL3(';1\@Z<1S:O"[=*,D6YUGJ")VR!2J
M*$$ \!77?N%V2Z7[&TQ<PVGL.=T_UNNME8.>LL/:I5[IVN=?+I:9-UM'7.N*
M4,A(J3C.D0,PG)U)_,/Y*7(C%-$D7!&A_8,'OVJMUJ=XID'L2K6:,GJ-9ZS%
MW6NVMHH 04G3YV,;S,/8DY,P_9H1;R-=)JF66.FFCY"502F 0P//?\A7?BX]
MU*7?_CX^+&GW3LKN;9*;&E[SVG0W[.L:%T_K!])@ALJ&E>P#XIH5G:+-7F[F
M%3>1?W!6J+UT*!UGI"(D"CNR'6?MM\=VA-+]][%VS=6#</3>1JLE5^C&ET)&
MB=.&/4^"KPP&Y^O&I-:)M96WW^Z0NK'*\F2\6-8S]5:'2<*E9D,(B%&_*90^
MAO;/:?1S<G5)"#I';?>-7_QFR7;;5<U9Z)8Z1U'U9%-+?,;&VI :P=Q=EV#9
M+)=QB("N,P;JS))KWE2&4*Q71,&/3;?NV]:1%<ANW^G]@6.*K%HFZQK;LE"5
M&6H.V]>WC74_,*Q,1?X:*CHES;$8':5E<7^[*U]JUMMJ>I,ONJJ[8&4=+!EF
MZ3INYZ/2IDP,NTVI(Q9G_<SV#U,\D*YO>B6&7>7AU0D+%*:\>LKI4KYL"Q_K
MNUMH2=-.E/,ZY&-8Z<B4T5%5% DH^(CJ32-51%\[%TW:4;M6&WBY4::YEXV!
MJ=+C1HL*_75D=B/:5KT65 9;,W78@)+6-_%Q<"XD&#.'))-#2"#IRH%W^Q](
MU/H7<_6BW7BH0(]:;*W[ Z#VP^M;(MDHM2M/91WK6PU&<OB%A2EHQK2+E9]=
MFK:[F1$&3=[)L$51]M8<#Y-,?#]U.T?VCB^T>K$;?%-XINX<5[3+^R$L>FJM
M9U$Y1M'WJE1$Y$OK+"R,+'3LBA&-"2YXAB20%1JW2!NU*F$LH        ?0
M#@ _D ,#7 8# PZWET.ZP=DKM&[&W'K%*P7>&@'%2C;7!W79&OK$%44E#S:5
M>?S.M+=2WLS#(3#A=VBV?&=D;.'*ID1)YF 0L\;XDNAQ_P"MJ2WJ"(\B"O8W
MM"H3G\1 I]SB #R. _\ -']!A#\VFK*8WXF'L%V6'G^43;A$P_SC@;3?$9T#
M,'KI:P'X$IN%-^]DSEY(8#%$2FV^(<E$ $!X]!#G RTT)UNTQU@I9-=:)H4-
MKZE_J;R:<14<K*/WCV:D!,>0F)6=FW\K.3<D\$" =5TX4.)0'U]>,"^F P&
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M6%MTC9%Q2K$$ZFTW,^PD9/WVLFF5!TDL'O:KAA"<1\O<$#)G\ 4425$I1,(
M7R2_9^_U' NI@,!@,#XI&0:1+![)OU#),H]JL\=*$17<J%0;IF54%)LU36=.
M51*7\J:1#J*&X*4HF$ $,)2_(UU:,'(/]Z_];U [>*E^GJ '1T:HF/ ^GH(@
M/U#D! 1#=_YQCJY_[/[U_P"NZ@]NR?Y%-&D$<!_YQCJY_P"S^\__ "1.V_\
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MM4==*JWJ.HJC#U*/3;$1=.F;5$9>66*)E#/)F7%$'DFX5<#[A@.)40.=0Q2
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M4CE0Q#^TI6ZZ^&3ED2E3 9F47()2^PGXA-C ^!9V/!,@$\C*^0%*!0$ 2.(
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M(2<3)6*^5.S%:$LA"P\>4L^5A'MXEB$T -P"4!G%-$FR7O\ G[;=(B9>"%*
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M(1P)%.M>_P#6O:/0VI>PFI)A.9UWM^DPEVJSKDI7"#*7;^XK#R28&/\ ;3D
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MYN?W?SX'QJ?ZO]\6[E1$Q-4[A,DD<3+&3[4]DG0 !^"D]PA;HF/)S?3D1Y'
MCR[$?$5T+I/=[X_M+4RB;/3U=O65[ );-CD^PW8.;=3C:E45K.UD$+&PNC@M
M=1C) ZP&*99(ZOB!>0$.,"10G^K]?%08$5@TSM=T8?;5.1/M-V*<)J")0,?@
MJ%].\%,3#]3J&]/J(C@?2O\  +\4JKA,R6AMD@8"&]]L7M!V6\BGX_%NEL$5
MOR\<_0./QP([=K_#S\>]7^3[IGURA]97IAJ+;O7+M-L.]5%UV$WXLO.6C6Z]
M&0J;L)EW<UYZ.3B4Y!V<J:*Z":HG'S WY $)#_\ S!/Q+J$, :"O1C<F+[I>
MR?9<P@)1X]'!]D>P''[1((!@:I_ #\3@DY-U[OSD@<^9E.R/919(0_$BBR&R
M4$2DX^O(!P ^HX&\G^K_ 'Q(G 1+UDMRI.1 RJ78_LHH1/TY'R,&U> $H>O\
MF!S)_P"K_P#Q'% PH];+2Z .!,)NP795T)3!SP4IR;*7*F)O]UP'X_3 Q_I^
MOJ+\(?>S30:@++53XY>_YX#0-^A;';K-;X?0/<6 3>ETY>@L-OD91_#53<]?
M.:$=IK.00+(HD'D/%/ ]0J?(D)Y>7EXASY@4#\\>HF GY ,(_L],"'[Y?NJN
MQMK:?H?:3K8U$_='HE=![!]=_M5%FSV_,8MF0FW-"/%VQBN7$%N6@-'# $/+
M\\B1N']0QP$,C>K79#6G;_KSJ3LGJ)_]W2-MU)E8&#520^Y?UV83(9K:J5.M
MRBH+.RTJP-G$=((G-Y(N$!YX\R<A?=<!*F83B80#CD"G.4WJ(<<&(4Q@]<#S
MK?ZP=W@5TYH.!Z9Z[LQXK;';1K,MKV]9*.G,E0^LT:D+:[2#@&8E=QSG9\D4
M:ZQ6 2+ BJ[43'^S]0@\^(SHRR[G]M8)*Q-$5NOG6 U/V+MIJ5NZ_1+7*QYF
MP:8T>HX]I-!1:2D(D)67)P9P:%C_  /P9V4PA[\3*J++&.<YCF,H/*AA #+&
M,<3F6.4G!$C*'.(^!0\"!P!?0 P.]@42FFH\YC\'(HIXAY+@)@]HP\?D,"8_
M]<&!=[ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8'P.Y-FR(NHX4.4K8@*+>""ZPD((IAR((IJ#Z>
MZ C^POYAX* B 1N[M^08B,Q8]:].]>O>V6X(5B^/((U*7;1VIJ;(,&XKN&5K
MV<1M)Q+N;03\A&*CP75.H04%%VJX@40Z;5O3N4[ &IV^>X6U#=@YU5)I:*'0
MX$#5_050:23=!U'+P50:*$6DWJ9/:.+UX=21Y(9)5=5(ZB1@DUBX.&A&Z+.'
MBV,6S;)I(MF;!LDT9M4D4Q222:M4"D0;)IICX@4A2@ >F!$-\GWQ0,_D LVD
MM@TK:"6AMEZX>2U3N5Y9U!K;9"YZ2L::KN3IY8YS)QC!2R5RS 25@'3_ .[8
MLW"SLJJ"A')@P+1_"?KC7_5EWVPZ76FO,H[N)I'8D2]W)LER]>.[%VFTQ8DI
M-[UL["I)O7:Q&D,I372U=<QL>DC'0LU%NT"$**G A/2 @( (#R @ @(?00'U
M 0_EP-#%*</$P<AR \?@/ \AS^WU# @<WPL'QG?(S5>U$8)8CI_\C5MIVB^U
MK5+V$8/4O;D6J4#U\[#/$C@5",@]J1R)JE97(>T07A&+M8XF_K!6\=VJ[K_Q
MCVZ['4B"-OWJYI#L;;-'QW6&FZ_C!WG.4S3->J58V7LC15W0E(Y&[7%/;SJ9
M!Q7)TAD)&-CCI1KQFZ(!' 4*7K]\CGR8@28[=72Q?'CU DU&ZT=U#Z_V\JG:
M;:];,(*IM^R?8:.(V2UNQE&RHE=UFH$!P0IC).'WN%'D);.N_6#0'5'6$+IW
MKOJ:FZBUU!C[K.MT^*3CBKO#"8RLK-R7FO+V.P.S&$SF0?N'+QPH83'4-S@7
MY(0I X*'  4I0#D1 "E#@H  B(!Z?L^N!OP&!C-5.UNF[3V6VSU+8S\LWW?I
MNCT;8]GJLS R<2C)4?8JKY*"L].E'Z23:YQ+.08BQD'#'W48]\H1NJ8%#^.!
MDR @( (#R ^H"'J @/T$!P/G=(%<)>V8I3 !TU  P<@!TC HF;QY*!O%0H#P
M(@ AZ#Z8$#'699+XUOD8OW1Z96/&=3>]D[<NQW2A\]5!.$UUV \2S/8[K(P<
M*G*W:-9PSQ.WUIF7Q-[3ET@F4PDY,$]95DSI^Z4W*8^H&]>!+]0. _B02CSS
M]./7 PL[E=_^JO1>H-+%V%VM'5J:M!'#/7>LH-LI:]N;/ER$4]F*UMK2(%2Q
MVIVX6\4O>*FFP1.8OON$2CY8'CQ^1+6?878,I*][[IU$?]5]9;DLC1K5:O9Y
MM&5VBL_6@EW<S-[4J<;$$-KQ6^1L3^LI,CJJ-OU"-E %NHYD47*X8S](MXQ>
MF-M?P[/0*EMB]AR\U=].MG@PDR$%V+9,$992.CV5GEZ_19 NUXR';2\:-A=/
M8&,L4:=T:,DWBS)(H>A[4&P=6,*O =Z+/6(9IM:S*/8:+JG8F\W[=UGNJ\'(
M>R3=6C;%%TR/L9XZ77G%(4QW51C(%JY9 C"NHYD*:CL)MNINVMJ;>U:RNNYM
M:2&H;._FY]C&5)\BNS-(U5&6/_!]M+"2 'L%8-8X%1%0\;)F^\;+$5Y#P\>
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M<$X B*R93%&>?>/ *-?(H>S4I%>?0A"F,8QQ\/; HF$1$3&$!\>> XY'\ #
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MEUEA'_-*F&S , \?MXP.G1_UD7KXJJ1$.J';4AC'\#B>&U:)4?J F.*.R%1
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M(Q[Y8KA-G(.TGJ MWS5LL0,%MP]7?DXU_P!C.M#76->KW::A];9#9+;0&_\
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M9(ERZK\S'V*AORM-KZ/V549MA;J#9;)1+"V9S](N5+MT&@X^PF&)$'9$E$%
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M@44,D],DQ4 I!'\K@Q6X_P#=! G.!!Y\=?77Y(([J!H^Q]=^T76'6FKMJ5N
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MG;4:3%/H.JFD*AL2W4]-:&B)&6FW;!NY;PI51(=RJ8#G-R.!G"! 'T#[-?\
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M2-BT5W1BN)%VFF)^ (3RY,(!@1OC\\OQTAZC?MA\!_\ PHN/_ME@9&UOY*=
M7"&86&LUO=4Q"R;9L\82+;6$D1%TU>-4'K5=,KEX@L!%VCE-0OD4!$IPP.6>
M^2+0U7B7L[/UC=<7$1R"KEZ^7UA('2;H(IG655.1N]66$J:29C#XE$> P,;
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M&?3509?QFM4I5]'6H).13F'C:GIP+9@=ZH+LIA7:^C<%5P%$ ^HW="AH23*
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MM QL78^TO4C8$T\0@)NXSQ$ >7*_:2LSA:MS'FK_ &27VIP3_P"%44#T08#
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MG]QR*9DCE"ZWR@]>+O766N_D4ZI42&==KNC\Z]V.[KE;C$HZ>[*=='D<9CV
MT78%V+?[^SOY*C@:0ARJF771=L3I("0S@. DUTGN"@]B=0ZXWKJ>;:S^LMKU
M"%N])F&ISJ"\A9UFF\3([.<YS%DHY90[-TF8"&1<ME""'IR(74334#GA00^G
MT$P?M_?@<8D./]<I%_V HJJ3Q_>'ASSS@:^TJ7@>")\& P"1=<XB8.>!_M _
M*(<CP(>OK@>;7Y\NCJEJJ<7WRHK,I++J2N_P3V'9, 44-9M'%.Z)7=D.F)2>
MX[E]*2LJNH[!'E1>O2+A/Z,DC8$#G67MS?M,6ZK:OO7??MGU<ZO2C"[.8/\
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M*;U^G "'I@=<K\)70"5?H'=P?94I??2(F5#O!W%(($,J43@/_OZC#Y>GIXB
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MVNU>U"_9/5TG-7"HV*=O;]G+T"A[99-(IN?3;#6M@='DO*2 8J8FR(&%P*:
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M!#[=A 5OLS3XM2;AV_B!5++&/$4@ 5B 8)RDU"JD!0G/@;U*(@)>0_ 0 >!
M!_?ZX')@8K=SNJ]'[I==-G]<-BM/_==V'7%&3*;3\1?U*UM%B2-2N<*(*$51
MF*C8F35\F(<>\1,Z CX+* (8?_$WVDONUM.W70'9#SB^W/3"U)Z%WXP7$_%I
M+7VIVM W)&BL=19S"[2J\>5R#@3G!9ZW<'*82'3,8+R]G^\FE:'+V#KE3XN?
M[,]G9VK2!$.K&D4T+#L((V<8.HU%[LN?%0*5H>G._N!]R<MSR/:E1\C($<G
M$Q"EM"=*J=M?IAU[U?\ (!UGT!L+9=-U+6Z39Z_8H&H;?95Q*O,/T&#CHF]R
M%;:N7<DTJS5HD\>L0025=@J9 ?;$.0D!I%#I.M*K 477=2KM&I=5C48>M5.I
MP[" KL#%H  ),8F'BT&S!BV)QSXIIE 1$1'U$1P*LP-BAP33.H8!$"%,<0+P
M(\%#D>.1 /H&!&!KSY,Z=V)[,1NCNH>J=D]F-<UVQ2<#OOM-4TXZK];-,/(A
MI(%7@HW85G]E+=5U_7&)6CB*JR;@C#R.99UYD%# L3\K'61_(;DZ8]^ZII _
M9R;ZC[+;U_9&@WD&G?AL6C=JOVE?M&R=9425%Y$$W=H^<<,[!&/$6Q7CF-(]
M;>[_ ,&*834M2@JF8RJ12F.4HF(<@D.)1Y]OWBCR)#&3 O).."C^7Z!@0:=_
M(I;H'VNU7\K%62>---V1K7.L_P D$/'$5.V5TM,RZ<?IGLO(LVQ%2+2772Y2
MA&DJY$ICGK$FMSZ(X$YD=)1\LT;OXMXUD6#MLU>,W[)=)RR>,WK=)VT=-'*)
MSHN&SEJL10AR")3$. @(@.!]V!AKWTZBUGNOUAV%H:7DEJI89;]-MVJ]CQP@
MG/ZGW72'B=DU3M"NN?$RJ$K4KC'M51\!**K0RR(B!%# (6R^,ON!8>W'7L%-
MKQ:5/[0Z'M4WU\[::W$I45:=O;6IR15DD6;;\JY:ML-J5O8(-0Y?!6-D"@0Q
MO PX$BXCQZC@6EW/O#4/7[7=EVGN[9E.U)KJJ-@<SUXODVQKU>CB&*)TD1?2
M*B2+N0<@42HM$O<<N#B!")F$Q0$/,ITPI_>K86P.U%6^,DZG4_XS^P>TD]Q:
MS["]E]13$?L77]AN#-4VXPZ8]>[ _CUI:A7Z?,65B)BWM8J.CE7*RJ#1SR0A
M@G(Z>_'-UYZ?R$Y?J_&6?:O8J[)D_O/[6;WGO[S>P^R'!TP%T23OLJF9:N5P
MZQC"E!0J<=#->?%-N/'D(9[&420\$P+XE$0* $* $)SSX\_0I0,(< 'U$<"/
M+N+\F'77J)+PVM7RUSW7V:MZ1E-;]2NOM;<;,W_>3^2)4W2M4AS*MJ15N%@%
M:9L*T;&HI\G!4QB>(A@<KUD[R?(>4L[\CE^<=8NMLFHFI'?'?UCV$[+.V>%/
M[H_8]M.R-?3CK#9UG )HB[JU668Q)R&,DN[,/N$,$FU4Z^]?Z'IA7KG0]/ZX
MIFAE:W-U%WJ&K5=C7Z,_K=D8*Q-@BG$/'M4V[HTTQ=*%<.G *N3_ -<3F4X'
M C9^.6PO^JVRMI_$[LJP2DM(: 9N]N].;?8E51>[*Z66J64_0($KQP(_K4[H
M":E%*^]%,?)%@DB $*D@;@)A !8"@)FSD@\!Y$.D)5""(>I3I\B8IBC]0_ <
M#01,!?(R:A2A]1,7CCUX]0$>0_HP+&]ENNNM.W&@MK]<MOPZLOKK<-,E:58/
M8( R$6#XGE&6"#5'D6E@K,P1%^Q6#CP=-R"8?'G \2&]OD)^5G0ZC#JIM/L1
M':PLW2.>K-3?66O0(PKC=AM>KB\UCL3>-]L3UZA+:SVS2XQ@9>/C#1[!T1=<
M5@7>>X*(>FK=-+;_ "_?&=K3:^IQE-2[LGX"B]GNJ]DE&4K"S^G.R=#*Z>1*
M9%)5@T?J5N2F2.X)5P0A$Y6(6]XPBFN @%W^G7R(:GWQU6UYNS==TI&@MFD<
M3>MM^4+9MGB*!_=QV UT_P#X>VA1O&VO8H!\+"0[V/*03BK%O6HD\B@!A#.B
MHW>G;"@&=KH%MK-VJ\B*P1UEJ,_#V: D?85,BL,?,P;V0C7I452^)Q25,!3"
M #Z^F!UFT-I:XTM1K!L[;]]J>K]>5*-<REANMZGF5<K$.U(AY K)RKQ4C! /
M(Q0*50X*J&, (%4.( (0W?X[.WOR)QRU*^++5K+7NGGOZE#VKY&>TU:G&6HE
MT6ZB[557K/IJ7;LK3O24:.DQ\)-ZV;P)3E(*GD/B8H9.==/BYT3UIE7N[K,R
MLW=+N1[<E/J=F.T#UA>-AO+@DBM)1K/7*$DN6DZ5@5)8H(M&L,T:%;D4$ZCL
M!$PB&*U3[&]@?C8Z;:-?;6Z9;8>4'6;^IN.YFY)38>N5;' V?<VR)*9W9N>J
M:YHD_?[+L6'C+]<E5U'3P\>0S!7R 5?#Q$*P4^0OL?V_MZU#^*71,);M?5:?
M>PMW[Z]HX>V4/JNQ5AWR+:2KFFZ4S;1NQMXS'/BD5VQ(VBVR)Q43,K^8P!=0
MM3^<I7DRF\OBS1]PZ@B1/1O:!8J)?<.4@%4/L1(Q_P"S #>A2AR/T# [?7?9
M'LIUWN.VZ]\D^T.K+>I5K1D?ONE;%T92MDT&LFKD#<)&H;)K<NEL&QV.3LML
MC9%[7C-&<:F*RP2Z3<I!.Y(.!C5KGY<9&C]L;Y3N_DEH_HUH"Y=?JAO'K#6]
MQV,:5NQ>$L6QIR@,_P"^0SZ14B(RZV6'K9YXU>;-%5*X@]1;NG*JQ5? ,P3_
M ##?%EY"'_G$.I')$E%C<[<K8@":8E\Q]!'GCR#T^N!B#4?F_P"L#?L/V46O
MN_-6%Z74J.T)!Z$WK0ZE<[A WK95Q@+#*[3J\Q=J(QML0YF85XDQ30C0;-7#
M1%3_ +HMYD*%[&WSG?$ZN!W#;N!!'3$XE%1'5.^/; W(B*?N)ZJ%<PAQ_GE*
M/[>!],#E'YQ_BC 1,'<"/,(_4J>H]^J\<_L -5^8E ?Q$,#YC?.I\3Y/$0[@
M,#B=5T@!"ZEWP90%616AG)%&Z.KE7J/@5\D("=,"GY'Q$0 1 /F-\[?Q.^Z)
M [<"=;_01TEV'6 >"\CXC_=,43?E_=@<:GSO_%"F8$E>V#@@F3,<#J:,[()I
M"4O(FY5'40,RF#]AE _?@5%KCYL/C"VOL&E:KH79\)>Z[$ML'1:BP?ZFWA78
MN2MEF?(1D##N+%8-;QM9BE)1^Z3234>.T$?,X 8Y?3 RO[3=T.K_ $FJM<N?
M:7;45J.#MUF/4JZ,FPL<O(R<JVCS2TJX3A*K%3<G^@UR-+[TK)F2"/BTQ+]R
MLF*B8'"^='OU*VA4XB_:SMM;V-1I]HB^@;E1IN*M58FFJ_B)%(R9AG;QB[."
M9@.HD!O=2+_PA2F_+@52Y(D]9O(YZB@\CI!LLRD(YV@BYCWS%R7P<L7C%8AV
MKEDY)^51$Y!24((E,42B("%+4G7U$U;68JBZPI=6UY0X$CPL%3J5!1M:K,.,
MG(.9B2"-A(ENU8,@>RKY=PH"9"@998YOJ8>0JP $?I@<@@ %^@<\!_U,#0IU
M"%'Q,)2CSR(" #Z@)1X'^L'(&'Z8$7G9WXMM6;AV)*=E>NNQ=A=(.ZBY 6'L
M=H1V@U;W]VV;^RU:[WU5('-0]R1*R8 BL:1;)R!4BB)7)A'QP(5?E'[T_)3I
MKJ_*=.^Y6G(#7DSMN;;5-W\A^@)-^UZ\; U S53=VF*^R<(HS.C-U7E8K:.<
M-I)TVC$(]XZ4:*@H4@8'Q_ZN]9-[V+MAVDE#)CM/64QJR@H;CWQLX)VS[9@K
M166T3!Z2TG3MK/9%<MGJS*K@^D7<<H@8K!HDD\%<RBR/D'L:K($&:0\@ 1*4
MYB>G'B8?R\AQZ (AZ8%V\!@,!@,!@,!@=3.3\%6(QU-V6:B:]#,2>X]EYR19
MQ,6S3$0*!W4@_6;M&Y!$>.3G .<"CJIN#5=ZFW5;IFQ*;:9]E&J3+B(@;#&2
MD@2'2?%C%)<K9HX545BTY(X-Q<$ R(+#X>7EZ8%Q\!@,#XGLE'1A6YY%^RCR
M/'K6-:&>ND&I74B^5!!DP;"N=,%WKQ8P$22+RHH8>"@(X%(([3UDXGTJHAL2
MC+V=9P#1&NHVR!5G%79D3N"M4XHC\SX[HS=,R@)@3S$@";CCUP.20V=K:)AR
M6*4V#2(Z 41B'*<X^M<$TB%&]@04=0*Y))=^1F=&;:I'49F XE<IE$R8F !'
M Y2;'UXI)+0R=\IJDNWA"V9>*)9X0TBC7#M"/R3ZK(KX7*<*9BH58'0E!#V3
M ?R\1 <#KT-NZH<D@%&^SM?+IVMRX95<Z-RKJI;&\:/48UVT@C$D3!+.6LBY
M3;J$0]PQ%U"IF #F HAL?;AU)%N9YE)[1UW&O*J=).T-7]TK;-S6U%UR-D"3
MZ#B235ASKN%"D(#@$Q,80 .1P*G<VNK,VXO'EE@&K0L ZM1G3F8CD&Q:NQ(B
MJ]LAEU7!4BP#--RF95X(_;I@H43'#R#D.EF]GZUK29UK'L*D0*24HV@U59FU
M048FG-O(UC,LX90[U^B4DJ\B)-LZ2;B(+*-W"2A2B10@B'T0NQ-?V1VZCZ[>
M:?/OV3PT<\90MEAI1VU?D1>N#L7#9B]761=D0C7)Q3,4#@5NJ(APF?@/GE-G
MZU@UXQM-;!I,0XFHY&8AT).U0;%:5B'/G]O*QR;E\D=[&N/;-X+I@9(_B/!A
MX' T?;0UI&21X>2V'1X^73D&\2I%OK9 M) DJ[^Z^UC#LUWZ;@L@Y^Q6]M$2
M^X?VC\%'Q'@/CA]P:EL4B,/ ;0UY.2X.R1XQ41=*W)20/U3.")L?L6<DLZ^\
M.=HJ4$O#S$R1PXY*/ =JPV'0)29;UR,O%0D; [8_J;6"862&>3#F.\!4^_;Q
MK=ZH\79^V43>X4@D\?7GC /MB:_BY>0K\G>:?'3T3$N)Z5A7]EAF<M&0;1H:
M0=3$A'.'J;MG%M6!174<*$*D1$/,Q@+ZX'2I;GU"NQJLFCM'7RD=>7ZL537Q
M;A "UM$H@9-->-@5_O\ VY1^W66(FHBB)U"*J$(8 .<I1#D'<>HRF=D-M+71
M31\HG!OBC=:V!F<RJ=VFE$NBC) *$DHI'N"@B;A0104#C^S/P%Q\!@,!@,#:
M<Q2%,<P\%(43&'@1X H<B/  (CP'[,"DKK?:7KRN2]LO5LK]+K,&Q.^E[':)
M1G"P<4V ? J[Z3D5FS)N4RGH4#*%$X^@<X$8T;W8VAW.>6NI?'X-8-3JA:W-
M'V'V;O@M5XZJ3;)!!R^B*;K%5#]9=SXLWR"S=:<123,BHFL5DNBJDH8+^:%Z
M&:CU+?)'<MM)/;H["3,:V83F]MIR2U@M3A%%XI(D8UY@NZ5BJDP9NUSBB1B@
MD"*9A22,FA_8%#-YQ&,7:*K9TV3<MG":B+ANX#WD'""Q/;60<)*>1%T5TA$A
MR' 2G(8Q1 2F$!"$KHX)OC\[>;)^,RR*.6VA=GH7GLY\=<Z^4758Q5(?3A9'
M?O4UFZ5!3E[I:Z2YIV!;"H90U8F/ H<,QY"<(I@, "'/ _3D!#]WT$ ' UP,
M0>\_4:I]U^M.QM$3\HZJ<].-HVR:RV3%&%*PZGW%2'J=CU7M&NNB?VS65I-O
M9MW7]F)3+MO>0$?!8X"%L_C<[63_ &7T"9AM]BTJG:;0UOE=!=KM?I"4BE;W
MA1R(MI><8-?!-8*CM*.%"T02XD*DM&RA"D$WM&$ D*P-!^@\?7@>/Q_R>G.!
MYN_F5Z^V#3%XJ7R :GV9NO1E4EOX-T;\@-EZ[/8J*V?,]8)*TQ""-WK[V1CI
M=.&G*4HLC'/9E!()5G%B@HR.4[/Q4"8#ICU:ZJ=8-7M(/JE0JY 4R[M(N[2U
M\CW;RS6S;DC,LR23:^W_ &7.N']PV1/S;20!R5_).U_$BWB@!$P H!F(  4
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MV< Z0$ZG*(C@7+OWR?6W=5PL.B_BVU EW,V97Y)S6[OO^7F5Z;TATA-H")9
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M E^5!),#&4Y2\3<']\IT!*(^OJ5<J9@  ]>?H >OT# (+HE4040.3WBJ)K)
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M*,?PL[',Y>'E63V-E(J1;I.XZ2CI)HNPD&#]FN0Z#MD^8N5$5DE"F(HF<2F
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M7.PZXP?0S.;?N'%HD;F"(M;!JJL4UBU6N%OV3 V=H[B%8>/8+/@?H>V*0&Y
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M+/:_H>@ BK1-!T4 'VV[* :I/C(&$'#Q8X^6!)_R!"E\SASP "8>"^1O0O/
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MBX*5DE&I B]AP<<WFF,J!B(&E&2R@"F4R0"&2$%9MC]L8B'JT,Q=L&E!DI2
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MM:AU*Z783# 4J+%&*VFKG)1:,^]01F)M0#%%54Z$>T$X&$)T#+"KP)Q'\H
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MYG^J6RUOT+-TEDK]+?Q;L*T35WNL@I;$]D51*5+)VJPNW1!+&LTR>[XE2 @
M A<Z+Z?_ #;,3N%1^37J.W46;_;^3/X^3IB9/R\P!8'.W52'3*?UX*4IO]V
M>F!V*W4_YO''CX_*EU5;B4#![J/QR01ER@?CGVE'&UEB)CZ?Z!L"R^KOC%^6
MO3]MW1=J%\I6@HZP=@]FDV[MAP[Z"0<VC,W-*HUVCI##MY#92J=<@BUZK-""
MR0\B>][BI3%,H/ 7RCNGWS0H._>D?EBZ_N6WBKPS+\<=)(D!CE$"%*<VR2J
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MF%28UO=,)7PL[VIZOL2KN20H3"V1UJ<.;!-ZID8Z7>&@9(MRJHN3NI%NW%\
M*'8$78+.O,.-DCUM9,IR_FA+DX6T/L!S:5[3(VJ*<S\I=FDK-:ZFGSL0N8R2
MC2=F055?)SB4?'N5DT'8E#[9(Z(6^;RO63].4?PL1NN H]/JE.UY8;E!I,5Z
MM5YC71/;HM3E;$F]EYQY;&B:3,[:0CS/(-R*[(JSTYG"9% KN.V9U<@5Z_'1
MC.Q7B<@]I;-*F]ES1[IZ^V-'!)P5KM$_8;S,P, [6EF<>Y"(=&<D(Y:-N&)?
M:3*4 H96R]3S2,M3WC+9$^N:XM8ZNU67O$0M%516C75S;7<31PE[^SAZ!6QM
MFJBBO'.UV*\FV;)(HHKL0\2!4,92.M+AA:Y-*M[4IE>BJ+MJ0DV+UTB6'V%3
M(2\7"=V,W8":1GG$A^@V*VO6R29EF"R<>^200\F8 ! ^F4'JQNB-9:R7B;S!
M?QQ?)]Q%UNJOUX$]AG)&.<T_9T?7YFAS3V"5@H:N?\JL9X]Z!(]-X5?W2/%1
M# YK8745U78NG-"[*S#!Y#0&LJ76Z_+*QM:W5$5#^*9F"L,:8UUC8Q\M3B-W
M\DBZL+R(=JE237(BY R'F'5/+ITOB*==EVU:L$'68MK'.[-KZN4Z?ATDH[8&
MM(MP^8Q=%BVK=%RSF*M2_P!*EV3)(XFD4%VJR8KKF]T+D0O8CK_J>;E-;T*O
M2Q8!HQ<;%DUJ@2FLJ+7(B>8JRY'E9AW]K@Y.693QF:KE-E68R24.[7.H=(IW
M'D<+B63LLPJ"*"]FU%NB'2-#6J;>&6K]2<?IJ%.A"V69;J_87AW^IKE@3?<)
MGCOO6QS%.W]T'::C<H?/'=M=5NHV"?R2=B@5IM.]*#'.FD/.JQ0Z\K[:SSR4
MG+4><ME7,JO%/$@9@UD'0.G1A;%'[@BB1 O/1;FM=8UT^=4RZT9TS>)M%H:\
MQD?'R1P6CF$F@[:+0\M.PTBR4;R)2&.W=JBBX3505!-9)1,H5M@,!@:"'("'
M[<"*SO- R?7O9&O._%&@9:91UFWC*5V3@X$BJ\K;=)/Y14&%J^Q14(BZ=ZOG
M)([EPH9-14(IRJIP)6*9<"3Z"FXRR0\;/0SM!_$S#%I)QCYJJ1=L]CW[=)XR
M=(+)B9-5)PU7(<!*(AZ_4<#ML!@1S]W?C?T'V_UQ<FBU.J&O.PKY@,CJKL_3
M*?!PFY=3[*A5FTO1[I"72+:LK(Y:PM@CFRCUFL\.B]9 J@</!0> YOC5[96+
MM9HAP;;D,TIW:C0MKF>O_;37:93-EJAO*AF20G9&-9J&45&D;'C%&EB@5RF.
MW6CY H)'4\#&P)$L#Y'SUM&LG<B]7;M63%NL\>NW3A%JU:LVR9EG+IPY<'3;
MMT&Z!#'.<YBD*4HB80 !' ARV#\H-KWO;Y_1OQ7ZBC>W^Q*](O(*_P#8NPRC
MNK=(-$RK0X-7*%JV\BB=QMZX1K@3&-6Z4G(/."""[AL "80Q;[!_&UV7K56I
M/?\ L78*^=S?D4ZI7")WU3:K(-4:/UT?U&OQ<DRVIUWTKH!FY4@J:O<Z'.R9
M(>P/E']H5FFK(ZCU,ODE@3H=?=W:\[+:-USOG5<P$_KS;-.C;E6)$J()NA83
M#7W%8V0;'#EM-P;T%6#YNH *(/6RJ:@ 8I@P/#U\G_8?O&\[SWBG[ZV<2I3O
M5';<+M?J-5J+%*U75]<JKP%I'4'8)J@11:T;!LRD6X<0T\K(R2S)-5%_&E:)
MHK* 8/9)T'[;UKNOUHHV\85I^BV!\DYK6T:@<X&<43;=96-&7VH+E,LNM[+&
M53^Y8J"8Q',4[:+IF,54!P,S<# C=>O759V]0]D5J6C*^VM=SC(Z6FW\.[F8
MJL;!492$)#V!Y#,9:&:N6FPJZL>KO5GBBB;60;Q"Y4Q5*"A0P$[C-'_QU]UJ
M3\C57;.DM!]@#U_1/>V&8LO?;PJBR@--5[Y4;L@.1LZK3INFQ?.!(H)T$3I
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M/ B >1>1*(@ B41#CD/V>F!@!VT^-_K]VUGX3:$P6TZ?[)TML".M^U6BIO\
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M-/TW/6:98V'?VOZA7C>Q'5^V;%F%&KL[]N*CIS$K),TP2;,E28$Y %* B;@
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MJ]BHRS*Q$J2N24ZT5?PT?8%&*R4&]EF2#AFN[C6DLHBJNDFLFJJF02$$!-Y
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M3C&OQ\38&I$GT*RBHG[U.0"0+- SA(PKJ6 PI)+MP6DC+I@FJ J""7N"/!P
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M7\M3HZ=BG^W#;QM, ZVW?-E:VD6CF$H4M+T&F1D*X91\I+LW2CE^JD=JDH1
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M;#J#*R6>VMMA3A3'<HR'9/>=L1;;9[62R"H\?93"D+14#E_Y)6$0\3X$XD)
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MD[K-?82#DC?[TSAT=5=01<*%\1P,EA ?V#_1@<IRF'C@IA^OX#^[ W> C]?
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M!V;4ZEL&@6".2B)C75SK,98J?(Q:!B"DQ=0,HT<Q*J0%3)P(I>28ID%,2&(
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MHVM6*F2+M,7LU7X4DM.SD37')%'2$/&H#]T1(R2G@HY7"E*GUUM<.>U,G/\
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M@O-K]?V+MNBW22F-52YSKM&QP\EHT/>_,=7\P3. MYAY  >O[#<A^[@?QY#
MT$Y $#&2,H("!N/=4*GR4>0 Q"\ ( (>O[<"&[Y*6,AU*VAI[Y9=<0;Y^;22
M#727=RLP+857^R^F5XFFI#VM\DG[*<C8NOMU70F(U0_DN2/5<H%-XB7@)=ZU
M:8"Z5Z N-/FXRTU"WQ$99:G8X9=)W&3]:G&2$E"34>Z;KN$G+.5C72:Z9RB
M<'\1#R*.!:KL5V;TCU3H9MC[XV)7M>5I1<K2)++'<.Y^UR/D #"4>J12;RT7
M.>.40\6L8S=*)@/FJ!$BF. 1N_Q)\A?R7PXQVF8NS_&QU$G5?*1W=:(YG(=P
MMSUQ1)JN5UJZL//.,TQ'3@"4[62<*.794.3)G*H($ )2>K71SKMU"@%(S3U.
M*A-2S9,+9L*RJFG]E79X8A?N9&T6YX4L@Z<OE?)58B8(I'5,)A)S@9>E#Q*!
M?V  ?0 ^@<?0   _FP-<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@: (& !*(& ?H(" @/\@AZ8&+W9&G-;&:
MD2KU/3$PA"J6N/0JN]Y ["ENY2QPJ#:,LS#P8ROW=FJZS$2)(@@115@_>$3<
MME#%4P+%R?659X4A+!8-;5A@RD L4YM&JV24K^P-B1,KM*K7>/>VET>,0&%)
M4OT< @U3R\PF#]LS AV[<%43!TK#KA(2K?9:5DV?JNU[=G;/&2:K"._@ANR%
MO%;&0M4D>4&P4"[VRLR$O')G349)@\A4G"YDU&;A'R\PXK9U-L,E))/2737T
M/8;#+(-FVOW8:Y0CW<5 46JPSEO%6:+TA"V!_*'E($%74<:,6K";9R"JD2HX
M(!S!OMO6*;]V8787W6=,5DI&J6#9=7DYI 89"NU&@N:Y6I8@5ZL4&,B'TK/B
MXBI1="(C&<E7)-9,P"X9M@.%?:^TRYC]BP.R(>'T%&5ELA[ZU7UM,P_\/U)
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M4DN@Z:HID0\@=+BN1(JBAA.(@ 6Z[)4R"L-MT[-S=GUI#FA9&SQ$/ ['GXB
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M0R*/F1I'QC%)!DV2*J8Q_P"S3(!C&$P@)A,80J8  /H !R/(\  <C].?3\>
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MSI%P41"7;XBN]KCNGUA7=['EHUSV(T;9W&INPB48S:,&4I;F#,)6O[!C8V,
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MMK$H^Y'6JAVY@[C7:)P*83H H4!3.0Q@RB,8"@)C#P >HC^P/YL"*KY2NO\
MT3WG1M<27=2Q2E<0U;;'-IU^K1+C(5':=A<2D:>)LNO:\>O":W3-=OS B"#]
MC'^RHLLV;G*LFHF0V!@G\>_3[N32=0VWK_3)DW6SIJAMZ^6[3%PD*&UB^V%M
MTQ=I5>=84BZLU71GS.7@G+YTU1GYI0DPYBP;>Z1ZH(BF$VFB^K6G.OS!TEKR
MKJ,)N7*B-HN<I).IJ[W!=$RYRK6:TO>))X(+N%%?91^V:$.J;P2 .>0R.P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M''H'H/[OKQ@:X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# TY 1X_$,!SQ]0'^CG_('(X&GD'[#?\ 8'_[7 T,
MH4H"(\@ ?B)1*'[/J8  ,#:"R0AS[A _<)R\_P#PPX&OO)?\:G_V9?\ ;P-
M5*;^H J!^(D$A@#]PB!_K@!5X^J:G]!?^VP-/>#_ (M3^@O_ &V ]X/^+4_H
M+_VV ]X/^+4_H+_VV ]X/^+4_H+_ -M@/>#_ (M3^@O_ &V ]X/^+4_H+_VV
M!N!4@AZB!!_8<2@/\O'(X&ON)_\ &$_[(O\ MX'&=RBF( )^1$.?R@)_Z1*
M@&!L^\0_#W!_WJ*IOZ?$@\8&OW;?\3^/^_*8O/\ )R 8&[[EO^"I!_WH^7](
M!R(8&@ND #GW _H-_M8&W[UOSX^1N?V^VIQ_V0%$!P-!>H  \"<X_@4J9^1_
MD$Q2E_RX&@/DA$ $BQ1']J1A /Y1+Y!@;ONT?_5@_P#KL_\ U0P'WB/[%/\
MO9O]K ?>(_L4_P"]F_VL!]XB/T]P?_79O]K T%ZB'U]S_O9_]K  \3$> 37_
M )?:-P/\F!K]VG_H+?\ >C8#[Q'C_NO/^C[*HF_R$$/\N ^\2XY\5OY/85Y_
MH\,!]VF/T37$/V^PI_U2\X#[LG_%N!_]<*?]4,!]V3_BW'_>%/\ :P.;W _T
M5/\ O9_]K >X'^BI_P![/_M8&@*@/H!%?3]J9B_Y3@4!P-WG^TIP_P"MY_\
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M_+@;/[B-D_\ 2I[&_P!'7[_F)P-W]P^Q_P#I5=C?Z.O_ /S#8&XNB]CDY_\
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M2[1F#\3FOM) 1_'U$FOBF_=Z8&@]9Y,P\CV4[3?S;$JA0_H+1 # T_PRR?\
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M*<_M[,;+]/\ \JE^N!S(]58<GEY;?[4FYXX]SLKLT_[?IQ,AQ@?4'5N(+_\
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MVY%O"-:4\@E7[DM?5^Q2,^(DIY$ YD^3" >L4GKY_P"_'_(  /\ EP-^ P&
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M6GK#2-V0VA=F7_6>N+]:$K?(3U>V7$LJM8HY-']9J;Q--XU<G7%H\3.BW,9
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M%!Y-R4WAY!SQ].0YP/T3T_\ A%?^L_\ I\#FP& P& P& P& P& P& P& P&
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M+'%[QT6\D'X-(FXV%Q7D8N]T>%6<^"(V/]"C(Z7:- 'W':*3KP 11X$/<[R
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M@%>;0E]NNMG66/C'6U8:KPLJ59:;JC=A_#4122T6K/053C19J3%BL$_/O)Q
MCM,XMXLK8YQ2<NT&:.!F'274V^IE2?65$S>QO:S N[ W,B#8R$VYBFJTJB9N
M'HW,D_.H42!Z$XX_# J? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M9^KJS8-)4:A5UDBY:4Q%& E'U_C)&OI+.7L0TLU7C+&TA1B4'4(YKDE-K$,
M*$$?!(*@U-TY=5BVU*Q7-6E!&:^7DGE+@:_!5B>79OW9-?%2?2-@L>NF#Q5Z
M TPX$?-$F<V1 Z*;F1?K)BZ$,^. _8']&!KP'TX]/V8# 8#@!^H<X# 8#CGZ
MX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MBFB0H<8%=8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
18# 8# 8# 8# 8# 8# 8'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>ttnp-20180630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<xbrli:xbrl xmlns:ttnp="http://www.titanpharm.com/20180630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2018-01-31">
<link:schemaRef xlink:type="simple" xlink:href="ttnp-20180630.xsd" />
<xbrli:context id="P01_01_2018To06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_10_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-08-10</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P05_01_2018To05_25_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-05-01</xbrli:startDate>
<xbrli:endDate>2018-05-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_25_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-05-25</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2016">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:HorizonWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:HorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:HorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:HorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:HorizonWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To06_30_2018_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2016_NewAccountingPronouncementMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:NewAccountingPronouncementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_27_2017_MinimumMembersrtRangeAxis_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:SeriesWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-27</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ttnp:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-27</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_27_2017_MaximumMembersrtRangeAxis_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:SeriesWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-27</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis_VentureLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:VentureLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ttnp:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-27</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis_VentureLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:VentureLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ttnp:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-07-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To07_27_2017_VentureLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:VentureLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-07-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P02_01_2018To02_02_2018_VentureLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:VentureLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-02-01</xbrli:startDate>
<xbrli:endDate>2018-02-02</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn02_02_2018_VentureLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:VentureLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-02-02</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2018To03_21_2018_MolteniLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:MolteniLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-03-01</xbrli:startDate>
<xbrli:endDate>2018-03-21</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_21_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:MolteniWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-21</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_21_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:NewHorizonWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-21</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_21_2018_MolteniLoanMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:MolteniLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-21</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To04_18_2018_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:SeriesWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-04-18</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn04_18_2018_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:SeriesWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-04-18</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-08-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2018To08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-08-01</xbrli:startDate>
<xbrli:endDate>2018-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2018To08_03_2018_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-08-01</xbrli:startDate>
<xbrli:endDate>2018-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_07_2018_MaximumMembersrtRangeAxis_OmnibusEquityIncentivePlan2015MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:OmnibusEquityIncentivePlan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-08-07</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_07_2018_OmnibusEquityIncentivePlan2015MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:OmnibusEquityIncentivePlan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-08-07</xbrli:instant>
</xbrli:period>
</xbrli:context>
<ttnp:PurchaseAgreementTextBlock id="Factid_1391186" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Molteni Purchase Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 21, 2018, we entered into an Asset Purchase, Supply and Support Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with Molteni pursuant to which Molteni acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application (&amp;#8220;MAA&amp;#8221;) under review by the European Medicines Agency (&amp;#8220;EMA&amp;#8221;), and will have the exclusive right to commercialize the Probuphine product supplied by us in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the &amp;#8220;Molteni Territory&amp;#8221;).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We received an initial payment of &amp;#8364;2.0 million (approximately $2.4 million) for the purchased assets and will receive additional potential payments totaling upon the achievement of certain regulatory and product label milestones.&amp;#160;Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties.&amp;#160;&lt;/div&gt;In August 2018, we entered into an amendment to the Purchase Agreement described below in Note 10. &amp;#8220;Subsequent Events.&amp;#8221;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We concluded that the performance obligations identified in the Purchase Agreement included the transfer of the intellectual property and our efforts towards the approval by the EMA and other regulatory bodies. The initial closing payment was allocated between the transfer of the intellectual property and our efforts related to the EMA approval as&amp;#160;&lt;/div&gt;set forth below.&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We used the expected cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards the approval by the EMA and other regulatory bodies. This includes employee related expenses as well as other manufacturing, regulatory and clinical costs which will be incurred as part of our efforts. We believe that the services will be at a consistent rate and will be substantially complete as of December 31, 2018. As such we will recognize the revenue ratably over the balance of year ending December 31, 2018. If the facts and circumstances change, we will reassess these assumptions. The costs associated with these services will be expensed over the same period.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We used the residual approach to value the transfer of the intellectual property at approximately $1.0 million as we had not established and had no reliable way to establish a standalone selling price for the intellectual property.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the outcome of the milestone and earn-out payments being unpredictable due to the involvement of third parties, we believe that using the most likely amount method is appropriate. Any subsequent revenue related to milestone and earn-out payments will be recognized at the time the milestones are achieved or when the related net sales have occurred.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Agreement provides that we will supply Molteni with semi-finished product (i.e., the implant, the applicator and related technology) on an exclusive basis at a fixed price through December 31, 2019, with subsequent price increases not to exceed annual cost increases to us for the active pharmaceutical ingredient and under our current manufacturing agreement. Revenue will be recognized when the semi-finished product has been transferred to Molteni.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Molteni will be prohibited from marketing a Competitor Product (as defined in the Agreement) in the Territory for the five year period following approval of the MAA. Thereafter, Molteni will be required to pay us a low single digit royalty on net sales of any Competitor Product.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents changes in contract assets and liabilities during the six months ended June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&amp;#160;thousands&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Beginning&amp;#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending&lt;br/&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,448&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,509&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:PurchaseAgreementTextBlock>
<ttnp:WarrantLiabilityDisclosureTextBlock id="Factid_1391189" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;Until they expired by their terms on April 18, 2018,&amp;#160;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;we had warrants outstanding to purchase an aggregate of 983,395 shares of common stock &lt;/div&gt;at an exercise price of&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;$4.85 per share.&amp;#160;The&amp;#160;warrants&amp;#160;contained a provision where the warrant holder had the option to receive cash&amp;#160;equal to the Black Scholes fair value of the remaining unexercised portion of the warrant&amp;#160;as cash settlement in the event that there was a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, &lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt; required that these warrants be&amp;#160;classified as liabilities. The fair value of these warrants was determined using the Lattice valuation model, and the changes in the fair value were recorded in the Condensed Statements of Operations and Comprehensive Loss.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:WarrantLiabilityDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock id="Factid_1391190" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Debt Agreements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2017, we entered into a venture loan and security agreement (&amp;#8220;Original Loan Agreement&amp;#8221;) with Horizon Technology Finance Corporation (&amp;#8220;Horizon&amp;#8221;), pursuant to which we received a loan in the amount of $7.0 million&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Original Loan Agreement provided for repayment of the loan on an interest-only basis through December 31, 2018, followed by monthly payments of principal and accrued interest for the balance of the 46-month term. The loan bears interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of the loan will be due on the scheduled maturity date for such loan. The Original Loan Agreement also contained a prepayment penalty based on a percentage of the then outstanding principal balance, equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months following such period, and 2% thereafter.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our obligations under the Original Loan Agreement were secured by a first priority security interest in all of our assets, with the exception of our intellectual property. We agreed not to pledge or otherwise encumber our intellectual property assets, subject to certain exceptions.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Original Loan Agreement included customary affirmative and restrictive covenants, excluding any covenants to attain or maintain certain financial metrics, and also included customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% could be applied to the outstanding loan balance, and Horizon could declare all outstanding obligations immediately due and payable and take such other actions as set forth in such agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Original Loan Agreement, we issued Horizon seven-year warrants to purchase an aggregate of 280,612 shares of our common stock (&amp;#8220;Horizon Warrants&amp;#8221;). The per share exercise price of the Horizon Warrants is the lower of (i) $1.96 or (ii) the price per share of any securities that may be issued by the Company in an equity financing during the 18 months following the agreement date. We agreed to file a registration statement covering the resale of the shares underlying the Horizon Warrants. In accordance with ASC 480, &lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt;, as amended by ASU, No. 2017-11, which we early adopted during 2017, the Horizon Warrants have been classified as equity and their fair value at the time of issuance was determined using a Lattice valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the Horizon Warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;July 27, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;47&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The anti-dilution provisions contained in the outstanding Series A warrants were triggered by the Horizon Warrant issuance, resulting in a reduction of the exercise price of such warrants from $4.89 to $4.85 per share.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February 2, 2018, we entered into an amendment to the Original Loan Agreement (the &amp;#8220;Amended Loan Agreement&amp;#8221;) pursuant to which we prepaid $3.0 million of the outstanding $7.0 million principal amount and provided Horizon with a lien on our intellectual property. The other terms of the Original Loan Agreement remained unchanged.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 21, 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the &amp;#8220;Restated Loan Agreement&amp;#8221;) with Horizon and&amp;#160;Molteni&amp;#160;pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed collateral agent and assumed majority and administrative control of the debt. Under the Restated Loan Agreement, the interest only payment and forbearance periods were extended to December 31, 2019. In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizon&amp;#8217;s loan amount. The lien on our intellectual property remains in place at this time. As the present value of the cash flows under the terms of the Restated Loan Agreement is less than 10% different from the remaining cash flows under the terms of the Amended Loan Agreement prior to being amended and restated, the Restated Loan Agreement was accounted for as a debt modification. Accordingly, expenses incurred as a result of the modification were expensed as incurred and the previously deferred fees and costs related to the debt will continue to be amortized over the remaining term along with the related warrants issued as part of the&lt;/div&gt;&amp;#160;agreement described in Note 9 &amp;#8220;Rights Agreement.&amp;#8221;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Restated Loan Agreement, we issued Horizon seven-year warrants to purchase 40,000 shares of our common stock at an exercise price of $1.20 per share. The Horizon Warrants have been classified as equity and their fair value at the time of issuance was determined using a Black Scholes valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the new Horizon warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 21, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
<ttnp:RightsAgreementTextBlock id="Factid_1391195" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rights Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;In consideration of Molteni&amp;#8217;s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into an agreement (as amended in May 2018, the &amp;#8220;Rights Agreement&amp;#8221;) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase &lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; 540,000 shares of our common stock at an exercise price of $1.20&amp;#160;&lt;/div&gt;per share (the &amp;#8220;Molteni Warrants&amp;#8221;), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) appoint one member of our board of directors under certain circumstances and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights. The board designation, observer and information rights will terminate at such time as Molteni ceases to beneficially own at least one percent of our outstanding capital stock (inclusive of the shares issuable upon conversion of debt under the Restated Loan Agreement and exercise of the Molteni Warrants). The Molteni Warrants have been classified as equity and their fair value at the time of issuance was determined using a Black Scholes valuation model. The amount was allocated equally between the Restated Loan Agreement and the Purchase Agreement and was recorded in the Condensed Balance Sheet as a discount to the debt obligation and a contract asset, respectively.&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the Molteni Warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 21, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:RightsAgreementTextBlock>
<ttnp:CompanyPolicyPolicyTextBlock id="Factid_1391314" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;We are a pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We are currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&amp;#174;, a product approved in the U.S. for management of opiate dependence. We operate in only one business segment, the development of pharmaceutical products.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:CompanyPolicyPolicyTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Factid_1391171" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss&amp;#160;per common share for the three and six-months ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px; vertical-align: bottom; width: 48%; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;used for basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,451&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt 45pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(612&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;used for diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,641&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted-average outstanding common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of dilutive potential common shares resulting from options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of dilutive potential common shares resulting from warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average shares outstanding&amp;#8212;diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,201&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;per common share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock id="Factid_1391313" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Organization and Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;We are a pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We are currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&amp;#174;, a product approved in the U.S. for management of opiate dependence. We operate in only one business segment, the development of pharmaceutical products.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 24.5pt; background: none;"&gt;&amp;#160;&lt;div style="background: none; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: 0.34in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information and with the instructions to Form&amp;#160;10-Q and Article&amp;#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six-month periods ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2017, or any future interim periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance sheet at December&amp;#160;31, 2017 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals,&amp;#160;Inc. Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2017, as filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared assuming we will continue as a going concern.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June 30, 2018, we had cash and cash equivalents of approximately $1.6 million, which we believe,&amp;#160;along with the payment from L. Molteni &amp;amp; C. Dei Frattelli Alitti Societ&amp;#224; Di Esercizio S.P.A. (&amp;#8220;Molteni&amp;#8221;) in August,&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; are sufficient to fund our planned operations&amp;#160;into mid-September 2018. If extended, the convertible loan from Molteni should provide funds&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; through the&amp;#160;end&amp;#160;of&amp;#160;the&amp;#160;third quarter.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We will require additional funds to finance our operations, including the&amp;#160;commercialization of Probuphine in the U.S., completion of the Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage clinical studies. While we are currently&amp;#160;&lt;/div&gt;considering&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the various financing alternatives available to us, our efforts to address our liquidity requirements may not be successful.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Going concern assessment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.17in; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;With the implementation of FASB's standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, we will assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &amp;#8220;look-forward period&amp;#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based upon the above assessment, we concluded that, at the date the financial statements in this Quarterly Report on Form 10-Q for the months ended June 30, 2018, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning January 1, 2018, we have followed the provisions of ASC Topic 606, &lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;. The guidance provides a unified model to determine how revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We generate revenue principally from collaborative research and development arrangements, technology licenses, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Transaction Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Allocation of Consideration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Timing of Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs and Related Accrual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization, or CRO, activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&amp;#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. ASU No. 2016-18 is intended to reduce diversity in practice in the classification and presentation of changes in restricted cash on the Condensed Statement of Cash Flows. The ASU requires that the Condensed Statement of Cash Flows explain the change in total cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The ASU also requires a reconciliation between the total of cash, cash equivalents and restricted cash presented on the Condensed Statement of Cash Flows and the cash and cash equivalents balance presented on the Condensed Balance Sheet. We adopted ASU No. 2016-18, and the guidance has been retrospectively applied to all periods presented. The adoption of the guidance did not have an impact on our Condensed Balance Sheet or Statement of Operations and Comprehensive Loss.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2017, the Financial Accounting Standards Board, or FASB, issued a two-part Accounting Standards Update, or ASU, No. 2017-11, &lt;div style="font-style:italic;display:inline;"&gt;I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception&lt;/div&gt; amending guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017- 11 for the year ended December 31, 2017, and retrospectively applied ASU 2017-11 as required. There was no retrospective impact as a result of the adoption of ASU 2017-11 on the financial statements. See Note 10, &amp;#8220;Debt Agreements&amp;#8221;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for fiscal years beginning after December 31, 2017, and for interim periods within those years. The adoption of ASU No. 2016-15 did not have a material impact on our statements of cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &lt;div style="font-style:italic;display:inline;"&gt;Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; (c) classification on the statement of cash flows; and (d) accounting for forfeitures. We adopted the provisions of ASU 2016-09 in the first quarter of 2017. We have elected to continue to estimate forfeitures based on the estimated number of awards expected to vest. In addition, the adoption of ASU 2016-09 resulted in the recognition of $12.0 million of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based payment awards, are now classified as cash flows from operating activities on our statements of cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The adoption of ASU 2016-09 did not have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. This ASU requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach, with early adoption permitted. We are currently evaluating the impact of this new standard on the financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt; and has subsequently issued several supplemental or clarifying ASUs (collectively, &amp;#8220;ASC 606&amp;#8221;), ASC 606 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASC 606 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASC 606 recognized at the date of adoption.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We adopted the new standard effective January 1, 2018 under the modified retrospective transition method, applying the new guidance to the most current period presented. Upon adoption, there was no change to the units of accounting previously identified under legacy GAAP, which are now considered performance obligations under the new guidance, and there was no change to the revenue recognition pattern for each performance obligation. Therefore, the adoption of the new standard resulted in no cumulative effect to the opening accumulated deficit balance.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We assessed the impact that the adoption of ASC 606 will have on our financial statements by analyzing our current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential differences in the application of ASC 606. Additionally, we performed a comprehensive review of our current processes and systems to determine and implement changes required to support the adoption of ASC 606 on January 1, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have evaluated events that have occurred after June 30, 2018 and through the date that the financial statements are issued.&amp;#160;&lt;/div&gt;See Note 10. &amp;#8220;Subsequent Events&amp;#8221;.&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 &amp;#8211; quoted prices in active markets for identical assets or liabilities;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &amp;#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 &amp;#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. Our warrant liabilities are classified within level 3 of the fair value hierarchy because the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recorded no fair value adjustment of the warrant liabilities for the three and six-month periods ended June 30, 2018. We recorded non-cash gains on decreases in the fair value of approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;190&lt;/div&gt;,000 and $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;612&lt;/div&gt;,000 for the three and six-month periods ended June 30, 2017, respectively, in our Condensed Statements of Operations and Comprehensive Loss. The underlying warrants expired by their terms on April 18, 2018. See Note 7&amp;#160;&amp;#8220;Warrant Liability&amp;#8221; for further discussion on the calculation of the fair value of the warrant liability.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Factid_1391261" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the stock-based compensation expense recorded for awards under the stock option plans for the three and six-month periods ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;128&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;318&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 1pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;254&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;516&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;558&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 2.5pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;382&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;803&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No tax benefit was recognized related to stock-based compensation expense since we have accumulated operating losses and we have established a full valuation allowance to offset all the potential tax benefits associated with our deferred tax assets.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense for the three and six-month periods ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected holding period (years) &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average volatility factor &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.89&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated forfeiture rates &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top; text-align:justify"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated forfeiture rates are based on historical data.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 24.5pt; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options to purchase approximately 5,000 and 60,000 shares of common stock were granted during the three-month periods ended June 30, 2018 and 2017, respectively. Options to purchase approximately 950,000 and 496,000 shares of common stock were granted during the six-month periods ended June 30, 2018 and 2017, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes option activity for the six-month period ended June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Option&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January 1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,728&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;950&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.46&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,648&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.44&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="background: none; font-size: 10pt; text-indent: 0.34in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No shares of restricted stock were awarded to employees, directors and consultants during the three and six-month periods ended June 30, 2018 and 2017.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June 30, 2018, there was approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.6&lt;/div&gt; million of total unrecognized compensation expense related to non-vested stock options. This expense is expected to be recognized over a weighted-average period of 0.7 years.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:EarningsPerShareTextBlock id="Factid_1391170" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: separate; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss&amp;#160;per share excludes the effect of dilution and is computed by dividing net loss&amp;#160;by the weighted-average number of shares outstanding for the period. Diluted net loss&amp;#160;per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss&amp;#160;per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss&amp;#160;per common share for the three and six-months ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px; vertical-align: bottom; width: 48%; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;used for basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,451&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt 45pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(612&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;used for diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,641&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted-average outstanding common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of dilutive potential common shares resulting from options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of dilutive potential common shares resulting from warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average shares outstanding&amp;#8212;diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,204&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,201&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&amp;#160;per common share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss&amp;#160;per common share. These are excluded from the calculation due to their anti-dilutive effect for the three and six-months ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average anti-dilutive common shares resulting from options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,658&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,437&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,730&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;517&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 7.2pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,140&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,057&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:ComprehensiveIncomeNoteTextBlock id="Factid_1391182" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;Comprehensive loss &lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the periods presented is comprised solely of our net loss. We had no items of other comprehensive loss&amp;#160;during the three and six-month periods ended June 30, 2018 and 2017. Comprehensive loss for the three and six-month periods ended June 30, 2018 was $0.9 million and $3.5 million, respectively. Comprehensive loss for the three and six-month periods ended June&amp;#160;30, 2017 was $3.5 million and $6.5 million, respectively.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
<ttnp:LicenseRightsDisclosureTextBlock id="Factid_1391319" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Braeburn License&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;Until its termination in May 2018, we were party to&amp;#160;a license agreement (as amended, the &amp;#8220;License Agreement&amp;#8221;) pursuant to which we had granted Braeburn Pharmaceuticals, Inc. (&amp;#8220;Braeburn&amp;#8221;) the exclusive commercialization rights to Probuphine in the United States and its territories and Canada. Under the License Agreement, we received certain milestone payments, as well as royalties on net sales of Probuphine. Upon receipt of approval, our obligation was fulfilled and we recognized as revenue the full amount of the milestone payment. In addition, we were entitled to receive a low single digit royalty on sales by Braeburn of other competing continuous delivery treatments for opioid dependence as defined in the License Agreement. The License Agreement provided for us to be reimbursed by Braeburn for any development services and activities undertaken at Braeburn&amp;#8217;s request. Under ASC 606, there was no change in the amount or timing of revenue recognized under this agreement. In February 2016, Braeburn sublicensed rights to develop and commercialize Probuphine in Canada to Knight Therapeutics, Inc. (&amp;#8220;Knight&amp;#8221;).&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;On May 25, 2018, we entered into a Termination and Transition Services Agreement (the &amp;#8220;Transition Agreement&amp;#8221;) with Braeburn pursuant to which we regained all rights to the commercialization and clinical development of Probuphine in the United States and Canada.&amp;#160;Braeburn paid us&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;$1.0&amp;#160;&lt;/div&gt;million, transferred inventory to us with a value of approximately $1.1 million and agreed to provide support services through December 28, 2018. In addition, the Transition Agreement provides for the immediate transfer to us of all regulatory documentation and development data related to Probuphine. The estimated fair value of the inventory received was determined using available inputs such as existing supply agreements, prior selling prices and remaining life to expiration. We recognized approximately $2.1 million of license related revenue related to this transaction in the three month period ended June 30, 2018. The sublicense to Knight was assigned to Titan as part of the Transition Agreement.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:LicenseRightsDisclosureTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Factid_1391166" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the stock-based compensation expense recorded for awards under the stock option plans for the three and six-month periods ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;128&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;318&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 1pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;254&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;516&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;558&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 2.5pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;382&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;803&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock id="Factid_1391262" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense for the three and six-month periods ended June 30, 2018 and 2017:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; white-space: nowrap;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected holding period (years) &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average volatility factor &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.89&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated forfeiture rates &lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top; text-align:justify"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0px; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated forfeiture rates are based on historical data.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Factid_1391346" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;These are excluded from the calculation due to their anti-dilutive effect for the three and six-months ended June 30, 2018 and 2017:&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average anti-dilutive common shares resulting from options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,658&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,437&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 12pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,730&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;517&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 7.2pt; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,140&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,057&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_1391315" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information and with the instructions to Form&amp;#160;10-Q and Article&amp;#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six-month periods ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2017, or any future interim periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance sheet at December&amp;#160;31, 2017 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals,&amp;#160;Inc. Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2017, as filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared assuming we will continue as a going concern.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June 30, 2018, we had cash and cash equivalents of approximately $1.6 million, which we believe,&amp;#160;along with the payment from L. Molteni &amp;amp; C. Dei Frattelli Alitti Societ&amp;#224; Di Esercizio S.P.A. (&amp;#8220;Molteni&amp;#8221;) in August,&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; are sufficient to fund our planned operations&amp;#160;into mid-September 2018. If extended, the convertible loan from Molteni should provide funds&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; through the&amp;#160;end&amp;#160;of&amp;#160;the&amp;#160;third quarter.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We will require additional funds to finance our operations, including the&amp;#160;commercialization of Probuphine in the U.S., completion of the Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage clinical studies. While we are currently&amp;#160;&lt;/div&gt;considering&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the various financing alternatives available to us, our efforts to address our liquidity requirements may not be successful.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<ttnp:GoingConcernAssessmentPolicyTextBlock id="Factid_1391316" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Going concern assessment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.17in; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;With the implementation of FASB's standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, we will assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &amp;#8220;look-forward period&amp;#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based upon the above assessment, we concluded that, at the date the financial statements in this Quarterly Report on Form 10-Q for the months ended June 30, 2018, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ttnp:GoingConcernAssessmentPolicyTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock id="Factid_1391168" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes option activity for the six-month period ended June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(in&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Option&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January 1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,728&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;950&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.46&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,648&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.44&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_1391317" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning January 1, 2018, we have followed the provisions of ASC Topic 606, &lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;. The guidance provides a unified model to determine how revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We generate revenue principally from collaborative research and development arrangements, technology licenses, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Transaction Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Allocation of Consideration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Timing of Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:InProcessResearchAndDevelopmentPolicy id="Factid_1391152" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs and Related Accrual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization, or CRO, activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&amp;#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_1391007" contextRef="P04_01_2018To06_30_2018" unitRef="pure" decimals="3">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_1391008" contextRef="P04_01_2017To06_30_2017" unitRef="pure" decimals="2">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_1391017" contextRef="P01_01_2018To06_30_2018" unitRef="pure" decimals="3">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_1391018" contextRef="P01_01_2017To06_30_2017" unitRef="pure" decimals="3">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_1391092" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-5">900000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_1391093" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-5">3500000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_1391094" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-5">3500000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_1391095" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-5">6500000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ProceedsFromSaleOfProductiveAssets id="Factid_1391096" contextRef="P01_01_2018To06_30_2018" unitRef="EUR" decimals="-5">2000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
<us-gaap:ProceedsFromSaleOfProductiveAssets id="Factid_1391097" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-5">2400000</us-gaap:ProceedsFromSaleOfProductiveAssets>
<us-gaap:NetIncomeLoss id="Factid_1390967" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3474000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_1390968" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-6456000</us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments id="Factid_1391019" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments id="Factid_1391020" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments id="Factid_1391009" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments id="Factid_1391010" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_1391065" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-869000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_1391066" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-3451000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_1391077" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_1391173" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-6456000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_1391153" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. ASU No. 2016-18 is intended to reduce diversity in practice in the classification and presentation of changes in restricted cash on the Condensed Statement of Cash Flows. The ASU requires that the Condensed Statement of Cash Flows explain the change in total cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The ASU also requires a reconciliation between the total of cash, cash equivalents and restricted cash presented on the Condensed Statement of Cash Flows and the cash and cash equivalents balance presented on the Condensed Balance Sheet. We adopted ASU No. 2016-18, and the guidance has been retrospectively applied to all periods presented. The adoption of the guidance did not have an impact on our Condensed Balance Sheet or Statement of Operations and Comprehensive Loss.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2017, the Financial Accounting Standards Board, or FASB, issued a two-part Accounting Standards Update, or ASU, No. 2017-11, &lt;div style="font-style:italic;display:inline;"&gt;I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception&lt;/div&gt; amending guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017- 11 for the year ended December 31, 2017, and retrospectively applied ASU 2017-11 as required. There was no retrospective impact as a result of the adoption of ASU 2017-11 on the financial statements. See Note 10, &amp;#8220;Debt Agreements&amp;#8221;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for fiscal years beginning after December 31, 2017, and for interim periods within those years. The adoption of ASU No. 2016-15 did not have a material impact on our statements of cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &lt;div style="font-style:italic;display:inline;"&gt;Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; (c) classification on the statement of cash flows; and (d) accounting for forfeitures. We adopted the provisions of ASU 2016-09 in the first quarter of 2017. We have elected to continue to estimate forfeitures based on the estimated number of awards expected to vest. In addition, the adoption of ASU 2016-09 resulted in the recognition of $12.0 million of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based payment awards, are now classified as cash flows from operating activities on our statements of cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The adoption of ASU 2016-09 did not have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. This ASU requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach, with early adoption permitted. We are currently evaluating the impact of this new standard on the financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt; and has subsequently issued several supplemental or clarifying ASUs (collectively, &amp;#8220;ASC 606&amp;#8221;), ASC 606 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASC 606 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASC 606 recognized at the date of adoption.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We adopted the new standard effective January 1, 2018 under the modified retrospective transition method, applying the new guidance to the most current period presented. Upon adoption, there was no change to the units of accounting previously identified under legacy GAAP, which are now considered performance obligations under the new guidance, and there was no change to the revenue recognition pattern for each performance obligation. Therefore, the adoption of the new standard resulted in no cumulative effect to the opening accumulated deficit balance.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We assessed the impact that the adoption of ASC 606 will have on our financial statements by analyzing our current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential differences in the application of ASC 606. Additionally, we performed a comprehensive review of our current processes and systems to determine and implement changes required to support the adoption of ASC 606 on January 1, 2018.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock id="Factid_1391318" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have evaluated events that have occurred after June 30, 2018 and through the date that the financial statements are issued.&amp;#160;&lt;/div&gt;See Note 10. &amp;#8220;Subsequent Events&amp;#8221;.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_1391281" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">1614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_1391282" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">7522000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Factid_1391191" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the Horizon Warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;July 27, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;47&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Factid_1391192" contextRef="P01_01_2018To06_30_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the new Horizon warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 21, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1390995" contextRef="P04_01_2018To06_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">156000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1390996" contextRef="P04_01_2017To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">128000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1390997" contextRef="P04_01_2018To06_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">246000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1390998" contextRef="P04_01_2017To06_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">254000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1390999" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">402000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391000" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">382000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391001" contextRef="P01_01_2018To06_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">318000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391002" contextRef="P01_01_2017To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">245000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391003" contextRef="P01_01_2018To06_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">516000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391004" contextRef="P01_01_2017To06_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="USD" decimals="-3">558000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391005" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">834000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_1391006" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">803000</us-gaap:AllocatedShareBasedCompensationExpense>
<ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability id="Factid_1391174" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">612000</ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability>
<ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability id="Factid_1391078" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">0</ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability>
<ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability id="Factid_1391067" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">0</ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability>
<ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability id="Factid_1391068" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">190000</ttnp:AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_1391011" contextRef="P04_01_2018To06_30_2018">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_1391012" contextRef="P04_01_2017To06_30_2017">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_1391021" contextRef="P01_01_2018To06_30_2018">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_1391022" contextRef="P01_01_2017To06_30_2017">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<dei:DocumentType id="Factid_1412391" contextRef="P01_01_2018To06_30_2018">10-Q</dei:DocumentType>
<us-gaap:RevenueRecognitionMilestoneMethodDescription id="Factid_1391347" contextRef="P01_01_2018To06_30_2018">receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties.</us-gaap:RevenueRecognitionMilestoneMethodDescription>
<dei:AmendmentFlag id="Factid_1412392" contextRef="P01_01_2018To06_30_2018">false</dei:AmendmentFlag>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_1390969" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">224000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_1390970" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">203000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate id="Factid_1391023" contextRef="P01_01_2018To06_30_2018" unitRef="pure" decimals="4">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate id="Factid_1391024" contextRef="P01_01_2017To06_30_2017" unitRef="pure" decimals="4">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate id="Factid_1391013" contextRef="P04_01_2018To06_30_2018" unitRef="pure" decimals="4">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate id="Factid_1391014" contextRef="P04_01_2017To06_30_2017" unitRef="pure" decimals="4">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_1391036" contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">2728000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_1391069" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-869000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_1391070" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-3641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_1391079" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_1391175" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-7068000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Factid_1391196" contextRef="P01_01_2018To06_30_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions used to value the Molteni Warrants were as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"&gt;&lt;tr&gt;&lt;td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 21, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="white-space: pre-wrap; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:RestrictedCash id="Factid_1391283" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">361000</us-gaap:RestrictedCash>
<us-gaap:RestrictedCash id="Factid_1391284" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">361000</us-gaap:RestrictedCash>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="Factid_1391155" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 &amp;#8211; quoted prices in active markets for identical assets or liabilities;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &amp;#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 &amp;#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. Our warrant liabilities are classified within level 3 of the fair value hierarchy because the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recorded no fair value adjustment of the warrant liabilities for the three and six-month periods ended June 30, 2018. We recorded non-cash gains on decreases in the fair value of approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;190&lt;/div&gt;,000 and $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;612&lt;/div&gt;,000 for the three and six-month periods ended June 30, 2017, respectively, in our Condensed Statements of Operations and Comprehensive Loss. The underlying warrants expired by their terms on April 18, 2018. See Note 7&amp;#160;&amp;#8220;Warrant Liability&amp;#8221; for further discussion on the calculation of the fair value of the warrant liability.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<ttnp:FairValueAssumptionsDateOfIssuance id="Factid_1391216" contextRef="P01_01_2018To06_30_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">2018-03-21</ttnp:FairValueAssumptionsDateOfIssuance>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_1391137" contextRef="PAsOn03_21_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="shares" decimals="0">540000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391138" contextRef="PAsOn03_21_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_1391561" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">70000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_1391562" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_1391563" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">70000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_1391564" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:AccountsReceivableNetCurrent id="Factid_1390879" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">189000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent id="Factid_1390880" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">65000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_1391037" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement id="Factid_1391015" contextRef="P04_01_2018To06_30_2018" unitRef="pure" decimals="2">0.25</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
<ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement id="Factid_1391016" contextRef="P04_01_2017To06_30_2017" unitRef="pure" decimals="2">0.27</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
<ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement id="Factid_1391025" contextRef="P01_01_2018To06_30_2018" unitRef="pure" decimals="2">0.26</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
<ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement id="Factid_1391026" contextRef="P01_01_2017To06_30_2017" unitRef="pure" decimals="2">0.28</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
<us-gaap:OtherNoncashExpense id="Factid_1390971" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">208000</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense id="Factid_1390972" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:OtherNoncashExpense>
<dei:DocumentPeriodEndDate id="Factid_1412393" contextRef="P01_01_2018To06_30_2018">2018-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_1412394" contextRef="P01_01_2018To06_30_2018">2018</dei:DocumentFiscalYearFocus>
<us-gaap:FairValueAdjustmentOfWarrants id="Factid_1390974" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-612000</us-gaap:FairValueAdjustmentOfWarrants>
<ttnp:FairValueAssumptionsDateOfIssuance id="Factid_1391209" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">2017-07-27</ttnp:FairValueAssumptionsDateOfIssuance>
<ttnp:FairValueAssumptionsDateOfIssuance id="Factid_1391210" contextRef="P01_01_2018To06_30_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">2018-03-21</ttnp:FairValueAssumptionsDateOfIssuance>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_1391565" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">1857000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_1391566" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">2501000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_1391567" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">3713000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_1391568" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">4627000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_1391038" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_1391176" contextRef="P01_01_2017To06_30_2017" unitRef="shares" decimals="-3">21199000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_1391072" contextRef="P01_01_2018To06_30_2018" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_1391055" contextRef="P04_01_2018To06_30_2018" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_1391056" contextRef="P04_01_2017To06_30_2017" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:InventoryNet id="Factid_1391305" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">1317000</us-gaap:InventoryNet>
<us-gaap:InventoryNet id="Factid_1391306" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">0</us-gaap:InventoryNet>
<us-gaap:ContractWithCustomerAssetGross id="Factid_1390847" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">291000</us-gaap:ContractWithCustomerAssetGross>
<us-gaap:ContractWithCustomerAssetGross id="Factid_1390848" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">0</us-gaap:ContractWithCustomerAssetGross>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions id="Factid_1391057" contextRef="P04_01_2018To06_30_2018" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions id="Factid_1391058" contextRef="P04_01_2017To06_30_2017" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions id="Factid_1391073" contextRef="P01_01_2018To06_30_2018" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions id="Factid_1391177" contextRef="P01_01_2017To06_30_2017" unitRef="shares" decimals="-3">2000</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="Factid_1391039" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_1391569" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">1380000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_1391570" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">1197000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_1391571" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">2995000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_1391572" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">2548000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391080" contextRef="P04_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">3658000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391081" contextRef="P04_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">2437000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391082" contextRef="P04_01_2018To06_30_2018_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="-3">1482000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391083" contextRef="P04_01_2017To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="-3">1117000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391084" contextRef="P04_01_2018To06_30_2018" unitRef="shares" decimals="-3">5140000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391085" contextRef="P04_01_2017To06_30_2017" unitRef="shares" decimals="-3">3554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391086" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">3327000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391087" contextRef="P01_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">2324000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391088" contextRef="P01_01_2018To06_30_2018_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="-3">1730000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391089" contextRef="P01_01_2017To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="-3">517000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391090" contextRef="P01_01_2018To06_30_2018" unitRef="shares" decimals="-3">5057000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_1391091" contextRef="P01_01_2017To06_30_2017" unitRef="shares" decimals="-3">2841000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ShareBasedCompensation id="Factid_1390975" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">834000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_1390976" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">803000</us-gaap:ShareBasedCompensation>
<dei:DocumentFiscalPeriodFocus id="Factid_1412395" contextRef="P01_01_2018To06_30_2018">Q2</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_1412396" contextRef="P01_01_2018To06_30_2018">TITAN PHARMACEUTICALS INC</dei:EntityRegistrantName>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Factid_1391169" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" unitRef="USD" decimals="-5">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:OperatingExpenses id="Factid_1391573" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">3307000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_1391574" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">3698000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_1391575" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">6778000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_1391576" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">7175000</us-gaap:OperatingExpenses>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_1391040" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants id="Factid_1391178" contextRef="P01_01_2017To06_30_2017" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants id="Factid_1391074" contextRef="P01_01_2018To06_30_2018" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants id="Factid_1391059" contextRef="P04_01_2018To06_30_2018" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants>
<ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants id="Factid_1391060" contextRef="P04_01_2017To06_30_2017" unitRef="shares" decimals="-3">0</ttnp:IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_1390885" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">424000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_1390886" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">595000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Factid_1390887" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">4617000</us-gaap:Assets>
<us-gaap:Assets id="Factid_1390888" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">8905000</us-gaap:Assets>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_1391061" contextRef="P04_01_2018To06_30_2018" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_1391062" contextRef="P04_01_2017To06_30_2017" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_1391075" contextRef="P01_01_2018To06_30_2018" unitRef="shares" decimals="-3">21204000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_1391179" contextRef="P01_01_2017To06_30_2017" unitRef="shares" decimals="-3">21201000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_1391041" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">3648000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Factid_1391052" contextRef="P01_01_2018To06_30_2018">P8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_1390977" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">124000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_1390978" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-3500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<dei:EntityCentralIndexKey id="Factid_1412397" contextRef="P01_01_2018To06_30_2018">0000910267</dei:EntityCentralIndexKey>
<ttnp:FairValueAssumptionsRate id="Factid_1391211" contextRef="P01_01_2018To06_30_2018_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="2">0.86</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391213" contextRef="P01_01_2018To06_30_2018_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="4">0.0282</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391214" contextRef="P01_01_2018To06_30_2018_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="2">0.00</ttnp:FairValueAssumptionsRate>
<us-gaap:IncreaseDecreaseInInventories id="Factid_1391311" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">1317000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories id="Factid_1391312" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInventories>
<dei:CurrentFiscalYearEndDate id="Factid_1412398" contextRef="P01_01_2018To06_30_2018">--12-31</dei:CurrentFiscalYearEndDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_1391027" contextRef="P04_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" unitRef="shares" decimals="-3">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_1391028" contextRef="P04_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" unitRef="shares" decimals="-3">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_1391029" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" unitRef="shares" decimals="-3">950000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_1391030" contextRef="P01_01_2017To06_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" unitRef="shares" decimals="-3">496000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<ttnp:WarrantsToPurchaseCommonStockShares id="Factid_1391110" contextRef="P04_01_2018To04_18_2018_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="shares" decimals="0">983395</ttnp:WarrantsToPurchaseCommonStockShares>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_1391581" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-230000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_1391582" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-20000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_1391583" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-428000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_1391584" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-10000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_1391031" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="shares" decimals="-3">2796000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_1391032" contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:EarningsPerShareBasic id="Factid_1391180" contextRef="P01_01_2017To06_30_2017" unitRef="USD_per_Share" decimals="2">-0.30</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_1391076" contextRef="P01_01_2018To06_30_2018" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_1391063" contextRef="P04_01_2018To06_30_2018" unitRef="USD_per_Share" decimals="2">-0.04</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_1391064" contextRef="P04_01_2017To06_30_2017" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareBasic>
<us-gaap:FairValueAdjustmentOfWarrants id="Factid_1391585" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants id="Factid_1391586" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-190000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants id="Factid_1391587" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants id="Factid_1391588" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-612000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391111" contextRef="PAsOn04_18_2018_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">4.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<dei:EntityFilerCategory id="Factid_1412399" contextRef="P01_01_2018To06_30_2018">Non-accelerated Filer</dei:EntityFilerCategory>
<ttnp:FairValueAssumptionsRate id="Factid_1391199" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="pure" decimals="2">0.47</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391204" contextRef="P01_01_2018To06_30_2018_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="2">0.86</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391201" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="pure" decimals="4">0.0212</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391202" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="pure" decimals="2">0.00</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391206" contextRef="P01_01_2018To06_30_2018_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="4">0.0282</ttnp:FairValueAssumptionsRate>
<ttnp:FairValueAssumptionsRate id="Factid_1391207" contextRef="P01_01_2018To06_30_2018_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="pure" decimals="2">0.00</ttnp:FairValueAssumptionsRate>
<us-gaap:IncreaseDecreaseInContractReceivablesNet id="Factid_1390983" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">72000</us-gaap:IncreaseDecreaseInContractReceivablesNet>
<us-gaap:IncreaseDecreaseInContractReceivablesNet id="Factid_1390984" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInContractReceivablesNet>
<dei:TradingSymbol id="Factid_1412400" contextRef="P01_01_2018To06_30_2018">TTNP</dei:TradingSymbol>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_1390955" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">59000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_1390956" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">80000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:NonoperatingIncomeExpense id="Factid_1391589" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-230000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_1391590" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">170000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_1391591" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-428000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_1391592" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">602000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:EarningsPerShareDiluted id="Factid_1391071" contextRef="P01_01_2018To06_30_2018" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted id="Factid_1391053" contextRef="P04_01_2018To06_30_2018" unitRef="USD_per_Share" decimals="2">-0.04</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted id="Factid_1391054" contextRef="P04_01_2017To06_30_2017" unitRef="USD_per_Share" decimals="2">-0.17</us-gaap:EarningsPerShareDiluted>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_1391033" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">0.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:AccountsPayableCurrent id="Factid_1390889" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">575000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_1390890" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">821000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_1390863" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">474000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_1390864" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">289000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Factid_1391034" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:NetIncomeLoss id="Factid_1391593" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-869000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_1391594" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-3451000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_1391595" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3474000</us-gaap:NetIncomeLoss>
<dei:EntityCommonStockSharesOutstanding id="Factid_1412401" contextRef="PAsOn08_10_2018" unitRef="shares" decimals="0">21203744</dei:EntityCommonStockSharesOutstanding>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_1390961" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-2855000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_1390962" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-5630000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="Factid_1391035" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">8.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_1390865" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">401000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_1390866" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">354000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent id="Factid_1390867" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">939000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent id="Factid_1390868" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenueCurrent>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_1391045" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">5.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:EarningsPerShareDiluted id="Factid_1391604" contextRef="P01_01_2017To06_30_2017" unitRef="USD_per_Share" decimals="2">-0.33</us-gaap:EarningsPerShareDiluted>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_1390963" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">53000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_1390964" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">26000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_1390965" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-53000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_1390966" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_1391046" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:LongTermDebtCurrent id="Factid_1390869" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">0</us-gaap:LongTermDebtCurrent>
<us-gaap:LongTermDebtCurrent id="Factid_1390870" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">3000000</us-gaap:LongTermDebtCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_1390871" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">2389000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_1390872" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">4464000</us-gaap:LiabilitiesCurrent>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_1391047" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD_per_Share" decimals="2">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391194" contextRef="PAsOn07_27_2017_MinimumMembersrtRangeAxis_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">4.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391116" contextRef="PAsOn07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis" unitRef="USD_per_Share" decimals="2">1.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391124" contextRef="PAsOn07_27_2017_MaximumMembersrtRangeAxis_SeriesWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">4.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_1391129" contextRef="PAsOn03_21_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_1391048" contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_1391049" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:LongTermDebtNoncurrent id="Factid_1390873" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">3541000</us-gaap:LongTermDebtNoncurrent>
<us-gaap:LongTermDebtNoncurrent id="Factid_1390874" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">3584000</us-gaap:LongTermDebtNoncurrent>
<us-gaap:InvestmentsFairValueDisclosure id="Factid_1390993" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-5">1600000</us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:Liabilities id="Factid_1390849" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">5930000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_1390850" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">8048000</us-gaap:Liabilities>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Factid_1391050" contextRef="P01_01_2018To06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:DebtInstrumentFaceAmount id="Factid_1391112" contextRef="PAsOn07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis_VentureLoanMemberusgaapDebtInstrumentAxis" unitRef="USD" decimals="-5">7000000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:RepaymentsOfLongTermDebt id="Factid_1390947" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">3000000</us-gaap:RepaymentsOfLongTermDebt>
<us-gaap:RepaymentsOfLongTermDebt id="Factid_1390948" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfLongTermDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_1390949" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_1390950" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:DebtInstrumentMaturityDate id="Factid_1391114" contextRef="P07_01_2017To07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis_VentureLoanMemberusgaapDebtInstrumentAxis">2018-12-31</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_1391042" contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD" decimals="-3">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_1391043" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD" decimals="-3">115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:CommitmentsAndContingencies id="Factid_1390851" contextRef="PAsOn06_30_2018" unitRef="USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_1390852" contextRef="PAsOn12_31_2017" unitRef="USD" xsi:nil="true" />
<ttnp:DeferredTaxAssetsUnrecognizedTaxBenefit id="Factid_1390994" contextRef="PAsOn03_31_2016_NewAccountingPronouncementMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="USD" decimals="-5">12000000</ttnp:DeferredTaxAssetsUnrecognizedTaxBenefit>
<ttnp:WarrantExpirationDate id="Factid_1391164" contextRef="P01_01_2018To06_30_2018">2018-04-18</ttnp:WarrantExpirationDate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Factid_1391044" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="USD" decimals="-3">57000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:DebtInstrumentTerm id="Factid_1391115" contextRef="P07_01_2017To07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis_VentureLoanMemberusgaapDebtInstrumentAxis">P46M</us-gaap:DebtInstrumentTerm>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_1390951" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-5908000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_1390952" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-5656000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_1391291" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">7883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_1391292" contextRef="PAsOn12_31_2016" unitRef="USD" decimals="-3">14006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CommonStockValue id="Factid_1390853" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">297855000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_1390854" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">297855000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital id="Factid_1390855" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">27577000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital id="Factid_1390856" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">26273000</us-gaap:AdditionalPaidInCapital>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_1391293" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">1975000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_1391294" contextRef="PAsOn06_30_2017" unitRef="USD" decimals="-3">8350000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_1390857" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">-326745000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_1390858" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">-323271000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_1390859" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">-1313000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_1390860" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">857000</us-gaap:StockholdersEquity>
<us-gaap:InterestPaidNet id="Factid_1390981" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">234000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet id="Factid_1390982" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_1391130" contextRef="PAsOn03_21_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="shares" decimals="0">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_1391117" contextRef="PAsOn07_27_2017_HorizonTechnologyFinanceCorporationMemberdeiLegalEntityAxis" unitRef="shares" decimals="0">280612</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_1390861" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">4617000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_1390862" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">8905000</us-gaap:LiabilitiesAndStockholdersEquity>
<ttnp:WarrantsIssued id="Factid_1390985" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">470000</ttnp:WarrantsIssued>
<ttnp:WarrantsIssued id="Factid_1390986" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</ttnp:WarrantsIssued>
<ttnp:DebtInstrumentFinalPaymentOnEachLoanTranchepercentage id="Factid_1391113" contextRef="P07_01_2017To07_27_2017_VentureLoanMemberusgaapDebtInstrumentAxis" unitRef="pure" decimals="2">0.05</ttnp:DebtInstrumentFinalPaymentOnEachLoanTranchepercentage>
<us-gaap:EarlyRepaymentOfSubordinatedDebt id="Factid_1391125" contextRef="P02_01_2018To02_02_2018_VentureLoanMemberusgaapDebtInstrumentAxis" unitRef="USD" decimals="-5">3000000</us-gaap:EarlyRepaymentOfSubordinatedDebt>
<us-gaap:LongTermDebt id="Factid_1391126" contextRef="PAsOn02_02_2018_VentureLoanMemberusgaapDebtInstrumentAxis" unitRef="USD" decimals="-5">7000000</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt id="Factid_1391127" contextRef="PAsOn03_21_2018_MolteniLoanMemberusgaapDebtInstrumentAxis" unitRef="USD" decimals="-5">4000000</us-gaap:LongTermDebt>
<ttnp:ConversionOfDebtToEquityDescription id="Factid_1391193" contextRef="P03_01_2018To03_21_2018_MolteniLoanMemberusgaapDebtInstrumentAxis">In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizon&amp;#8217;s loan amount.</ttnp:ConversionOfDebtToEquityDescription>
<us-gaap:ProceedsFromSubordinatedShortTermDebt id="Factid_1391128" contextRef="P03_01_2018To03_21_2018_MolteniLoanMemberusgaapDebtInstrumentAxis" unitRef="USD" decimals="-5">2400000</us-gaap:ProceedsFromSubordinatedShortTermDebt>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_1390881" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">421000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_1390882" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">362000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_1390957" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-14000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_1390958" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-2988000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<ttnp:ContractWithCustomerAssetAdditions id="Factid_1391103" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">291000</ttnp:ContractWithCustomerAssetAdditions>
<ttnp:ContractWithCustomerAssetDeductions id="Factid_1391104" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">0</ttnp:ContractWithCustomerAssetDeductions>
<us-gaap:DeferredRevenue id="Factid_1391106" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenue>
<us-gaap:DeferredRevenueAdditions id="Factid_1391107" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">2448000</us-gaap:DeferredRevenueAdditions>
<us-gaap:DeferredRevenueRevenueRecognized1 id="Factid_1391304" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">1509000</us-gaap:DeferredRevenueRevenueRecognized1>
<us-gaap:DeferredRevenue id="Factid_1391109" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">939000</us-gaap:DeferredRevenue>
<ttnp:EstimatedSellingPrice id="Factid_1391100" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-5">1400000</ttnp:EstimatedSellingPrice>
<us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments id="Factid_1391101" contextRef="P01_01_2018To06_30_2018_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="USD" decimals="-5">1000000</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock id="Factid_1391187" contextRef="P01_01_2018To06_30_2018">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents changes in contract assets and liabilities during the six months ended June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&amp;#160;thousands&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Beginning&amp;#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8206;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending&lt;br/&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,448&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,509&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<us-gaap:SubsequentEventsTextBlock id="Factid_1391197" contextRef="P01_01_2018To06_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="word-wrap: break-word; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;On August 3, 2018, we entered into an amendment (the &amp;#8220;Amendment&amp;#8221;) to the Purchase Agreement with Molteni. Under the Amendment, Molteni made an immediate payment to us of &amp;#8364;950,000 (approximately $1,109,000) and has committed to make a convertible loan to us of &amp;#8364;550,000 (approximately $642,000) provided we have submitted our response to the 120-day letter from the EMA on or prior to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of &amp;#8364;2.0 million (approximately $2,335,000) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019, at the earliest. The loan (the &amp;#8220;Convertible Loan&amp;#8221;), if made, will convert automatically into shares of our common stock upon the issuance by the EMA of marketing approval for Probuphine at a conversion price per share equal to the lower of (i) the closing price on the loan funding date and (ii) the closing price on the conversion date. In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum. The Convertible Loan will contain other covenants and events of default substantially consistent with the Restated Loan Agreement.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;On August 7, 2018, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 2,500,000 to 3,500,000.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<ttnp:ProceedsFromExclusiveCommercializationRights id="Factid_1391198" contextRef="P05_01_2018To05_25_2018" unitRef="USD" decimals="-5">1000000</ttnp:ProceedsFromExclusiveCommercializationRights>
<ttnp:FairValueAssumptionsTerm id="Factid_1391205" contextRef="P01_01_2018To06_30_2018_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis">P7Y</ttnp:FairValueAssumptionsTerm>
<ttnp:FairValueAssumptionsTerm id="Factid_1391200" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">P7Y</ttnp:FairValueAssumptionsTerm>
<ttnp:WeightedAverageFairValueAssumptionsOfWarrants id="Factid_1391208" contextRef="P01_01_2018To06_30_2018_NewHorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">0.81</ttnp:WeightedAverageFairValueAssumptionsOfWarrants>
<ttnp:WeightedAverageFairValueAssumptionsOfWarrants id="Factid_1391203" contextRef="P01_01_2018To06_30_2018_HorizonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">1.02</ttnp:WeightedAverageFairValueAssumptionsOfWarrants>
<ttnp:FairValueAssumptionsTerm id="Factid_1391212" contextRef="P01_01_2018To06_30_2018_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis">P7Y</ttnp:FairValueAssumptionsTerm>
<ttnp:WeightedAverageFairValueAssumptionsOfWarrants id="Factid_1391215" contextRef="P01_01_2018To06_30_2018_MolteniWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="USD_per_Share" decimals="2">0.81</ttnp:WeightedAverageFairValueAssumptionsOfWarrants>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_1391295" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">1614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_1391296" contextRef="PAsOn06_30_2017" unitRef="USD" decimals="-3">8350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalents id="Factid_1391297" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">361000</us-gaap:RestrictedCashAndCashEquivalents>
<us-gaap:RestrictedCashAndCashEquivalents id="Factid_1391298" contextRef="PAsOn06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:RestrictedCashAndCashEquivalents>
<ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents id="Factid_1391301" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">1975000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
<ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents id="Factid_1391302" contextRef="PAsOn06_30_2017" unitRef="USD" decimals="-3">8350000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
<us-gaap:AssetsCurrent id="Factid_1390883" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="-3">4193000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_1390884" contextRef="PAsOn12_31_2017" unitRef="USD" decimals="-3">8310000</us-gaap:AssetsCurrent>
<ttnp:LicenseRevenueNet id="Factid_1391540" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">2593000</ttnp:LicenseRevenueNet>
<ttnp:LicenseRevenueNet id="Factid_1391542" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">77000</ttnp:LicenseRevenueNet>
<ttnp:LicenseRevenueNet id="Factid_1391544" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">3657000</ttnp:LicenseRevenueNet>
<ttnp:LicenseRevenueNet id="Factid_1391545" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">117000</ttnp:LicenseRevenueNet>
<us-gaap:OperatingIncomeLoss id="Factid_1391577" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">-639000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_1391578" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">-3621000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_1391579" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">-3046000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_1391580" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">-7058000</us-gaap:OperatingIncomeLoss>
<us-gaap:IncreaseDecreaseInDeferredRevenue id="Factid_1390959" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">939000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue id="Factid_1390960" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:InventoryNet id="Factid_1391320" contextRef="PAsOn05_25_2018" unitRef="USD" decimals="-5">1100000</us-gaap:InventoryNet>
<ttnp:LicenseRevenue1 id="Factid_1391321" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-5">2100000</ttnp:LicenseRevenue1>
<ttnp:AmountReceivedUnderAmendmentToPurchaseAgreement id="Factid_1391339" contextRef="PAsOn08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="EUR" decimals="0">950000</ttnp:AmountReceivedUnderAmendmentToPurchaseAgreement>
<ttnp:AmountReceivedUnderAmendmentToPurchaseAgreement id="Factid_1391340" contextRef="PAsOn08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="USD" decimals="0">1109000</ttnp:AmountReceivedUnderAmendmentToPurchaseAgreement>
<us-gaap:ConvertibleDebt id="Factid_1391341" contextRef="PAsOn08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="EUR" decimals="0">550000</us-gaap:ConvertibleDebt>
<us-gaap:ConvertibleDebt id="Factid_1391342" contextRef="PAsOn08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="USD" decimals="0">642000</us-gaap:ConvertibleDebt>
<us-gaap:LongTermPurchaseCommitmentMilestones id="Factid_1391343" contextRef="P08_01_2018To08_03_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">On August 3, 2018, we entered into an amendment (the &amp;#8220;Amendment&amp;#8221;) to the Purchase Agreement with Molteni. Under the Amendment, Molteni made an immediate payment to us of &amp;#8364;950,000 (approximately $1,109,000) and has committed to make a convertible loan to us of &amp;#8364;550,000 (approximately $642,000) provided we have submitted our response to the 120-day letter from the EMA on or prior to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of &amp;#8364;2.0 million (approximately $2,335,000) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019, at the earliest.</us-gaap:LongTermPurchaseCommitmentMilestones>
<us-gaap:DebtInstrumentInterestRateTerms id="Factid_1391344" contextRef="P08_01_2018To08_03_2018_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum.</us-gaap:DebtInstrumentInterestRateTerms>
<us-gaap:CommonStockSharesAuthorized id="Factid_1391345" contextRef="PAsOn08_07_2018_MaximumMembersrtRangeAxis_OmnibusEquityIncentivePlan2015MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="shares" decimals="0">3500000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized id="Factid_1391348" contextRef="PAsOn08_07_2018_OmnibusEquityIncentivePlan2015MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="shares" decimals="0">2500000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_1391547" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">75000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_1391549" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_1391551" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">75000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_1391553" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:Revenues id="Factid_1391554" contextRef="P04_01_2018To06_30_2018" unitRef="USD" decimals="-3">2668000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_1391556" contextRef="P04_01_2017To06_30_2017" unitRef="USD" decimals="-3">77000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_1391558" contextRef="P01_01_2018To06_30_2018" unitRef="USD" decimals="-3">3732000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_1391560" contextRef="P01_01_2017To06_30_2017" unitRef="USD" decimals="-3">117000</us-gaap:Revenues>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="EUR">
<xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="#Factid_1391011" xlink:type="locator" xlink:label="loc_1" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_5643">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.
</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_5643" order="1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391012" xlink:type="locator" xlink:label="loc_2" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5643" order="1" xlink:from="loc_2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391021" xlink:type="locator" xlink:label="loc_3" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5643" order="1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391022" xlink:type="locator" xlink:label="loc_4" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5643" order="1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391013" xlink:type="locator" xlink:label="loc_5" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_5644">Weighted average volatility is based on the historical volatility of our common stock.
</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_5644" order="1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391014" xlink:type="locator" xlink:label="loc_6" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5644" order="1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391023" xlink:type="locator" xlink:label="loc_7" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5644" order="1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391024" xlink:type="locator" xlink:label="loc_8" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5644" order="1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391015" xlink:type="locator" xlink:label="loc_9" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_5645">Estimated forfeiture rates are based on historical data.
</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_5645" order="1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391016" xlink:type="locator" xlink:label="loc_10" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5645" order="1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391025" xlink:type="locator" xlink:label="loc_11" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5645" order="1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_1391026" xlink:type="locator" xlink:label="loc_12" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_5645" order="1" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>ttnp-20180630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<schema targetNamespace="http://www.titanpharm.com/20180630" elementFormDefault="qualified" xmlns:ttnp="http://www.titanpharm.com/20180630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2018-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.titanpharm.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" id="CondensedStatementsOfOperationsAndComprehensiveIncomeLoss">
<link:definition>1003 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
<link:definition>1004 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1005 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlans" id="StockPlans">
<link:definition>1006 - Disclosure - Stock Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1007 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/ComprehensiveLoss" id="ComprehensiveLoss">
<link:definition>1008 - Disclosure - Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/BraeburnLicense" id="BraeburnLicense">
<link:definition>1009 - Disclosure - Braeburn License</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreement" id="MolteniPurchaseAgreement">
<link:definition>1010 - Disclosure - Molteni Purchase Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/WarrantLiability" id="WarrantLiability">
<link:definition>1011 - Disclosure - Warrant Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/DebtAgreements" id="DebtAgreements">
<link:definition>1012 - Disclosure - Debt Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/RightsAgreement" id="RightsAgreement">
<link:definition>1013 - Disclosure - Rights Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1014 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlansTables" id="StockPlansTables">
<link:definition>1016 - Disclosure - Stock Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1017 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementTables" id="MolteniPurchaseAgreementTables">
<link:definition>1018 - Disclosure - Molteni Purchase Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/DebtAgreementsTables" id="DebtAgreementsTables">
<link:definition>1019 - Disclosure - Debt Agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/RightsAgreementTables" id="RightsAgreementTables">
<link:definition>1020 - Disclosure - Rights Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>1021 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlansDetails" id="StockPlansDetails">
<link:definition>1022 - Disclosure - Stock Plans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlansDetails1" id="StockPlansDetails1">
<link:definition>1023 - Disclosure - Stock Plans (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlansDetails2" id="StockPlansDetails2">
<link:definition>1024 - Disclosure - Stock Plans (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/StockPlansDetailsTextual" id="StockPlansDetailsTextual">
<link:definition>1025 - Disclosure - Stock Plans (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
<link:definition>1026 - Disclosure - Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails1" id="NetLossPerShareDetails1">
<link:definition>1027 - Disclosure - Net Loss Per Share (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual" id="ComprehensiveLossDetailsTextual">
<link:definition>1028 - Disclosure - Comprehensive Loss (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual" id="BraeburnLicenseDetailsTextual">
<link:definition>1029 - Disclosure - Braeburn License (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails" id="MolteniPurchaseAgreementDetails">
<link:definition>1030 - Disclosure - Molteni Purchase Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual" id="MolteniPurchaseAgreementDetailsTextual">
<link:definition>1031 - Disclosure - Molteni Purchase Agreement (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual" id="WarrantLiabilityDetailsTextual">
<link:definition>1032 - Disclosure - Warrant Liability (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/DebtAgreementsDetails" id="DebtAgreementsDetails">
<link:definition>1033 - Disclosure - Debt Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/DebtAgreementsDetailsTextual" id="DebtAgreementsDetailsTextual">
<link:definition>1034 - Disclosure - Debt Agreements (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/RightsAgreementDetails" id="RightsAgreementDetails">
<link:definition>1035 - Disclosure - Rights Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/RightsAgreementDetailsTextual" id="RightsAgreementDetailsTextual">
<link:definition>1036 - Disclosure - Rights Agreement (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.titanpharm.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
<link:definition>1037 - Disclosure - Subsequent Events (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20180630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20180630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20180630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20180630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
<import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
<element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseRevenueNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_LicenseRevenueNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_WarrantsIssued" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAndCashEquivalentsAndRestrictedCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseRightsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_LicenseRightsDisclosureAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseRightsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_LicenseRightsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="PurchaseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_PurchaseAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="PurchaseAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_PurchaseAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilityDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_WarrantLiabilityDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="RightsAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_RightsAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="RightsAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_RightsAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="CompanyPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_CompanyPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GoingConcernAssessmentPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_GoingConcernAssessmentPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="HorizonWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_HorizonWarrantsMember" substitutionGroup="xbrli:item" />
<element name="NewHorizonWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_NewHorizonWarrantsMember" substitutionGroup="xbrli:item" />
<element name="MolteniWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_MolteniWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsUnrecognizedTaxBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WarrantExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_WarrantExpirationDate" substitutionGroup="xbrli:item" />
<element name="EstimatedForfeitureRatesForOptionsGrantedToManagement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" substitutionGroup="xbrli:item" />
<element name="ScheduleOfStockOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_ScheduleOfStockOptionsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" substitutionGroup="xbrli:item" />
<element name="IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ComprehensiveIncomeLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_ComprehensiveIncomeLossTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ComprehensiveIncomeLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_ComprehensiveIncomeLossLineItems" substitutionGroup="xbrli:item" />
<element name="NonRefundableUpFrontLicenseFeeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_NonRefundableUpFrontLicenseFeeTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="NonRefundableUpFrontLicenseFeeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_NonRefundableUpFrontLicenseFeeLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromExclusiveCommercializationRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_ProceedsFromExclusiveCommercializationRights" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseRevenue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_LicenseRevenue1" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PurchaseAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_PurchaseAgreementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PurchaseAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_PurchaseAgreementLineItems" substitutionGroup="xbrli:item" />
<element name="ContractWithCustomerAssetAdditions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_ContractWithCustomerAssetAdditions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractWithCustomerAssetDeductions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_ContractWithCustomerAssetDeductions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EstimatedSellingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ttnp_EstimatedSellingPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeriesWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_SeriesWarrantsMember" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_WarrantsToPurchaseCommonStockShares" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_FairValueAssumptionsRate" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsDateOfIssuance" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_FairValueAssumptionsDateOfIssuance" substitutionGroup="xbrli:item" />
<element name="WeightedAverageFairValueAssumptionsOfWarrants" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_WeightedAverageFairValueAssumptionsOfWarrants" substitutionGroup="xbrli:item" />
<element name="VentureLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_VentureLoanMember" substitutionGroup="xbrli:item" />
<element name="MolteniLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_MolteniLoanMember" substitutionGroup="xbrli:item" />
<element name="HorizonTechnologyFinanceCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_HorizonTechnologyFinanceCorporationMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" substitutionGroup="xbrli:item" />
<element name="ConversionOfDebtToEquityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ttnp_ConversionOfDebtToEquityDescription" substitutionGroup="xbrli:item" />
<element name="AmountReceivedUnderAmendmentToPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OmnibusEquityIncentivePlan2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ttnp_OmnibusEquityIncentivePlan2015Member" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>ttnp-20180630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedBalanceSheets" roleURI="http://www.titanpharm.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareDetails" roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xlink:label="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" use="optional" order="30" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenueNet" xlink:label="loc_TTNP_LicenseRevenueNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_TTNP_LicenseRevenueNet" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashExpense" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="60" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="70" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="90" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet" use="optional" order="100" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="110" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="10" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>ttnp-20180630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DocumentAndEntityInformation" roleURI="http://www.titanpharm.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedBalanceSheets" roleURI="http://www.titanpharm.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsTables" roleURI="http://www.titanpharm.com/role/DebtAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementTables" roleURI="http://www.titanpharm.com/role/RightsAgreementTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails" roleURI="http://www.titanpharm.com/role/StockPlansDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails1" roleURI="http://www.titanpharm.com/role/StockPlansDetails1" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails2" roleURI="http://www.titanpharm.com/role/StockPlansDetails2" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetailsTextual" roleURI="http://www.titanpharm.com/role/StockPlansDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareDetails" roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareDetails1" roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails1" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#ComprehensiveLossDetailsTextual" roleURI="http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#BraeburnLicenseDetailsTextual" roleURI="http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreementDetails" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreementDetailsTextual" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#WarrantLiabilityDetailsTextual" roleURI="http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsDetails" roleURI="http://www.titanpharm.com/role/DebtAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsDetailsTextual" roleURI="http://www.titanpharm.com/role/DebtAgreementsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementDetails" roleURI="http://www.titanpharm.com/role/RightsAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementDetailsTextual" roleURI="http://www.titanpharm.com/role/RightsAgreementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.titanpharm.com/role/SubsequentEventsDetailsTextual" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_187555" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_187558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentInformationTable_187558" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_187558" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187557" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187557" xlink:to="loc_us-gaap_ClassOfStockDomain_187556" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187556_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187557" xlink:to="loc_us-gaap_ClassOfStockDomain_187556_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentType_187411" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36" xlink:to="loc_us-gaap_AssetsAbstract_37" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_AssetsCurrentAbstract_38" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_217482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_217482" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_RestrictedCash_44" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_46" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_AssetsCurrent_47" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_228856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_InventoryNet_228856" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_48" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_Assets_49" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_Liabilities_57" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_CommitmentsAndContingencies_58" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_StockholdersEquityAbstract_41" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_CommonStockValue_59" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_AdditionalPaidInCapital_60" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_StockholdersEquity_62" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_63" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_56" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_51" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_DeferredRevenueCurrent_53" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_LongTermDebtCurrent_54" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_LiabilitiesCurrent_55" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableCurrent_50" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_36" xlink:to="loc_us-gaap_StatementTable_34" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35" xlink:to="loc_us-gaap_ClassOfStockDomain_42" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_42_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35" xlink:to="loc_us-gaap_ClassOfStockDomain_42_default" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_195" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_206" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_207" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_208" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_NetIncomeLoss_209" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_EarningsPerShareBasic_210" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_EarningsPerShareDiluted_211" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_212" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_213" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_StatementTable_193" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_193" xlink:to="loc_srt_ProductOrServiceAxis_194" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_194" xlink:to="loc_srt_ProductsAndServicesDomain_199" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_199_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_194" xlink:to="loc_srt_ProductsAndServicesDomain_199_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_RevenuesAbstract_196" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_229302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_229302" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenueNet" xlink:label="loc_ttnp_LicenseRevenueNet_229311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_ttnp_LicenseRevenueNet_229311" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_229329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_us-gaap_Revenues_229329" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_OperatingExpensesAbstract_197" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_OperatingIncomeLoss_205" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_202" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_203" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_OperatingExpenses_204" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_228860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_228860" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_365" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_StatementTable_363" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_363" xlink:to="loc_us-gaap_StatementClassOfStockAxis_364" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_364" xlink:to="loc_us-gaap_ClassOfStockDomain_372" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_372_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_364" xlink:to="loc_us-gaap_ClassOfStockDomain_372_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_382" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_NetIncomeLoss_373" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_374" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_OtherNoncashExpense_375" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_376" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_ShareBasedCompensation_377" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_379" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_380" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_381" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_378" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet_217496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet_217496" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_228864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_228864" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_386" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_387" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_388" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_389" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_383" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_384" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" xlink:to="loc_us-gaap_InterestPaidNet_391" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsIssued" xlink:label="loc_ttnp_WarrantsIssued_217497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" xlink:to="loc_ttnp_WarrantsIssued_217497" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_224098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_224098" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_224102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_224102" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_224184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_224184" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_StatementTable_66" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_67" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_68" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_68_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_68_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonWarrantsMember" xlink:label="loc_ttnp_HorizonWarrantsMember_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_68" xlink:to="loc_ttnp_HorizonWarrantsMember_70" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_68" xlink:to="loc_ttnp_NewHorizonWarrantsMember_71" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_79" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_79" xlink:to="loc_us-gaap_StatementTable_75" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76" xlink:to="loc_us-gaap_ClassOfStockDomain_80" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_80_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76" xlink:to="loc_us-gaap_ClassOfStockDomain_80_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_77" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_77" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_78" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_78_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_77" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_78_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_78" xlink:to="loc_ttnp_MolteniWarrantsMember_81" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_82" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_srt_RangeAxis_86" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_86" xlink:to="loc_srt_RangeMember_97" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_86" xlink:to="loc_srt_RangeMember_97_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_87" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_dei_LegalEntityAxis_87" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_87" xlink:to="loc_dei_EntityDomain_98" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_87" xlink:to="loc_dei_EntityDomain_98_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_TitleOfIndividualAxis_89" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_89" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_89" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_101" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_101_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_101_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_DebtInstrumentAxis_92" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_103" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_103_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_93" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_93" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_104" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_93" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_104_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_95" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_95_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_95_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_95" xlink:to="loc_us-gaap_NewAccountingPronouncementMember_105" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_106" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_107" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xlink:label="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit_108" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantExpirationDate" xlink:label="loc_ttnp_WarrantExpirationDate_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_ttnp_WarrantExpirationDate_109" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_118" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_113" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_114" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_114_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_114_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_114" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_116" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_114" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_117" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" xlink:to="loc_us-gaap_PlanNameAxis_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_122" xlink:to="loc_us-gaap_PlanNameDomain_124" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_124_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_122" xlink:to="loc_us-gaap_PlanNameDomain_124_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_125" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_126" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_127" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_128" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_129" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_145" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_146" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_147" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_148" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_149" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_139" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_141" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_142" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_143" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfStockOptionsTable" xlink:label="loc_ttnp_ScheduleOfStockOptionsTable_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_ttnp_ScheduleOfStockOptionsTable_132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable_132" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" xlink:to="loc_us-gaap_EmployeeStockOptionMember_137" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable_132" xlink:to="loc_us-gaap_AwardTypeAxis_135" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_155" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_156" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_150" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_152" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_153" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_154" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_171" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_172" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_AwardTypeAxis_161" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_PlanNameAxis_162" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_162" xlink:to="loc_us-gaap_PlanNameDomain_168" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_162" xlink:to="loc_us-gaap_PlanNameDomain_168_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" xlink:to="loc_us-gaap_EmployeeStockOptionMember_169" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_TitleOfIndividualAxis_160" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_160" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_160" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166_default" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_177" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_185" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions_186" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants_187" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_188" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" xlink:to="loc_us-gaap_EarningsPerShareDiluted_190" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" xlink:to="loc_us-gaap_EarningsPerShareBasic_189" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_NetIncomeLossAbstract_178" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_182" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xlink:label="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability_183" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_184" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_StatementTable_175" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_175" xlink:to="loc_us-gaap_StatementClassOfStockAxis_176" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_176" xlink:to="loc_us-gaap_ClassOfStockDomain_181" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_176" xlink:to="loc_us-gaap_ClassOfStockDomain_181_default" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_223" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_223_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_223_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_218" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_218" xlink:to="loc_us-gaap_EquityComponentDomain_219" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_218" xlink:to="loc_us-gaap_EquityComponentDomain_219_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219" xlink:to="loc_us-gaap_WarrantMember_224" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" xlink:to="loc_us-gaap_EmployeeStockOptionMember_225" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_226" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossLineItems" xlink:label="loc_ttnp_ComprehensiveIncomeLossLineItems_231" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossTable" xlink:label="loc_ttnp_ComprehensiveIncomeLossTable_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ttnp_ComprehensiveIncomeLossLineItems_231" xlink:to="loc_ttnp_ComprehensiveIncomeLossTable_229" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_ComprehensiveIncomeLossTable_229" xlink:to="loc_us-gaap_StatementClassOfStockAxis_230" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_230" xlink:to="loc_us-gaap_ClassOfStockDomain_232" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_230" xlink:to="loc_us-gaap_ClassOfStockDomain_232_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_ComprehensiveIncomeLossLineItems_231" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_233" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeLineItems" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeTable" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_us-gaap_TypeOfArrangementAxis_237" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_237" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_237" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_244" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_244_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_srt_RangeAxis_240" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_240" xlink:to="loc_srt_RangeMember_241" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_240" xlink:to="loc_srt_RangeMember_241_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ProceedsFromExclusiveCommercializationRights" xlink:label="loc_ttnp_ProceedsFromExclusiveCommercializationRights_223404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_ttnp_ProceedsFromExclusiveCommercializationRights_223404" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_228870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_us-gaap_InventoryNet_228870" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenue1" xlink:label="loc_ttnp_LicenseRevenue1_228871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_ttnp_LicenseRevenue1_228871" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementLineItems" xlink:label="loc_ttnp_PurchaseAgreementLineItems_217504" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTable" xlink:label="loc_ttnp_PurchaseAgreementTable_217503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_ttnp_PurchaseAgreementTable_217503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_PurchaseAgreementTable_217503" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217505" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217505" xlink:to="loc_us-gaap_ClassOfStockDomain_217506" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217506_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217505" xlink:to="loc_us-gaap_ClassOfStockDomain_217506_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_217507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_217507" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="loc_ttnp_ContractWithCustomerAssetAdditions_217508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_ttnp_ContractWithCustomerAssetAdditions_217508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="loc_ttnp_ContractWithCustomerAssetDeductions_217509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_ttnp_ContractWithCustomerAssetDeductions_217509" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_217511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenue_217511" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_217512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenueAdditions_217512" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_217513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_217513" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementLineItems" xlink:label="loc_ttnp_PurchaseAgreementLineItems_256" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTable" xlink:label="loc_ttnp_PurchaseAgreementTable_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_ttnp_PurchaseAgreementTable_254" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_255" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_257" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_257_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_217517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_ValuationTechniqueAxis_217517" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_217518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_217517" xlink:to="loc_us-gaap_ValuationTechniqueDomain_217518" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_217518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_217517" xlink:to="loc_us-gaap_ValuationTechniqueDomain_217518_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_217524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" xlink:to="loc_us-gaap_IntellectualPropertyMember_217524" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_258" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_260" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedSellingPrice" xlink:label="loc_ttnp_EstimatedSellingPrice_217515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_ttnp_EstimatedSellingPrice_217515" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_217516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_217516" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_263" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_264" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_265" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_265_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_SeriesWarrantsMember" xlink:label="loc_ttnp_SeriesWarrantsMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265" xlink:to="loc_ttnp_SeriesWarrantsMember_271" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_272_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_267" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_267" xlink:to="loc_us-gaap_EquityComponentDomain_273" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_273_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_267" xlink:to="loc_us-gaap_EquityComponentDomain_273_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_268" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_srt_RangeAxis_269" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_269" xlink:to="loc_srt_RangeMember_275" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_275_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_269" xlink:to="loc_srt_RangeMember_275_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsToPurchaseCommonStockShares" xlink:label="loc_ttnp_WarrantsToPurchaseCommonStockShares_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" xlink:to="loc_ttnp_WarrantsToPurchaseCommonStockShares_276" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_284" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xlink:label="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_284" xlink:to="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsRate" xlink:label="loc_ttnp_FairValueAssumptionsRate_223606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsRate_223606" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsTerm" xlink:label="loc_ttnp_FairValueAssumptionsTerm_223607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsTerm_223607" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsDateOfIssuance" xlink:label="loc_ttnp_FairValueAssumptionsDateOfIssuance_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsDateOfIssuance_289" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:label="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_294" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_284" xlink:to="loc_us-gaap_StatementTable_280" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_281" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_286" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_286_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_286_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_282" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_282" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_283" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_282" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_283_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonWarrantsMember" xlink:label="loc_ttnp_HorizonWarrantsMember_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_283" xlink:to="loc_ttnp_HorizonWarrantsMember_287" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_283" xlink:to="loc_ttnp_NewHorizonWarrantsMember_288" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223608" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223608" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223609" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223609_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223608" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223609_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_223610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_223610" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223611" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_223612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_223612" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223613" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_308" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xlink:label="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage_328" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarlyRepaymentOfSubordinatedDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt_331" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_LongTermDebt_332" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ConversionOfDebtToEquityDescription" xlink:label="loc_ttnp_ConversionOfDebtToEquityDescription_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_ttnp_ConversionOfDebtToEquityDescription_333" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt_334" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_318" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_319" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_320" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentTerm_321" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_325" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_298" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_298" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_309" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_298" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_309_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_299" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_300" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_300_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_SeriesWarrantsMember" xlink:label="loc_ttnp_SeriesWarrantsMember_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_300" xlink:to="loc_ttnp_SeriesWarrantsMember_310" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_300" xlink:to="loc_ttnp_NewHorizonWarrantsMember_311" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" xlink:to="loc_us-gaap_RelatedPartyDomain_312" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" xlink:to="loc_us-gaap_RelatedPartyDomain_312_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_srt_RangeAxis_302" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_302" xlink:to="loc_srt_RangeMember_303" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_303_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_302" xlink:to="loc_srt_RangeMember_303_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_303" xlink:to="loc_srt_MaximumMember_313" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_303" xlink:to="loc_srt_MinimumMember_314" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_DebtInstrumentAxis_304" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_304" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_305" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_305_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_304" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_305_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_VentureLoanMember" xlink:label="loc_ttnp_VentureLoanMember_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_305" xlink:to="loc_ttnp_VentureLoanMember_315" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniLoanMember" xlink:label="loc_ttnp_MolteniLoanMember_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_305" xlink:to="loc_ttnp_MolteniLoanMember_316" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_dei_LegalEntityAxis_306" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_306" xlink:to="loc_dei_EntityDomain_307" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_306" xlink:to="loc_dei_EntityDomain_307_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonTechnologyFinanceCorporationMember" xlink:label="loc_ttnp_HorizonTechnologyFinanceCorporationMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_307" xlink:to="loc_ttnp_HorizonTechnologyFinanceCorporationMember_317" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsRate" xlink:label="loc_ttnp_FairValueAssumptionsRate_223618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsRate_223618" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsTerm" xlink:label="loc_ttnp_FairValueAssumptionsTerm_223619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsTerm_223619" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsDateOfIssuance" xlink:label="loc_ttnp_FairValueAssumptionsDateOfIssuance_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsDateOfIssuance_344" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:label="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_349" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_us-gaap_StatementTable_337" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223620" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223620" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223621" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223621_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223620" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223621_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_223622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_223622" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223623" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_223624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_223624" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223625" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_StatementClassOfStockAxis_338" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_342" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_342_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_339" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_339" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_340" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_339" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_340_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340" xlink:to="loc_ttnp_MolteniWarrantsMember_343" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_356" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_356" xlink:to="loc_us-gaap_StatementTable_352" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_352" xlink:to="loc_us-gaap_StatementClassOfStockAxis_353" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353" xlink:to="loc_us-gaap_ClassOfStockDomain_357" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_357_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353" xlink:to="loc_us-gaap_ClassOfStockDomain_357_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_352" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_354" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_355" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_355_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_355_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_355" xlink:to="loc_ttnp_MolteniWarrantsMember_358" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_359" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/SubsequentEventsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_228885" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_228881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_SubsequentEventTable_228881" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_228882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_228882" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_228883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_228882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_228883" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_228883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_228882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_228883_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_228884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_228883" xlink:to="loc_us-gaap_SubsequentEventMember_228884" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_228895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_srt_CurrencyAxis_228895" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_228896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_228895" xlink:to="loc_currency_AllCurrenciesDomain_228896" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_228896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_228895" xlink:to="loc_currency_AllCurrenciesDomain_228896_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_228917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_228917" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_228918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_228917" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_228918" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_228918_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_228917" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_228918_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_228919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_228918" xlink:to="loc_us-gaap_ConvertibleDebtMember_228919" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_229233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_srt_RangeAxis_229233" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_229235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_229233" xlink:to="loc_srt_RangeMember_229235" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_229235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_229233" xlink:to="loc_srt_RangeMember_229235_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_229237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_229235" xlink:to="loc_srt_MaximumMember_229237" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_229248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_PlanNameAxis_229248" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_229249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_229248" xlink:to="loc_us-gaap_PlanNameDomain_229249" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_229249_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_229248" xlink:to="loc_us-gaap_PlanNameDomain_229249_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_OmnibusEquityIncentivePlan2015Member" xlink:label="loc_ttnp_OmnibusEquityIncentivePlan2015Member_229251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_229249" xlink:to="loc_ttnp_OmnibusEquityIncentivePlan2015Member_229251" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xlink:label="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement_228894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement_228894" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_228905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_ConvertibleDebt_228905" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMilestones_228906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMilestones_228906" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_228907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_228907" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_228908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_228908" use="optional" order="25" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>ttnp-20180630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DocumentAndEntityInformationAbstract" xlink:label="loc_ttnp_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_DocumentAndEntityInformationAbstract" xlink:to="lab_ttnp_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xml:lang="en-US">Contract with Customer, Asset, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xml:lang="en-US">Contract assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xml:lang="en-US">Contract with Customer, Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xml:lang="en-US">Contract with Customer, Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, at amounts paid-in</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued clinical trials expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other expense:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Non-cash gain on changes in the fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Non-cash gain on changes in fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Less change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares used in computing basic net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted-average outstanding common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares used in computing diluted net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares outstanding&#8212;diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Product revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenueNet" xlink:label="loc_ttnp_LicenseRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_LicenseRevenueNet" xml:lang="en-US">License Revenue Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_LicenseRevenueNet" xml:lang="en-US">License revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_LicenseRevenueNet" xlink:to="lab_ttnp_LicenseRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_LicenseRevenueNet" xml:lang="en-US">Revenue from multiple-deliverable arrangements that include licensing fees revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (loss) from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of goods sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Other Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Non-cash interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractReceivablesNet" xml:lang="en-US">Increase (Decrease) in Contract Receivables, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractReceivablesNet" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInContractReceivablesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Payments on long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of furniture and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsIssued" xlink:label="loc_ttnp_WarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_WarrantsIssued" xml:lang="en-US">Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_WarrantsIssued" xml:lang="en-US">Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_WarrantsIssued" xlink:to="lab_ttnp_WarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_WarrantsIssued" xml:lang="en-US">Warrants issued.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Schedule of non-cash transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:to="lab_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xml:lang="en-US">It represents the amount of cash and cash equivalents and restricted cash equivalents.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US">Share-based Compensation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Plans [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xml:lang="en-US">Comprehensive Loss Note [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRightsDisclosureAbstract" xlink:label="loc_ttnp_LicenseRightsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_LicenseRightsDisclosureAbstract" xml:lang="en-US">Braeburn License [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_LicenseRightsDisclosureAbstract" xlink:to="lab_ttnp_LicenseRightsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_LicenseRightsDisclosureAbstract" xml:lang="en-US">Braeburn license.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRightsDisclosureTextBlock" xlink:label="loc_ttnp_LicenseRightsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_LicenseRightsDisclosureTextBlock" xml:lang="en-US">License Rights Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_LicenseRightsDisclosureTextBlock" xml:lang="en-US">Braeburn License [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_LicenseRightsDisclosureTextBlock" xlink:to="lab_ttnp_LicenseRightsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_LicenseRightsDisclosureTextBlock" xml:lang="en-US">License rights disclosure.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementAbstract" xlink:label="loc_ttnp_PurchaseAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_PurchaseAgreementAbstract" xml:lang="en-US">Purchase Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_PurchaseAgreementAbstract" xlink:to="lab_ttnp_PurchaseAgreementAbstract" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTextBlock" xlink:label="loc_ttnp_PurchaseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_PurchaseAgreementTextBlock" xml:lang="en-US">Purchase Agreement [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_PurchaseAgreementTextBlock" xlink:to="lab_ttnp_PurchaseAgreementTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantLiabilityDisclosureTextBlock" xlink:label="loc_ttnp_WarrantLiabilityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_WarrantLiabilityDisclosureTextBlock" xml:lang="en-US">Warrant Liability Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_WarrantLiabilityDisclosureTextBlock" xlink:to="lab_ttnp_WarrantLiabilityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_WarrantLiabilityDisclosureTextBlock" xml:lang="en-US">Warrant liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementAbstract" xlink:label="loc_ttnp_RightsAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_RightsAgreementAbstract" xml:lang="en-US">Rights Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_RightsAgreementAbstract" xlink:to="lab_ttnp_RightsAgreementAbstract" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementTextBlock" xlink:label="loc_ttnp_RightsAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_RightsAgreementTextBlock" xml:lang="en-US">Rights Agreement [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_RightsAgreementTextBlock" xlink:to="lab_ttnp_RightsAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_RightsAgreementTextBlock" xml:lang="en-US">The disclosure of rights agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="loc_ttnp_CompanyPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_CompanyPolicyPolicyTextBlock" xml:lang="en-US">Company Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_CompanyPolicyPolicyTextBlock" xlink:to="lab_ttnp_CompanyPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_CompanyPolicyPolicyTextBlock" xml:lang="en-US">The company.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:label="loc_ttnp_GoingConcernAssessmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_GoingConcernAssessmentPolicyTextBlock" xml:lang="en-US">Going Concern Assessment [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:to="lab_ttnp_GoingConcernAssessmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_GoingConcernAssessmentPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for Going concern assessment</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonWarrantsMember" xlink:label="loc_ttnp_HorizonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_HorizonWarrantsMember" xml:lang="en-US">Horizon Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_HorizonWarrantsMember" xlink:to="lab_ttnp_HorizonWarrantsMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_NewHorizonWarrantsMember" xml:lang="en-US">New Horizon Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_NewHorizonWarrantsMember" xlink:to="lab_ttnp_NewHorizonWarrantsMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_MolteniWarrantsMember" xml:lang="en-US">Molteni Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_MolteniWarrantsMember" xlink:to="lab_ttnp_MolteniWarrantsMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Schedule of Organization and Summary of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Organization and summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xml:lang="en-US">Defined Benefit Plan, Asset Categories [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xml:lang="en-US">Plan Asset Categories [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementMember" xml:lang="en-US">Adjustments for New Accounting Pronouncement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementMember" xlink:to="lab_us-gaap_NewAccountingPronouncementMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Schedule of Organization and Summary of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Schedule of organization and summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xlink:label="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xml:lang="en-US">Deferred Tax Assets Unrecognized Tax Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xlink:to="lab_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xml:lang="en-US">The amount of unrecognized tax benefit recognized in deferred tax assets.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantExpirationDate" xlink:label="loc_ttnp_WarrantExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_WarrantExpirationDate" xml:lang="en-US">Warrant Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_WarrantExpirationDate" xlink:to="lab_ttnp_WarrantExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_WarrantExpirationDate" xml:lang="en-US">It represents the expiration date of warrant.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xml:lang="en-US">Schedule of Share-based Goods and Nonemployee Services Transaction [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Weighted-average risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xml:lang="en-US">Expected dividend payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected holding period (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Weighted-average volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xml:lang="en-US">Estimated Forfeiture Rates for Options Granted to Management</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xml:lang="en-US">Estimated forfeiture rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:to="lab_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xml:lang="en-US">Estimated forfeiture rates for options granted to management.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfStockOptionsTable" xlink:label="loc_ttnp_ScheduleOfStockOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ScheduleOfStockOptionsTable" xml:lang="en-US">Schedule of Stock Options [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable" xlink:to="lab_ttnp_ScheduleOfStockOptionsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options, Exercisable at June 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Beginning of Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at End of Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Options, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options, Cancelled or forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at June 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Cancelled or forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at June 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Option Term, Outstanding (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Option Term, Exercisable at June 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted-average period for recognizing non-vested stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xml:lang="en-US">Incremental Common Shares Attributable To Assumed Exercise Of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xml:lang="en-US">Effect of dilutive potential common shares resulting from options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xlink:to="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xml:lang="en-US">This element represents the number of incremental common shares attributable to assumed exercise of options.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xml:lang="en-US">Incremental Common Shares Attributable To Assumed Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xml:lang="en-US">Effect of dilutive potential common shares resulting from warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xlink:to="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xml:lang="en-US">Incremental common shares attributable to assumed exercise of warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net loss per common share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss used for basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xlink:label="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xml:lang="en-US">Amount Of Dilutive Securities, Fair Value Adjustment to warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xml:lang="en-US">Less change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xlink:to="lab_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xml:lang="en-US">Amount of Dilutive Securities, Fair Value Adjustment to warrant Liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss used for diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted-average anti-dilutive common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossTable" xlink:label="loc_ttnp_ComprehensiveIncomeLossTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ComprehensiveIncomeLossTable" xml:lang="en-US">Comprehensive Income Loss [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ComprehensiveIncomeLossTable" xlink:to="lab_ttnp_ComprehensiveIncomeLossTable" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossLineItems" xlink:label="loc_ttnp_ComprehensiveIncomeLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ComprehensiveIncomeLossLineItems" xml:lang="en-US">Comprehensive Income Loss [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_ComprehensiveIncomeLossLineItems" xml:lang="en-US">Comprehensive Loss [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ComprehensiveIncomeLossLineItems" xlink:to="lab_ttnp_ComprehensiveIncomeLossLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Loss, Net of Tax, Attributable to Parent, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeTable" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_NonRefundableUpFrontLicenseFeeTable" xml:lang="en-US">Non Refundable up Front License Fee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable" xlink:to="lab_ttnp_NonRefundableUpFrontLicenseFeeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_NonRefundableUpFrontLicenseFeeTable" xml:lang="en-US">Non Refundable up Front License Fee [Table]</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeLineItems" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_NonRefundableUpFrontLicenseFeeLineItems" xml:lang="en-US">Non Refundable up Front License Fee [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems" xlink:to="lab_ttnp_NonRefundableUpFrontLicenseFeeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_NonRefundableUpFrontLicenseFeeLineItems" xml:lang="en-US">Non refundable up front license fee.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ProceedsFromExclusiveCommercializationRights" xlink:label="loc_ttnp_ProceedsFromExclusiveCommercializationRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ProceedsFromExclusiveCommercializationRights" xml:lang="en-US">Proceeds from Exclusive Commercialization Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ProceedsFromExclusiveCommercializationRights" xlink:to="lab_ttnp_ProceedsFromExclusiveCommercializationRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ProceedsFromExclusiveCommercializationRights" xml:lang="en-US">Cash received for exclusive commercialization rights during the current period.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenue1" xlink:label="loc_ttnp_LicenseRevenue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_LicenseRevenue1" xml:lang="en-US">License Revenue 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_LicenseRevenue1" xml:lang="en-US">License Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_LicenseRevenue1" xlink:to="lab_ttnp_LicenseRevenue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_LicenseRevenue1" xml:lang="en-US">Amount of license revenue realised from Termination and Transition Services Agreement during the year.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTable" xlink:label="loc_ttnp_PurchaseAgreementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_PurchaseAgreementTable" xml:lang="en-US">Purchase Agreement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_PurchaseAgreementTable" xlink:to="lab_ttnp_PurchaseAgreementTable" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementLineItems" xlink:label="loc_ttnp_PurchaseAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_PurchaseAgreementLineItems" xml:lang="en-US">Purchase Agreement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_PurchaseAgreementLineItems" xlink:to="lab_ttnp_PurchaseAgreementLineItems" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="loc_ttnp_ContractWithCustomerAssetAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ContractWithCustomerAssetAdditions" xml:lang="en-US">Contract With Customer Asset Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_ContractWithCustomerAssetAdditions" xml:lang="en-US">Contract with Customer, Asset additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ContractWithCustomerAssetAdditions" xlink:to="lab_ttnp_ContractWithCustomerAssetAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ContractWithCustomerAssetAdditions" xml:lang="en-US">The amount of increase in contract assets.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="loc_ttnp_ContractWithCustomerAssetDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ContractWithCustomerAssetDeductions" xml:lang="en-US">Contract With Customer Asset Deductions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_ContractWithCustomerAssetDeductions" xml:lang="en-US">Contract with Customer, Asset Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ContractWithCustomerAssetDeductions" xlink:to="lab_ttnp_ContractWithCustomerAssetDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ContractWithCustomerAssetDeductions" xml:lang="en-US">The amount of decrease in contract assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueAdditions" xml:lang="en-US">Deferred Revenue, Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAdditions" xlink:to="lab_us-gaap_DeferredRevenueAdditions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xml:lang="en-US">Deferred Revenue, Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US">Proceeds from Sale of Productive Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodDescription" xml:lang="en-US">Revenue Recognition, Milestone Method, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodDescription" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedSellingPrice" xlink:label="loc_ttnp_EstimatedSellingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_EstimatedSellingPrice" xml:lang="en-US">Estimated Selling Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_EstimatedSellingPrice" xlink:to="lab_ttnp_EstimatedSellingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_EstimatedSellingPrice" xml:lang="en-US">The value of estimated selling price.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xml:lang="en-US">Finite-Lived Intangible Assets, Translation and Purchase Accounting Adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_SeriesWarrantsMember" xlink:label="loc_ttnp_SeriesWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_SeriesWarrantsMember" xml:lang="en-US">Series Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_SeriesWarrantsMember" xml:lang="en-US">Series A Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_SeriesWarrantsMember" xlink:to="lab_ttnp_SeriesWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_SeriesWarrantsMember" xml:lang="en-US">Series A Warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsToPurchaseCommonStockShares" xlink:label="loc_ttnp_WarrantsToPurchaseCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_WarrantsToPurchaseCommonStockShares" xml:lang="en-US">Warrants To Purchase Common Stock Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_WarrantsToPurchaseCommonStockShares" xlink:to="lab_ttnp_WarrantsToPurchaseCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_WarrantsToPurchaseCommonStockShares" xml:lang="en-US">This element represents the number of warrants issued to purchase common stock shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xlink:label="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xml:lang="en-US">Fair Value Assumptions Of Assets And Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xlink:to="lab_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xml:lang="en-US">Fair Value Assumptions Of Assets And Liabilities</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsRate" xlink:label="loc_ttnp_FairValueAssumptionsRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_FairValueAssumptionsRate" xml:lang="en-US">Fair Value Assumptions Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_FairValueAssumptionsRate" xlink:to="lab_ttnp_FairValueAssumptionsRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_FairValueAssumptionsRate" xml:lang="en-US">Fair value assumption rate for warrants.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsTerm" xlink:label="loc_ttnp_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_FairValueAssumptionsTerm" xml:lang="en-US">Fair Value Assumptions Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_FairValueAssumptionsTerm" xlink:to="lab_ttnp_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_FairValueAssumptionsTerm" xml:lang="en-US">Expected term of warrants.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsDateOfIssuance" xlink:label="loc_ttnp_FairValueAssumptionsDateOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_FairValueAssumptionsDateOfIssuance" xml:lang="en-US">Fair Value Assumptions, Date of Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ttnp_FairValueAssumptionsDateOfIssuance" xml:lang="en-US">Date of issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_FairValueAssumptionsDateOfIssuance" xlink:to="lab_ttnp_FairValueAssumptionsDateOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_FairValueAssumptionsDateOfIssuance" xml:lang="en-US">The date of issuance relating to fair value assumptions.</label>
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:label="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xml:lang="en-US">Weighted Average Fair Value Assumptions of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xml:lang="en-US">Weighted-average fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xml:lang="en-US">Weighted-average fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:to="lab_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xml:lang="en-US">Weighted-average fair value assumptions of warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_VentureLoanMember" xlink:label="loc_ttnp_VentureLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_VentureLoanMember" xml:lang="en-US">Venture Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_VentureLoanMember" xlink:to="lab_ttnp_VentureLoanMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniLoanMember" xlink:label="loc_ttnp_MolteniLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_MolteniLoanMember" xml:lang="en-US">Molteni Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_MolteniLoanMember" xlink:to="lab_ttnp_MolteniLoanMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonTechnologyFinanceCorporationMember" xlink:label="loc_ttnp_HorizonTechnologyFinanceCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_HorizonTechnologyFinanceCorporationMember" xml:lang="en-US">Horizon Technology Finance Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_HorizonTechnologyFinanceCorporationMember" xlink:to="lab_ttnp_HorizonTechnologyFinanceCorporationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xlink:label="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xml:lang="en-US">Debt Instrument, Final Payment on Each Loan Tranche,Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xlink:to="lab_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xml:lang="en-US">Represents the percentage rate of final payment on each loan tranche.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarlyRepaymentOfSubordinatedDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarlyRepaymentOfSubordinatedDebt" xml:lang="en-US">Early Repayment of Subordinated Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt" xlink:to="lab_us-gaap_EarlyRepaymentOfSubordinatedDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ConversionOfDebtToEquityDescription" xlink:label="loc_ttnp_ConversionOfDebtToEquityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_ConversionOfDebtToEquityDescription" xml:lang="en-US">Conversion of Debt to Equity Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_ConversionOfDebtToEquityDescription" xlink:to="lab_ttnp_ConversionOfDebtToEquityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_ConversionOfDebtToEquityDescription" xml:lang="en-US">The description of effect of conversion of debt to equity during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSubordinatedShortTermDebt" xml:lang="en-US">Proceeds from Subordinated Short-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromSubordinatedShortTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xlink:label="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xml:lang="en-US">Amount Received Under Amendment To Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xlink:to="lab_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xml:lang="en-US">Amount received on behalf of amendment to purchase agreement from Molteni.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentMilestones" xml:lang="en-US">Long-term Purchase Commitment, Milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentMilestones" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateTerms" xlink:to="lab_us-gaap_DebtInstrumentInterestRateTerms" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_OmnibusEquityIncentivePlan2015Member" xlink:label="loc_ttnp_OmnibusEquityIncentivePlan2015Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ttnp_OmnibusEquityIncentivePlan2015Member" xml:lang="en-US">Omnibus Equity Incentive Plan 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ttnp_OmnibusEquityIncentivePlan2015Member" xml:lang="en-US">2015 Omnibus Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ttnp_OmnibusEquityIncentivePlan2015Member" xlink:to="lab_ttnp_OmnibusEquityIncentivePlan2015Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ttnp_OmnibusEquityIncentivePlan2015Member" xml:lang="en-US">2015 Omnibus Equity Incentive Plan .</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>ttnp-20180630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 11-August-2018 [04:06:29] {PM} EST - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DocumentAndEntityInformation" roleURI="http://www.titanpharm.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedBalanceSheets" roleURI="http://www.titanpharm.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlans" roleURI="http://www.titanpharm.com/role/StockPlans" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShare" roleURI="http://www.titanpharm.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#ComprehensiveLoss" roleURI="http://www.titanpharm.com/role/ComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#BraeburnLicense" roleURI="http://www.titanpharm.com/role/BraeburnLicense" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreement" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreement" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#WarrantLiability" roleURI="http://www.titanpharm.com/role/WarrantLiability" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreements" roleURI="http://www.titanpharm.com/role/DebtAgreements" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreement" roleURI="http://www.titanpharm.com/role/RightsAgreement" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#SubsequentEvents" roleURI="http://www.titanpharm.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansTables" roleURI="http://www.titanpharm.com/role/StockPlansTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareTables" roleURI="http://www.titanpharm.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreementTables" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsTables" roleURI="http://www.titanpharm.com/role/DebtAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementTables" roleURI="http://www.titanpharm.com/role/RightsAgreementTables" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails" roleURI="http://www.titanpharm.com/role/StockPlansDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails1" roleURI="http://www.titanpharm.com/role/StockPlansDetails1" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetails2" roleURI="http://www.titanpharm.com/role/StockPlansDetails2" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#StockPlansDetailsTextual" roleURI="http://www.titanpharm.com/role/StockPlansDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareDetails" roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#NetLossPerShareDetails1" roleURI="http://www.titanpharm.com/role/NetLossPerShareDetails1" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#ComprehensiveLossDetailsTextual" roleURI="http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#BraeburnLicenseDetailsTextual" roleURI="http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreementDetails" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#MolteniPurchaseAgreementDetailsTextual" roleURI="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#WarrantLiabilityDetailsTextual" roleURI="http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsDetails" roleURI="http://www.titanpharm.com/role/DebtAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#DebtAgreementsDetailsTextual" roleURI="http://www.titanpharm.com/role/DebtAgreementsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementDetails" roleURI="http://www.titanpharm.com/role/RightsAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#RightsAgreementDetailsTextual" roleURI="http://www.titanpharm.com/role/RightsAgreementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="ttnp-20180630.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.titanpharm.com/role/SubsequentEventsDetailsTextual" />
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DocumentAndEntityInformationAbstract" xlink:label="loc_ttnp_DocumentAndEntityInformationAbstract_187559" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_187558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_DocumentAndEntityInformationAbstract_187559" xlink:to="loc_dei_DocumentInformationTable_187558" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_187558" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187557" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187557" xlink:to="loc_us-gaap_ClassOfStockDomain_187556" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_187555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_187558" xlink:to="loc_dei_DocumentInformationLineItems_187555" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentType_187411" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187555" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33" xlink:to="loc_us-gaap_StatementTable_34" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35" xlink:to="loc_us-gaap_ClassOfStockDomain_42" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementLineItems_36" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36" xlink:to="loc_us-gaap_AssetsAbstract_37" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_AssetsCurrentAbstract_38" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_RestrictedCash_44" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_228856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_InventoryNet_228856" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_217482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_217482" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_46" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38" xlink:to="loc_us-gaap_AssetsCurrent_47" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_48" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_37" xlink:to="loc_us-gaap_Assets_49" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableCurrent_50" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_51" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_DeferredRevenueCurrent_53" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_LongTermDebtCurrent_54" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_LiabilitiesCurrent_55" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_56" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_Liabilities_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_CommitmentsAndContingencies_58" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_StockholdersEquityAbstract_41" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_CommonStockValue_59" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_AdditionalPaidInCapital_60" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_StockholdersEquity_62" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_63" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_192" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_192" xlink:to="loc_us-gaap_StatementTable_193" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_193" xlink:to="loc_srt_ProductOrServiceAxis_194" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_194" xlink:to="loc_srt_ProductsAndServicesDomain_199" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_193" xlink:to="loc_us-gaap_StatementLineItems_195" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_RevenuesAbstract_196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenueNet" xlink:label="loc_ttnp_LicenseRevenueNet_229311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_ttnp_LicenseRevenueNet_229311" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_229302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_229302" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_229329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_196" xlink:to="loc_us-gaap_Revenues_229329" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_OperatingExpensesAbstract_197" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_228860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_228860" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_202" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_203" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_OperatingExpenses_204" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_197" xlink:to="loc_us-gaap_OperatingIncomeLoss_205" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_206" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_207" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_198" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_208" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_NetIncomeLoss_209" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_EarningsPerShareBasic_210" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_EarningsPerShareDiluted_211" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_212" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_213" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_362" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_362" xlink:to="loc_us-gaap_StatementTable_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_363" xlink:to="loc_us-gaap_StatementClassOfStockAxis_364" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_364" xlink:to="loc_us-gaap_ClassOfStockDomain_372" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_363" xlink:to="loc_us-gaap_StatementLineItems_365" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_NetIncomeLoss_373" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_374" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_OtherNoncashExpense_375" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_376" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_ShareBasedCompensation_377" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_367" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_378" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_228864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_228864" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet_217496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInContractReceivablesNet_217496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_379" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_380" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_368" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_381" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_366" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_382" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_383" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_369" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_384" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_386" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_370" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_387" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_388" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_389" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_390" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" xlink:to="loc_us-gaap_InterestPaidNet_391" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsIssued" xlink:label="loc_ttnp_WarrantsIssued_217497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_371" xlink:to="loc_ttnp_WarrantsIssued_217497" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_224098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_224098" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_224102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_224102" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_224184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_224097" xlink:to="loc_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_224184" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_394" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_397" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_397" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_398" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_400" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_400" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/ComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_403" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_403" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_404" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/BraeburnLicense">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRightsDisclosureAbstract" xlink:label="loc_ttnp_LicenseRightsDisclosureAbstract_406" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRightsDisclosureTextBlock" xlink:label="loc_ttnp_LicenseRightsDisclosureTextBlock_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_LicenseRightsDisclosureAbstract_406" xlink:to="loc_ttnp_LicenseRightsDisclosureTextBlock_407" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreement">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementAbstract" xlink:label="loc_ttnp_PurchaseAgreementAbstract_2" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTextBlock" xlink:label="loc_ttnp_PurchaseAgreementTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementAbstract_2" xlink:to="loc_ttnp_PurchaseAgreementTextBlock_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/WarrantLiability">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_5" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantLiabilityDisclosureTextBlock" xlink:label="loc_ttnp_WarrantLiabilityDisclosureTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_5" xlink:to="loc_ttnp_WarrantLiabilityDisclosureTextBlock_6" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreement">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementAbstract" xlink:label="loc_ttnp_RightsAgreementAbstract_11" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementTextBlock" xlink:label="loc_ttnp_RightsAgreementTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_RightsAgreementAbstract_11" xlink:to="loc_ttnp_RightsAgreementTextBlock_12" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_223402" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_223403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_223402" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_223403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="loc_ttnp_CompanyPolicyPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_ttnp_CompanyPolicyPolicyTextBlock_15" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:label="loc_ttnp_GoingConcernAssessmentPolicyTextBlock_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_ttnp_GoingConcernAssessmentPolicyTextBlock_17" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_19" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_21" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_22" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_24" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_26" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_27" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_30" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_31" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreementTables">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementAbstract" xlink:label="loc_ttnp_PurchaseAgreementAbstract_223392" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_223393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementAbstract_223392" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_223393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65" xlink:to="loc_us-gaap_StatementTable_66" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_67" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_68" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonWarrantsMember" xlink:label="loc_ttnp_HorizonWarrantsMember_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_68" xlink:to="loc_ttnp_HorizonWarrantsMember_70" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_68" xlink:to="loc_ttnp_NewHorizonWarrantsMember_71" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_StatementLineItems_69" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementTables">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementAbstract" xlink:label="loc_ttnp_RightsAgreementAbstract_74" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_RightsAgreementAbstract_74" xlink:to="loc_us-gaap_StatementTable_75" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76" xlink:to="loc_us-gaap_ClassOfStockDomain_80" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_77" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_77" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_78" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_78" xlink:to="loc_ttnp_MolteniWarrantsMember_81" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75" xlink:to="loc_us-gaap_StatementLineItems_79" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_82" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84" xlink:to="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_srt_RangeAxis_86" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_86" xlink:to="loc_srt_RangeMember_97" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_dei_LegalEntityAxis_87" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_87" xlink:to="loc_dei_EntityDomain_98" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_TitleOfIndividualAxis_89" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_89" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_100" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_90" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_101" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_102" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_DebtInstrumentAxis_92" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_103" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_93" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_93" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_104" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_95" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_95" xlink:to="loc_us-gaap_NewAccountingPronouncementMember_105" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_85" xlink:to="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_106" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_107" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit" xlink:label="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit_108" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantExpirationDate" xlink:label="loc_ttnp_WarrantExpirationDate_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_96" xlink:to="loc_ttnp_WarrantExpirationDate_109" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_111" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_113" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_114" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_116" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_114" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_117" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_112" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_115" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_118" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_120" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_120" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" xlink:to="loc_us-gaap_PlanNameAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_122" xlink:to="loc_us-gaap_PlanNameDomain_124" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_121" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_125" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_126" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_123" xlink:to="loc_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_129" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_131" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ScheduleOfStockOptionsTable" xlink:label="loc_ttnp_ScheduleOfStockOptionsTable_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_131" xlink:to="loc_ttnp_ScheduleOfStockOptionsTable_132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable_132" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_134" xlink:to="loc_us-gaap_EmployeeStockOptionMember_137" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable_132" xlink:to="loc_us-gaap_AwardTypeAxis_135" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ScheduleOfStockOptionsTable_132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_139" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_141" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_142" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_143" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_144" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_145" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_146" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_147" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_148" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_149" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_150" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_151" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_152" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_153" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_154" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_155" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_136" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_156" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/StockPlansDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_158" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_158" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_TitleOfIndividualAxis_160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_160" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_166" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_AwardTypeAxis_161" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_PlanNameAxis_162" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_162" xlink:to="loc_us-gaap_PlanNameDomain_168" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_163" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_164" xlink:to="loc_us-gaap_EmployeeStockOptionMember_169" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_159" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_172" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_174" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_174" xlink:to="loc_us-gaap_StatementTable_175" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_175" xlink:to="loc_us-gaap_StatementClassOfStockAxis_176" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_176" xlink:to="loc_us-gaap_ClassOfStockDomain_181" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_175" xlink:to="loc_us-gaap_StatementLineItems_177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_NetIncomeLossAbstract_178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_182" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability" xlink:label="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability_183" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_178" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_185" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions_186" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants" xlink:label="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants_187" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_179" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_188" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_177" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" xlink:to="loc_us-gaap_EarningsPerShareBasic_189" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_180" xlink:to="loc_us-gaap_EarningsPerShareDiluted_190" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/NetLossPerShareDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_215" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_215" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_223" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_218" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_218" xlink:to="loc_us-gaap_EquityComponentDomain_219" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219" xlink:to="loc_us-gaap_WarrantMember_224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_220" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_221" xlink:to="loc_us-gaap_EmployeeStockOptionMember_225" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_216" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_222" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_226" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_228" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossTable" xlink:label="loc_ttnp_ComprehensiveIncomeLossTable_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_228" xlink:to="loc_ttnp_ComprehensiveIncomeLossTable_229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ComprehensiveIncomeLossTable_229" xlink:to="loc_us-gaap_StatementClassOfStockAxis_230" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_230" xlink:to="loc_us-gaap_ClassOfStockDomain_232" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ComprehensiveIncomeLossLineItems" xlink:label="loc_ttnp_ComprehensiveIncomeLossLineItems_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ComprehensiveIncomeLossTable_229" xlink:to="loc_ttnp_ComprehensiveIncomeLossLineItems_231" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_ComprehensiveIncomeLossLineItems_231" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_233" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRightsDisclosureAbstract" xlink:label="loc_ttnp_LicenseRightsDisclosureAbstract_235" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeTable" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_LicenseRightsDisclosureAbstract_235" xlink:to="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_us-gaap_TypeOfArrangementAxis_237" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_237" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_238" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_244" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_srt_RangeAxis_240" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_240" xlink:to="loc_srt_RangeMember_241" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NonRefundableUpFrontLicenseFeeLineItems" xlink:label="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeTable_236" xlink:to="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ProceedsFromExclusiveCommercializationRights" xlink:label="loc_ttnp_ProceedsFromExclusiveCommercializationRights_223404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_ttnp_ProceedsFromExclusiveCommercializationRights_223404" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_228870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_us-gaap_InventoryNet_228870" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_LicenseRevenue1" xlink:label="loc_ttnp_LicenseRevenue1_228871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_NonRefundableUpFrontLicenseFeeLineItems_242" xlink:to="loc_ttnp_LicenseRevenue1_228871" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementAbstract" xlink:label="loc_ttnp_PurchaseAgreementAbstract_217502" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTable" xlink:label="loc_ttnp_PurchaseAgreementTable_217503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementAbstract_217502" xlink:to="loc_ttnp_PurchaseAgreementTable_217503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_217503" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217505" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217505" xlink:to="loc_us-gaap_ClassOfStockDomain_217506" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementLineItems" xlink:label="loc_ttnp_PurchaseAgreementLineItems_217504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_217503" xlink:to="loc_ttnp_PurchaseAgreementLineItems_217504" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_217507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_217507" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="loc_ttnp_ContractWithCustomerAssetAdditions_217508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_ttnp_ContractWithCustomerAssetAdditions_217508" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="loc_ttnp_ContractWithCustomerAssetDeductions_217509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_ttnp_ContractWithCustomerAssetDeductions_217509" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_217510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_217510" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_217511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenue_217511" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_217512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenueAdditions_217512" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_217513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_217513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_217514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_217504" xlink:to="loc_us-gaap_DeferredRevenue_217514" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementAbstract" xlink:label="loc_ttnp_PurchaseAgreementAbstract_253" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementTable" xlink:label="loc_ttnp_PurchaseAgreementTable_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementAbstract_253" xlink:to="loc_ttnp_PurchaseAgreementTable_254" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_255" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_217517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_ValuationTechniqueAxis_217517" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_217518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_217517" xlink:to="loc_us-gaap_ValuationTechniqueDomain_217518" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_217521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_217524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_217522" xlink:to="loc_us-gaap_IntellectualPropertyMember_217524" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_PurchaseAgreementLineItems" xlink:label="loc_ttnp_PurchaseAgreementLineItems_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementTable_254" xlink:to="loc_ttnp_PurchaseAgreementLineItems_256" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_258" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_260" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_EstimatedSellingPrice" xlink:label="loc_ttnp_EstimatedSellingPrice_217515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_ttnp_EstimatedSellingPrice_217515" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_217516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_PurchaseAgreementLineItems_256" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_217516" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_262" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_262" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_263" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_264" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_265" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_SeriesWarrantsMember" xlink:label="loc_ttnp_SeriesWarrantsMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265" xlink:to="loc_ttnp_SeriesWarrantsMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_267" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_267" xlink:to="loc_us-gaap_EquityComponentDomain_273" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_268" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_srt_RangeAxis_269" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_269" xlink:to="loc_srt_RangeMember_275" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_263" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WarrantsToPurchaseCommonStockShares" xlink:label="loc_ttnp_WarrantsToPurchaseCommonStockShares_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" xlink:to="loc_ttnp_WarrantsToPurchaseCommonStockShares_276" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_279" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_279" xlink:to="loc_us-gaap_StatementTable_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_281" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_286" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_282" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_282" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_283" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonWarrantsMember" xlink:label="loc_ttnp_HorizonWarrantsMember_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_283" xlink:to="loc_ttnp_HorizonWarrantsMember_287" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_283" xlink:to="loc_ttnp_NewHorizonWarrantsMember_288" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223608" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223608" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223609" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_223610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_223610" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_223612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_223612" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223611" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223609" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223613" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_280" xlink:to="loc_us-gaap_StatementLineItems_284" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract" xlink:label="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_284" xlink:to="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsDateOfIssuance" xlink:label="loc_ttnp_FairValueAssumptionsDateOfIssuance_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsDateOfIssuance_289" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsRate" xlink:label="loc_ttnp_FairValueAssumptionsRate_223606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsRate_223606" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsTerm" xlink:label="loc_ttnp_FairValueAssumptionsTerm_223607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_FairValueAssumptionsTerm_223607" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:label="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract_223599" xlink:to="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_294" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/DebtAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_296" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_296" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_297" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_298" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_298" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_309" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_299" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_300" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_SeriesWarrantsMember" xlink:label="loc_ttnp_SeriesWarrantsMember_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_300" xlink:to="loc_ttnp_SeriesWarrantsMember_310" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_NewHorizonWarrantsMember" xlink:label="loc_ttnp_NewHorizonWarrantsMember_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_300" xlink:to="loc_ttnp_NewHorizonWarrantsMember_311" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_301" xlink:to="loc_us-gaap_RelatedPartyDomain_312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_srt_RangeAxis_302" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_302" xlink:to="loc_srt_RangeMember_303" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_303" xlink:to="loc_srt_MaximumMember_313" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_303" xlink:to="loc_srt_MinimumMember_314" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_DebtInstrumentAxis_304" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_304" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_305" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_VentureLoanMember" xlink:label="loc_ttnp_VentureLoanMember_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_305" xlink:to="loc_ttnp_VentureLoanMember_315" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniLoanMember" xlink:label="loc_ttnp_MolteniLoanMember_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_305" xlink:to="loc_ttnp_MolteniLoanMember_316" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_dei_LegalEntityAxis_306" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_306" xlink:to="loc_dei_EntityDomain_307" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_HorizonTechnologyFinanceCorporationMember" xlink:label="loc_ttnp_HorizonTechnologyFinanceCorporationMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_307" xlink:to="loc_ttnp_HorizonTechnologyFinanceCorporationMember_317" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_297" xlink:to="loc_us-gaap_DebtInstrumentLineItems_308" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_318" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_319" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_320" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_DebtInstrumentTerm_321" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_325" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage" xlink:label="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage_328" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarlyRepaymentOfSubordinatedDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_EarlyRepaymentOfSubordinatedDebt_331" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_LongTermDebt_332" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_ConversionOfDebtToEquityDescription" xlink:label="loc_ttnp_ConversionOfDebtToEquityDescription_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_ttnp_ConversionOfDebtToEquityDescription_333" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_308" xlink:to="loc_us-gaap_ProceedsFromSubordinatedShortTermDebt_334" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementDetails">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementAbstract" xlink:label="loc_ttnp_RightsAgreementAbstract_336" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_RightsAgreementAbstract_336" xlink:to="loc_us-gaap_StatementTable_337" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_StatementClassOfStockAxis_338" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_342" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_339" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_339" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_340" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340" xlink:to="loc_ttnp_MolteniWarrantsMember_343" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223620" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223620" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223621" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_223622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_223622" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_223624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_223624" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_223623" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_223621" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_223625" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_337" xlink:to="loc_us-gaap_StatementLineItems_341" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsDateOfIssuance" xlink:label="loc_ttnp_FairValueAssumptionsDateOfIssuance_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsDateOfIssuance_344" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsRate" xlink:label="loc_ttnp_FairValueAssumptionsRate_223618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsRate_223618" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_FairValueAssumptionsTerm" xlink:label="loc_ttnp_FairValueAssumptionsTerm_223619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_FairValueAssumptionsTerm_223619" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_WeightedAverageFairValueAssumptionsOfWarrants" xlink:label="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_ttnp_WeightedAverageFairValueAssumptionsOfWarrants_349" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/RightsAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_RightsAgreementAbstract" xlink:label="loc_ttnp_RightsAgreementAbstract_351" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnp_RightsAgreementAbstract_351" xlink:to="loc_us-gaap_StatementTable_352" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_352" xlink:to="loc_us-gaap_StatementClassOfStockAxis_353" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353" xlink:to="loc_us-gaap_ClassOfStockDomain_357" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_352" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_354" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_355" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_MolteniWarrantsMember" xlink:label="loc_ttnp_MolteniWarrantsMember_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_355" xlink:to="loc_ttnp_MolteniWarrantsMember_358" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_352" xlink:to="loc_us-gaap_StatementLineItems_356" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_359" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.titanpharm.com/role/SubsequentEventsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_228878" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_228881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_228878" xlink:to="loc_us-gaap_SubsequentEventTable_228881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_228882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_228882" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_228883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_228882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_228883" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_228884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_228883" xlink:to="loc_us-gaap_SubsequentEventMember_228884" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_228895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_srt_CurrencyAxis_228895" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_228896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_228895" xlink:to="loc_currency_AllCurrenciesDomain_228896" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_228917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_228917" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_228918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_228917" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_228918" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_228919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_228918" xlink:to="loc_us-gaap_ConvertibleDebtMember_228919" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_229233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_srt_RangeAxis_229233" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_229235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_229233" xlink:to="loc_srt_RangeMember_229235" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_229237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_229235" xlink:to="loc_srt_MaximumMember_229237" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_229248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_PlanNameAxis_229248" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_229249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_229248" xlink:to="loc_us-gaap_PlanNameDomain_229249" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_OmnibusEquityIncentivePlan2015Member" xlink:label="loc_ttnp_OmnibusEquityIncentivePlan2015Member_229251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_229249" xlink:to="loc_ttnp_OmnibusEquityIncentivePlan2015Member_229251" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_228885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_228881" xlink:to="loc_us-gaap_SubsequentEventLineItems_228885" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="ttnp-20180630.xsd#ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement" xlink:label="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement_228894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement_228894" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_228905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_ConvertibleDebt_228905" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMilestones_228906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMilestones_228906" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_228907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_228907" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_228908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_228885" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_228908" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768049888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Aug. 10, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TITAN PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TTNP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,203,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768475936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 7,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Contract assets</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">8,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="nump">8,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued clinical trials expenses</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,389<span></span>
</td>
<td class="nump">4,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="nump">3,541<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,930<span></span>
</td>
<td class="nump">8,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, at amounts paid-in</a></td>
<td class="nump">297,855<span></span>
</td>
<td class="nump">297,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">27,577<span></span>
</td>
<td class="nump">26,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(326,745)<span></span>
</td>
<td class="num">(323,271)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(1,313)<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 4,617<span></span>
</td>
<td class="nump">$ 8,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768582960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_LicenseRevenueNet', window );">License revenue</a></td>
<td class="nump">$ 2,593<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 3,657<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,307<span></span>
</td>
<td class="nump">3,698<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">7,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(639)<span></span>
</td>
<td class="num">(3,621)<span></span>
</td>
<td class="num">(3,046)<span></span>
</td>
<td class="num">(7,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Non-cash gain on changes in the fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(230)<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (3,451)<span></span>
</td>
<td class="num">$ (3,474)<span></span>
</td>
<td class="num">$ (6,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per common share</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per common share</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_LicenseRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_LicenseRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769002240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (3,451)<span></span>
</td>
<td class="num">$ (3,474)<span></span>
</td>
<td class="num">$ (6,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Non-cash gain on changes in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractReceivablesNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(2,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,855)<span></span>
</td>
<td class="num">(5,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,908)<span></span>
</td>
<td class="num">(5,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,883<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 8,350<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 8,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of cash and cash equivalents and restricted cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables arising from the contracting of goods and services, net for uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929372752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Summary of Significant Accounting Policies</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">The Company</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;">We are a pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We are currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&#174;, a product approved in the U.S. for management of opiate dependence. We operate in only one business segment, the development of pharmaceutical products.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 24.5pt; background: none;">&#160;<div style="background: none; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: 0.34in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six-month periods ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2017, or any future interim periods.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The balance sheet at December&#160;31, 2017 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals,&#160;Inc. Annual Report on Form&#160;10-K for the year ended December&#160;31, 2017, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming we will continue as a going concern.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At June 30, 2018, we had cash and cash equivalents of approximately $1.6 million, which we believe,&#160;along with the payment from L. Molteni &amp; C. Dei Frattelli Alitti Societ&#224; Di Esercizio S.P.A. (&#8220;Molteni&#8221;) in August,</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> are sufficient to fund our planned operations&#160;into mid-September 2018. If extended, the convertible loan from Molteni should provide funds</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> through the&#160;end&#160;of&#160;the&#160;third quarter.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We will require additional funds to finance our operations, including the&#160;commercialization of Probuphine in the U.S., completion of the Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage clinical studies. While we are currently&#160;</div>considering&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">the various financing alternatives available to us, our efforts to address our liquidity requirements may not be successful.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Going concern assessment</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.17in; margin-top: 0px; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">With the implementation of FASB's standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, we will assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based upon the above assessment, we concluded that, at the date the financial statements in this Quarterly Report on Form 10-Q for the months ended June 30, 2018, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Beginning January 1, 2018, we have followed the provisions of ASC Topic 606, <div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div>. The guidance provides a unified model to determine how revenue is recognized.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We generate revenue principally from collaborative research and development arrangements, technology licenses, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Obligations</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction Price</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allocation of Consideration</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Timing of Recognition</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs and Related Accrual</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization, or CRO, activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In November 2016, the FASB issued ASU No. 2016-18, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of Cash Flows (Topic 230): Restricted Cash</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. ASU No. 2016-18 is intended to reduce diversity in practice in the classification and presentation of changes in restricted cash on the Condensed Statement of Cash Flows. The ASU requires that the Condensed Statement of Cash Flows explain the change in total cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The ASU also requires a reconciliation between the total of cash, cash equivalents and restricted cash presented on the Condensed Statement of Cash Flows and the cash and cash equivalents balance presented on the Condensed Balance Sheet. We adopted ASU No. 2016-18, and the guidance has been retrospectively applied to all periods presented. The adoption of the guidance did not have an impact on our Condensed Balance Sheet or Statement of Operations and Comprehensive Loss.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In July 2017, the Financial Accounting Standards Board, or FASB, issued a two-part Accounting Standards Update, or ASU, No. 2017-11, <div style="font-style:italic;display:inline;">I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception</div> amending guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017- 11 for the year ended December 31, 2017, and retrospectively applied ASU 2017-11 as required. There was no retrospective impact as a result of the adoption of ASU 2017-11 on the financial statements. See Note 10, &#8220;Debt Agreements&#8221;.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2016, the FASB issued ASU No. 2016-15, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</div></div><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for fiscal years beginning after December 31, 2017, and for interim periods within those years. The adoption of ASU No. 2016-15 did not have a material impact on our statements of cash flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2016, the FASB issued ASU No. 2016-09, <div style="font-style:italic;display:inline;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</div> (&#8220;ASU 2016-09&#8221;). ASU 2016-09 addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; (c) classification on the statement of cash flows; and (d) accounting for forfeitures. We adopted the provisions of ASU 2016-09 in the first quarter of 2017. We have elected to continue to estimate forfeitures based on the estimated number of awards expected to vest. In addition, the adoption of ASU 2016-09 resulted in the recognition of $12.0 million of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based payment awards, are now classified as cash flows from operating activities on our statements of cash flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASU 2016-09 did not have a material impact on our results of operations or financial condition.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2016, the FASB issued ASU No. 2016-02, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. This ASU requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach, with early adoption permitted. We are currently evaluating the impact of this new standard on the financial statements.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the FASB issued ASU No. 2014-09, <div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div> and has subsequently issued several supplemental or clarifying ASUs (collectively, &#8220;ASC 606&#8221;), ASC 606 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASC 606 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASC 606 recognized at the date of adoption.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We adopted the new standard effective January 1, 2018 under the modified retrospective transition method, applying the new guidance to the most current period presented. Upon adoption, there was no change to the units of accounting previously identified under legacy GAAP, which are now considered performance obligations under the new guidance, and there was no change to the revenue recognition pattern for each performance obligation. Therefore, the adoption of the new standard resulted in no cumulative effect to the opening accumulated deficit balance.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We assessed the impact that the adoption of ASC 606 will have on our financial statements by analyzing our current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential differences in the application of ASC 606. Additionally, we performed a comprehensive review of our current processes and systems to determine and implement changes required to support the adoption of ASC 606 on January 1, 2018.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Events</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated events that have occurred after June 30, 2018 and through the date that the financial statements are issued.&#160;</div>See Note 10. &#8220;Subsequent Events&#8221;.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 3 &#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. Our warrant liabilities are classified within level 3 of the fair value hierarchy because the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recorded no fair value adjustment of the warrant liabilities for the three and six-month periods ended June 30, 2018. We recorded non-cash gains on decreases in the fair value of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">190</div>,000 and $<div style="letter-spacing: 0px; top: 0px;;display:inline;">612</div>,000 for the three and six-month periods ended June 30, 2017, respectively, in our Condensed Statements of Operations and Comprehensive Loss. The underlying warrants expired by their terms on April 18, 2018. See Note 7&#160;&#8220;Warrant Liability&#8221; for further discussion on the calculation of the fair value of the warrant liability.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768602384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Plans</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the stock-based compensation expense recorded for awards under the stock option plans for the three and six-month periods ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">156</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">128</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">318</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">245</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 1pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">246</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">254</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">516</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">558</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 2.5pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expenses</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">402</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">382</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">834</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">803</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No tax benefit was recognized related to stock-based compensation expense since we have accumulated operating losses and we have established a full valuation allowance to offset all the potential tax benefits associated with our deferred tax assets.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense for the three and six-month periods ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.9</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.0</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.7</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.1</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend payments</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected holding period (years) <div style="vertical-align: super;font-size: smaller;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.4</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.5</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.4</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.5</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average volatility factor <div style="vertical-align: super;font-size: smaller;display:inline;">2</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.91</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.88</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.89</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.88</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated forfeiture rates <div style="vertical-align: super;font-size: smaller;display:inline;">3</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">27</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">26</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top; text-align:justify"><td style="width: 0px; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</div></td></tr></table><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 0px; padding: 0px;"></td><td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted average volatility is based on the historical volatility of our common stock.</div></td></tr></table><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 0px; padding: 0px;"></td><td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated forfeiture rates are based on historical data.</div></td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 24.5pt; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase approximately 5,000 and 60,000 shares of common stock were granted during the three-month periods ended June 30, 2018 and 2017, respectively. Options to purchase approximately 950,000 and 496,000 shares of common stock were granted during the six-month periods ended June 30, 2018 and 2017, respectively.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes option activity for the six-month period ended June 30, 2018:</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"><tr><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Options</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Option<br/>Term</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,728</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.32</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.75</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">30</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">950</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.97</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(18</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8.36</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cancelled or forfeited</div></div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(12</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.46</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at June 30, 2018</div></div></td><td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,648</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.42</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.44</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">115</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at June 30, 2018</div></div></td><td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,796</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.00</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.88</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="background: none; font-size: 10pt; text-indent: 0.34in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No shares of restricted stock were awarded to employees, directors and consultants during the three and six-month periods ended June 30, 2018 and 2017.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2018, there was approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">0.6</div> million of total unrecognized compensation expense related to non-vested stock options. This expense is expected to be recognized over a weighted-average period of 0.7 years.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609332256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: separate; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">3.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Net Loss Per Share</div></td></tr></table><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss&#160;per share excludes the effect of dilution and is computed by dividing net loss&#160;by the weighted-average number of shares outstanding for the period. Diluted net loss&#160;per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss&#160;per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss&#160;per common share for the three and six-months ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px; vertical-align: bottom; width: 48%; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;used for basic earnings per share</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(869</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,451</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,474</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(6,456</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt 45pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less change in fair value of warrant liability</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(190</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(612</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;used for diluted earnings per share</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(869</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,641</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,474</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(7,068</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted-average outstanding common shares</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,199</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive potential common shares resulting from options</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive potential common shares resulting from warrants</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding&#8212;diluted</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,201</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;per common share:</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.04</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.30</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.04</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.17</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.33</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr></table></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss&#160;per common share. These are excluded from the calculation due to their anti-dilutive effect for the three and six-months ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average anti-dilutive common shares resulting from options</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,658</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,437</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,327</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,324</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average anti-dilutive common shares resulting from warrants</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,482</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,117</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,730</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">517</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 7.2pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,140</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,554</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,057</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,841</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929371456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Loss Note [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Comprehensive Loss</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">Comprehensive loss <div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">for the periods presented is comprised solely of our net loss. We had no items of other comprehensive loss&#160;during the three and six-month periods ended June 30, 2018 and 2017. Comprehensive loss for the three and six-month periods ended June 30, 2018 was $0.9 million and $3.5 million, respectively. Comprehensive loss for the three and six-month periods ended June&#160;30, 2017 was $3.5 million and $6.5 million, respectively.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609332256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Braeburn License<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_LicenseRightsDisclosureAbstract', window );"><strong>Braeburn License [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_LicenseRightsDisclosureTextBlock', window );">Braeburn License [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Braeburn License</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">Until its termination in May 2018, we were party to&#160;a license agreement (as amended, the &#8220;License Agreement&#8221;) pursuant to which we had granted Braeburn Pharmaceuticals, Inc. (&#8220;Braeburn&#8221;) the exclusive commercialization rights to Probuphine in the United States and its territories and Canada. Under the License Agreement, we received certain milestone payments, as well as royalties on net sales of Probuphine. Upon receipt of approval, our obligation was fulfilled and we recognized as revenue the full amount of the milestone payment. In addition, we were entitled to receive a low single digit royalty on sales by Braeburn of other competing continuous delivery treatments for opioid dependence as defined in the License Agreement. The License Agreement provided for us to be reimbursed by Braeburn for any development services and activities undertaken at Braeburn&#8217;s request. Under ASC 606, there was no change in the amount or timing of revenue recognized under this agreement. In February 2016, Braeburn sublicensed rights to develop and commercialize Probuphine in Canada to Knight Therapeutics, Inc. (&#8220;Knight&#8221;).</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">On May 25, 2018, we entered into a Termination and Transition Services Agreement (the &#8220;Transition Agreement&#8221;) with Braeburn pursuant to which we regained all rights to the commercialization and clinical development of Probuphine in the United States and Canada.&#160;Braeburn paid us<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;$1.0&#160;</div>million, transferred inventory to us with a value of approximately $1.1 million and agreed to provide support services through December 28, 2018. In addition, the Transition Agreement provides for the immediate transfer to us of all regulatory documentation and development data related to Probuphine. The estimated fair value of the inventory received was determined using available inputs such as existing supply agreements, prior selling prices and remaining life to expiration. We recognized approximately $2.1 million of license related revenue related to this transaction in the three month period ended June 30, 2018. The sublicense to Knight was assigned to Titan as part of the Transition Agreement.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_LicenseRightsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Braeburn license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_LicenseRightsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_LicenseRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License rights disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_LicenseRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929388320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Molteni Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementAbstract', window );"><strong>Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementTextBlock', window );">Purchase Agreement [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Molteni Purchase Agreement</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On March 21, 2018, we entered into an Asset Purchase, Supply and Support Agreement (the &#8220;Purchase Agreement&#8221;) with Molteni pursuant to which Molteni acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application (&#8220;MAA&#8221;) under review by the European Medicines Agency (&#8220;EMA&#8221;), and will have the exclusive right to commercialize the Probuphine product supplied by us in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the &#8220;Molteni Territory&#8221;).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We received an initial payment of &#8364;2.0 million (approximately $2.4 million) for the purchased assets and will receive additional potential payments totaling upon the achievement of certain regulatory and product label milestones.&#160;Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties.&#160;</div>In August 2018, we entered into an amendment to the Purchase Agreement described below in Note 10. &#8220;Subsequent Events.&#8221;</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We concluded that the performance obligations identified in the Purchase Agreement included the transfer of the intellectual property and our efforts towards the approval by the EMA and other regulatory bodies. The initial closing payment was allocated between the transfer of the intellectual property and our efforts related to the EMA approval as&#160;</div>set forth below.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We used the expected cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards the approval by the EMA and other regulatory bodies. This includes employee related expenses as well as other manufacturing, regulatory and clinical costs which will be incurred as part of our efforts. We believe that the services will be at a consistent rate and will be substantially complete as of December 31, 2018. As such we will recognize the revenue ratably over the balance of year ending December 31, 2018. If the facts and circumstances change, we will reassess these assumptions. The costs associated with these services will be expensed over the same period.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We used the residual approach to value the transfer of the intellectual property at approximately $1.0 million as we had not established and had no reliable way to establish a standalone selling price for the intellectual property.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As a result of the outcome of the milestone and earn-out payments being unpredictable due to the involvement of third parties, we believe that using the most likely amount method is appropriate. Any subsequent revenue related to milestone and earn-out payments will be recognized at the time the milestones are achieved or when the related net sales have occurred.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Agreement provides that we will supply Molteni with semi-finished product (i.e., the implant, the applicator and related technology) on an exclusive basis at a fixed price through December 31, 2019, with subsequent price increases not to exceed annual cost increases to us for the active pharmaceutical ingredient and under our current manufacturing agreement. Revenue will be recognized when the semi-finished product has been transferred to Molteni.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Molteni will be prohibited from marketing a Competitor Product (as defined in the Agreement) in the Territory for the five year period following approval of the MAA. Thereafter, Molteni will be required to pay us a low single digit royalty on net sales of any Competitor Product.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in contract assets and liabilities during the six months ended June 30, 2018:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(</div><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">in&#160;thousands</div></div><div style="font-weight:bold;display:inline;">)</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Beginning&#160;</div><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">Balance</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ending<br/>Balance</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June 30, 2018</div></div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">291</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">291</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,448</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1,509</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">939</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609002912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WarrantLiabilityDisclosureTextBlock', window );">Warrant Liability Disclosure [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Warrant Liability</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">Until they expired by their terms on April 18, 2018,&#160;<div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">we had warrants outstanding to purchase an aggregate of 983,395 shares of common stock </div>at an exercise price of<div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;$4.85 per share.&#160;The&#160;warrants&#160;contained a provision where the warrant holder had the option to receive cash&#160;equal to the Black Scholes fair value of the remaining unexercised portion of the warrant&#160;as cash settlement in the event that there was a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, <div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div> required that these warrants be&#160;classified as liabilities. The fair value of these warrants was determined using the Lattice valuation model, and the changes in the fair value were recorded in the Condensed Statements of Operations and Comprehensive Loss.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WarrantLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WarrantLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597521504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Debt Agreements</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In July 2017, we entered into a venture loan and security agreement (&#8220;Original Loan Agreement&#8221;) with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;), pursuant to which we received a loan in the amount of $7.0 million</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Original Loan Agreement provided for repayment of the loan on an interest-only basis through December 31, 2018, followed by monthly payments of principal and accrued interest for the balance of the 46-month term. The loan bears interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of the loan will be due on the scheduled maturity date for such loan. The Original Loan Agreement also contained a prepayment penalty based on a percentage of the then outstanding principal balance, equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months following such period, and 2% thereafter.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our obligations under the Original Loan Agreement were secured by a first priority security interest in all of our assets, with the exception of our intellectual property. We agreed not to pledge or otherwise encumber our intellectual property assets, subject to certain exceptions.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Original Loan Agreement included customary affirmative and restrictive covenants, excluding any covenants to attain or maintain certain financial metrics, and also included customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% could be applied to the outstanding loan balance, and Horizon could declare all outstanding obligations immediately due and payable and take such other actions as set forth in such agreement.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Original Loan Agreement, we issued Horizon seven-year warrants to purchase an aggregate of 280,612 shares of our common stock (&#8220;Horizon Warrants&#8221;). The per share exercise price of the Horizon Warrants is the lower of (i) $1.96 or (ii) the price per share of any securities that may be issued by the Company in an equity financing during the 18 months following the agreement date. We agreed to file a registration statement covering the resale of the shares underlying the Horizon Warrants. In accordance with ASC 480, <div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div>, as amended by ASU, No. 2017-11, which we early adopted during 2017, the Horizon Warrants have been classified as equity and their fair value at the time of issuance was determined using a Lattice valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the Horizon Warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">July 27, 2017</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">47</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.12</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.02</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The anti-dilution provisions contained in the outstanding Series A warrants were triggered by the Horizon Warrant issuance, resulting in a reduction of the exercise price of such warrants from $4.89 to $4.85 per share.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On February 2, 2018, we entered into an amendment to the Original Loan Agreement (the &#8220;Amended Loan Agreement&#8221;) pursuant to which we prepaid $3.0 million of the outstanding $7.0 million principal amount and provided Horizon with a lien on our intellectual property. The other terms of the Original Loan Agreement remained unchanged.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On March 21, 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the &#8220;Restated Loan Agreement&#8221;) with Horizon and&#160;Molteni&#160;pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed collateral agent and assumed majority and administrative control of the debt. Under the Restated Loan Agreement, the interest only payment and forbearance periods were extended to December 31, 2019. In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizon&#8217;s loan amount. The lien on our intellectual property remains in place at this time. As the present value of the cash flows under the terms of the Restated Loan Agreement is less than 10% different from the remaining cash flows under the terms of the Amended Loan Agreement prior to being amended and restated, the Restated Loan Agreement was accounted for as a debt modification. Accordingly, expenses incurred as a result of the modification were expensed as incurred and the previously deferred fees and costs related to the debt will continue to be amortized over the remaining term along with the related warrants issued as part of the</div>&#160;agreement described in Note 9 &#8220;Rights Agreement.&#8221;</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Restated Loan Agreement, we issued Horizon seven-year warrants to purchase 40,000 shares of our common stock at an exercise price of $1.20 per share. The Horizon Warrants have been classified as equity and their fair value at the time of issuance was determined using a Black Scholes valuation model and was recorded in the Condensed Balance Sheet as a discount to the debt obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the new Horizon warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">March 21, 2018</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.82</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.81</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609002912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Rights Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_RightsAgreementAbstract', window );"><strong>Rights Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_RightsAgreementTextBlock', window );">Rights Agreement [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-weight:bold;display:inline;">Rights Agreement</div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">In consideration of Molteni&#8217;s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into an agreement (as amended in May 2018, the &#8220;Rights Agreement&#8221;) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase <div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> 540,000 shares of our common stock at an exercise price of $1.20&#160;</div>per share (the &#8220;Molteni Warrants&#8221;), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) appoint one member of our board of directors under certain circumstances and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights. The board designation, observer and information rights will terminate at such time as Molteni ceases to beneficially own at least one percent of our outstanding capital stock (inclusive of the shares issuable upon conversion of debt under the Restated Loan Agreement and exercise of the Molteni Warrants). The Molteni Warrants have been classified as equity and their fair value at the time of issuance was determined using a Black Scholes valuation model. The amount was allocated equally between the Restated Loan Agreement and the Purchase Agreement and was recorded in the Condensed Balance Sheet as a discount to the debt obligation and a contract asset, respectively.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the Molteni Warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">March 21, 2018</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.82</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.81</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_RightsAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_RightsAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_RightsAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_RightsAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768495360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="word-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="word-wrap: break-word; vertical-align: top; width: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="word-wrap: break-word; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0in; text-indent: 0in; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Events</div></div></div></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;">On August 3, 2018, we entered into an amendment (the &#8220;Amendment&#8221;) to the Purchase Agreement with Molteni. Under the Amendment, Molteni made an immediate payment to us of &#8364;950,000 (approximately $1,109,000) and has committed to make a convertible loan to us of &#8364;550,000 (approximately $642,000) provided we have submitted our response to the 120-day letter from the EMA on or prior to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of &#8364;2.0 million (approximately $2,335,000) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019, at the earliest. The loan (the &#8220;Convertible Loan&#8221;), if made, will convert automatically into shares of our common stock upon the issuance by the EMA of marketing approval for Probuphine at a conversion price per share equal to the lower of (i) the closing price on the loan funding date and (ii) the closing price on the conversion date. In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum. The Convertible Loan will contain other covenants and events of default substantially consistent with the Restated Loan Agreement.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;">On August 7, 2018, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 2,500,000 to 3,500,000.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757974304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_CompanyPolicyPolicyTextBlock', window );">Company Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">The Company</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;">We are a pharmaceutical company developing proprietary therapeutics utilizing our proprietary long-term drug delivery platform for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We are currently transitioning to a commercial stage enterprise having recently re-acquired Probuphine&#174;, a product approved in the U.S. for management of opiate dependence. We operate in only one business segment, the development of pharmaceutical products.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six-month periods ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2017, or any future interim periods.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The balance sheet at December&#160;31, 2017 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals,&#160;Inc. Annual Report on Form&#160;10-K for the year ended December&#160;31, 2017, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming we will continue as a going concern.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At June 30, 2018, we had cash and cash equivalents of approximately $1.6 million, which we believe,&#160;along with the payment from L. Molteni &amp; C. Dei Frattelli Alitti Societ&#224; Di Esercizio S.P.A. (&#8220;Molteni&#8221;) in August,</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> are sufficient to fund our planned operations&#160;into mid-September 2018. If extended, the convertible loan from Molteni should provide funds</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> through the&#160;end&#160;of&#160;the&#160;third quarter.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We will require additional funds to finance our operations, including the&#160;commercialization of Probuphine in the U.S., completion of the Probuphine Phase IV clinical trials mandated by the FDA and advancement of our current ProNeura development programs to later stage clinical studies. While we are currently&#160;</div>considering&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">the various financing alternatives available to us, our efforts to address our liquidity requirements may not be successful.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_GoingConcernAssessmentPolicyTextBlock', window );">Going Concern Assessment [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Going concern assessment</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.17in; margin-top: 0px; text-indent: 0.5in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">With the implementation of FASB's standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, we will assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based upon the above assessment, we concluded that, at the date the financial statements in this Quarterly Report on Form 10-Q for the months ended June 30, 2018, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Beginning January 1, 2018, we have followed the provisions of ASC Topic 606, <div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div>. The guidance provides a unified model to determine how revenue is recognized.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We generate revenue principally from collaborative research and development arrangements, technology licenses, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Obligations</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction Price</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allocation of Consideration</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Timing of Recognition</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In Process Research and Development, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs and Related Accrual</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization, or CRO, activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In November 2016, the FASB issued ASU No. 2016-18, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of Cash Flows (Topic 230): Restricted Cash</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. ASU No. 2016-18 is intended to reduce diversity in practice in the classification and presentation of changes in restricted cash on the Condensed Statement of Cash Flows. The ASU requires that the Condensed Statement of Cash Flows explain the change in total cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The ASU also requires a reconciliation between the total of cash, cash equivalents and restricted cash presented on the Condensed Statement of Cash Flows and the cash and cash equivalents balance presented on the Condensed Balance Sheet. We adopted ASU No. 2016-18, and the guidance has been retrospectively applied to all periods presented. The adoption of the guidance did not have an impact on our Condensed Balance Sheet or Statement of Operations and Comprehensive Loss.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In July 2017, the Financial Accounting Standards Board, or FASB, issued a two-part Accounting Standards Update, or ASU, No. 2017-11, <div style="font-style:italic;display:inline;">I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception</div> amending guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017- 11 for the year ended December 31, 2017, and retrospectively applied ASU 2017-11 as required. There was no retrospective impact as a result of the adoption of ASU 2017-11 on the financial statements. See Note 10, &#8220;Debt Agreements&#8221;.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2016, the FASB issued ASU No. 2016-15, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</div></div><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for fiscal years beginning after December 31, 2017, and for interim periods within those years. The adoption of ASU No. 2016-15 did not have a material impact on our statements of cash flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2016, the FASB issued ASU No. 2016-09, <div style="font-style:italic;display:inline;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</div> (&#8220;ASU 2016-09&#8221;). ASU 2016-09 addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; (c) classification on the statement of cash flows; and (d) accounting for forfeitures. We adopted the provisions of ASU 2016-09 in the first quarter of 2017. We have elected to continue to estimate forfeitures based on the estimated number of awards expected to vest. In addition, the adoption of ASU 2016-09 resulted in the recognition of $12.0 million of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based payment awards, are now classified as cash flows from operating activities on our statements of cash flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASU 2016-09 did not have a material impact on our results of operations or financial condition.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2016, the FASB issued ASU No. 2016-02, </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. This ASU requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach, with early adoption permitted. We are currently evaluating the impact of this new standard on the financial statements.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the FASB issued ASU No. 2014-09, <div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div> and has subsequently issued several supplemental or clarifying ASUs (collectively, &#8220;ASC 606&#8221;), ASC 606 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASC 606 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASC 606 recognized at the date of adoption.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We adopted the new standard effective January 1, 2018 under the modified retrospective transition method, applying the new guidance to the most current period presented. Upon adoption, there was no change to the units of accounting previously identified under legacy GAAP, which are now considered performance obligations under the new guidance, and there was no change to the revenue recognition pattern for each performance obligation. Therefore, the adoption of the new standard resulted in no cumulative effect to the opening accumulated deficit balance.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We assessed the impact that the adoption of ASC 606 will have on our financial statements by analyzing our current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential differences in the application of ASC 606. Additionally, we performed a comprehensive review of our current processes and systems to determine and implement changes required to support the adoption of ASC 606 on January 1, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Events</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated events that have occurred after June 30, 2018 and through the date that the financial statements are issued.&#160;</div>See Note 10. &#8220;Subsequent Events&#8221;.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 3 &#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. Our warrant liabilities are classified within level 3 of the fair value hierarchy because the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recorded no fair value adjustment of the warrant liabilities for the three and six-month periods ended June 30, 2018. We recorded non-cash gains on decreases in the fair value of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">190</div>,000 and $<div style="letter-spacing: 0px; top: 0px;;display:inline;">612</div>,000 for the three and six-month periods ended June 30, 2017, respectively, in our Condensed Statements of Operations and Comprehensive Loss. The underlying warrants expired by their terms on April 18, 2018. See Note 7&#160;&#8220;Warrant Liability&#8221; for further discussion on the calculation of the fair value of the warrant liability.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_GoingConcernAssessmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Going concern assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_GoingConcernAssessmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763017296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the stock-based compensation expense recorded for awards under the stock option plans for the three and six-month periods ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">156</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">128</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">318</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">245</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 1pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">246</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">254</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">516</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">558</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 2.5pt; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expenses</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">402</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">382</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">834</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">803</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense for the three and six-month periods ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; text-align: center; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div><br/><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px; white-space: nowrap;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: 0px none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.9</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.0</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.7</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.1</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend payments</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected holding period (years) <div style="vertical-align: super;font-size: smaller;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.4</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.5</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.4</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.5</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average volatility factor <div style="vertical-align: super;font-size: smaller;display:inline;">2</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.91</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.88</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.89</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.88</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding-bottom: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; margin-left: 0in;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated forfeiture rates <div style="vertical-align: super;font-size: smaller;display:inline;">3</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">27</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">26</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top; text-align:justify"><td style="width: 0px; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</div></td></tr></table><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 0px; padding: 0px;"></td><td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted average volatility is based on the historical volatility of our common stock.</div></td></tr></table><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 99%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 0px; padding: 0px;"></td><td style="width: 24px; text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3)</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated forfeiture rates are based on historical data.</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes option activity for the six-month period ended June 30, 2018:</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">&#160;</div><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"><tr><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Options</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Option<br/>Term</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; width: 11%;"><div style="margin-bottom: 0.0001pt; text-align: center; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,728</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.32</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.75</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">30</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">950</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.97</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(18</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8.36</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cancelled or forfeited</div></div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(12</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.46</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at June 30, 2018</div></div></td><td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,648</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.42</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.44</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">115</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background: none; margin-top: 0px;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at June 30, 2018</div></div></td><td style="width: 1%; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,796</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.00</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.88</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: left; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 2.5pt double black; width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; font-family: calibri, sans-serif; font-size: 10pt; margin-right: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57</div></div></td><td style="border-image: initial; width: 1%; padding: 0in 0in 1.25pt; font-size: 10pt; line-height: 10pt; text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929526480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss&#160;per common share for the three and six-months ended June 30, 2018 and 2017:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px; vertical-align: bottom; width: 48%; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="1" style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;used for basic earnings per share</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(869</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,451</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,474</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(6,456</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt 45pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less change in fair value of warrant liability</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(190</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(612</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;used for diluted earnings per share</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(869</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,641</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,474</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(7,068</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted-average outstanding common shares</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,199</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive potential common shares resulting from options</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.13in; line-height: normal; margin-left: 0.13in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive potential common shares resulting from warrants</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding&#8212;diluted</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">21,201</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net loss&#160;per common share:</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-right: 0in; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.04</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.30</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 0px 18pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.04</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.17</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.16</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(0.33</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;">These are excluded from the calculation due to their anti-dilutive effect for the three and six-months ended June 30, 2018 and 2017:</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none; border-collapse: separate; margin-bottom: 0.001pt; width: 100%; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0px 1pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; text-align: center; white-space: nowrap; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px; vertical-align: bottom; width: 48%; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; border-top: 0px none;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; vertical-align: bottom; width: 11%; border-bottom: 1pt solid rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 12pt; vertical-align: bottom; width: 48%; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average anti-dilutive common shares resulting from options</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,658</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,437</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,327</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,324</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt 12pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-indent: -0.17in; line-height: normal; margin-left: 0.17in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average anti-dilutive common shares resulting from warrants</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,482</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,117</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,730</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">517</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt 7.2pt; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,140</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,554</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,057</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.5pt double rgb(0, 0, 0); border-top: 0px none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,841</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759449360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Molteni Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementAbstract', window );"><strong>Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in contract assets and liabilities during the six months ended June 30, 2018:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;;text-align:left;"><tr><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(</div><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">in&#160;thousands</div></div><div style="font-weight:bold;display:inline;">)</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: &quot;times new roman&quot;, times, serif;;display:inline;"><div style="font-weight:bold;display:inline;">Beginning&#160;</div><div style="font-weight:bold;display:inline;">&#8206;</div><div style="font-weight:bold;display:inline;">Balance</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; width: 11%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ending<br/>Balance</div></div></div></div></td><td style="border-top: none; padding: 0in 0in 0.5pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June 30, 2018</div></div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">291</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">291</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities:</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; margin-right: 0in; white-space: nowrap;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 48%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: none; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,448</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1,509</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: left; line-height: normal; margin-left: 0in; text-indent: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; width: 10%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal; margin-right: 0in; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">939</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; vertical-align: bottom; width: 1%; text-align: left;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929517264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the Horizon Warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">July 27, 2017</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">47</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.12</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.02</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the new Horizon warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">March 21, 2018</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.82</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.81</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759361248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Rights Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember', window );">Molteni Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions used to value the Molteni Warrants were as follows:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.25in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 93%;"><tr><td colspan="5" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Date of issuance</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">March 21, 2018</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 87.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected price volatility</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.82</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of warrants</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.81</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-wrap; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768657568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule of Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Less change in fair value of warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 18,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember', window );">Adjustments for New Accounting Pronouncement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule of Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit', window );">Deferred Tax Assets Unrecognized Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unrecognized tax benefit recognized in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DeferredTaxAssetsUnrecognizedTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the expiration date of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757962832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758241664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected holding period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility factor</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.91%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">0.89%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement', window );">Estimated forfeiture rates</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Weighted average volatility is based on the historical volatility of our common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Estimated forfeiture rates are based on historical data.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated forfeiture rates for options granted to management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769235408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 2) - Employee Stock Option [Member]<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding | shares</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted | shares</a></td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired | shares</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Cancelled or forfeited | shares</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding | shares</a></td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">2,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable at June 30, 2018 | shares</a></td>
<td class="nump">2,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Beginning of Period | $ / shares</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired | $ / shares</a></td>
<td class="nump">8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled or forfeited | $ / shares</a></td>
<td class="nump">5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at End of Period | $ / shares</a></td>
<td class="nump">3.42<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at June 30, 2018 | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Option Term, Outstanding (Years)</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Option Term, Exercisable at June 30, 2018</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at June 30, 2018 | $</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758394496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details Textual) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognizing non-vested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768176128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss used for basic earnings per share</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (3,451)<span></span>
</td>
<td class="num">$ (3,474)<span></span>
</td>
<td class="num">$ (6,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability', window );">Less change in fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss used for diluted earnings per share</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (3,641)<span></span>
</td>
<td class="num">$ (3,474)<span></span>
</td>
<td class="num">$ (7,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average outstanding common shares</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions', window );">Effect of dilutive potential common shares resulting from options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants', window );">Effect of dilutive potential common shares resulting from warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding&#8212;diluted</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Dilutive Securities, Fair Value Adjustment to warrant Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AmountOfDilutiveSecuritiesFairValueAdjustmentToWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the number of incremental common shares attributable to assumed exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental common shares attributable to assumed exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758290400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details 1) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted-average anti-dilutive common shares</a></td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">5,057<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted-average anti-dilutive common shares</a></td>
<td class="nump">3,658<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">3,327<span></span>
</td>
<td class="nump">2,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted-average anti-dilutive common shares</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929443600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comprehensive Loss (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss, Net of Tax, Attributable to Parent, Total</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929391872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Braeburn License (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 25, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_NonRefundableUpFrontLicenseFeeLineItems', window );"><strong>Non Refundable up Front License Fee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ProceedsFromExclusiveCommercializationRights', window );">Proceeds from Exclusive Commercialization Rights</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_LicenseRevenue1', window );">License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_LicenseRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of license revenue realised from Termination and Transition Services Agreement during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_LicenseRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NonRefundableUpFrontLicenseFeeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable up front license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NonRefundableUpFrontLicenseFeeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ProceedsFromExclusiveCommercializationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for exclusive commercialization rights during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ProceedsFromExclusiveCommercializationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758242960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Molteni Purchase Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementLineItems', window );"><strong>Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Contract with Customer, Asset</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetAdditions', window );">Contract with Customer, Asset additions</a></td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetDeductions', window );">Contract with Customer, Asset Deductions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Contract with Customer, Asset</a></td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred Revenue, Deductions</a></td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929440864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Molteni Purchase Agreement (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementLineItems', window );"><strong>Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">&#8364; 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodDescription', window );">Revenue Recognition, Milestone Method, Description</a></td>
<td class="text">receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties.<span></span>
</td>
<td class="text">receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_EstimatedSellingPrice', window );">Estimated Selling Price</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_PurchaseAgreementLineItems', window );"><strong>Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Finite-Lived Intangible Assets, Translation and Purchase Accounting Adjustments</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_EstimatedSellingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of estimated selling price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_EstimatedSellingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the overall arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768040256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Details Textual) - Series A Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 18, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WarrantsToPurchaseCommonStockShares', window );">Warrants To Purchase Common Stock Shares | shares</a></td>
<td class="nump">983,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WarrantsToPurchaseCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the number of warrants issued to purchase common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WarrantsToPurchaseCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769220400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsDateOfIssuance', window );">Date of issuance</a></td>
<td class="text">Jul. 27,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WeightedAverageFairValueAssumptionsOfWarrants', window );">Weighted-average fair value of warrants</a></td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsTerm', window );">Fair Value Assumptions Term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">2.12%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember', window );">Horizon Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsDateOfIssuance', window );">Date of issuance</a></td>
<td class="text">Mar. 21,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WeightedAverageFairValueAssumptionsOfWarrants', window );">Weighted-average fair value of warrants</a></td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsTerm', window );">Fair Value Assumptions Term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions Of Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsDateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date of issuance relating to fair value assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsDateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions Of Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsOfAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumption rate for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WeightedAverageFairValueAssumptionsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average fair value assumptions of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WeightedAverageFairValueAssumptionsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_HorizonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769463840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2018</div></th>
<th class="th"><div>Mar. 21, 2018</div></th>
<th class="th"><div>Jul. 27, 2017</div></th>
<th class="th"><div>Apr. 18, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ttnp_HorizonTechnologyFinanceCorporationMember', window );">Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ttnp_VentureLoanMember', window );">Venture Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage', window );">Debt Instrument, Final Payment on Each Loan Tranche,Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarlyRepaymentOfSubordinatedDebt', window );">Early Repayment of Subordinated Debt</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ttnp_VentureLoanMember', window );">Venture Loan [Member] | Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">46 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ttnp_MolteniLoanMember', window );">Molteni Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_ConversionOfDebtToEquityDescription', window );">Conversion of Debt to Equity Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizon&#8217;s loan amount.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSubordinatedShortTermDebt', window );">Proceeds from Subordinated Short-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember', window );">Series A Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember', window );">Series A Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember', window );">New Horizon Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ConversionOfDebtToEquityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of effect of conversion of debt to equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ConversionOfDebtToEquityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage rate of final payment on each loan tranche.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DebtInstrumentFinalPaymentOnEachLoanTranchepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarlyRepaymentOfSubordinatedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of long-term borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in case of liquidation of the entity's assets before its maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarlyRepaymentOfSubordinatedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSubordinatedShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSubordinatedShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ttnp_HorizonTechnologyFinanceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ttnp_HorizonTechnologyFinanceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttnp_VentureLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttnp_VentureLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttnp_MolteniLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttnp_MolteniLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_NewHorizonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758612256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Rights Agreement (Details) - Molteni Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsDateOfIssuance', window );">Date of issuance</a></td>
<td class="text">Mar. 21,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_WeightedAverageFairValueAssumptionsOfWarrants', window );">Weighted-average fair value of warrants</a></td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsTerm', window );">Fair Value Assumptions Term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_FairValueAssumptionsRate', window );">Fair Value Assumptions Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsDateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date of issuance relating to fair value assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsDateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumption rate for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WeightedAverageFairValueAssumptionsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average fair value assumptions of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WeightedAverageFairValueAssumptionsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759373424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Rights Agreement (Details Textual) - Molteni Warrants [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 21, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="nump">540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_MolteniWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758658176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Textual) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 03, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement', window );">Amount Received Under Amendment To Purchase Agreement</a></td>
<td class="nump">$ 1,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt</a></td>
<td class="nump">$ 642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMilestones', window );">Long-term Purchase Commitment, Milestones</a></td>
<td class="text">On August 3, 2018, we entered into an amendment (the &#8220;Amendment&#8221;) to the Purchase Agreement with Molteni. Under the Amendment, Molteni made an immediate payment to us of &#8364;950,000 (approximately $1,109,000) and has committed to make a convertible loan to us of &#8364;550,000 (approximately $642,000) provided we have submitted our response to the 120-day letter from the EMA on or prior to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of &#8364;2.0 million (approximately $2,335,000) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019, at the earliest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">2015 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum [Member] | 2015 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt Instrument, Interest Rate Terms</a></td>
<td class="text">In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received on behalf of amendment to purchase agreement from Molteni.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AmountReceivedUnderAmendmentToPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_OmnibusEquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_OmnibusEquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " "J@0Y-N%V3?.\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>*$Y**2;UI6.G#08K;.QF;+4UBQ-C:R1]^SE>
MFS*V!]C1TN]/GT"M]D(/ 9_#X#&0Q7@WN:Z/0OLM.Q%Y 1#U"9V*94KTJ7D8
M@E.4GN$(7ND/=42HJVH-#DD910IF8.$7(I.MT4('5#2$"][H!>\_0Y=A1@-V
MZ+"G"+SDP.0\T9^GKH4;8(81!A>_"V@68J[^B<T=8)?D%.V2&L>Q')N<2SMP
M>'MZ?,GK%K:/I'J-Z5>T@LX>M^PZ^;79W>\?F*PKOBFJ3<%7>[X6O!;-ZGUV
M_>%W$W:#L0?[CXVO@K*%7W<AOP!02P,$%     @ JH$.39E<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MS<4J^^OAE+:7'<R"IEV;=K#K3O=;LYY5,_JQ#+RY\]'F&9!5CX@QXM\B:XK
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M9'I7MX>J.2[[#93^I#:G87/(N>Y0+?\'4$L#!!0    ( *J!#DUM;4B!/00
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MO3&-;LW[7]KI..IT=WW(];[IOL;M]VJXKAL>&G,:KR*]ZWWH\G]02P,$%
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M/;>43,5_@RM('QZ4^!PE2AM74O;6H9I8O!3%7\==Z+@/X\UV/\'6 >D$2&?
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MVH?C/9[M-&:3X4T__R"V?./B+U!+ P04    " "J@0Y-_>$5E[4!  #2 P
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MP+.=QVPVO!F6'\36;US^!5!+ P04    " "J@0Y-6(PW[K8!  #2 P  &0
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M:&5E=',O<VAE970Q-2YX;6QU56UOFS 0_BO(/Z &\AX!4M.IVJ1-BCJM^^S
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M*N:T;R7]@I-6=TDPM.K\/U!+ P04    " "J@0Y-#Q4%P6L"   Y"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R-5MN.FS 0_17$!ZRY.2$10=I<
MJE9JI=56VSX[Q EH 5/;"=N_KVT< L:;YB78PSG'<P9K)DE+Z#O+,>;.1U76
M;.7FG#=+ %B6XPJQ)]+@6KPY$EHA+K;T!%A#,3HH4E6"P/-FH$)%[::)BKW0
M-"%G7A8U?J$..U<5HG_7N"3MRO7=:^"U..5<!D":-.B$?V+^UKQ0L0.]RJ&H
M<,T*4CL4'U?NL[_<^9XD*,2O K=LL':DE3TA[W+S[;!R/9D1+G'&I002CPO>
MX+*42B*//UK4[<^4Q.'ZJOY%F1=F]HCA#2E_%P>>K]S8=0[XB,XE?R7M5ZP-
M0=?1[K_C"RX%7&8BSLA(R=2ODYT9)Y56$:E4Z*-[%K5ZMEK_2K,3 DT(>H(X
M^QXAU(3P1HCN$B)-B!X] 6H"-$X G7=5S"WB*$TH:1W:W8<&R6OG+Z'X7)D,
MJJ^CWHEZ,A&]I/["3\!%"FG,NL,$ PR,QI#M%'(3 2*!/HO EL4ZF-"#\0&;
M*0)"(X?_BNSNBHS2#*W%"A4_'!4KL M$5H%("40C@="H=H>9*TRM,)%G5F.*
M"6,#LYUBXM#X;#L+Q@OMAJ#5$+08BNP",ZO [/&2SJT"\P=*VF'@P*8/9T9)
M+9@@-DHZQ82^@=E-,4'TR26+K89BBZ%/!!96@<7C)14MWMH4O >*JD'SD5.S
MJC;0M'E,0= WE'8V$(P-6V#0]BI,3VH&,2<CYYK+D@RB_9Q[#F3;-.)K?[GQ
M+?&MG(NJS=[DNZ'Z ]%343-G3[AHUJJE'@GA6.3N/8GKD(LYWF]*?.1R.1=K
MV@VS;L-)HP<UZ/\MI/\ 4$L#!!0    ( *J!#DV\5?BRT0(  "$+   9
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MXT/-C[J_S<V]')K+X4&+SC7.\=B];_X 4$L#!!0    ( *J!#DT'8KBK1P(
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M*S3\\,:LR"X K0+0", ;@7CB=H=!!E-W10;0G]@Q!X5H=B@6)1]-TFWG()#
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MZ$K.C+WJP]=BYWK:$!#(I5; :KG  0C10LK&VZ3ISBDU\79_5?]B:E>UG+&
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MI)YNU)S;;F87DG5#HT;CWR+_"U!+ P04    " "J@0Y-U.6YQ-4!   _!
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M# /%#F09P\#A]=4RAH'IBC40B<B5*B:& 0RC9; 7#=?!<))0./RX_J,P0(P
M2AP6&""^ 2#& /$U "$1.19'Q@ Q (@=BR-C@/@&@!@#Q(B-R\41BAR+(V.
M&/R;L./U$!@@<0-  @,D$$"7SQ:)V+59P@ ) !"[4G5LN,0-U6(81'1-M4 T
M6AR#P5:VD/7.;N(;;ZT.I3U!#'K/!X4'MEOA#WEWROB>UKNL;+P7I<V&VFY[
MMTII:7())X:JO3G8G!NYW.KV-C;W=;>[[QI:5?W))3@?GY;_ %!+ P04
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M=V]R:W-H965T<R]S:&5E=#,V+GAM;&U3VV[;, S]%4$?$#EVTP:!;6!I46S
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MT7@\B#BNSA@/R)>ML.0>W\/L2.A\,!_0MNE6),>;8;KP;'YU]3]02P,$%
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MF*=E]4^$ 8 ,>_/T-IME]7[[GO"EKOA2)X!62SW4;'Z0Y:U#G<\S!"KL2YZ
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M<<<><Y3  ^T)B&SQF"O# \6PICT&VVISO/(NR87^T*#7Z^4R*9_PK>OL+L]
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M3:!\$T'\F0$]' T1%)_2.]1:<8SK@W\;T&4JT;ZU>"+@PO4 T:NH449?K.<
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MAT^#:QI;K>-:G_IIQ>P-2//Y]4_1^V* ^'ET,)K$1L%VUVX#Z3[F<T(9AUD
M_ME@V<Q1DEOX,':DA;<7+A:X'OQ7)_#^$XG3 ,).V@5@GJ>HRQ#^W3+A>0AN
M*-$>$HIP?2AU%N6O-!?[12R6^R.=%F59/,)G8A1)\#K ;"KCL^C%^R)J5D<+
M4(AJ$OH)3$[*0 AOH/8HV9 =@,0=BU-3_48)8H8<1'QKB& $T$AHUJ(H?CV
M93WBN?+"A'[A@^AJR?E>-0X:Z#>:S\J:[RG,X1$NCMC>5Q"+9+JAW W6_6N.
MU@2V,R05D)0IW!S\T-X*PT)(@G77J@+=#'^%9V#9*9Q3#;_"S?U;.A/Z$W)8
M&H8XKR!']"M(^X;O-@D6O$RG"N_"I17[C4R@%A$R-<[)'%?A"2CEB!F!\83(
M?/C$N+: &UL0\8$%+#:\#<CH!/48!0"4\LDP>9O,ZJ)D[8YAVX(Z')B7\A$M
M5JL%D"V *L$S@(&5.Q)@"+AJI0Z$YKQ4,?"5O ?G]!"XX%X%6@PBIIYDG[1;
M!!@0MT'65>-2YFFZQ.>G?.0D@83$"205X&93E$3ND9?+)92+2LR<?.(@F<+K
MI4 Z_0Q2']^;)=$?66\'EG>IL"T<9UBO5P4/DTQ!RP] _D@L6 1=Q/"8-8!M
M]S>3X_L+\]O%4X?L^Q<G^R[9K]BA5M$*YMF<^$$G#;.BAA$Q=.@<35.CL4Z!
M8"A :6FQ>X!^S(08;YW\&CT"RE7K*;*/&G<X+];3&L$$0^"$YA)LD 7UI/PR
MB-CO ,;'U-'!023>3OA_5MSEM/SH1\>-_B4!_@+W8A1(FP](DQ>+XI&.+V51
MJ2(( 4:?7U]$-Z"7SZ+CX7'L)B :K>$@#+/H L2\ N2<"B4GMH+4SFVKA@\R
MC-#;,Y@4P,1^4!3..UVI$9E\67] 1I+.[O-B4=P]@61 ?F&A-W> EF5.;]R1
MC7A 9DRDF\SI2XIW$15:%V4'YTTL045 \PR)8<"2V-J,[+F8D7S%!(FLP*PA
MI7B;2(<E07"ZR.X$P:;!U<EPV@7O5LGS7,2.!3*_"B5N-A&A7>PJ=QQ:R3))
M_O U3LJ:$1Z1;H897\E'_QLI(WC"(!C=(OTG[#>K YP&!",4O2M3!?"CVPZC
M'&$&SE_5Z:IZ&>UE(-3/D4+>DMW"2ZFP-- JT[GXR]$VF98/L!5',F>"+Z]@
M%!A&=^=&>;Q/B<YO&0T9:!_(/1LS@SW1*W.R&,UJNQJ\^;+\8'&PNB4PYG7I
M!&<VZSI7 A]26\Y'<QP*7TC$D%T3<9]91,3Q'_85H0S\6J,KS]B,7O"TP2:+
M0M4KNAE[,%MIZ('!&(!1'NTAFZSV\>31+UG=/D4I<)R>:0<8F.@^_V"6<][S
M!ET?/4]B.0[6M$/<-FKBB3\A/'-SY J(F1 8%C!8AEO#KDB,9!F=%$Y+L@;1
M!U0P-Z)+EX*VT*@3]-##O; DR6,BFO[<'U55H/?96F!*-KD60'390,Y&:A10
M2+\DZENLA,T8CI-AX*L86)C&JBA+_@W>K! S9$!*BF:>)./9!E C/P0R*QB%
MYT3;B*6 ))\Z&YT[,YQ$3(G&=:"6_PH]?AR6YW;22\T]M.I@<2APCTY>5>0R
M+%G[Q9UZ8[JQX\*&W?I_46$$Y<::#'_RG=/YDP@O!ZK)?)I=Z$1B9U7$#)WP
M^6H+S'N0BTP5HAXCO:P7HGS80#-Q'W<<UF<$<\7&1+^IF.RZ74/@-'C-2[$W
M!G<\&+J8HOA;,:X4SA#;(K2#Z,:0I(]$DA1GIR"1@SSR6832;E(WB#!X L0E
M8#7T[7H%G!^-#';1YF!I0$)T>'@)/V#%>1H^KLR'\:![8MYTDWNV".P@>K-F
M$SK1Q#X!Q+GGD>:8U;JYT3:P8,R9%94[BVPY79=(H@'7^>ZN"F0-CB,U=\[8
M+)(&+YG"P3HYPP8:[3D#TZ"=A8YJ!UZ.V+^1/YS78M='YY<P''K!"%L!I:DZ
MCIH$D11#:Q 45C!PS[:PQRE3,.$TY<@*HSCI]HU=66T%#3-]&][HB[P3/:3"
M0-I?T?0J@RQA<<6<KCOPHJRR6AWJ^U%E/-AZ+?'_LH+#?23[).HNQ0PTSE@,
M:!)31&OUC,4#*JNV+WL0O6O?(6>#P"E%ZR"K(%,#H8"HH0C#DG@8Q\JJV+V^
M&_#Y>K"&ZP<5>D4R^0 5OE 8#U@1P"FM)(*J+)Z2!=U&0L0R/T!-R^.-E\@Z
M"$AP,19XR<E#C\.S&D&?"^M'JX1$'WD1&0&/JCO3\JGJX>F\0$D6OP?.C5_Q
MC:<+N''%?#_9/.%D]\IK*'R;V!0+:]U+]CU)YU?GO '%'YAD;VH>ZJ$1;HD5
MQF,B^+U/CE?\U+5>[Q3T*I'[B.5'),TH5*)I+"/>[3[?!_(0"+ZACA;8TU+K
M-A==O4H;^B#:=("O*<%N^Y+4>/^W]?Q.?5#>\"G!//G\H(,:.L+5)]=Z3M10
M< ;198](3AL)94LF8\EB)B'EGM8 2\KF9!'&6P,KD7N"!T7TL$?R(+"L$5;$
MCPY6BS5:S,L[%+[=4#?.:F6M!3;:QGCN'/@RXY=M@=+=*#;F^R=9UTSR@ ?H
M?5-;,!!$[[]BCS=;3<396VP0Y+LF('8:4'W[MLY:JJ;G['<H3"8=3(Q0LK'^
M,CUP7 J(/Z$+^RKIS&D.="<2V/11' \=&-4]^C1S7,,BS>]J<V,; %%J0,.H
M?C^(-&*4!=HJ<*Q:<; @I8N3%E 2@/L'@ZY7%*_L!%4X<R3JQB+M@$?$9!/\
MTXQ#1UE%H/,BV$Y3"O?&J&_ ^+^O4S*2$9/+#2_T^$?D52SUS#AX97999,4E
M-F5<MI\\B&1P9P<A0/*%PM1(BJMW]]-[(NS>_"5L@NT P*8<_U/7L=@KSJ(3
M4V<,7^68 @KH0?]JRH[IE4MM8JQC,1%I2K9,0]D=(4$W.Y]KS)?WE\BD3"7Z
M3LKQ?Y7HXF[L$JCA"G!]G'%$%TFT)Y)T:30U(\(IK]7%8HU(3G8T4$6Z5!<'
M^#^\MUK7!JA&$']M!/$+EJWATT_"]R@1BX(F>F1W%PZMD@3YU7)QLJ$QGOZ@
MO:#%S?YMI0^0]$7=3P&Y"^:$RGUUDA@=%&SLI0'B1JY'&)SM#4"$&W!35X6H
M\+282UV<>TNBGOAI D7#X@!LNH)+.N.0%[:P.+6F"$(\ 4$N/GV(C7(#@M\*
MXSXY_4Q>$F=O[)3]4A),>9150MX,<;*X$!YXN$(G!#W#WDR*O[Y#\=%,PZYK
MT7JJ0N@5QY^3W(GRA[NH12X6\\#SK>"ZZ/@4*3%'=_D3902=/N'V);_$>;8S
MC?VHTD"1$RI*5GMG%MZH,^J9#:*?.JVLCL\$JFW]M,*%$(6;TT6S@(/7PJ72
MK+@-AB#@RM-OSB_$PZMM,PP6L$(RL6QZ$ Z37"9I#FK @GT[,']!-]=9SS69
M#Y&+\*Q2\X4R-[55SX'<8Z J&^>:&06#0-)0\:(*-+6*9;MIRO# KS1ZOF49
MEQDTJ@TEG?PI"+P47OS<8" 1+?@)24]5$9,X@/A*B/7=@Y#%]$\P0"5#[W#S
M>L$MV>F(@MZ1"P1M;4)=2QE7&2@YC'$Z#,L-PJ#+(B_6$N%1H=/@/1!NC9<Y
M9G420QS45VX<?,<'Z 2ZML'L%/C_AK(@]MB&.CX<[K^,3#(Q/3)HCL,**<?E
M<&(/T LTNJ.:FW$PP@J1)ILYH,P6 $OO1V#2$<:QFV2;9D2^:'$7+KBO9R,<
MS87+=2%I!/.=7L9S7"2Z7@Z?P[\XK[8_?4#CUKS]<DY1\E.F(ZV]E*V/[(B/
M*M!@JI2BO(LR.2AN#P2_Z/: -N,_X97*<CPHA-X*/!(_N!B0TOHQ%6F41Y!$
MAQVS)>08O:Z]'="J#?2'ONG=WC#XC_+(-0:U,EF<%Q2"W4)[G>]NG;'[VVFQ
M95H# T/U Y!W\<3L36RWH'II2(Y;AH0+SHM 4W#C!JYI$-^RY0H9<\$"=<_:
M$2,"2'WP?FLB^T%2Y-NB(O$E^I<UK)?#0>G>.X=Q1PA3%?U8P'\D"R"!B)5"
M)%']6!R0(M[Y6ACZ%"M83PY&HSBZ&MB7D(-?2+B%7\P5!:TSP:+ K-<8#?.)
M(C#>I D'3. NKZZ0Y,$%G 5^."Q'<0NT'X0ESIA'%SW,](YBX J*J_Z4HI6&
M+%+=$R/VR<K>%R" @H@\XVHH*NKIUSW#PEMB,Z,KJ8E+LJ4DNIZ!5(]!MZ)!
M7FDHY$Z$>;(C8;X(::C9%;U!51Y6<DOIDX_.4B9A=J0.D5\$<1Z'LIE:N+:*
MV:EJ]5NHNUR');,"=PV /Z04UYL]B$>):X9@R%=E0N8X[J$KOCF?!]D1>@]=
MC NR;1JM?2$;L&W<2>_O">^FB;((\KSHJKTCP6^'HQR>Q71=->TS.N!*(\&'
M+Z.K)270N.B\2U(TTI3KD1QP&(X<GKUB75N5>7?<IHI"E)[CJ$QA P==#!MM
M_4TZ+2F09)?=C^/H+2<\"=Z>'HWW([&)!%R93>N D6GJ<H-)%Q6W':R/5%^3
M$4N)D4:JY'0#_Z+1_VC_>8X!K=DR XV.=297=,1#5"-!!8_R]-$'AV[&XJ[(
MS5[,QBO.(<V>ZI"ZX:UK;,-;%G.V,@:,R5GR8MX(+ !YE6+""L7CNE:G4A"B
MVY#4%1LDB#'8;]$?;B^W@+#@:",6'-$=V"UTZ$8MLIW0E@C976%[$G<>"05N
M9:";KH7XD>U*F(N/>/&9<V*;D/"7!$-J%CVG@7&F:-<Q(3N+1J",WUXN]F58
M5MDR&_HH CE2U"HXE5 HO%!<L1',,R;K:/_/:)D]*W3C&M,6@QE7B'R5K?:,
M2[ >#*@X'AX'H44FP@\5/$&[0.2JFY?'GV4C$DUT+/:O=2)[ZRQB@NR3@AGG
M<:Q&="BB)WJ_!:9&:/L)X[)TX3::+R]4TI>!,,:D,D$F;,X'#:U85YC"Y?T
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MO/CFOMV'K*(:/11ZQ=H.C"9KF5DSB'I>',1,O2 O W,I+55J:==?7,T"^Y&
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MW?PRZ$V;7FY'%1IS]:Z1A#]\C1SRQ1+%-Y 8OI[Y]\+/<O_=X6CY^1>KC5_
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MN.@W4_ME711#4S83DXJV&^!-&]N]^_N_4$L#!!0    ( *J!#DW9UYQ$DP$
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M[ M02P$"% ,4    " "J@0Y-'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    " "J@0Y-9O,+8((   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *J!
M#DVX79-\[P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( *J!#DV97)PC$ 8  )PG   3              "
M ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ JH$.37%\5(=C
M @  % @  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( *J!#DV6,7.FC0,  %L0   8              "
M 9$+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "J@0Y-
ML=K05>0#  "M$@  &               @ %4#P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ JH$.36UM2($]!   &Q4  !@
M     ( !;A,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M *J!#DTT"F(ML@$  -(#   8              "  >$7  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "J@0Y-%E$08+8!  #2 P  &
M            @ ')&0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ JH$.3?I&-!:V 0  T@,  !@              ( !M1L  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *J!#DW\L]J8M@$  -(#
M   8              "  :$=  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "J@0Y-L>=UH+8!  #2 P  &               @ &-'P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ JH$.3?WA%9>U
M 0  T@,  !D              ( !>2$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "J@0Y-6(PW[K8!  #2 P  &0
M@ %E(P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *J!
M#DV\M=[\M0$  -(#   9              "  5(E  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ JH$.39%6-^:U 0  T@,  !D
M         ( !/B<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "J@0Y-K8:-;;<!  #2 P  &0              @ $J*0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *J!#DUWL5YJ#P(  )P&
M   9              "  1@K  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ JH$.3:C1QLC/ 0  G 0  !D              ( !7BT
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "J@0Y-@X&5
M0<$!   W!   &0              @ %D+P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( *J!#DWQ33AJM0$  -(#   9
M  "  5PQ  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MJH$.3;=GCMG& 0  > 0  !D              ( !2#,  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "J@0Y-DM[K^;$!  #2 P  &0
M            @ %%-0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( *J!#DVEUYD>5 (  +8'   9              "  2TW  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ JH$.30\5!<%K @
M.0@  !D              ( !N#D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "J@0Y-O%7XLM$"   A"P  &0              @ %:
M/   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *J!#DTW
M2C;@\0(  ,D+   9              "  6(_  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ JH$.30=BN*M' @  !P<  !D
M     ( !BD(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J!#DU.;*XJ)0(  )L&   9              "
M 6M/  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ JH$.
M3:$.QWD; @  .08  !D              ( !QU$  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "J@0Y-U.6YQ-4!   _!   &0
M        @ $95   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( *J!#DV!+I-8Z (  $H-   9              "  256  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ JH$.33$P8Q E P  4@X
M !D              ( !1%D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "J@0Y-HM]_B2$"  "H!@  &0              @ &@7
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *J!#DT4D%?C
MI0$  ($#   9              "  ?A>  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ JH$.3<-0U45/ @  [P<  !D
M ( !U&   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "J
M@0Y-]Y"R#4!3   T-0$ %               @ %:8P  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    " "J@0Y-RGP!QUL"   =#   #0
M    @ ',M@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *J!#DW1VJ3+"0,
M "H8   /              "  5*Y  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "J@0Y-V=><1),!   D%P  &@              @ &(O   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "J@0Y-IAQR7Y\!  "3
M%P  $P              @ %3O@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    +@ N '0,   CP      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>71</ContextCount>
  <ElementCount>160</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/CondensedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/ComprehensiveLoss</Role>
      <ShortName>Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Braeburn License</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/BraeburnLicense</Role>
      <ShortName>Braeburn License</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Molteni Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/MolteniPurchaseAgreement</Role>
      <ShortName>Molteni Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Debt Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/DebtAgreements</Role>
      <ShortName>Debt Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Rights Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/RightsAgreement</Role>
      <ShortName>Rights Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/StockPlans</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/NetLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Molteni Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/MolteniPurchaseAgreementTables</Role>
      <ShortName>Molteni Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/MolteniPurchaseAgreement</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Debt Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/DebtAgreementsTables</Role>
      <ShortName>Debt Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/DebtAgreements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Rights Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/RightsAgreementTables</Role>
      <ShortName>Rights Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/RightsAgreement</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Stock Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlansDetails</Role>
      <ShortName>Stock Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Stock Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlansDetails1</Role>
      <ShortName>Stock Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Stock Plans (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlansDetails2</Role>
      <ShortName>Stock Plans (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Stock Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/StockPlansDetailsTextual</Role>
      <ShortName>Stock Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Net Loss Per Share (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/NetLossPerShareDetails1</Role>
      <ShortName>Net Loss Per Share (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/NetLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Comprehensive Loss (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/ComprehensiveLossDetailsTextual</Role>
      <ShortName>Comprehensive Loss (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/ComprehensiveLoss</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Braeburn License (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/BraeburnLicenseDetailsTextual</Role>
      <ShortName>Braeburn License (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/BraeburnLicense</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Molteni Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/MolteniPurchaseAgreementDetails</Role>
      <ShortName>Molteni Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/MolteniPurchaseAgreementTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Molteni Purchase Agreement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/MolteniPurchaseAgreementDetailsTextual</Role>
      <ShortName>Molteni Purchase Agreement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/MolteniPurchaseAgreementTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Warrant Liability (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/WarrantLiabilityDetailsTextual</Role>
      <ShortName>Warrant Liability (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/WarrantLiability</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Debt Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/DebtAgreementsDetails</Role>
      <ShortName>Debt Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/DebtAgreementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Debt Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/DebtAgreementsDetailsTextual</Role>
      <ShortName>Debt Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/DebtAgreementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Rights Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/RightsAgreementDetails</Role>
      <ShortName>Rights Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/RightsAgreementTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Rights Agreement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/RightsAgreementDetailsTextual</Role>
      <ShortName>Rights Agreement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/RightsAgreementTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ttnp-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.titanpharm.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.titanpharm.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ttnp-20180630.xml</File>
    <File>ttnp-20180630.xsd</File>
    <File>ttnp-20180630_cal.xml</File>
    <File>ttnp-20180630_def.xml</File>
    <File>ttnp-20180630_lab.xml</File>
    <File>ttnp-20180630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001144204-18-044671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-044671-xbrl.zip
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M(<$'$N4%/,!BR6()8ID:)T+*7=P"C9ND/060;'D,["[R'=A1LOCT+,;O?!D
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M0,( 2*F5WBLK4CV9*%_#*#"RG5J:P[+2Z"GX*K\K:[Q)=PD;$S<8^P7MA%0
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M$3!/<*K6-A-F'*6!CW()'B29"'CAGVE(BKG0UJOG7!DYNK8*%'JF=3+?["O
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M6%Q\^;OX(^H@AC]J]XY;8!]@'2FQ*G>P:N+@PH6_3ZSUQSU'&UC'/^=VSFS
M7@[ARU8>:[!"41VL2/$_B83W9Y0T!=:L-I@!%L]7F+5&J&9H?<W+BCM#[B9M
M4N+X<%\XBK]37W**TEX&485U'41Q'%WAF0I\%YT6L+706Y;)9;="[;S(@4V
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M5F^.*:+0'9VN%%7+ENMMS;<(&NV5"P5%K2T=S'#ZEA!%T31-F,=6:"]OI#O
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M!7W(<YAI;V/*5!>1V) JORQ6#W172L2QMGNX6(:P510\'P"/JFRK^-KEA)0
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MDA7Z:>=$YD; LXHMP8G%?U:QY5IX<%V<LAF*;YRT3:8BL!UT%[XY.#E8HGV
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M@\H@)VHSA@>E&*9!("YED-JV91!$5Q+;A1%$PZ%1"7XGDK$2TRB!Y=8R*$\
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M45W=O&?CWEC,+1A@5"4L%+2I:MU'QAKJRL%@)HX7#&&HT(2:_<!*85&BQB,
M>OS$[QQ?=00 0$M1SUS_+ICP>F*R!/T474M.*IZ91G)RX#?^GX5?QK$&+REF
M<=$<ED\E9W#.+[?80:2ESQUU%$YU@Z..+3OCV#!O^"WP>Z/3V/?APMT1F &6
MJ[+;A)M$B[\%Y^0*U&,WX22/@>-EQ@,FGBYV@H\&K&VC"5?H$AU^KPH44P&6
MXVF(+>5]FIB4H!5TE"E$2OF.<B\7>+18F[%L*L"K[S8^&!.+_HO2[16;910-
M\% _$_#J0N& F.#<D?,@Z O5J P<*L!HZ%Z?C!F,E;E@\'(E%680D"H<7^ ]
M #[G<]M). -O"I/O?LH^@&><W0$6]\^EX66\*:JFR'+"-\>1$@/TKQL@4=23
M0'B4%\V%W_NF*CJEVYJ/+XGM)&D>NNJI\#0\*_N0Y!GH(\$CB9Z#2U0-)QX4
M(40T<!'/>13.5U),]#SH_9GZH!JFB!<8UMP'*W9]L'!XDC\9KO#S.&(PMI%W
M C<Q=PSHJPO$"!^ WT*OZO 93 O\T#0F'&7F3W-#XIB(J24)3EIU_83JH \A
MJ0V['[O.:#B$TQ1#C,Y<,N8X4I6,4!4%Q^00QMXTX1-QH%37!;B2#=T:GFKA
MF"#[#@>XR!92OK'!\:I*,:CDWM^--N6Z;_)O$[$_^$X%]H'!+GB!T.V-!U_X
M-L<?W2O)K!:WV%[Y[N!XO$9$JV$NJO%XBZ8]L4W@^"(>+8S0]6?096C,%?;K
MHLHZ=ZA)2>H#5>*,#6:>AF8K^;;ZJ#JZ&['5X.M \,57H'UK\RAU&/I^O0E)
MV?N&SC:$<M/:&>TEE-F ;PQ<TB:#W!J!CX%<0309^F:J<Q?Z&OZ4G<+=7@^+
MMT5I6("EN0!S(5"FFXW>)T<EF8PE/RFZ4.FX"K^D5E*:(-O5\[QR35Y6BE/N
M:JZTM,[,RO2S)699X2JGC1.8=Z?Q8\P**]4BF!TT9[TY&9^4H$])C;FE>%0E
M 7I95:':4TE#["C$IK421S<QIBV9U+9@4]O>UZT@4%^0.+GL(S*FK''=.;]N
M/'!!I*,W7LFQ5KTJI'&5IT0-(+>\:!_!'#DKTB(Y*W)6>W-6-\83N2IR5>T"
MN54E8;='.^Q ,T,$.T>V)I[YVJ1O+PTK-C)O:ONN:NGN:?P9?]+XW(M_GW,G
M_D5<[)Q(TQ'I .ZKV@"(X*8]<)/D5/UM.%5T.I1XU;&C#VZ-[(2M%-L004CC
M(60]7=("N[F:)&= SF!=9["\;A(QQZ,%BS*M$< W5V<$\ 3PQ/8)0HCMDR;)
M&9 S(+9/8%'#MM2*$G3%<%&8Y1I813HM-/PPK/:7_"S>>&[FKE;NG'VK4.([
M=[GJX,&;]!&@]>G"&B:RB3>I]8K"YS+9:[E]<&6R>CSC-[RH<'\T00I5;1X7
MU,MH?0727W8UKZM81QT79._/5)Y;<5IE-*[=.+:OF%T)]/=>D);\Q_:5[2NZ
M '+NK4#KM>8NN75RZ^36]^36^\O#^^36R7.06V^-<LBMDUMOHJ&06]^O:0Q6
M[-J36R?/06Z]-<HAMTYNO8F&0FY]OZ;1'X[(K9/GJ"E+8S02-E"^!5\I0T-D
M^%&&QJ$@X1_<XHYJRJJR^LRP#-=#TWNH>L%"=0-9*[F3,C/VQ-4S2BK/S*A>
M+:#N/ WR P<WF:60O^OJ.403]TT3:\C56 7^R]-UB3"V%"@J^I8J#B'B"$0
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MP- -:,4)0=%V$U(=ZP1)2Y\[>2,,8(.3-RT[<D-HL.4*KNIJ3<QK_,(CKM6
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MT]7-NQ<N^BUPB<#FX-/4DOF4Q=C$;L*G_IC+P+WML*N;/]A7NXOT>=A11J<
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M'J;71(8E<FVD4;TYZ9VDDV>4'F*0>*8#,MB^]WIB/'']\H1IW#0#D<7W\/?
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M"CA=W"S!%JWYMEOS72?LZEMLSK1N(]=8U>ZN2L!)$+G0=2#.JQ&L"S!%A)V
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M[44/_R_N[1(!-I9SL*X=%\@Y&.U!T.&Z$'4H04?KFGF!H.,-!17.F>ON)R!
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M:;1:*F$[%C'52TGLPUMZ%ZZX,C553UD0JUFP5(Q.1R3C.KB2%)D6)9J WS)
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M>6HOJ%XJ2N$6=W@I37Q1[GO5-#&BE]WMSBT1<F6(:]^^+SQ;-,Q@UW:]VN4
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M?[ID4FSX"01QYZ:Z>&U88/9<"G@+C'UBFZ;]B*L%3]P]/(?E@[!@T+%UCT3
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MTYFP\J*_VR"S4=*B9AKS_[^]*^MM&TG"[POL?VAH9W820 </48>=&-#8#M:
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M YOVX05@R?#PFAI/E."/]J"^)H\BRJC[@V/+'>@JG:U$95G@U*!:+"F)VJI
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M8S$VQ<7;8.]I8T ]E>^9(^C&HK\;YFUCKJTQ()U*!1-A8&/A381^V_CJJ_0
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MPRGGCCX(/\AG#-HP 9^HVVDQ:NWVEU;.#IZ2,99RBU]GA)43:/YDJ"\@-[T
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M655%@(F25WPHCDW0N\@]+@FC6SY1?!?^:*,T?^4!F#F ^K/Y<7%;**#/ICK
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M\P9)>9.4OW\I&%N^''XCOC8:[-N@<U1/##]+[C!:(W/"=8J7'Q;X [!G/$<
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M\_G5PTIF)EWR*5%Y4 2B+XDE7<*Y2@&+S-9L-<GR-(L!<?CVRQW\5891DPQ
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M!6AMW62F6;QT-DE8.;TOFY0ALMG-OB6>$O3@!"5UBDZO@CFN!SX'KA 6]-T
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MCU R@5@,+S-6U0#I>$ALRGV3E+]_*1CC:8<*5E;\1LV:77DCK090 PZ=46R
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M@:A^>,,^COLF4'=F)Y WSU]"Q%=?'(I9M\;2M=$.()E85XQ\B&/*>=7,&39
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MP0T2=-IU @&V+UA]NY ^?*QI[Q8,0HZ-$ 'X!K*1Q@7 D*O;W7CR,4OIK=V
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METIZR)X5DZEB-5L*]:<#7B0++"TW7AI9FFW^/9OF19 7B_FD$:GC&SD:.22
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M]0$3KV/I\CZ_7*IRLL.?4$QM^ </JY:,G%)DM=7QJL&U908ROBZ3>%U;[]H
MV_S[M$/LI!"P>)2=Y/\G%6B;QR,\"+66K)Q6L+75\\KAMF7G_X<)[7SM&P1=
M\HF3#[F3@L$*07=2)/ H[)HG0U;?3Q-\RZ? .4%3SO+.*^VGP:27]7MJO<:_
MB\SP+(F]"MQ3P\F*2=Q3W30<IDU^R+-BE=-2JJ^=4/@5:VO- ,QG6=E7O9UZ
M+J+ H?2>SR*G.]C2X4CA70X#$CU]SRYQ1.?'G#X<70WOE/&B?]&M3<NHXLV$
MSER&DRFR.CC^U$\;+A<IOJN4DN+'H*H[8A NEE 0)QUL/)B,;\[=)X/[=*87
M@J7KJF<E!5\[H>F%6%OK!@Q!XFNMD+'^B4D3]0UE/^W)A<*]EC\@*?6MTPE'
M794'%^%(^+43"D=B;:T9CGI?//UP9*:^5O9W 0D924*TD^5-%9'3CDX*;ULZ
M.BE<[72B4R^==)F69$98Q"&K8.4F'3[^Y@E%*I7FG*7'VR]7M>].-45CH\OM
MXV/.@NE8^-]C+EGLDROFE,4.>0(EB_D[-4-15BE9;/#14RA9;*([9S?H? II
MKI2IB&E>W[);U5$7*V5L[*4>3=MTYS,$DT^H0V/6K/@TR5M>SZL>&A,N5G^O
MIW3GZUY[9.P$%\ K18;%3Y!-# L>Q6#SZ]M =Y^-.? IXBZF56<STE,]DKN:
MIDVO/_@Y:77G\BL6C/ PE,Z8FLMO)M]B6@",_/Y=1N;L05@>@X0^/_+-BLOY
M2=R<T#I_FK;A2DVT7*$>6^N\9V0^L077OT)-=4552CDLIO#EWT_W":3YH6+I
MA,*,.'$ZH5D^YLB$=)1I->?FA$+S-&W#S80=AF;W>=L9%C -SEY/E&&BQHII
M7]N0X3!*M^]RG.,=SG.IL#_%Y=-EREYN)=QRJP7ITRMK?<AE;%U:1ZIG7II/
MR./G)_(5U'UF(XJFH _$K(LMSDU7 1; TPLX?R9K:/%2_6.6/N."1A :8(K[
MK R2_M_?947Y,2O_CLM;'&:/:?Q/Y56#%;\)\?3#"IJ3/QU1?0S)ICH;U'ZQ
MFM+0TVY]5Z8?)&U*]()+U'W3B]<GUH*@]/6*M?#W.W#?:N?B?9;7OZ+M5"L<
MUXS\'AQ=IF/GWK^I=U39 WH]9J 6,^ :YUZ*/73ZR>O>Z*(FS=*S6M\%>]0G
M.XCT]KN(ILJ(X"S$*L.!'P^H5?\[XQ6_?@>>/* VD,GZ 34/WC6R,YC-PVF\
MM=S!<+2RKRHC7.^8N_7SM-N'@JWT%8"T[\HA-"?(J4U-59VPMTU9-\/=F/,X
M.=+6/S==+O_8BN%@N(#LYSC-]G%*4?@]I!-.A>O8':=B=<:+OY=IF+-U/!NB
M]EE:?6Q;EGG\<"SIXOT^8\^?XZC9E;[>U;DX@=LMT:FK5X/GRCZ&8Z\_5'78
MN&"_2W2?H;K3[J#%]:Y)T8.\1[ZT)BYV.QR6- 9%--[$SV2FF96D_YBH)JQ4
M4U2J(?]_3$HZZ:1^U3QS#?8"\R+^,'BCV1]G,'K.?&DHW#_%!<))E63-\8'T
MQ3*IY1-&:3M4Q3W7&>(CZ+L.F8(%M>O@QG4(=0V:I5Y!GZ:"GX*<%4]9-BAV
MO?H=%7O2+QL6FX[=G@U91Q/3P^(GB18\CXMCGU@@,*[B$"M&1D/'L ]Z#22L
MH]Y"&=H@IWNMQ0W.FRQ('&[3J%Y@&*S,C'MPF1,UEHKS[9J2IARK^+9!C!J1
M.;N+99?16;?I\GW$)4JRHJ IPP%:05=>EBCDTGEV$'3G743;)#ID>WQ%5&[@
M2Y+V#CU'QK$(1U5#]"5M^M5P%D""W0TQ!)DKPF<HC$4BL3D'3T(H(3,&OA(O
M4#!_#N*D&D7K\95N/3QE240B&_-,8P<PZ G,-4RD-'":IAOJ,<VLNM=3/?C
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MW+0=@@6Q6:8>!#1X.QN=0%C*WK?#"U==V^J(<+9#.P: 0P< 3 &04 "4U0>
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M9'4[)+^3AQ5_THI"J1:PT'%X=\Q.M;SEW_KO](JO;N/8[."-[>&;19;8Q,'
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M+MJ_$UJQG$Q. ),_)?^,:;T4^H[M-D\GPD$ <\CF3_N7;P4!&JJ#U%;U.:&
MYVD6SJFY]R).GDB8Y0FA0Z9I.3<EM&\T$@XF<?S=C_Q2,KQ0P58? ^E@%YXW
MJ5Y=!6&H())%-O7ASMC41UIAAM+,H$)2"WU0++7=Z *#PK9S*@B-,46DF-PV
M69=X+F'VO-%9?@E;!1R^S__,Z0OU\JQ^E>X@)CMR_#D$LK===61NV[1E.*6V
M;K4/@*B0;>#JA+93B"I.MVWF*R_^>KY(XZVX?4 @R!=0'>(D(2UL<&Z;KHN[
M@L)2O]$.@&.^&]IR36= <+L*N/1NF/(NAVM11!-EMV8?/P<T(-_:&5K1\B;>
M&K[;X6VM+11ZSM:V'P<1VY'_K;56F<)MR)*);I)O(XJ%K&_R+(7[_R2,IM>Y
MY!QC_+> !6O,1MTTR;">B@5FR KY4D25WF=^DCFJO(4!+KV,ROC8;TF<]K):
M\G_-&^QCOT=MM0)S1=:?A72;ZDOWK.+*-#G+Z6N1)<Q"(FEU0SM_(TD0IFLC
M+$L[M3\&DK0S(-:4\K642.>2\IOE7!X<WMW7Q0]6D[#'!9+Q:\"(G:9M2Q9(
MKL@Z%\FWHB915_&L76_;T%_&KP$9V%&I5NLO5V2=R_;OA/XBWZ[VL2L'6ZV[
M'(&9>D:@O%Z=1Z[J[N)416TQO>MNX[> "FO"JFW478[ 3#V(X&AL7G-BUV*Z
MEC>%VR0,>@G,TQL!D&9-4+6-6JXE1E.O1CA@%N/Z4IAFE[[F@+E1 ('6!&*C
MS /3HC3U@(;E^X!,;$O)H$\%K8$ A=;$:ELY&UI(T]23(U:[^N1R:QB;\":$
MUE" Q+^WH[ 7>9IZ1,7Q78)AP\*:%II#\0;CO[?[L1=YFGIWQNJ]8G>NT./=
M=H)N4XRF'N#9(=,GDO8KC@!H^^E>-25&4^\#67 <>I2+[%%[P;@C-"@7_GX:
M1T5>6.[/:%KX4#8/MCL:('/W7;88(NW\3)(MYZ(.PN,O*#SA]5+:HOUH@,K=
M=PICB-34"U$6[!YFCIN7(*4P2L.@J+.PG9O"YF\",3^=R.T%9^K%*PLTVLR"
ML"FD+2WLM1\%:G;?9=RCY$P]_651;8X'^ SL13M3H6-\A+!*K!+1EH\"<M3O
M]S![OH0E\S6<@,P;BJ[Q IB)'P)AV>D7V2"3,]-[D(3;]48>PHR*8XU5DG7.
M;.\-#K!] CT0RU8A@0#<+CS2 $9%=4=FI8?O.7QYB,\CV!S>I6GIFE\"X2$?
M+P2<*BJ!"D*WBY"T+$MQ@.TIV=K"P #N=B&2]IY0BXI9'" '^3&TPK3?60;?
M[9(JK=[P.,#V4&UMU6GB=KMV2>LG/0Z0XQ>;1(@)JX[;4$T0"RO6E?^_0]'"
M]0= 5-@^MJW-:AV)&*K,8:'R&"UW>&!QN<,ZI?I*44=JJ-;%;A0\/$"V5^D0
MQZ9> JYS]0G++QK8]<H.L%UZ6]MX3$FK<RD)2Q8@T;NIUW'T2E+JK*<"2!_B
MS)]5_SM]._4ZSOZ+9.M75546,-._Z0T.L:VSAK1*LCCV([C.525V5)7+T/:+
M.%G\B;83^:>W.Q#@#MORZ*;2"Z1IJDJ%!<$9'2)8+"@ >(AMWNI5M7L3F:E*
M%=65?$L!&-<DNP(< *F OHC"V';XQ;F?T&#$U3 4 B]X78"1?82Y#YP4*B0-
MF=AH"(-%O@&(Q<B91PP,;@<KK!"=SOPT711PEA@7N7U (-A1;0R")%2R0;@=
M>%#%)#7W-1M[@R/LDYZ8'3:E/"!N1PFL1*%DFFDT!H%A%V71GY.UT;OM](>#
MQF4$QPY"CQL*^SNS/0@"NYH(AQPVE0(0._%:]":^5S@Z4N5^B.%\/8^C8@EZ
MCF> +(4S=1@HTRW]$BQIR%<5 ;4JNJ"($/6=9<Y[@2?S.(^RFZ>S<)9GX2NY
M)T&>P'6>I.N'2"?_RM.L6.WBWWUZP8+YXC\6#Y RE,#$9T%>R%Y<98TP![>K
M?]^*NK3J$Z.0E=#6K?TMD".R_[;'A60#HR%W?D9M?4B:4DMB+(N%PE&77ERK
M"6 *QPO=3P$AV,D)6B>/=OAVXB4+5>BR(XG6=V".(5MRVC'>37LJT$V%"AA^
M3AQ6RJ28-86#@JZ/!8:3+$O"QSPK5\[BW70R69;1N'E:&'QY1Y5.'P5Q(9N'
M3&B**3F8\N=;H3:+0YIAO5E^%02&;,- 5IQ-09ARGV-6\. (='%N:\A5?[/B
M?0E$B&Q(V<)V)09ORNF,>2"N>V^*_?@DFBR0MW"C<;X (L,.]=$Z_FK!,N6^
MQ5Q)F(!U>0=Q(%]RM'C3H+Y$9JJJ/N[]I@Y0;A7A]/ &Q\B3N@>Z-[#U6#H>
M-3YCX'* QG P1O ?KB*=3Z(LG#2,KN=OP2P'<BY 1VET4%Z2>/-4AZ%>$\/$
M#X&PD"^+8AHY'LP>9/ SP&3M_1\.L)W9/1"L&Z!2".'O': R'&(G+HK940Y0
M*8#L2(!*F7Y%M3Z.:&J,ZBQG]0,Q8L<[;'^F\P7A=@1,#9=TPC/;@R!L\4/Q
M>>*<U/EXW*XDL;!+2C-)-]K!FH?L>!;PP3&S-<=O*#YE$J;!+$[SA'S+PXD?
MT7+TMB6,=Z@UL"K3,AQB6]&VMIRKRV-WBU28K#,P'"('(ZL3VDXAJCC=+CUA
MMLK <(@<6*!#'&?G%X-SNZ9$QX7T2B&>W=1/@+BQ$_RVMO^8E9GCA3 Z"J.,
M5>U/0<OO@Z21;9UF=:87O:R*JL?8F2UY-RC4A#R3* 5I4#\';A7P1;DD!=_&
M1D-@0ZO*-R?F:$,8ZPA?GL-!V@>&A>W-98B)$0TD!_'3^%^QK(Z0[I"*7&G;
M\4?.5[CN;,<?81_+Q.RHV_%'W+-2_W9\O655=.Y6Z@=@D6[DK2:B!B9#9G;<
M*!D&U&N2W3P]^&^BR<GO!;)!\K9I4,>9J3)4_26C;ND@^37QR6.>P-<"0$G:
M'B,Y2\CBJW<TRC0]6]FJ!0=%E6X@>JU &,[@KN/HCCSET83._-]>X 9!8R2+
M7[X@W' 5U:XP2*1+F;H(&0N=,C*W3Y;4_';S5*E@)'MDA=4>!($43J)'%7MM
M$T!R^U!9K=!_$DU 3/[Z+P_P3RE, )I(([4M:WX)A(<<="#@E&-4:8,0,]XD
M7>I'2H+/T_CURX2$I6K /]0U O[D79&I/SLOGG[AS'%&*\")9 'H,K.Y0###
M/[0).Q<_:51OX@WWD<(!N.)NLM(<L%6!&VF25997^+<Z+_ G[XXN"YPIM/'?
M 2"FH:7EY&% L.K=#G6.N-M:K06 1+J',V3-(:,Z4JQPAU;7!ZF51+$[0$<R
M<7693/H(L0(7..3>)G% R"2E;J7"Q40- #3CEJ;4^K/PKX*%\G;%8UCG&S20
M=W\/:2/39XO!=BNT;@<P7$:O(-4X>;\F(I]7M1EUY1QA%7_ORK,0$)JC7V)Z
M(C!6]C/=K&8E'$SS=-=YR /DOL_[>SR#7N%MG@3/?DI.I@DIKJG:I9=Y:W[]
MPS(S);<#3>(8[PU-[$/UGQ":)=FMR]%@FN#E@F)M*&(P;ML?C:>UC?>0@AU5
MN-+V;"_PN&V'[.S<IE*PI2 VER-U%_<"CF5>[H;J2F]N_!XE1LQ3O-9$5$7C
M=O;8*1R@Z%Y#7^(ZS=,LAAO)29J23/90B+AC*1U,_X\"<SROMA(P0R;*E^+1
M#UA(DLQ4D3$N@)/))!06H)/W+.$C^7':\:J+S)!=TW#E."Z ,S+)@W:LKKN6
MX#&=.H9I94 S9"#%#C_J;[D>8!I>^ERN!UP#C+8%M5RNSR.LHM;+]S07!@P!
MX;66I2 P33>M&>8A,60>[;(#]T*J:)N6=2F%@^D3,45S$Y+CR5(U?*O_63YD
M*'J+4MJW%))55JR6O NP=3;26O$N0<<EW*K[<Z<EG'MWUB^VR]R6[3"\FPH6
M-FE_'X^L,;Z/K=+G31%IF-W'?&5V9'NZSQ]3\F<.D,ZI_U*A- FG!PC#1F/[
MF/_NI B'VT9V!C2IK9W;!P2"71]0Q)0RN54T;A>'H\\Y%1P\D. Y"@&F9,JR
M.Y3;L57&6NFDE2!QVRC?!">=M;PNI420 ^\E9*DR7$-D59"P-L<7811FY"I\
M)9-+8"2:AJ#QA>$J_?K^W?]7G!1>0LF$UOA*(3>L:D\M9WD;>%;%)9M4BS7>
M:W\N7Q$TOU3*#SEAO W?VIHC1.]VU3B 2F8S$M ;YVT2P[4X>Y?F<?$[E5)!
MKB?9EDFV7BB M2W8VF@(QA@S[59] U#"X79\=#4D_-ZGM<O@+X77\G6AWH(Y
M*^\,(K+533_F9MVJPG+<%;!IXR[J%H8SDF9Q1+Z3[#F>G)$T2,("GT )=#[C
M#0]L=>_RU4$?H*DX;E.+]WF:A7/J;+B'72>,IK=)&'!MI,S&Y77'*HN:D#L%
M)*:L_O8=T8N<\%G)3C19"2X(:'4]^NK<ZNGMEI<ZC1\HQ6W5=J\TZ0VC-_4>
M7U79MN19JC_.CEO%</E,)DB^S%.[CC.B5+5&\PNPDFLEAQB-1U^,\28I1BA[
ME8G?"4 @/Z*B)6WV5)3!<]OCQ40GL;=Q^X! D._),K(T*%X#<MO]Q02GFFS"
MZ@5"0:Z:+N%+@^0J(LNR3NY)$I)TN8!Q#5C<MMX0*TE56>*,0S,?R4Y43KPC
M,WHCN/63[+U:.^GK>_6_2-9?]8^ F)&SP]HMR+H(W?:"53%)%^9F8Y@>R!X+
M7;KDI%>1N>W+ZNGMN@/D*)1V\UH!E-N^)T/OT!W:\O8DGR<VP0(\;K\[1$.H
MPDGH)^^E25XI&Y_7!R2('(S2<OJ* ;GMBJI HH[4FZ?*3B:/%Y1VADF ?#>6
ML,>A7!&87<XHT]4*#Y ?^]";KHS!H[F$ME:H\!#))L$0-H>-ZD@=]_XP]?%*
MX;4U<4>0#?(;G@;MAS54?;A@NIB7EB:6AWCI0J*5^.*H6.J+Y["XH34*70&S
MC8:'&B<,^Y,R-@Z?KD17,\5S_D8K,::D\%2O_F.Z^*^I*#FSU?= DC9>8X5:
M8@ P1W4ZF:NVY(T](X_9RI.=:I?5,Y4\^IAI^5S9'8",8T1[D,RMNMG0&QXA
M;XTB(4JL/14$;GM+#=?D.T)VT+ (DE#)!K$3'M+V5?B.["W!=\1_N(H#Q.UL
M0,/Q#$>V/!XHG:$2$&[G O80PW"$;&*7\-4BAN'(W&-SIBZ9_XB3\*\X4@MB
M8#8&6#9>$:HR9]PB!5"PO)F\)RK(#RV2>.T!G(TN#0E/8C1NNR*_$Y\>U.GF
M<1F]Y"K%+'A=Z&,,!U@%+_6W0BD,MUV1+'C2O9#?J90*LH-#2IDZTS54;CLE
MZP +P](_8QK^3X/AI6FM2OT+66$5OM2@4DT'Q!#M\E-VUH?SMQ<29&3R0)*Y
MMC(T.Y=B0K[S&-,$ 3Z[_*&=U> N3/^X2 BAB=U 6G8'6Z6V.O _4HH-V5AE
M3"T4<#KNGN5-A+/P-9R0:-)*/?@?*<6&?)\VOFH(<*+Y<@U;L54\]LW&</3&
MCF32MUO71H_FO>5<PR_\,*&UGFB.9SXOQ@5WV3+A\R2:++,?0Y+**E[J?XFJ
M]?@8^0+ (XIQ:>^ L _/JVG:ST 0-T^7\ <_XJ?)RWN"_##?,NC DB+G++@<
M@K7-:W R,/=L!6OP=%?1X9:V+S<RS&3V_DG=P,EA$^T]7]: Z>5"ATC:O@2(
M66NR?R(W<'*(1"LG]3NAQF$R.7DEB3\E;&DL3<+<,#B=CWC#8\PBSV;Y;H&<
MHP':=KC&PHP9^(14A,)8_-/Q <+E(W@FD[Q(*GB.DXPN$W1XTF@H03< @NPC
M% F8<S&1XG$\4LI<)?5C;,>3E"H.Q2) ;D=,F2VI/L+V/@F94B:WBN9G$%4E
MG@7=MM!R DL@_0RIV@RR&.W9F+RSYDN#Y"HBRT*J.I>%&6%[>J429]PX^$CL
M?*G46%C5"-OMUH8M,1JWPZJV7<%GM(>=)-!R]]3%Z'905M<:/B/LJ M=NN2D
M5Y%9%85EN#K : \[24!SAC*&;U=85 _U 49[2/$)#&%SV*B.U*[X)"4^OOMO
MX3SG1Z$UVL#*@,U)5>1-5ABCM2LP2(V7,)+S4FT#2)%<%:J\-$?K>$0.7:XO
MHS1+\N(!3O'AL=D8!(4=D=/RD,C#XGAUA4U82B]5\;J /)"K[?(X4F&TCL.V
M )Q_PACSA%S%?B2^H#<:PKIC%2]U23.NY1P,IF)F3'&R>$M:SDFC(>!!SL36
MYH2# 2WRA7XN72Z *0D^3^/7+Q,2EFL?_$-]R8,_>5=DZL_.HRSD&CX8K4 D
MV&GSFIL6%P1:>$LKMLK1<S>D>A. B.1=Y\J[24MSP*8"3@RG0A?ON,:S>/I^
M$48T;O$T3E[BI!"I4GJT_ .P@B 2UF2"L>II8N$XRUU)VMK<%*X4@NXY/4">
MCL9"" %QZ'4EU,6.4FHC[/>MA11K^%[5D')TQI4 FDUA7?@!.9G3][N4UX1U
M%Y '<GQ%"^;%8#CDNFG-^>[#I8MNB>R(?WDG;S2TH/1;)X*;<#@4NVG@X>0
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M,#$X,#8S,"YX;6Q02P$"% ,4    " "J@0Y-E54=9?(+   D=   $0
M        @ %QYP  ='1N<"TR,#$X,#8S,"YX<V102P$"% ,4    " "J@0Y-
M$G<6YP (  !.9@  %0              @ &2\P  ='1N<"TR,#$X,#8S,%]C
M86PN>&UL4$L! A0#%     @ JH$.35MP/>]C+P  /0X# !4
M ( !Q?L  '1T;G M,C Q.# V,S!?9&5F+GAM;%!+ 0(4 Q0    ( *J!#DTF
M4(+L7#T  #YR P 5              "  5LK 0!T=&YP+3(P,3@P-C,P7VQA
M8BYX;6Q02P$"% ,4    " "J@0Y-P\AT36LS   "< , %0
M@ 'J: $ ='1N<"TR,#$X,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$  (B<
$ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
